

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 June 2010 (24.06.2010)

(10) International Publication Number
WO 2010/071894 A2

(51) International Patent Classification:

A61K 38/10 (2006.01) *A61P 7/02* (2006.01)
C07K 7/08 (2006.01)

(21) International Application Number:

PCT/US2009/069060

(22) International Filing Date:

21 December 2009 (21.12.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/139,272 19 December 2008 (19.12.2008) US

(71) Applicants (for all designated States except US): **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH). **3B PHARMACEUTICALS GMBH** [DE/DE]; Danckelmannstrasse 53, D-14059 Berlin (DE). **COSMIX MOLECULAR BIOLOGICALS GMBH** [DE/DE]; Am Rebenring 31, D-38106 Braunschweig (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DOCKAL, Michael** [AT/AT]; Mariahilferstrasse 173-175/2/54, A-1150 Vienna (AT). **EHRlich, Hartmut** [DE/AT]; Dr. Heinrich-Maier-Strasse 20/1, A-1180 Vienna (AT). **SCHEIFLINGER, Friedrich** [AT/AT]; Michelbeuerngasse 4/17, A-1090 Vienna (AT). **REIMER, Ulf** [DE/DE]; Dunckerstrabe 25, D-10437 Berlin (DE). **REINEKE, Ulrich** [DE/DE]; Danckelmannstrasse 53, D-14059 Berlin (DE). **POLAKOWSKI, Thomas** [DE/DE]; Duncker-

strasse 26a, D-10437 Berlin (DE). **SCHNEIDER, Eberhard** [DE/DE]; Am Söhlberg 4, D-38321 Denkte (DE).

(74) Agents: **KISSLING, Heather, R.** et al.; MARSHALL, GERSTEIN & BORUN LLP, 233 S. Wacker Drive, Suite 6300, Sears Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TFPI INHIBITORS AND METHODS OF USE

(57) Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.



WO 2010/071894 A2

TFPI INHIBITORS AND METHODS OF USE

TECHNICAL FIELD OF THE INVENTION

[0001] The invention generally relates to peptides that bind Tissue Factor Pathway Inhibitor (TFPI) and uses thereof.

CROSS REFERENCE TO RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

[0002] This application claims priority to U.S. Provisional Patent Application No. 61/139,272, filed December 19, 2008, the disclosure of which is incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

[0003] Hemostasis relies on the complex coagulation cascade, wherein a series of events mediated by blood clotting factors lead to conversion of prothrombin to thrombin. Factor X (FX) activation is the central event of both the intrinsic and extrinsic pathways of the coagulation cascade. The extrinsic pathway has been proposed as the primary activator of the coagulation cascade (Mackman et al., *Arterioscler. Thromb. Casc. Biol.*, 27, 1687-1693 (2007)). Circulating Tissue Factor (TF) and activated Factor VII (FVIIa) interact to form the “extrinsic complex,” which mediates activation of FX. The coagulation cascade is amplified by the intrinsic pathway, during which successive activation of factors XII, XI, IX, and VIII results in formation of the “intrinsic” FIXa-FVIIIa complex that also mediates FX activation. Activated FX promotes thrombin formation, which is required for the body to create fibrin and effectively curb bleeding.

[0004] Severe bleeding disorders, such as hemophilia, result from disruption of the blood coagulation cascade. Hemophilia A, the most common type of hemophilia, stems from a deficiency in factor VIII, while hemophilia B is associated with deficiencies in Factor IX (FIX). Hemophilia C is caused by a deficiency in Factor XI (FXI) (Cawthorn et al., *Blood*, 91(12), 4581-4592 (1998)). There is currently no cure for hemophilia and other clotting diseases. Factor replacement therapy is the most common treatment for blood coagulation disorders. However, blood clotting factors typically are cleared from the bloodstream shortly after administration. To be effective, a patient must receive frequent intravenous infusions of

plasma-derived or recombinant factor concentrates, which is uncomfortable, requires clinical settings, is expensive, and is time consuming. In addition, therapeutic efficacy of factor replacement therapy can diminish drastically upon formation of inhibitory antibodies. Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies that neutralize Factor VIII (FVIII) (Peerlinck and Hermans, *Haemophilia*, 12, 579-590 (2006)). Few therapeutic options exist for patients with anti-Factor antibodies.

[0005] Thus, there exists a need in the art for compositions and methods for treating blood coagulation disorders. The invention provides such compositions and methods.

SUMMARY OF THE INVENTION

[0006] The invention provides peptides that bind to Tissue Factor Pathway Inhibitor (TFPI), including TFPI antagonistic peptides having the ability to modulate the blood coagulation cascade. For example, the invention provides a peptide comprising the amino acid sequence $X_7X_8X_9X_{10}X_{11}X_{12}X_{13}X_{14}X_{15}X_{16}X_{17}X_{18}X_{19}X_{20}X_{21}$ (SEQ ID NO: 3109), wherein

X_7 is selected from the group consisting of L, P, K, S, W, V, N, and Q;

X_8 is selected from the group consisting of L, R, N, F, and I;

X_9 is selected from the group consisting of Y, V, P, and C;

X_{10} is selected from the group consisting of F, L, and G;

X_{11} is selected from the group consisting of L, W, V, A, M, T, and S;

X_{12} is selected from the group consisting of T, F, V, R, A, D, L, E, S, and Y;

X_{13} is selected from the group consisting of I, M, G, Q, D, and R;

X_{14} is selected from the group consisting of G, W, Y, L, M, and H;

X_{15} is selected from the group consisting of N, P, F, H, K, and Y;

X_{16} is selected from the group consisting of M, D, E, V, G, and K;

X_{17} is selected from the group consisting of G, I, R, S, T, and L;

X_{18} is selected from the group consisting of M, K, L, and I;

X_{19} is selected from the group consisting of Y, G, R, and S;

X_{20} is selected from the group consisting of A, E, S, C, and Y; and

X_{21} is selected from the group consisting of A, V, K, and E.

[0007] In one aspect, the peptide comprises one or more N-terminal amino acid(s) directly linked to X_7 , wherein the N-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of

X_6 ,
 X_5X_6 ,
 $X_4X_5X_6$,
 $X_3X_4X_5X_6$ (SEQ ID NO: 3110),
 $X_2X_3X_4X_5X_6$ (SEQ ID NO: 3111), and
 $X_1X_2X_3X_4X_5X_6$ (SEQ ID NO: 3112), wherein

X_1 is selected from the group consisting of T and G; X_2 is selected from the group consisting of F and V; X_3 is selected from the group consisting of V, W, Y, and F; X_4 is selected from the group consisting of D, Q, and S; X_5 is selected from the group consisting of E, T, N, and S; and X_6 is selected from the group consisting of R, H, K, and A.

[0008] Alternatively or in addition, the peptide comprises one or more C-terminal amino acids directly linked to X_{21} , wherein the C-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of

X_{22} ,
 $X_{22}X_{23}$,
 $X_{22}X_{23}X_{24}$,
 $X_{22}X_{23}X_{24}X_{25}$ (SEQ ID NO: 3113),
 $X_{22}X_{23}X_{24}X_{25}X_{26}$ (SEQ ID NO: 3114), and
 $X_{22}X_{23}X_{24}X_{25}X_{26}X_{27}$ (SEQ ID NO: 3115), wherein

X_{22} is selected from the group consisting of Q, I, E, W, R, L, and N; X_{23} is selected from the group consisting of L, V, M, and R; X_{24} is selected from the group consisting of K, L, A, and Y; X_{25} is F; X_{26} is G; and X_{27} is T.

[0009] In one aspect, the invention provides a peptide comprising the amino acid sequence set forth in SEQ ID NOs: 1-7, such as a peptide comprising the amino acid sequence set forth in any one of JBT0132, JBT0303, JBT0193, JBT0178, JBT0120, and JBT0224, which inhibits TFPI activity within the blood coagulation cascade. The invention also provides a peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence Phe-Gln-Ser-Lys-Gly-Asn-Val-Phe-Val-Asp-Gly-Tyr-Phe-Glu-Arg-Leu-Arg-Ala-Lys-Leu (FQSKGNVFVDGYFERLRACL) (SEQ ID NO: 32).

[0010] In addition, the invention provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (I): X_{1001} - X_{1002} - X_{1003} - X_{1004} - X_{1005} - X_{1006} - X_{1007} - X_{1008} - X_{1009} - X_{1010} - X_{1011} - X_{1012} - X_{1013} - X_{1014} - X_{1015} - X_{1016} - X_{1017} - X_{1018} - X_{1019} - X_{1020} (SEQ ID NO: 3116). In formula (I),

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

X1002 is an amino acid selected from the group consisting of G, K and Q;

X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X1004 is an amino acid selected from the group consisting of A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y;

X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y;

X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L, Nmv, P, Q, S, V, W and Y;

X1008 is an amino acid selected from the group consisting of F, H, K, W and Y;

X1009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V;

X1010 is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y;

X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg;

X1012 is Y;

X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y;

X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X1015 is an amino acid selected from the group consisting of (omega-methyl)-R, D, E, K and R;

X1016 is L;

X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

X1019 is an amino acid selected from the group consisting of Bhk, K, R and V; and

X1020 is either present or absent, whereby, in case X1020 is present, it is an amino acid selected from the group consisting of Aib, BhI, C, F, G, H, I, K, L, Nml, Q, R, S, T, V, W and Y.

[0011] In one aspect, the peptide that binds TFPI comprises the structure of formula (III): X1001-Q-X1003-X1004-X1005-X1006-I/V-X1008-V-X1010-G-Y-C/F-X1014-R-L-X1017-X1018-K-K/L (III) (SEQ ID NO: 3117). In formula (III), X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 are each independently selected from any amino acid.

[0012] The invention further provides a TFPI-binding peptide comprising the structure of formula (V): X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118). In formula (V), X2001, X2002, and X2023 independently are either present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W; and X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W. Additionally,

X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;

X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;

X2005 is W;

X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R V and W;

X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;

X2008 is an amino acid selected from the group consisting of A, G, R, S and T;

X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, and V;

X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

X2011 is an amino acid selected from the group consisting of D, E, G, S and T;

X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, T, t, V, v, W and w;

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;

X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;

X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, T, V, W and Y;

X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

X2018 is an amino acid selected from the group consisting of C and D (preferably X2018 is C);

X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;

X2020 is an amino acid selected from the group consisting of F and W;

X2021 is an amino acid selected from the group consisting of I, L and V; and

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W.

When X2023 is present in the peptide, X2023 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y. The peptide comprises a cyclic structure generated by a linkage between X2007 and X2018, indicated in Formula (V) by brackets.

[0013] The invention also provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (VI): X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V-X2010-D-X2012-X2013-G-I/T-X2016-S/T-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119). In formula (VI), X2001, X2002 and X2023 are each independently present or absent.

X2008, X2010, X2012, X2013, X2016 and X2022, as well as X2001, X2002, and X2023 when present, are each independently selected from any amino acid. The peptide comprises a cyclic structure generated by a linkage between X2007 and X2018, indicated in Formula (VI) by brackets.

[0014] In one aspect, the invention provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (VIII): X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In formula (VIII), X3001 and X3002 are each independently present or absent. When present, X3001 is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y; and X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L. With respect to the remainder of formula (VIII),

X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;

X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

X3015 is an amino acid selected from the group consisting of A, K and R;

X3016 is an amino acid selected from the group consisting of A, F, K and R;

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P; and

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G.

[0015] Additionally, the invention provides a TFPI-binding peptide comprising the structure of formula (IX): X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H-X3013-X3014-K/R-R-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121), wherein X3001, X3002, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. In addition, the invention includes a peptide that binds TFPI, wherein the peptide comprises an amino acid sequence having at least 60% identity to the sequence of formula (X): Ac-GYASFPWFVQLHVHKRSWEMA-NH₂ (SEQ ID NO: 223). In the context of the disclosure, any peptide encompassed by any of formulas (I) to (X) and any TFPI-binding peptide described herein is also referred to as “the peptide of the invention” and as “a peptide as described herein.”

[0016] In some embodiments, the peptide of the invention binds TFPI-1 (e.g., TFPI-1 α) and, optionally, improves TFPI-regulated thrombin generation in the absence of FVIII, FIX, and/or FXI. A composition (e.g., a pharmaceutical composition) comprising the peptide also is provided.

[0017] In addition, the invention provides methods of using the peptide of the invention. For example, the invention provides a method of inhibiting a TFPI comprising contacting the TFPI with a peptide as described herein. The invention also provides a method of enhancing thrombin formation in a clotting factor-deficient subject, a method for increasing blood clot formation in a subject, and a method of treating a blood coagulation disorder in a subject. The methods are, in their entirety, also referred to herein as, e.g., “the method of the invention.” The methods comprise administering to the subject a peptide as provided herein in an amount effective to enhance thrombin formation, an amount effective to enhance blood clot formation, or an amount effective to treat the blood coagulation disorder in the subject. Unless explicitly indicated to the contrary, the description provided herein with respect to one peptide of the invention or method of the invention applies to each and every peptide of the invention and method of the invention, respectively. Further aspects of the invention include use of the peptide of the invention for the manufacture of a medicament, a method for targeting a cell displaying TFPI, a method for treating or diagnosing a subject suffering from a disease or at risk of suffering from a disease, and a method of purifying TFPI. The preceding methods are, in their entirety, also referred to herein as, e.g., “the method of the invention.”

DESCRIPTION OF THE FIGURES

[0018] Figure 1 is an illustration of the blood coagulation cascade.

[0019] Figure 2 is an illustration of the secondary structure of Tissue Factor Pathway Inhibitor-1.

[0020] Figure 3 is an illustration of the formation of a quaternary complex comprising Tissue Factor, Factor Xa (FXa), Factor VIIa (FVIIa), and TFPI.

[0021] Figure 4 is a listing of amino acid sequences of various TFPI-inhibitory peptides denoting amino acid substitutions (bolded and underlined) in reference to peptide JBT0293.

[0022] Figure 5 is an illustration of mRNA display selection of TFPI-inhibitor peptides.

[0023] Figure 6A is an illustration of the EC₅₀ binding ELISA and Figure 6B is an illustration of the IC₅₀ ELISA described in Example 1.

[0024] Figure 7 is a binding ELISA curve comparing % OD (y-axis) and concentration [nM] (x-axis) for biotinylated peptide JBT0132.

[0025] Figures 8A-8D are competition ELISA curves comparing % OD (y-axis) and concentration [nM] (x-axis) for exemplary peptides of the invention.

[0026] Figures 9A and 9B are sensorgrams plotting RU (y-axis) against time in seconds (x-axis) for peptides JBT0120 and JBT0132.

[0027] Figures 10A and 10B are sensorgrams plotting RU (y-axis) against time in seconds (x-axis) for peptide JBT0120 interaction with Tissue Factor Pathway Inhibitor-1 and Tissue Factor Pathway Inhibitor-2.

[0028] Figures 11A and 11B are graphs comparing amount of thrombin generated (nM) (y-axis) and time in minutes (x-axis) for peptide JBT0120 and peptide JBT0132 in a plasma-based assay.

[0029] Figures 12-18 are tables listing the amino acid sequences of various TFPI-inhibitory peptides; EC₅₀ and percent inhibition of TFPI observed in the FXa inhibition assay; EC₅₀ and percent inhibition of TFPI observed in the extrinsic tenase inhibition assay; and FEIBA, Factor VIII (FVIII) Immunate, or Factor IX (FIX) equivalent activities (mU/mL) in plasma-based assays. “*” denotes negative controls.

[0030] Figures 19-21 are tables listing the results from BIAcore analysis of several TFPI-binding peptides. “*” denotes negative controls.

[0031] Figures 22-30 are tables listing the amino acid sequences of various TFPI-binding peptides; EC₅₀ and percent inhibition of TFPI observed in the FXa inhibition assay; EC₅₀ and percent inhibition of TFPI observed in the extrinsic tenase inhibition assay; and FEIBA, FVIII Immunate, or FIX equivalent activities (mU/mL) in plasma-based assays. “*” denotes negative controls.

[0032] Figure 31 is a graph comparing a pharmacokinetic characteristic (concentration of peptide (y-axis) versus time after administration (x-axis)) of a PEGylated TFPI-binding peptide to the pharmacokinetic characteristic of same peptide lacking PEG. The peptides were administered intravenously to C57Bl6 mice at a dose of 10 mg/kg. Three biological samples were analyzed for the presence of peptide at each time point.

[0033] Figures 32-39 are tables listing the amino acid sequences and IC₅₀ or EC₅₀ values of various peptides of the invention. “*” denotes negative controls.

DETAILED DESCRIPTION OF THE INVENTION

[0034] The invention provides peptides that block the inhibitory activity of Tissue Factor Pathway Inhibitor-1 (herein referred to as TFPI) within the blood coagulation cascade. Upon vascular injury, Tissue Factor (TF) complexes with Factor VIIa to form the “extrinsic complex” or “extrinsic tenase complex,” which activates Factors IX and X (Figure 1). TFPI is the main natural regulator of TF/FVIIa extrinsic complex activity and by extension, plays a role in controlling thrombin generation (Panteleev et al., *Eur. J. Biochem.*, 249, 2016-2031 (2002)). TFPI is a 43 kDa serine protease inhibitor comprising three Kunitz-type inhibitory domains (Figure 2). Kunitz domain 1 of TFPI binds FVIIa and Kunitz domain 2 binds FXa, enabling the inhibitor to form a quaternary FXa-TFPI-FVIIa-TF complex that blocks activity of the TF/FVIIa extrinsic complex (Figure 3). TFPI binding of FXa also downregulates the common pathway of the coagulation cascade, during which FXa converts prothrombin to thrombin (Audu et al., *Anesth. Analg.*, 103(4), 841-845 (2006)). The invention provides, e.g., TFPI-inhibitory peptides that block TFPI’s inhibitory action on the blood coagulation cascade, thereby enhancing thrombin formation.

[0035] The amino acid sequences of several TFPI-binding peptides are provided herein. Conventional amino acids are identified according to their standard, one-letter or three-letter codes, as set forth in Table 1.





TABLE 1









3-letter codes	1-letter code	Amino acids	3-letter codes	1-letter code	Amino acids
Ala	A	Alanine	Met	M	Methionine
Cys	C	Cysteine	Asn	N	Asparagine
Asp	D	Aspartic acid	Pro	P	Proline
Glu	E	Glutamic acid	Gln	Q	Glutamine
Phe	F	Phenylalanine	Arg	R	Arginine
Gly	G	Glycine	Ser	S	Serine









His	H	Histidine	Thr	T	Threonine
Ile	I	Isoleucine	Val	V	Valine
Lys	K	Lysine	Trp	W	Tryptophan
Leu	L	Leucine	Tyr	Y	Tyrosine








[0036] Non-conventional amino acids and additional peptide building blocks are identified according to a three-letter code (with the exception of Ttds, which is a common four-letter abbreviation) found in Table 2.









TABLE 2









Name	Abbreviation	Structure
2-aminobutyric acid	Abu	
2-Amino-isobutyric acid	Aib	
β-Alanine	Bal	
β-Homoglutamatic acid	Bhe	






Name	Abbreviation	Structure
β -Homophenylalanine	Bhf	
β -Homolysine	Bhk	
β -Homoleucine	Bhl	
β -Homoasparagine	Bhn	
β -Homoglutamine	Bhq	
β -Homoarginine	Bhr	
β -Homoserine	Bhs	
β -Homotyrosine	Bhy	

Name	Abbreviation	Structure
β -Homoaspartic acid	Bhd	
β -Homovaline	Bhv, Btl	
β -Homoasparagin	Bhn, Btq	
(S)-Cyclohexylalanine	Cha	
(S)-Citrullin	Cit	
(S)-2,4-Diaminobutyric acid	Dab	
(S)-Diaminopropionic acid	Dap	
(S)-2-Propargylglycine	Eag	

Name	Abbreviation	Structure
(S)-N(omega)-nitro-arginine	Eew	
L-homophenylalanine	Hfe	
(S)-Homo-arginine	Har	
(S)-Homo-citrulline	Hci	
(S)-Homo-cysteine	Hcy	
(S)-2-Amino-5-methyl-hexanoic acid	Hle	
(S)-Homo-lysine	Hly	

Name	Abbreviation	Structure
(S)-Norleucine	Nle	
(S)-N-Methylalanine	Nma	
(S)-N-Methyl-Aspartic acid	Nmd	
(S)-N-Methyl-glutamic acid	Nme	
(S)-N-Methyl-phenylalanine	Nmf	
N-Methyl-glycine	Nmg	
(S)-N-Methyl-lysine	Nmk	
(S)-N-Methyl-leucine	Nml	

Name	Abbreviation	Structure
(S)-N-Methyl-arginine	Nmr	
(S)-N-Methyl-serine	Nms	
(S)-N-Methyl-valine	Nmv	
(S)-N-Methyl-tyrosine	Nmy	
(S)-2-Amino-pentanoic acid	Nva	
(S)-2-Pyridyl-alanine	Opa	
(S)-Ornithine	Orn	
L-phenylglycin	Phg	

Name	Abbreviation	Structure
4-Phenyl-butyric acid	PhPrCO	
Polyethylene glycol	PEG	
Selenomethionine	Sem	
1,2,3,4-L-tetrahydroisoquinolinecarboxylic acid	Tic	
(13-Amino-4,7,10-trioxa-tridecyl)-succinamic acid	Ttds	
Carboxyfluorescein	FAM	

[0037] The amino acid sequences of the peptides provided herein are depicted in typical peptide sequence format, as would be understood by the ordinary skilled artisan. For example, the three-letter code or one-letter code of a conventional amino acid, or the three-letter code or abbreviation for a non-conventional amino acid, indicates the presence of the amino acid in a specified position within the peptide sequence. The code for each non-

conventional amino acid is connected to the code for the next and/or previous amino acid in the sequence by a hyphen. Adjacent amino acids are connected by a chemical bond (typically an amide bond). The formation of the chemical bond removes a hydroxyl group from the 1-carboxyl group of the amino acid when it is located to the left of the adjacent amino acid (e.g., Hle-adjacent amino acid), and removes a hydrogen from the amino group of the amino acid when it is located on the right of the adjacent amino acid (e.g., adjacent amino acid-Hle). It is understood that both modifications can apply to the same amino acid and apply to adjacent conventional amino acids present in amino acid sequences without hyphens explicitly illustrated. Where an amino acid contains more than one amino and/or carboxy group in the amino acid side chain, the 2- or 3-amino group and/or the 1-carboxy group generally are used for the formation of peptide bonds. For non-conventional amino acids, a 3-letter code was used where the first letter indicates the stereochemistry of the C- α -atom. For example, a capital first letter indicates that the L-form of the amino acid is present in the peptide sequence, while a lower case first letter indicating that the D-form of the correspondent amino acid is present in the peptide sequence. When one-letter code is used, a lower case letter represents a D-amino acid, while an upper case letter represents an L-amino acid. Unless indicated to the contrary, the amino acid sequences are presented herein in N- to C-terminus direction.

[0038] The C-termini of several TFPI-binding peptide sequences described herein are explicitly illustrated by inclusion of an OH, NH₂, or an abbreviation for a specific terminating amine linked to the C-terminal amino acid code via a hyphen. The N-termini of several peptides described herein are explicitly illustrated by inclusion of a hydrogen (for a free N-terminus), or an abbreviation for a specific terminating carboxylic acid or other chemical group linked to the N-terminal amino acid code via a hyphen.

[0039] The invention provides a peptide comprising the amino acid sequence X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉X₂₀X₂₁ (SEQ ID NO: 3109), wherein (using single letter codes for amino acids)

X₇ is selected from the group consisting of L, P, K, S, W, V, N, and Q;

X₈ is selected from the group consisting of L, R, N, F, and I;

X₉ is selected from the group consisting of Y, V, P, and C;

X₁₀ is selected from the group consisting of F, L, and G;

X₁₁ is selected from the group consisting of L, W, V, A, M, T, and S;

X₁₂ is selected from the group consisting of T, F, V, R, A, D, L, E, S, and Y;

X₁₃ is selected from the group consisting of I, M, G, Q, D, and R;

X₁₄ is selected from the group consisting of G, W, Y, L, M, and H;

X₁₅ is selected from the group consisting of N, P, F, H, K, and Y;

X₁₆ is selected from the group consisting of M, D, E, V, G, and K;

X₁₇ is selected from the group consisting of G, I, R, S, T, and L;

X₁₈ is selected from the group consisting of M, K, L, and I;

X₁₉ is selected from the group consisting of Y, G, R, and S;

X₂₀ is selected from the group consisting of A, E, S, C, and Y; and

X₂₁ is selected from the group consisting of A, V, K, and E.

[0040] In addition to the core structure set forth above, X₇-X₂₁, other structures that are specifically contemplated are those in which one or more additional amino acids are attached to the core structure (e.g., linked to the N-terminus or the C-terminus of the amino acid sequence X₇-X₂₁). Thus, the invention includes peptides comprising the core structure and further comprising one or more N-terminal amino acid(s) comprising an amino acid sequence selected from the group consisting of:

X₆,

X₅X₆,

X₄X₅X₆,

X₃X₄X₅X₆ (SEQ ID NO: 3110),

X₂X₃X₄X₅X₆ (SEQ ID NO: 3111), and

X₁X₂X₃X₄X₅X₆ (SEQ ID NO: 3112);

wherein X₆ is directly linked to X₇ of the core structure amino acid sequence, and

X₁ is selected from the group consisting of T and G;

X₂ is selected from the group consisting of F and V;

X₃ is selected from the group consisting of V, W, Y, and F;

X₄ is selected from the group consisting of D, Q, and S;

X₅ is selected from the group consisting of E, T, N, and S; and

X₆ is selected from the group consisting of R, H, K, and A.

The peptide of the invention in one aspect comprises or consists of the amino acid sequence QSKKNVFVFGYFERLRAK (SEQ ID NO: 1).

[0041] In another embodiment, the peptide of the invention comprising the core structure comprises one or more C-terminal amino acid(s) comprising an amino acid sequence selected from the group consisting of:

X₂₂,

X₂₂X₂₃,

X₂₂X₂₃X₂₄,
 X₂₂X₂₃X₂₄X₂₅ (SEQ ID NO: 3113),
 X₂₂X₂₃X₂₄X₂₅X₂₆ (SEQ ID NO: 3114), and
 X₂₂X₂₃X₂₄X₂₅X₂₆X₂₇ (SEQ ID NO: 3115),

wherein X₂₂ is directly linked to X₂₁ of the core structure amino acid sequence, and

X₂₂ is selected from the group consisting of Q, I, E, W, R, L, and N;
 X₂₃ is selected from the group consisting of L, V, M, and R;
 X₂₄ is selected from the group consisting of K, L, A, and Y;
 X₂₅ is F;
 X₂₆ is G; and
 X₂₇ is T.

[0042] In one aspect, the peptide of the invention comprises or consists of the amino acid sequence VIVFTFRHNKLIGYERRY (SEQ ID NO: 4). It is also contemplated that the peptide of the invention comprises additional amino acids at both the N-terminus and the C-terminus of the core structure. In this aspect, the peptide comprises or consists of the amino acid sequence TFVDERLLYFLTIGNMGMYYAAQLKF (SEQ ID NO: 3), GVWQTHPRYFWTMWPDIKGEVIVLFGT (SEQ ID NO: 5), KWFCGMRDMKGTMSCVWVKF (SEQ ID NO: 6), or ASFPLAVQLHVSKRSKEMA (SEQ ID NO: 7).

[0043] The invention further includes peptides comprising the amino acid sequence X₃X₄X₅-F-X₇-NVF-X₁₁X₁₂-GY-X₁₅X₁₆-RLRAK-X₂₂ (SEQ ID NO: 2), wherein X₃ is Y or F; X₄ is Q or S; X₅ is N or S; X₇ is K, N, or Q; X₁₁ is V, A, S, or T; X₁₂ is F, A, D, L, Q, S, or Y; X₁₅ is F, K, or Y; X₁₆ is E or D; and X₂₂ is L or N.

[0044] In addition, the invention provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (I): X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019-X1020 (SEQ ID NO: 3116). In formula (I),

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

X1002 is an amino acid selected from the group consisting of G, K and Q;

X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X1004 is an amino acid selected from the group consisting of, A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y;

X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y;

X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S T, V, W and Y;

X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L, Nmv, P, Q, S, V, W and Y;

X1008 is an amino acid selected from the group consisting of F, H, K, W and Y;

X1009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V;

X1010 is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y;

X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg;

X1012 is Y;

X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y;

X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X1015 is an amino acid selected from the group consisting of (omega-methyl)-R, D, E, K and R;

X1016 is L;

X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y; and

X1019 is an amino acid selected from the group consisting of Bhk, K, R and V.

X1020 is either present or absent in formula (I) (i.e., in some instances, the peptide of the invention comprises the structure X1001-X1002-X1003-X1004-X1005-X1006-X1007-

X1008-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019 (SEQ ID NO: 3116)). When X1020 is present, it is an amino acid selected from the group consisting of Aib, Bhl, C, F, G, H, I, K, L, Nml, Q, R, S, T, V, W and Y.

[0045] For example, the peptide of the invention comprises the structure of formula (I) wherein X1001 is an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M, W and Y; X1002 is Q; X1003 is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V; X1004 is an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y; X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y; X1006 is an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y; X1007 is an amino acid selected from the group consisting of I, K, L, Q, V and Y; X1008 is an amino acid selected from the group consisting of F, H and Y; X1009 is an amino acid selected from the group consisting of f, I and V; X1010 is an amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y; X1011 is an amino acid selected from the group consisting of G and Nmg; X1012 is Y; X1013 is an amino acid selected from the group consisting of Aib, C, F, H, L, W and Y; X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y; X1015 is an amino acid selected from the group consisting of E and R; X1016 is L; X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, R, S, T, V and Y; X1018 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W; X1019 is an amino acid selected from the group consisting of K and R; and X1020 is an amino acid selected from the group consisting of Aib, Bhl, F, K, L, R and W (when X1020 is present in the peptide).

[0046] In one aspect, the peptide of the invention comprises the structure of formula (I) wherein X1001 is an amino acid selected from the group consisting of F, L, Y and M; X1002 is Q; X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C; X1004 is an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W; X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M; X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M; X1007 is an amino acid selected from the group consisting of I and V; X1008 is an amino acid selected from the group consisting of F, H and Y; X1009 is V; X1010 is an amino acid selected from the group consisting of A, D, E, K, M,

N, Q, R, F, H, P, S, V, W and Y; X1011 is G; X1012 is Y; X1013 is C or F; X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib; X1015 is R; X1016 is L; X1017 is an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M; X1018 is an amino acid selected from the group consisting of A, L, N, M and R; X1019 is K; and X1020 is K or L.

[0047] When amino acid X1020 is absent from formula (I), the peptide of the invention in one aspect further comprises amino acid X1000 at the N-terminus of formula (I), such that the peptide comprises or consists of the structure of formula (II): X1000-X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019 (II) (SEQ ID NO: 3122). When X1000 is present in the peptide, X1000 is an amino acid selected from the group consisting of A, E, and P, while the amino acids of X1001-X1019 are as defined above.

[0048] In an additional aspect, the TFPI-binding peptide of the invention comprises the structure of formula (III): X1001-Q-X1003-X1004-X1005-X1006-I/V-X1008-V-X1010-G-Y-C/F-X1014-R-L-X1017-X1018-K-K/L (III) (SEQ ID NO: 3117). X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 in formula (III) are each independently selected from any amino acid. For example, in formula (III),

X1001 is optionally an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y, such as an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M, W and Y (e.g., an amino acid selected from the group consisting of F, L, Y and M);

X1003 is optionally an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V (e.g., the amino acid is M, Q, R, S, T or C);

X1004 is optionally an amino acid selected from the group consisting of, A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y (e.g., an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W);

X1005 is optionally an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y, such as an amino

acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y (e.g., the amino acid is a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C or M);

X1006 is optionally an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y (e.g., an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M);

X1008 is optionally an amino acid selected from the group consisting of F, H, K, W and Y, such as an amino acid selected from the group consisting of F, H and Y;

X1010 is optionally an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y (e.g., an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y);

X1014 is optionally an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y (e.g., A, C, D, E, K, L, M, N, Q, R, T, V or Aib);

X1017 is optionally an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, R, S, T, V and Y (e.g., an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M); and/or

X1018 is optionally an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W (e.g., an amino acid selected from the group consisting of A, L, N, M and R).

[0049] In some embodiments, the peptide of the invention comprises one or more additional amino acid residues attached to the N- or C-terminus of the amino acid sequence. For example, the peptide comprising the structure of any one of formulas (I)-(III), in some embodiments, further comprises one or more N-terminal amino acid(s) directly linked to

X1001, wherein the N-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of

X1000,

X999-X1000,

X998-X999-X1000,

X997-X998-X999-X1000 (SEQ ID NO: 3123),

X996-X997-X998-X999-X1000 (SEQ ID NO: 3124),

X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125),

X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3126),

X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127),

X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3128),

X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3129),

and

X990-X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3130).

When the peptide comprises one or more N-terminal amino acids, X1000 is A or K; X999 is V or K; X998 is Q or K; X997 is L or K; X996 is R or K; X995 is G or K; X994 is V or K; X993 is G or K; X992 is S or K; X991 is K; and X990 is K.

[0050] In addition to the core structures set forth in formulas (I)-(III), other structures that are specifically contemplated are those in which one or more additional amino acids are attached to the C-terminus of the core structure directly linked to X1020. For example, the C-terminal addition optionally comprises an amino acid sequence selected from the group consisting of X1021, X1021-X1022, X1021-X1022-X1023, and X1021-X1022-X1023-X1024 (SEQ ID NO: 3131), wherein X1021 is T or K; X1022 is S or K; and X1023 and X1024 are K.

[0051] The invention further includes a TFPI-binding peptide comprising or consisting of an amino acid sequence having at least 60% identity (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95 % or 100% identity) to the amino acid sequence Ac-FQSK-Nmg-NVFVDGYFERL-Aib-AKL-NH₂ (formula IV) (SEQ ID NO: 164). In some instances, the peptide comprises or consists of the amino acid sequence of any one of formulas (I)-(III), as described herein. The invention also includes a peptide

comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-978 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 8-741 and 962-972 (such as SEQ ID NOs: 8-741, 962-968, 971, or 972) and/or selected from the group consisting of 742-961 (such as SEQ ID NOs: 744-961) and/or selected from the group consisting of SEQ ID NOs: 973-978).

[0052] The peptides of the invention, in some instances, comprise intramolecular disulfide bonds. In this regard, the peptide comprising the structure of formulas (I)-(III) contains at least two cysteine residues (e.g., the peptide contains two cysteine residues) that are spaced apart by at least three amino acid residues such that the cysteines form an intramolecular disulfide bond. In some instances, the cysteines are spaced apart by more than three amino acid residues. For example, in the peptide comprising the structure of formulas (I), (II), or (III), any two of X1000, X1001, X1003, X1004, X1005, X1006, X1010, X1011, X1013, X1014, X1017, X1018, X1020 and X1021 are optionally cysteines capable of forming a disulfide bridge. Accordingly, in some aspects, the peptide contains two cysteine residues: one of X1000, X1005, X1010 and X1014 is cysteine, and one of X1006, X1010, X1017 and X1021 is a cysteine. The invention contemplates all of the possible combinations of cysteine pairs, e.g., X1000 and X1006 are C; X1000 and X1010 are C; X1000 and X1017 are C; X1005 and X1017 are C; X1010 and X1017 are C; X1010 and X1021 are C; or X1014 and X1021 are C.

[0053] The invention further provides a peptide that binds TFPI, the peptide comprising the structure of formula (V): X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118), wherein the peptide forms a cyclic structure generated by a linkage, e.g., a disulfide bond, between X2007 and X2018 (denoted as brackets within formula (V)). In formula (V), X2001, X2002, and X2023 are independently either present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W; X2002 an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W; and X2023 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y. In addition,

X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;

X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;

X2005 is W;

X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;

X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K (e.g., C or Hcy);

X2008 is an amino acid selected from the group consisting of A, G, R, S and T;

X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem, and V;

X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;

X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;

X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;

X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;

X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

X2018 is an amino acid selected from the group consisting of C and D (e.g., X2018 is C);

X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;

X2020 is an amino acid selected from the group consisting of F and W;

X2021 is an amino acid selected from the group consisting of I, L and V; and

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W.

[0054] In some instances, in the peptide of the invention comprising the structure of formula (V),

X2001 is optionally an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L and S (when X2001 is present).;

X2002 is optionally an amino acid selected from the group consisting of A, D, F, G, H, K, L, P, R and S, such as an amino acid selected from the group consisting of A, F, H, K, L, M, R and S (e.g., H, F, M or R) (when X2002 is present);

X2003 is optionally an amino acid selected from the group consisting of A, F, K, L, S and Y, such as an amino acid selected from the group consisting of F, S and Y (e.g., F or Y);

X2004 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L and S (e.g., K);

X2005 is optionally W;

X2006 is optionally an amino acid selected from the group consisting of F, H, K and L (e.g., F or H);

X2007 is optionally an amino acid selected from the group consisting of C and HcY (e.g., X2007 is C);

X2008 is optionally an amino acid selected from the group consisting of A, G and S;

X2009 is optionally an amino acid selected from the group consisting of a, A, K, L, V, M, m, Nle, Sem, and p, such as an amino acid selected from the group consisting of M, Nle, p and V (e.g., M, Sem, or V);

X2010 is optionally an amino acid selected from the group consisting of A, G, K, L, P, R and S, such as an amino acid selected from the group consisting of A, K, L, P, R and S (e.g., K, P, or R);

X2011 is optionally an amino acid selected from the group consisting of D, G and S (e.g., D or S);

X2012 is optionally an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, l, M, m, Nle, P, S and s, such as an amino acid selected from the group

consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, S, and Sem (e.g., an amino acid selected from the group consisting of F, L, l, Sem, and M);

X2013 is optionally an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s, such as an amino acid selected from the group consisting of A, D, F, G, K, L and S (e.g., D, G, K, or S);

X2014 is optionally an amino acid selected from the group consisting of D, F, G, K, L and S (e.g., D or G);

X2015 is optionally an amino acid selected from the group consisting of A, D, F, G, I, K, L, M, Nle, S and T (e.g., I or T);

X2016 is optionally an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, and Y, such as an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem, and Y (e.g., D, F, M, Sem, or Y);

X2017 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, S, T and Y (e.g., S or T);

X2018 is optionally C;

X2019 is optionally an amino acid selected from the group consisting of A, F, L, S and V (e.g., A or V);

X2020 is optionally an amino acid selected from the group consisting of F and W (e.g., W);

X2021 is optionally an amino acid selected from the group consisting of L and V (e.g., V);

X2022 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W, such as an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W (e.g., an amino acid selected from the group consisting of F, L, K, R, P and W); and

X2023 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y, such as an amino acid selected from the group consisting of A, D, F, G, L, M, S and Y (e.g., an amino acid sequence selected from the group consisting of A, D, F, M, S and Y) (when X2023 is present).

[0055] The invention further includes a peptide that binds TFPI, wherein the peptide comprises the structure of formula (VI): X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V-

X2010-D-X2012-X2013-G-I/T-X2016-S/T-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119). In the peptide comprising the structure of formula (VI), X2001, X2002 and X2023 are each independently present or absent. If X2001, X2002, and/or X2023 are present, any of X2001, X2002 and X2023 is independently selected from any amino acid. In addition, X2008, X2010, X2012, X2013, X2016, and X2022 are each independently selected from any amino acid.

[0056] In some aspects, in the peptide of formula (VI),

X2001 is optionally an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S (e.g., an amino acid selected from the group consisting of A, D, F, G, H, K, L and S) (when X2001 is present);

X2002 is optionally an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L, M, P, R and S (e.g., an amino acid selected from the group consisting of A, F, H, K, L, M, R and S, such as H, F, M, or R) (when X2002 is present);

X2008 is optionally an amino acid selected from the group consisting of A, G, R, S and T, such as an amino acid selected from the group consisting of A, G and S;

X2010 is optionally an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V, such as an amino acid selected from the group consisting of A, G, K, L, P, R and S (e.g., an amino acid selected from the group consisting of A, K, L, P, R and S, such as K, P or R);

X2012 is optionally an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w, such as an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, l, M, m, Nle, P, S, s, and Sem (e.g., an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, S, and Sem, such as F, L, l, Sem, or M);

X2013 is optionally an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W, such as an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s (e.g., an amino acid selected from the group consisting of A, D, F, G, K, L and S, such as D, G, K or S);

X2016 is optionally an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y, such as an amino acid selected from the group

consisting of D, F, K, L, M, Nle, S, Sem, and Y (e.g., an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem, such as F, Sem, or M);

X2022 is optionally an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W, such as an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W (e.g., an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W, such as F, L, K, R, P or W); and/or

X2023 is optionally an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, M, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y (e.g., an amino acid selected from the group consisting of A, D, F, G, L, M, S and Y, such as A, D, F, M, S or Y) (when X2023 is present).

[0057] The TFPI-binding peptide of the invention, in one aspect, comprises an amino acid sequence having at least 60% identity (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% identity) to the sequence of formula VII: Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH₂ (VII) (SEQ ID NO: 1040). Optionally, the peptide comprises or consists of the amino acid sequence of formula (V)-(VII) as defined herein. The invention also includes a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1293 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1212 and 1290-1291 (such as SEQ ID NOs: 1001-120, 1290, or 1291) and/or selected from the group consisting of SEQ ID NOs: 1213-1289 and/or selected from the group consisting of 1292 and 1293).

[0058] The invention further provides a TFPI-binding peptide comprising the structure of formula (VIII): X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In formula (VIII), X3001 and X3002 are independently either present or absent in the peptide. If present, X3001 is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y; and X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L. In addition,

X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;

X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

X3015 is an amino acid selected from the group consisting of A, K and R;

X3016 is an amino acid selected from the group consisting of A, F, K and R;

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P; and

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G.

[0059] In some aspects of the invention, the peptide comprises the sequence of formula (VIII), wherein

X3001 is optionally an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y, such as an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y (when X3001 is present);

X3002 is optionally an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L, such as an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L (when X3002 is present);

X3003 is optionally an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W, such as an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W;

X3004 is optionally an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P, such as an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, N, R, S, T and P;

X3005 is optionally an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y, such as an amino acid selected from the group consisting of C, F, H, K, R and W;

X3006 is optionally an amino acid selected from the group consisting of P, H and A;

X3007 is optionally an amino acid selected from the group consisting of C, G, R, W, A and L, such as an amino acid selected from the group consisting of L, C, R and W;

X3008 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I, such as an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I;

X3009 is optionally an amino acid selected from the group consisting of C, I, R, V and K, such as an amino acid selected from the group consisting of C, R, V and K;

X3010 is optionally an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R, S and T, such as an amino acid selected from the group consisting of A, C, K, L, Q, R and S;

X3011 is optionally an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H, such as an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H;

X3012 is optionally an amino acid selected from the group consisting of H and R (e.g., H);

X3013 is optionally an amino acid selected from the group consisting of C, F, K, L, M, R, V and I, such as an amino acid selected from the group consisting of C, K, R, V and I;

X3014 is optionally an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K, such as an amino acid selected from the group consisting of A, S, C, F, H, I, R and K;

X3015 is optionally K or R;

X3016 is optionally K or R;

X3017 is optionally an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M, such as an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M;

X3018 is optionally an amino acid selected from the group consisting of A, K, C, I, L, R and W (e.g., K, C, I, R, or W);

X3019 is optionally an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I, such as an amino acid selected from the group consisting of C, E, H, K, R and I;

X3020 is optionally an amino acid selected from the group consisting of C, H, L, M, R, V, I and P (e.g., C, M, I, or P); and

X3021 is optionally an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, Y, F and G, such as an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G.

[0060] The invention further provides a peptide that binds TFPI and comprises the structure of formula (IX): X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H-X3013-X3014-K/R-R-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121). In formula (IX), X3001 and X3002 are independently either present or absent in the peptide. If present, X3001 and/or X3002 are independently selected from any amino acid. Likewise, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. When present, X3001 is optionally an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y, such as an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S,

T, W, E, H and Y (e.g., an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y). Likewise, when present, X3002 is optionally an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L, such as an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L (e.g., an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L). Also with respect to formula (IX),

X3003 is optionally an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, and Y, such as an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W (e.g., an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W);

X3004 is optionally an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P, such as an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P (e.g., an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, N, R, S, T and P);

X3005 is optionally an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y (e.g., an amino acid selected from the group consisting of C, F, H, K, R and W);

X3006 is optionally an amino acid selected from the group consisting of A, W, C, K, P, R and H, such as an amino acid selected from the group consisting of P, H and A;

X3007 is optionally an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y, such as an amino acid selected from the group consisting of C, G, R, W, A and L (e.g., L, C, R or W);

X3008 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I, such as an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I (e.g., an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I);

X3009 is optionally an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K, such as an amino acid selected from the group consisting of C, I, R, V and K (e.g., C, R, V or K);

X3010 is optionally an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group

consisting of A, C, G, H, I, K, L, M, Q, R, S and T (e.g., an amino acid selected from the group consisting of A, C, K, L, Q, R and S);

X3011 is optionally an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H, such as an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H (e.g., an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H);

X3013 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I, such as an amino acid selected from the group consisting of C, F, K, L, M, R, V, and I (e.g., C, K, R, V, or I);

X3014 is optionally an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K, such as an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K (e.g., an amino acid selected from the group consisting of A, S, C, F, H, I, R and K);

X3017 is optionally an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M, such as an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M (e.g., an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M);

X3018 is optionally an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y, such as an amino acid selected from the group consisting of A, K, C, I, L, R and W (e.g., K, C, I, R, or W);

X3019 is optionally an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I, such as an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I (e.g., C, E, H, K, R, or I);

X3020 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P, such as an amino acid selected from the group consisting of C, H, L, M, R, V, I and P (e.g., C, M, I, or P); and/or

X3021 is optionally an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G, such as an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, Y, F and G (e.g., an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G).

[0061] The TFPI-binding peptide of the invention comprises, in some aspects, an amino acid sequence having at least 60% identity (e.g., at least 65%, at least 70%, at least 75%, at

least 80%, at least 85%, at least 90%, at least 95% or 100% identity) to the sequence of formula (X): Ac-GYASFPWFVQLHVHKRSWEMA-NH₂ (X) (SEQ ID NO: 223).

Optionally, the peptide comprises or consists of the amino acid sequence of formula (VIII)-(IX) as defined herein. As used herein, “at least 60% identity” and similar terms encompass any integer from, e.g., 60%, to 100%, such as 60%, 61%, 62%, and the like. Also, the term “at least [percentage] identity” encompasses any percentage that is greater than or equal to the number of identical amino acids divided by the total number of amino acids of the peptide of the invention ($[\text{at least percentage identity}] \geq [\text{number of identical amino acids}] / [\text{total number of amino acids of the peptide of the invention}]$).

[0062] The invention also includes a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2498 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2296 and 2498 (such as SEQ ID NOs: 2001-2126, 2128-2296, or 2498) and/or selected from the group consisting of SEQ ID NOs: 2297-2497 (such as SEQ ID NOs: 2298-2497)). The invention further provides a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3108 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3064 (such as SEQ ID NOs: 3001-3048, 3051-3053, 3055, or 3057-3064) and/or selected from the group consisting of SEQ ID NOs: 3065-3084 (such as SEQ ID NOs: 3066-3084) and/or selected from the group consisting of SEQ ID NOs: 3085-3108).

[0063] The peptide of SEQ ID NOs: 1-7 also, in some aspects, comprises one or more amino acids attached at the N- or C-terminus of SEQ ID NOs: 1-7. For example, the invention includes a peptide comprising or consisting of the amino acid sequence of JBT0047, JBT0051, JBT0055, JBT0131, JBT0132, JBT0133, JBT0155, JBT0158, JBT0162, JBT0163, JBT0164, JBT0166, JBT0169, JBT0170, JBT0171, JBT0174, JBT0175, or JBT0293, all of which comprise the amino acid sequence of SEQ ID NO: 1. Exemplary peptides comprising the amino acid sequence of SEQ ID NO: 2 include peptides comprising or consisting of the amino acid sequence of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBT0302, JBT0303, JBT0304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, or JBT0311. Exemplary peptides comprising the amino acid sequence of SEQ ID NO: 3 comprise or consist of the amino acid sequence of JBT0049, JBT0053, JBT0057, JBT0190, JBT0193, or JBT0197. The invention further includes a peptide comprising or consisting of the amino acid sequence of JBT0050, JBT0054, JBT0058, JBT0129, JBT0130, JBT0205, JBT0208, JBT0211, JBT0212, JBT0217,

JBT0218, or JBT0219, all of which include the amino acid sequence of SEQ ID NO: 4. Exemplary peptides comprising SEQ ID NO: 5 include those comprising or consisting of the amino acid sequence of JBT0101, JBT0052, JBT0103, JBT0178, or JBT0182. The invention additionally includes a peptide comprising or consisting of the amino acid sequence of JBT0120, JBT0124, JBT0247, JBT0248, JBT0251, or JBT0252, each of which include the amino acid sequence of SEQ ID NO: 6. A peptide including the amino acid sequence of SEQ ID NO: 7, e.g., a peptide comprising or consisting of the amino acid sequence of JBT0122, JBT0126, JBT0221, JBT0224, JBT0225, JBT0226, JBT0228, JBT0232, or JBT0233, also provided by the invention. The peptides described herein are set forth in Table 5 of Example 1 and in Figures 12-18.

[0064] In certain embodiments, the peptide of the invention comprises or consists of the amino acid sequence of JBT0047, JBT0049, JBT0101, JBT0120, or JBT0122 or any of the inventive peptides described herein (e.g., a peptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1-3108, such as a peptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 8-741, 744-968, 971-978, 1001-1210, 1213-1289, 1290-1293, 2001-2126, 2128-2296, 2298-2498, 3001-3048, 3051-3053, 3055, 3057-3064, and 3067-3108), or a variant of any of the foregoing. By “variant” is meant a peptide comprising one or more amino acid substitutions, amino acid deletions, or amino acid additions to a parent amino acid sequence. Variants include, but are not limited to, peptides having an amino acid sequence that is at least 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the amino acid sequences provided herein while retaining the ability to bind TFPI and/or inhibit TFPI activity. In one embodiment, the peptide comprises or consists of the amino acid sequence of JBT0132, JBT0303, JBT0193, JBT0178, JBT0120, or JBT0224.

[0065] In one aspect, the peptide of the invention consists of 40 amino acids or less, such as 35 amino acids or less. Optionally, the peptide of the invention consists of 25 amino acids or less, or 10 amino acids or less. In various embodiments, the peptide comprises 15-35 amino acid residues (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 amino acid residues). However, it is also contemplated that a peptide described herein comprising one or more deletions is suitable in the context of the invention so long as the peptide blocks TFPI inhibition of the coagulation cascade and, optionally, binds TFPI. In one aspect, the peptide comprising one or more deletions is suitable in the context of the invention so long as the peptide binds TFPI and, optionally, blocks TFPI inhibition of the

coagulation cascade. In some aspects, amino acids are removed from within the amino acid sequence, at the N-terminus, and/or at the C-terminus. Such peptide fragments can comprise 3-14 amino acid residues (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid residues).

[0066] Optionally, the peptide of the invention comprises one or more amino acid substitutions (with reference to any of the amino acid sequences provided herein) that do not destroy the ability of the peptide to bind and/or inhibit TFPI. For instance, peptides comprising or consisting of the amino acid sequence selected from the group consisting of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBT0302, JBT0303, JBT0304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, or JBT0311 are substitutional mutants of the amino acid sequence of JBT0293 (the amino acid sequence of SEQ ID NO: 1 directly linked to a phenylalanine residue at the N-terminus and a lysine residue at the C-terminus) (see Figure 4). Amino acid substitutions include, but are not limited to, those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinities, and/or (4) confer or modify other physiochemical or functional properties on a peptide. In one aspect, the substitution is a conservative substitution, wherein an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art, and include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), beta-branched side chains (e.g., threonine, valine, and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). It will be appreciated, however, that a practitioner is not limited to creating conservative substitutions so long as the resulting peptide retains the ability to downregulate, in whole or in part, TFPI activity. The invention also embraces TFPI-inhibitory peptides comprising atypical, non-naturally occurring amino acids, which are well known in the art. Exemplary non-naturally occurring amino acids include ornithine, citrulline, hydroxyproline, homoserine, phenylglycine, taurine, iodotyrosine, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, 2-amino butyric acid, γ -amino butyric acid, 2-amino isobutyric acid, 3-amino propionic acid, norleucine, norvaline, sarcosine, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, a fluoro-amino acid, a 3-methyl amino acid, α -C-methyl amino acid, a N-methyl amino acid, 2-amino-isobutyric acid, β -homoglutamic acid, β -homophenylalanine, β -homolysine, β -

homoleucine, β -homoasparagine, β -homoglutamine, β -homoarginine, β -homoserine, β -homotyrosine, β -homoaspartic acid, β -homovaline, β -homoasparagin, (S)-cyclohexylalanine, (S)-citrullin, (S)-2,4-diaminobutyric acid, (S)-2,4-diaminobutyric acid, (S)-diaminopropionic acid, (S)-2-propargylglycine, (S)-N(omega)-nitro-arginine, L-homophenylalanine, S)-homo-arginine, (S)-homo-citrulline, (S)-homo-cysteine, (S)-2-amino-5-methyl-hexanoic acid, (S)-homo-lysine, (S)-norleucine, (S)-*N*-methylalanine, (S)-*N*-methyl-aspartic acid, (S)-*N*-methyl-glutamic acid, (S)-*N*-methyl-phenylalanine, *N*-methyl-glycine, (S)-*N*-methyl-lysine, (S)-*N*-methyl-leucine, (S)-*N*-methyl-arginine, (S)-*N*-methyl-serine, (S)-*N*-methyl-valine, (S)-*N*-methyl-tyrosine, (S)-2-amino-pentanoic acid, (S)-2-pyridyl-alanine, (S)-ornithine, L-phenylglycin, 4-phenyl-butyric acid and selenomethionine. The individual amino acids may have either L or D stereochemistry when appropriate, although the L stereochemistry is typically employed for all of the amino acids in the peptide.

[0067] The invention further includes TFPI-inhibitory peptide variants comprising one or more amino acids inserted within an amino acid sequence provided herein and/or attached to the N-terminus or C-terminus. In one aspect, the peptide further comprises one or more amino acids that facilitate synthesis, handling, or use of the peptide, including, but not limited to, one or two lysines at the N-terminus and/or C-terminus to increase solubility of the peptide. Suitable fusion proteins include, but are not limited to, proteins comprising a TFPI-inhibitory peptide linked to one or more polypeptides, polypeptide fragments, or amino acids not generally recognized to be part of the protein sequence. In one aspect, a fusion peptide comprises the entire amino acid sequences of two or more peptides or, alternatively, comprises portions (fragments) of two or more peptides. In addition to all or part of the TFPI-inhibitory peptides described herein, a fusion protein optionally includes all or part of any suitable peptide comprising a desired biological activity/function. Indeed, in some aspects, a TFPI-inhibitory peptide is operably linked to, for instance, one or more of the following: a peptide with long circulating half life, a marker protein, a peptide that facilitates purification of the TFPI-inhibitory peptide, a peptide sequence that promotes formation of multimeric proteins, or a fragment of any of the foregoing. In one embodiment, two or more TFPI-inhibitory peptides are fused together, linked by a multimerization domain, or attached via chemical linkage to generate a TFPI-inhibitory peptide complex. The TFPI-inhibitor peptides may be the same or different.

[0068] “Derivatives” are included in the invention and include TFPI-inhibitory peptides that have been chemically modified in some manner distinct from addition, deletion, or substitution of amino acids. In this regard, a peptide of the invention provided herein is

chemically bonded with polymers, lipids, other organic moieties, and/or inorganic moieties. Examples of peptide and protein modifications are given in Hermanson, *Bioconjugate Techniques*, Academic Press, (1996). Derivatives are prepared in some situations to increase solubility, stability, absorption, or circulating half-life. Various chemical modifications eliminate or attenuate any undesirable side effect of the agent. In this regard, the invention includes TFPI-inhibitory peptides covalently modified to include one or more water soluble polymer attachments. Useful polymers known in the art include, but are not limited to, polyethylene glycol (PEG) (e.g., PEG approximately 40 kD or 1 kD in size), polyoxyethylene glycol, polypropylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures of any of the foregoing. In one aspect, the peptide of the invention is a PEGylated peptide. For further discussion of water soluble polymer attachments, see U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; and 4,179,337. In another aspect, a peptide derivative includes a targeting moiety specific for a particular cell type, tissue, and/or organ. Alternatively, the peptide is linked to one or more chemical moieties that facilitate purification, detection, multimerization, and characterization of peptide activity. An exemplary chemical moiety is biotin. In addition, in one aspect, the peptides of the invention are acylated at the N-terminal amino acid of the peptide. In another aspect, the peptides of the invention are amidated at the C-terminal amino acid of the peptide. In a still further aspect, the peptides of the invention are acylated at the N-terminal amino acid of the peptide and are amidated at the C-terminal amino acid of the peptide.

[0069] Derivatives also include peptides comprising modified or non-proteinogenic amino acids or a modified linker group (see, e.g., Grant, *Synthetic Peptides: A User's Guide*, Oxford University Press (1992)). Modified amino acids include, for example, amino acids wherein the amino and/or carboxyl group is replaced by another group. Non-limiting examples include modified amino acids incorporating thioamides, ureas, thioureas, acylhydrazides, esters, olefines, sulfonamides, phosphoric acid amides, ketones, alcohols, boronic acid amides, benzodiazepines and other aromatic or non-aromatic heterocycles (see Estiarte et al., *Burgers Medicinal Chemistry*, 6th edition, Volume 1, Part 4, John Wiley & Sons, New York (2002)). Modified amino acids are often connected to the peptide with at least one of the above mentioned functional groups instead of an amide bond. Non-proteinogenic amino acids include, but are not limited, to β -alanine (Bal), norvaline (Nva), norleucine (Nle), 4-aminobutyric acid (γ -Abu), 2-aminoisobutyric acid (Aib), 6-aminohexanoic acid (ϵ -Ahx),

ornithine (Orn), hydroxyproline (Hyp), taurine, sarcosine, citrulline (Cit), cysteic acid (Coh), cyclohexylalanine (Cha), methioninesulfoxide (Meo), methioninesulfone (Moo), homoserinemethylester (Hsm), propargylglycine (Eag), 5-fluorotryptophan (5Fw), 6-fluorotryptophan (6Fw), 3',4'-dimethoxyphenyl-alanine (Ear), 3',4'-difluorophenylalanine (Dff), 4'-fluorophenyl-alanine (Pff), 1-naphthyl-alanine (1Ni), 1-methyltryptophan (1Mw), penicillamine (Pen), homoserine (Hse), t-butylglycine, t-butylalanine, phenylglycine (Phg), benzothienylalanine (Bta), L-homo-cysteine (Hcy), N-methyl-phenylalanine (Nmf), 2-thienylalanine (Thi), 3,3-diphenylalanine (Ebw), homophenylalanine (Hfe) and S-benzyl-L-cysteine (Ece). These and other non-proteinogenic amino acids may exist as D- or L-isomers. Examples of modified linkers include, but are not limited to, the flexible linker 4,7,10-trioxa-1,13-tridecanediamine (Ttds), glycine, 6-aminohexanoic acid, beta-alanine (Bal), and combinations of Ttds, glycine, 6-aminohexanoic acid and Bal.

[0070] Homologues of the amino acids constituting the peptides of the invention may be as set forth in Table 3.

TABLE 3

Amino Acid	Exemplary homologues
A	Aib, Bal, Eag, Nma, Abu, G, M, Nva, Nle
C	S, A, Hcy, M, L, I, V, Nmc, β -Cysteine
D	E, Homoglutamic acid, γ -Hydroxy-glutamic acid, γ -Carboxy-glutamic acid, Nmd, β -Aspartic acid, N, Q, Cysteic acid
E	D, Glu, Homoglutamic acid, γ -Hydroxy-glutamic acid, γ -Carboxy-glutamic acid, α -Aminoadipic acid, Nme, β -glutamic acid, Q, N, Cysteic acid
F	Hfe, Nmf, β -Phenylalanine, Phg, Bhf, Thienylalanine, Benzothienylalanine, Bromophenylalanine, Iodophenylalanine, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, Y, W, Naphtylalanine, Tic
G	A, Nmg
H	Nmh, 1-Methylhistidine, 3-Methylhistidine, Thienylalanine
I	L, V, Hle, Nva, Nle, β -Isoleucine, Nml, M, Nmi

K	Nmk, R, Nmr, β -Lysine, Dab, Dap, β -(1-Piperazinyl)-alanine, 2,6-Diamino-4-hexynoic acid, delta-Hydroxy-lysine, Har, omega-Hydroxy-norarginine, omega-Amino-arginine, omega-Methyl-arginine, β -(2-Pyridyl)-alanine, β -(3-Pyridyl)-alanine, 3-Amino-tyrosine, 4-Amino-phenylalanine, Hci, Cit
L	I, V, Hle, Nle, Nva, β -Isoleucine, Nml, M
M	I, V, Hle, Nva, R, Har, Nmm, Methioninesulfone
N	Nmn, β -Asparagine, Q, NmQ, β -Glutamine, Cys(3-propionic acid amide)-OH, Cys(O2-3-propionic acid amide)-OH
P	Azetidine-2-carboxylic acid, Hyp, α -Methyl-methionine, 4-Hydroxy-piperidine-2-carboxylic acid, Pip, α -Methyl-Pro
Q	N, Nmn, NmQ, β -Glutamine, Cys(3-propionic acid amide)-OH, Cys(O2-3-propionic acid amide)-OH
R	Nmk, K, Nmr, β -Lysine, Dab, Dap, Orn, β -(1-Piperazinyl)-alanine, 2,6-Diamino-4-hexynoic acid, delta-Hydroxy-lysine, Har, omega-Hydroxy-norarginine, omega-Amino-arginine, omega-Methyl-arginine, β -(2-Pyridyl)-alanine, β -(3-Pyridyl)-alanine, 3-Amino-tyrosine, 4-Amino-phenylalanine, Hci, Cit, Hle, L, Nle, M
S	T, Hse, β -Serine, C, β -Cyano-alanine, allo-Threonine
T	S, Homothreonine, β -Threonine, allo-Threonine
V	L, I, Hle, Nva, Nle, β -Valine, Nmv, M, Nmi, Nml
W	Nmw, β -Tryptophan, F, Hfe, Nmf, β -Phenylalanine, Phg, Bhf, Thienylalanine, Benzothienylalanine, Bromophenylalanine, Iodophenylalanine, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, Y, Naphtylalanine, Tic
Y	Nmy, β -Tyrosine, , F, Hfe, Nmf, β -Phenylalanine, Phg, Bhf, Thienylalanine, Benzothienylalanine, Bromophenylalanine, Iodophenylalanine, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, W, Naphtylalanine, Tic

[0071] In some embodiments, the peptide (CO-NH) linkages joining amino acids within the peptide of the invention are reversed to create a “retro-modified” peptide, i.e., a peptide comprising amino acid residues assembled in the opposite direction (NH-CO bonds) compared to the reference peptide. The retro-modified peptide comprises the same amino acid chirality as the reference peptide. An “inverso-modified” peptide is a peptide of the invention comprising amino acid residues assembled in the same direction as a reference peptide, but the chirality of the amino acids is inverted. Thus, where the reference peptide comprises L-amino acids, the “inverso-modified” peptide comprises D-amino acids, and vice versa. Inverso-modified peptides comprise CO-NH peptide bonds. A “retro-inverso modified” peptide refers to a peptide comprising amino acid residues assembled in the opposite direction and which have inverted chirality. A retro-inverso analogue has reversed termini and reversed direction of peptide bonds (i.e., NH-CO), while approximately maintaining the side chain topology found in the reference peptide. Retro-inverso peptidomimetics are made using standard methods, including the methods described in Meziere et al, *J. Immunol.*, 159, 3230-3237 (1997), incorporated herein by reference. Partial retro-inverso peptides are peptides in which only part of the amino acid sequence is reversed and replaced with enantiomeric amino acid residues.

[0072] TFPI-binding peptides of the invention (e.g., TFPI inhibitor peptides) are made in a variety of ways. In one aspect, the peptides are synthesized by solid phase synthesis techniques including those described in Merrifield, *J. Am. Chem. Soc.*, 85, 2149 (1963); Davis et al., *Biochem. Intl.*, 10, 394-414 (1985); Larsen et al., *J. Am. Chem. Soc.*, 115, 6247 (1993); Smith et al., *J. Peptide Protein Res.*, 44, 183 (1994); O'Donnell et al., *J. Am. Chem. Soc.*, 118, 6070 (1996); Stewart and Young, *Solid Phase Peptide Synthesis*, Freeman (1969); Finn et al., *The Proteins*, 3rd ed., vol. 2, pp. 105-253 (1976); and Erickson et al., *The Proteins*, 3rd ed., vol. 2, pp. 257-527 (1976). Alternatively, the TFPI-binding peptide (e.g., the TFPI-inhibitory peptide) is expressed recombinantly by introducing a nucleic acid encoding a TFPI-binding peptide (e.g., a TFPI-inhibitory peptide) into host cells, which are cultured to express the peptide. Such peptides are purified from the cell culture using standard protein purification techniques.

[0073] The invention also encompasses a nucleic acid comprising a nucleic acid sequence encoding a TFPI-inhibitory peptide of the invention. Methods of preparing DNA and/or RNA molecules are well known in the art. In one aspect, a DNA/RNA molecule encoding a peptide provided herein is generated using chemical synthesis techniques and/or using polymerase chain reaction (PCR). If desired, a TFPI-inhibitory peptide coding sequence is

incorporated into an expression vector. One of ordinary skill in the art will appreciate that any of a number of expression vectors known in the art are suitable in the context of the invention, such as, but not limited to, plasmids, plasmid-liposome complexes, and viral vectors. Any of these expression vectors are prepared using standard recombinant DNA techniques described in, e.g., Sambrook et al., *Molecular Cloning, a Laboratory Manual*, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994). Optionally, the nucleic acid is operably linked to one or more regulatory sequences, such as a promoter, activator, enhancer, cap signal, polyadenylation signal, or other signal involved with the control of transcription or translation.

[0074] Any of the TFPI-inhibitory peptides of the invention or nucleic acids encoding the peptides also is provided in a composition (e.g., a pharmaceutical composition). In this regard, the peptide is formulated with a physiologically-acceptable (i.e., pharmacologically-acceptable) carrier, buffer, excipient, or diluent, as described further herein. Optionally, the peptide is in the form of a physiologically acceptable salt, which is encompassed by the invention. "Physiologically acceptable salts" means any salts that are pharmaceutically acceptable. Some examples of appropriate salts include acetate, hydrochloride, hydrobromide, sulfate, citrate, tartrate, glycolate, and oxalate. If desired, the composition comprises one or more additional pharmaceutically-effective agents.

[0075] The peptide provided herein optionally inhibits at least one Tissue Factor Pathway Inhibitor-1 (e.g., TFPI-1 α) activity such as, but not limited to, an activity that downregulates the blood coagulation cascade. Without being bound by any specific mechanism of action, a proposed mechanism of inhibition may involve preventing formation of the quaternary TF-FVIIa-FXA-TFPI complex. The peptide may inhibit binding of TFPI to FXa (e.g., inhibit binding of TFPI Kunitz domain 2 to Factor Xa), the TF/FVIIa complex (e.g., inhibit binding of TFPI Kunitz domain 1 to the TF/FVIIa complex), TF alone, and/or FVIIa alone. With TFPI activity diminished, TF and FVIIa are free to activate FX which, in turn, enhances conversion of prothrombin to thrombin.

[0076] In one aspect, the peptide of the invention exhibits TFPI antagonistic activity in model and/or plasmatic systems. An exemplary model system for determining TFPI-inhibitory activity is the extrinsic tenase assay, which tests the ability of candidate peptides to restore extrinsic complex-mediated FX activation in the presence of TFPI (which is a natural inhibitor of the FX activation reaction) (see, e.g., Lindhout et al., *Thromb. Haemost.*, 74, 910-915 (1995)). Another model system for characterizing TFPI-inhibitory activity is the FXa

inhibition assay, wherein FXa activity is measured in the presence of TFPI (see Sprecher et al., *PNAS*, 91, 3353-3357 (1994)). The extrinsic tenase assay and the FXa inhibition assay are further described in Example 3. Optionally, the peptide of the invention enhances FX activation in the presence of TFPI with a half maximal effective concentration (EC_{50}) of less than or equal to 1×10^{-4} M, less than or equal to 1×10^{-5} M, less than or equal to 1×10^{-6} M, or less than or equal to 1×10^{-7} M.

[0077] In one aspect, TFPI-antagonist activity is characterized in a plasma-based assay. Thrombin formation is triggered in plasma substantially lacking FVIII or FIX activity (e.g., the residual coagulation factor activity is lower than 1%) in the presence of a candidate peptide. Thrombin formation can be detected using a fluorogenic or chromogenic substrate, as described in Example 4. A system for measuring thrombin activity is provided by Thrombinoscope BV (Maastricht, The Netherlands). Prothrombin conversion is measured using, e.g., a Thrombograph™ (Thermo Scientific, Waltham, MA), and the resulting data is compiled into a Calibrated Automatic Thrombogram generated by Thrombinoscope™ software available from Thrombinoscope BV. In certain embodiments, the TFPI-inhibitory peptide increases the amount of peak thrombin generated during the assay and/or decreases the time required to achieve peak thrombin formation. For example, the peptide improves TFPI-regulated thrombin generation in the absence of FVIII (e.g., in FVIII-depleted plasma) to at least 1% of the level of TFPI-dependent thrombin generation in normal plasma. Generally, normal (unafflicted) plasma contains about 0.5 U/mL to about 2 U/mL Factor VIII. Accordingly, in some instances, a TFPI-inhibitor peptide will enhance thrombin formation in the absence of FVIII to at least about 1% of that observed in the presence of 0.5 U/mL to 2 U/mL FVIII. In further embodiments, the peptide enhances thrombin formation in the absence of Factor VIII to at least about 2%, at least about 3%, at least about 5%, at least about 7%, or at least about 10% of the level of thrombin formation in normal plasma, i.e., in the presence of physiological levels of Factor VIII. In various aspects, the peptide is administered to an animal model of thrombin deficiency or hemophilia to characterize TFPI inhibitory activity *in vivo*. Such *in vivo* models are known in the art and include for example, mice administered anti-FVIII antibodies to induce hemophilia A (Tranholm et al., *Blood*, 102, 3615-3620 (2003)); coagulation factor knock-out models such as, but not limited to, FVIII knock-out mice (Bi et al., *Nat. Genet.*, 10(1), 119-121 (1995)) and FIX knock-out mice (Wang et al., *PNAS*, 94(21), 11563-66 (1997)); induced hemophilia-A in rabbits (Shen et al., *Blood*, 42(4), 509-521 (1973)); and Chapel Hill HA dogs (Lozier et al., *PNAS*, 99, 12991-12996 (2002)).

[0078] While not being bound to any particular theory or mechanism, the peptide of the invention provided herein may inhibit TFPI activity by blocking (competitively or allosterically) binding of TFPI and FXa. Alternatively or in addition, the peptide may inhibit binding of TFPI with a Tissue Factor (TF)/Factor VIIa complex. Thus, in certain aspects, the peptide specifically binds TFPI. Various peptides bind TFPI from any source including, but not limited to, mouse, rat, rabbit, dog, cat, cow, horse, pig, guinea pig, and primate. In one embodiment, the peptide binds human TFPI. Optionally, the TFPI-inhibitory peptide binds TFPI from more than one species (i.e., the peptide is cross-reactive among multiple species). In certain aspects, the peptide binds TFPI with a dissociation constant (K_D) of less than or equal to 1×10^{-4} M, less than or equal to 1×10^{-5} M, less than or equal to 1×10^{-6} M, or less than or equal to 1×10^{-7} M. Affinity may be determined using, for example and without limitation, any one, two, or more of a variety of techniques, such as affinity ELISA assay, a competitive ELISA assay, and/or surface plasmon resonance (BIAcore™) assay. When characterized using a competitive (IC_{50}) ELISA assay, the peptide of the invention optionally demonstrates an IC_{50} of less than or equal to about 50,000 nM. For example, the peptide demonstrates an IC_{50} of less than or equal to about 10,000 nM, such as an IC_{50} of less than or equal to about 5,000 nM, less than or equal to about 1,000 nM, or less than or equal to about 500 nM. In one aspect, the peptide demonstrates an IC_{50} of less than or equal to about 250 nM, less than or equal to about 100 nM, or less than or equal to about 50 nM. Exemplary peptides and their IC_{50} values are provided in Figures 32-39; in some instances, the peptides are classified into Groups A, B, C, D, E, F, and G (see Table 4 in Example 1) based on their IC_{50} values. In various aspects, the invention provides peptides falling within Groups A, B, C, D, E, F, and/or G as defined in Table 4. Affinity may also be determined by a kinetic method or an equilibrium/solution method. Such methods are described in further detail herein or known in the art.

[0079] As with all binding agents and binding assays, one of skill in the art recognizes that the various moieties to which a binding agent should not detectably bind in order to be biologically (e.g., therapeutically) effective would be exhaustive and impractical to list. Therefore, the term “specifically binds” refers to the ability of a peptide to bind TFPI with greater affinity than it binds to an unrelated control protein that is not TFPI. For example, the peptide may bind to TFPI with an affinity that is at least, 5, 10, 15, 25, 50, 100, 250, 500, 1000, or 10,000 times greater than the affinity for a control protein. In some embodiments, the peptide binds TFPI with greater affinity than it binds to an “anti-target,” a protein or other naturally occurring substance in humans to which binding of the peptide might lead to

adverse effects. Several classes of peptides or proteins are potential anti-targets. Because TFPI-inhibitory peptides exert their activity in the blood stream and/or at the endothelium, plasma proteins represent potential anti-targets. Proteins containing Kunitz domains (KDs) are potential anti-targets because KDs of different proteins share a significant similarity. Tissue Factor Pathway Inhibitor-2 (TFPI-2) is highly similar to TFPI-1 α and, like TFPI-1 α , contains KDs (Sprecher et al., *PNAS*, 91, 3353-3357 (1994)). Thus, in one aspect, the peptide of the invention binds to TFPI with an affinity that is at least 5, 10, 15, 25, or 50 times greater than the affinity for an anti-target, such as TFPI-2.

[0080] The invention further includes a method of inhibiting Tissue Factor Pathway Inhibitor-1 (TFPI). The method comprises contacting TFPI with a TFPI-binding peptide as described herein. Any degree of TFPI-activity inhibition is contemplated. For example, a TFPI-inhibitory peptide reduces TFPI-inhibition of the extrinsic pathway at least about 5% (e.g., at least about 10%, at least about 25%, or at least about 30%). In some embodiments, the TFPI-inhibitory peptide reduces TFPI activity within the extrinsic pathway at least about 50%, at least about 75%, or at least about 90% compared to TFPI activity in the absence of the peptide.

[0081] The invention further includes a method for targeting biological structures (including, but not limited to, cell surfaces and endothelial lining) where TFPI is located. The method comprises contacting the biological structure (e.g., including, without limitation, a cell displaying TFPI on the cell surface) with a TFPI-binding peptide described herein, optionally conjugated to a moiety that adds additional functionality to the peptide. The moiety can be a dye (such as a fluorescence dye), a radionuclide or a radionuclide-containing complex, a protein (e.g., an enzyme, a toxin, or an antibody) or a cytotoxic agent. For example, the peptide is linked or conjugated to an effector moiety that facilitates peptide detection and/or purification and/or comprises therapeutic properties. In one aspect, the TFPI-binding peptide or peptide conjugate is administered to a mammal to target a TFPI-displaying cell within the mammal. Optionally, the method further comprises detecting binding of the TFPI-binding peptide to TFPI. The method is useful for therapy and diagnostic of disease where TFPI is a suitable diagnostic marker or TFPI-expressing cells are a target for a therapeutic approach.

[0082] In some aspects, peptide-TFPI binding is detected indirectly. In this regard, the peptide is contacted with an interaction partner that binds the peptide of invention without significantly interfering with peptide-TFPI binding, and the interaction partner is detected. Exemplary interaction partners include, but are not limited to, antibodies, antigen-binding

antibody fragments, anticalins and antibody mimetics, aptamers, and spiegelmers.

Optionally, the interaction partner comprises a detection moiety to facilitate detection of an interaction partner-peptide complex. Methods of detecting, e.g., antibodies and fragments thereof, are well understood in the art. Similarly, detection moieties are widely used in the art to identify biological substances and include, for example, dye (e.g., fluorescent dye), radionuclides and radionuclide-containing complexes, and enzymes.

[0083] Thus, the invention provides a method for diagnosing a subject suffering from a disease or disorder, or at risk of suffering from a disease or disorder, wherein the disease or disorder is associated with or caused by aberrant TFPI activity. The method comprises administering to the subject the TFPI-binding peptide of the invention and detecting the TFPI-peptide complex. In some instances, the peptide of the invention is conjugated to a detectable moiety, and the method comprises detecting the detectable moiety. In other instances, the method comprises administering to the subject a TFPI-binding peptide interaction partner that binds the TFPI-binding peptide, and detecting the interaction partner. If desired, the interaction partner comprises or is conjugated to a detectable moiety, and the detectable moiety is detected. The presence of the detectable moiety indicates the presence of TFPI, thereby allowing diagnosis of a disease or disorder associated with TFPI (e.g., a disease or disorder which (i) can be treated by inhibiting TFPI or (ii) comprises symptoms which can be ameliorated or prevented by inhibiting TFPI). If administration of the peptide to the subject is not desired, a biological sample is obtained from the subject, contacted with the TFPI-binding peptide as described herein, and TFPI-peptide complexes are detected.

[0084] The peptides of the invention bind TFPI and, therefore, are useful for purifying TFPI or recombinant TFPI from a biological sample (e.g., a biological fluid, such as serum), fermentation extract, tissue preparations, culture medium, and the like. The invention includes methods of using the TFPI-binding in the commercial production of TFPI or in a method of characterizing TFPI molecules. For example, the invention includes a method of purifying TFPI. The method comprises contacting a sample containing TFPI with a peptide as defined herein under conditions appropriate to form a complex between TFPI and the peptide; removing the complex from the sample; and, optionally, dissociating the complex to release TFPI. Exemplary conditions appropriate to form a complex between TFPI and the peptide are disclosed in the Examples, and such conditions can be easily modified to dissociate the TFPI-peptide complex. In some embodiments, the peptide is immobilized to a support, e.g., a solid support, to facilitate recovery of TFPI. For example, in one embodiment, the peptide is immobilized to chromatography stationary phase (e.g., silica,

affinity chromatography beads, or chromatography resins), a sample comprising TFPI is applied to the stationary phase such that TFPI-peptide complexes are formed, the remainder of the sample is removed from the stationary phase, and TFPI is eluted from the stationary phase. In this regard, the peptides of the invention are, in one aspect, suitable for use in affinity chromatography techniques.

[0085] A method of enhancing thrombin formation in a clotting factor-deficient subject also is provided. The method comprises administering to the subject a peptide provided herein under conditions effective to inhibit TFPI. In this regard, the TFPI-inhibitory peptide is administered in an amount and under conditions effective to enhance thrombin formation in the subject. By “clotting factor-deficient” is meant that the subject suffers from a deficiency in one or more blood factors required for thrombin formation, such as FVIII, FIX, or FXI. Indeed, in one embodiment, the subject is deficient in FVIII. Alternatively or in addition, the subject is deficient in Factor IX. Clotting factor deficiencies are identified by examining the amount of factor in a clinical sample. Practitioners classify hemophilia according to the magnitude of clotting factor deficiency. Subjects suffering from mild hemophilia have approximately 5% to 30% of the normal amount (1 U/ml) of Factor VIII or Factor IX. Moderate hemophilia is characterized by approximately 1% to 5% of normal Factor VIII, Factor IX, or Factor XI levels, while subjects suffering from severe hemophilia have less than 1% of the normal amount of Factor VIII, Factor IX, or Factor XI. Deficiencies can be identified indirectly by activated partial thromboplastin time (APTT) testing. APTT testing measures the length of time required for a blood clot to form, which is longer for patients with Factor VIII Deficiency (hemophilia A), Factor IX Deficiency (hemophilia B), and Factor XI Deficiency (hemophilia C) compared to patients with normal clotting factor levels. Almost 100% of patients with severe and moderate Factor VIII deficiency can be diagnosed with an APTT. The invention further includes enhancing thrombin formation in a subject that does not suffer from a clotting factor deficiency. The method comprises administering to a subject (e.g., a subject comprising normal, physiological levels of clotting factor) a peptide provided herein under conditions effective to enhance thrombin formation.

[0086] In one aspect, the TFPI-inhibitory peptide is used for increasing blood clot formation in a subject. The method of increasing blood clot formation comprises administering to the subject a peptide described herein in an amount and under conditions effective to increase blood clot formation. It will be appreciated that the method need not completely restore the coagulation cascade to achieve a beneficial (e.g., therapeutic) effect. Any enhancement or increase in thrombin or blood clot formation that reduces the onset or

severity of symptoms associated with clotting factor deficiencies is contemplated. Methods of determining the efficacy of the method in promoting thrombin formation and blood clotting are known in the art and described herein.

[0087] The invention further includes a method of treating a blood coagulation disorder in a subject, the method comprising administering to the subject one or more TFPI-inhibitory peptides, such as any one or more of the peptides described herein, in an amount and under conditions effective to treat the blood coagulation disorder in the subject. In one aspect, the peptide is not a naturally-occurring peptide that inhibits TFPI activity. "Coagulation disorders" include bleeding disorders caused by deficient blood coagulation factor activity and deficient platelet activity. Blood coagulation factors include, but are not limited to, Factor V (FV), FVII, FVIII, FIX, FX, FXI, FXIII, FII (responsible for hypoprothrombinemia), and von Willebrand's factor. Factor deficiencies are caused by, for instance, a shortened *in vivo*-half-life of the factor, altered binding properties of the factor, genetic defects of the factor, and a reduced plasma concentration of the factor. Coagulation disorders can be congenital or acquired. Potential genetic defects include deletions, additions and/or substitution within a nucleotide sequence encoding a clotting factor whose absence, presence, and/or substitution, respectively, has a negative impact on the clotting factor's activity. Coagulation disorders also stem from development of inhibitors or autoimmunity (e.g., antibodies) against clotting factors. In one example, the coagulation disorder is hemophilia A. Alternatively, the coagulation disorder is hemophilia B or hemophilia C.

[0088] Platelet disorders are caused by deficient platelet function or abnormally low platelet number in circulation. Low platelet count may be due to, for instance, underproduction, platelet sequestration, or uncontrolled patent destruction. Thrombocytopenia (platelet deficiencies) may be present for various reasons, including chemotherapy and other drug therapy, radiation therapy, surgery, accidental blood loss, and other disease conditions. Exemplary disease conditions that involve thrombocytopenia are: aplastic anemia; idiopathic or immune thrombocytopenia (ITP), including idiopathic thrombocytopenic purpura associated with breast cancer; HIV-associated ITP and HIV-related thrombotic thrombocytopenic purpura; metastatic tumors which result in thrombocytopenia; systemic lupus erythematosus, including neonatal lupus syndrome splenomegaly; Fanconi's syndrome; vitamin B12 deficiency; folic acid deficiency; May-Hegglin anomaly; Wiskott-Aldrich syndrome; chronic liver disease; myelodysplastic syndrome associated with thrombocytopenia; paroxysmal nocturnal hemoglobinuria; acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy; alloimmune

thrombocytopenia, including maternal alloimmune thrombocytopenia; thrombocytopenia associated with antiphospholipid antibodies and thrombosis; autoimmune thrombocytopenia; drug-induced immune thrombocytopenia, including carboplatin-induced thrombocytopenia and heparin-induced thrombocytopenia; fetal thrombocytopenia; gestational thrombocytopenia; Hughes' syndrome; lupoid thrombocytopenia; accidental and/or massive blood loss; myeloproliferative disorders; thrombocytopenia in patients with malignancies; thrombotic thrombocytopenia purpura, including thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in cancer patients; post-transfusion purpura (PTP); autoimmune hemolytic anemia; occult jejunal diverticulum perforation; pure red cell aplasia; autoimmune thrombocytopenia; nephropathia epidemica; rifampicin-associated acute renal failure; Paris-Trousseau thrombocytopenia; neonatal alloimmune thrombocytopenia; paroxysmal nocturnal hemoglobinuria; hematologic changes in stomach cancer; hemolytic uremic syndromes (e.g., uremic conditions in childhood); and hematologic manifestations related to viral infection including hepatitis A virus and CMV-associated thrombocytopenia. Platelet disorders also include, but are not limited to, Von Willebrand Disease, paraneoplastic platelet dysfunction, Glanzman's thrombasthenia, and Bernard-Soulier disease. Additional bleeding disorders amenable to treatment with a TFPI-inhibitory peptide include, but are not limited to, hemorrhagic conditions induced by trauma; a deficiency in one or more contact factors, such as FXI, FXII, prekallikrein, and high molecular weight kininogen (HMWK); vitamin K deficiency; a fibrinogen disorder, including afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia; and alpha2-antiplasmin deficiency. In one embodiment, the TFPI-inhibitory peptide is used to treat excessive bleeding, such as excessive bleeding caused by surgery, trauma, intracerebral hemorrhage, liver disease, renal disease, thrombocytopenia, platelet dysfunction, hematomas, internal hemorrhage, hemarthroses, hypothermia, menstruation, pregnancy, and Dengue hemorrhagic fever. All of the above are considered "blood coagulation disorders" in the context of the disclosure.

[0089] In one aspect, the TFPI-inhibitory peptide of the invention is used to reverse the effects (in whole or in part) of one or more anticoagulants in a subject. Numerous anticoagulants are known in the art and include, for instance, heparin; coumarin derivatives, such as warfarin or dicumarol; TFPI; AT III; lupus anticoagulant; nematode anticoagulant peptide (NAPc2); FVIIa inhibitors; active-site blocked FVIIa (FVIIai); active-site blocked FIXa (FIXai); FIXa inhibitors; FXa inhibitors, including fondaparinux, idraparinux, DX-9065a, and razaxaban (DPC906); active-site blocked FXa (FXai); inhibitors of FVa or

FVIIIa, including activated protein C (APC) and soluble thrombomodulin; thrombin inhibitors, including hirudin, bivalirudin, argatroban, and ximelagatran; and antibodies or antibody fragments that bind a clotting factor (e.g., FV, FVII, FVIII, FIX, FX, FXIII, FII, FXI, FXII, von Willebrand factor, prekallikrein, or high molecular weight kininogen (HMWK)).

[0090] As used herein, “treating” and “treatment” refers to any reduction in the severity and/or onset of symptoms associated with a blood coagulation disorder. Accordingly, “treating” and “treatment” includes therapeutic and prophylactic measures. One of ordinary skill in the art will appreciate that any degree of protection from, or amelioration of, a blood coagulation disorder or symptom associated therewith is beneficial to a subject, such as a human patient. The quality of life of a patient is improved by reducing to any degree the severity of symptoms in a subject and/or delaying the appearance of symptoms. Accordingly, the method in one aspect is performed as soon as possible after it has been determined that a subject is at risk for developing a blood coagulation disorder (e.g., a deficiency in a clotting factor (e.g., FVIII, FIX, or FXI) is detected) or as soon as possible after a blood coagulation disorder (e.g., hemophilia A, hemophilia B, or hemophilia C) is detected. In an additional aspect, the peptide is administered to protect, in whole or in part, against excessive blood loss during injury or surgery.

[0091] In view of the above, the invention provides a peptide for use in a method for the treatment of a subject, such as a method for the treatment of a disease where the inhibition of TFPI is beneficial. In one aspect, the disease or disorder is a blood coagulation disorder. The subject is suffering from a disease or disorder or is at risk from suffering from a disease or disorder (or adverse biological event, such as excessive blood loss). The method comprises administering to the subject the peptide of the invention in an amount and under conditions effective to treat or prevent, in whole or in part, the disease or disorder. The invention further provides a peptide for use in the manufacture of a medicament. For example, the peptide can be used in the manufacture of a medicament for the treatment of a blood coagulation disorder, as described in detail herein.

[0092] In some embodiments, it is advantageous to administer to a subject a nucleic acid comprising a nucleic acid sequence encoding a TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention. Such a nucleic acid, in one aspect, is provided instead of, or in addition to, a TFPI-inhibitory peptide. Expression vectors, nucleic acid regulatory sequences, administration methods, and the like, are further described herein and in U.S. Patent Publication No. 20030045498.

[0093] A particular administration regimen for a particular subject will depend, in part, upon the TFPI- inhibitory peptide of the invention used, the amount of TFPI-binding peptide (e.g., TFPI-inhibitory peptide) administered, the route of administration, the particular ailment being treated, considerations relevant to the recipient, and the cause and extent of any side effects. The amount of peptide administered to a subject (e.g., a mammal, such as a human) and the conditions of administration (e.g., timing of administration, route of administration, dosage regimen) are sufficient to effect the desired biological response over a reasonable time frame. Dosage typically depends upon a variety of factors, including the particular TFPI-inhibitory peptide employed, the age and body weight of the subject, as well as the existence and severity of any disease or disorder in the subject. The size of the dose also will be determined by the route, timing, and frequency of administration. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect, and conventional range-finding techniques are known to those of ordinary skill in the art. Purely by way of illustration, in one aspect, the method comprises administering, e.g., from about 0.1 $\mu\text{g/kg}$ to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 1 $\mu\text{g/kg}$ up to about 75 mg/kg; or 5 $\mu\text{g/kg}$ up to about 50 mg/kg; or 10 $\mu\text{g/kg}$ up to about 20 mg/kg. In certain embodiments, the dose comprises about 0.5 mg/kg to about 20 mg/kg (e.g., about 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.3 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, 4.5 mg/kg, 5 mg/kg, 5.5 mg/kg, 6 mg/kg, 6.5 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg) of peptide. Given the chronic nature of many blood coagulation disorders, it is envisioned that a subject will receive the TFPI-inhibitory peptide over a treatment course lasting weeks, months, or years, and may require one or more doses daily or weekly. In other embodiments, the TFPI-inhibitory peptide is administered to treat an acute condition (e.g., bleeding caused by surgery or trauma, or factor inhibitor/autoimmune episodes in subjects receiving coagulation replacement therapy) for a relatively short treatment period, e.g., one to 14 days.

[0094] Suitable methods of administering a physiologically-acceptable composition, such as a pharmaceutical composition comprising a peptide described herein, are well known in the art. Although more than one route can be used to administer a peptide, a particular route can provide a more immediate and more effective reaction than another route. Depending on the circumstances, a pharmaceutical composition is applied or instilled into body cavities, absorbed through the skin or mucous membranes, ingested, inhaled, and/or introduced into circulation. In one aspect, a composition comprising a TFPI-inhibitory peptide is administered intravenously, intraarterially, or intraperitoneally to introduce the peptide of the

invention into circulation. Non-intravenous administration also is appropriate, particularly with respect to low molecular weight therapeutics. In certain circumstances, it is desirable to deliver a pharmaceutical composition comprising the TFPI-inhibitory peptide orally, topically, sublingually, vaginally, rectally; through injection by intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, urethral, or enteral means; by sustained release systems; or by implantation devices. If desired, the TFPI-inhibitory peptide is administered regionally via intraarterial or intravenous administration feeding a region of interest, e.g., via the femoral artery for delivery to the leg. In one embodiment, the peptide is incorporated into a microparticle as described in, for example, U.S. Patents 5,439,686 and 5,498,421, and U.S. Patent Publications 2003/0059474, 2003/0064033, 2004/0043077, 2005/0048127, 2005/0170005, 2005/0142205, 2005/142201, 2005/0233945, 2005/0147689, 2005/0142206, 2006/0024379, 2006/0260777, 2007/0207210, 2007/0092452, 2007/0281031, and 2008/0026068. Alternatively, the composition is administered via implantation of a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device in one aspect is implanted into any suitable tissue, and delivery of the desired molecule is in various aspects via diffusion, timed-release bolus, or continuous administration. In other aspects, the TFPI-inhibitory peptide is administered directly to exposed tissue during surgical procedures or treatment of injury, or is administered via transfusion of blood procedures. Therapeutic delivery approaches are well known to the skilled artisan, some of which are further described, for example, in U.S. Patent No. 5,399,363.

[0095] To facilitate administration, the TFPI-binding peptide (e.g., TFPI-inhibitory peptide) in one embodiment is formulated into a physiologically-acceptable composition comprising a carrier (i.e., vehicle, adjuvant, buffer, or diluent). The particular carrier employed is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the peptide, and by the route of administration. Physiologically-acceptable carriers are well known in the art. Illustrative pharmaceutical forms suitable for injectable use include without limitation sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U.S. Patent No. 5,466,468). Injectable formulations are further described in, e.g., *Pharmaceutics and Pharmacy Practice*, J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers. eds., pages 238-250 (1982), and *ASHP Handbook on Injectable Drugs*, Toissel,

4th ed., pages 622-630 (1986)). A pharmaceutical composition comprising a peptide provided herein is optionally placed within containers, along with packaging material that provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions include a tangible expression describing the reagent concentration, as well as, in certain embodiments, relative amounts of excipient ingredients or diluents that may be necessary to reconstitute the pharmaceutical composition.

[0096] When appropriate, the TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention is administered in combination with other substances and/or other therapeutic modalities to achieve an additional or augmented biological effect. Co-treatments include, but are not limited to, plasma-derived or recombinant coagulation factors, hemophilia prophylaxis treatments, immunosuppressants, plasma factor-inhibiting antibody antagonists (i.e., anti-inhibitors), antifibrinolytics, antibiotics, hormone therapy, anti-inflammatory agents (e.g., Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or steroidal anti-inflammatory substances), procoagulants, and pain relievers. In one aspect, the method is an adjunct therapy to traditional replacement factor treatment regimens involving administration of, e.g., FXIII, FXII, FXI (e.g., HEMOLEVEN® (Laboratoire français du Fractionnement et des Biotechnologies, Les Ulis, France) and FXI concentrate (BioProducts Laboratory, Elstree, Hertfordshire, UK)), FX, FIX (e.g., BENEFIX® Coagulation Factor IX (Wyeth, Madison, NJ); ALPHANINE® SD (Grifols, Los Angeles, CA); MONONINE® (CSL Behring, King of Prussia, PA); BEBULIN-VH™ (Baxter, Deerfield, IL); PROFILNINE® SD (Grifols, Los Angeles, CA); or PROPLEX T™ (Baxter, Deerfield, IL)), FVIII (e.g., ADVATE™ (Baxter, Deerfield, IL); HELIXATE® FS (CSL Behring, King of Prussia, PA); REFACTO® (Wyeth, Madison, NJ), XYNTHA™ (Wyeth, Madison, NJ), KOGENATE® and KOGENATE® FS (Bayer, Pittsburgh, PA); ALPHANATE® (Grifols, Los Angeles, CA); HEMOPHIL M™ (Baxter, Deerfield, IL); KOATE®-DVI (Talecris Biotherapeutics-USA, Research Triangle Park, NC); or MONARC-M™ (Baxter, Deerfield, IL)), FVIIa (e.g., NOVOSEVEN® FVIIa (Novo Nordisk, Princeton, NJ) and FVII concentrate (Baxter Bioscience, Vienna, Austria, or BioProducts Laboratory, Elstree, Hertfordshire, UK)), FV, FVa, FII, and/or FIII, to a subject. In some instances, the subject also receives FEIBA VH Immuno™ (Baxter BioScience, Vienna, Austria), which is a freeze-dried sterile human plasma fraction with Factor VIII inhibitor bypassing activity. FEIBA VH Immuno™ contains approximately equal units of Factor VIII inhibitor bypassing activity and Prothrombin Complex Factors (Factors II, VII, IX, and X and protein C). Other exemplary co-treatments include, but are not limited to, prekallikrein, high molecular weight kininogen (HMWK), Von Willebrand's factor, Tissue

Factor, and thrombin. Alternatively or in addition, the TFPI-inhibitory peptide is co-formulated with one or more different TFPI-inhibitory peptides.

[0097] The invention thus includes administering to a subject a TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention (or multiple TFPI-inhibitory peptides), in combination with one or more additionally suitable substances(s), each being administered according to a regimen suitable for that medicament. Administration strategies include concurrent administration (i.e., substantially simultaneous administration) and non-concurrent administration (i.e., administration at different times, in any order, whether overlapping or not) of the TFPI-inhibitory peptide and one or more additionally suitable agents(s). It will be appreciated that different components are optionally administered in the same or in separate compositions, and by the same or different routes of administration.

[0098] In some embodiments, the peptide of the invention is conjugated to a moiety, e.g., a therapeutic or diagnostic moiety, such as the detection moieties and co-treatments described above. Alternatively or in addition, the peptide is administered in combination with an interaction partner (e.g., an antibody, antibody fragment, anticalin, aptamer, or spiegelmer) that (a) binds the peptide and (b) is therapeutically active and/or is linked to a moiety that provides additional functionality to the interaction partner (e.g., a therapeutic, diagnostic, or detection agent). Suitable moieties include, but are not limited to, dyes, radionuclides, radionuclide-containing complexes, enzymes, toxins, antibodies, antibody fragments, and cytotoxic agents, and, in some instances, the moiety possesses therapeutic activity (i.e., achieves an advantageous or desired biological effect). The peptide conjugates or peptide-interaction partner pair is suitable for use in any of the methods described herein, such as methods of treating a subject suffering from a disease or disorder or at risk of suffering from a disease or disorder.

[0099] All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. In addition, the entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. For example, where protein therapy is described, embodiments involving polynucleotide therapy (using polynucleotides/vectors that encode the protein) are specifically contemplated, and the reverse also is true. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of

understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The invention includes, for instance, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. With respect to aspects of the invention described as a genus, all individual species are individually considered separate aspects of the invention. With respect to aspects of the invention described or claimed with “a” or “an,” it should be understood that these terms mean “one or more” unless context unambiguously requires a more restricted meaning. With respect to elements described as one or more within a set, it should be understood that all combinations within the set are contemplated.

EXAMPLES

Example 1

[00100] The following example describes production, identification, and screening of peptides for binding to TFPI.

[00101] Peptides candidates were obtained from commercial suppliers (e.g., PolyPeptide Laboratories SAS (Strasbourg, France) and JPT Peptide Technologies GmbH (Berlin, Germany)). Methods for synthesizing candidate peptides are provided above. Candidate peptides were synthesized as trifluoroacetate (TFA) salts with a purity >90% or >60%. All peptides were solved in DMSO to a stock concentration of 10 mM. TFPI-binding peptide sequences were identified using an mRNA display library. The mRNA display technology is superior to other library screening techniques for allowing for a diversity of 10^{14} different sequences within a starting pool and avoiding, e.g., the *in vivo* steps required for phage display. In brief, the technology involves directly linking mRNA to its encoded candidate peptide through a puromycin molecule (Figure 5). The mRNA display method is further described in International Patent Publication No. WO 2005/051985 and Liu et al., *Methods in Enzymology*, 318, 268-293 (2000). TFPI was immobilized to a solid support via biotin and exposed to candidate peptide-RNA complexes. TFPI-bound candidate peptide-RNA complexes were isolated, and the RNA reverse transcribed to obtain coding DNA. High affinity binders were obtained following six to ten selection rounds using a competitive elution strategy. Many of the candidate peptides were 31 amino acids in length (27 randomized amino acids and 2 amino acids flanking both termini).

[00102] Selected peptides were synthesized and subjected to peptide optimization using a microarray-based scan analysis to identify peptide fragments retaining TFPI-binding affinity. For example, a microarray-based scan of JBT0047 was performed using a series of 20 amino acid fragments of the peptide, the sequences of which overlapped by 19 amino acids. N- and C-terminal truncation analysis supplemented the scan analysis. The microarray scan results demonstrated that that peptide JBT0293 bound TFPI with the highest affinity. A series of substitution mutants based on the amino acid sequence of JBT0293 was generated and tested for TFPI binding properties.

[00103] The affinity of a subset of peptides for TFPI was demonstrated via an enzyme-linked immunosorbent assay (ELISA)-like assay (binding (EC_{50}) ELISA) performed with biotinylated peptides. Ninety-six well MaxiSorp plates (Nunc) were coated with 3 μ g/mL TFPI in coating buffer (15 mM Na_2CO_3 , 35 mM $NaHCO_3$, pH 9.6) over night. Plates were washed three times with 350 μ l wash buffer (HNaT: 175 mM NaCl, 25 mM HEPES, 5 mM $CaCl_2$, 0.1% Tween 80, pH 7.35), and subsequently blocked with 200 μ l 2% yeast extract in HNaT for 2 hours. Plates were then washed three times with 350 μ l HNaT. Biotinylated candidate peptides were diluted from a DMSO stock 1/200 in HNaT. The initial peptide concentration was 50 μ M if no precipitate appeared during the 1/200 dilution of the 10 mM peptide stock solution. Pre-dilutions of the peptide stock in DMSO were conducted if precipitates formed. The diluted peptides were applied to the Maxisorp plates, serial dilutions (1/3) were generated, and the dilutions were incubated for 1.5 hours at room temperature. Incubation was followed by three wash steps (350 μ l HNaT). Bound peptide was detected by incubation with horseradish peroxidase-conjugated streptavidin (1 hour), followed by three wash steps with HNaT and a subsequent chromogenic conversion of added TMB (3,3',5,5'-Tetramethylbenzidin). The assay is illustrated in Figure 6A.

[00104] Generally, peptide binding to immobilized TFPI was significantly above background. EC_{50} values for biotinylated peptides are given in Figures 32-39. The binding curve of one TFPI-binding peptide, JBT0132, is depicted in Figure 7. The EC_{50} of JBT0132 was calculated to be about 2.2 nM.

[00105] In addition, a competition (IC_{50}) ELISA was performed using biotinylated TFPI-binding peptides as “tracers” to compete for TFPI-binding with non-biotinylated candidate peptides. The assay principle is depicted in Figure 6B. Ninety-six well MaxiSorp plates (Nunc) were coated with 3 μ g/mL TFPI in coating buffer (15 mM Na_2CO_3 , 35 mM $NaHCO_3$, pH 9.6) over night. Plates were washed three times with 350 μ l wash buffer (HNaT: 175 mM NaCl, 25 mM HEPES, 5 mM $CaCl_2$, 0.1% Tween 80, pH 7.35), and blocked with 200 μ l 2%

yeast extract in HNaT for 2 hours. Plates were then washed three times with 350 μ l HNaT. Biotinylated tracer peptides were applied at a concentration corresponding to their respective EC₉₀ values determined in the binding ELISA (median if $n > 2$). A competitor stock solution of peptide (10 mM) was diluted 1/33.3 in HNaT without HSA, and a serial 1/3 dilution was prepared with HNaT with 3% DMSO. The dilution was further diluted with the biotinylated tracer peptide in a ratio of 1:6 (20 μ l competitor dilution and 100 μ l tracer peptide). The mixture of competitor and tracer peptide was applied to the TFPI-coated microtiter plate and incubated for 1.5 hours. The plates were washed three times with 350 μ l HNaT. Peptide-TFPI binding was detected by applying HRP-conjugated streptavidin to the microtiter plate, incubating the mixture for one hour, washing the plate three times with 350 μ l HNaT, applying TMB (3,3',5,5'-Tetramethylbenzidine), and detecting the subsequent chromogenic conversion of TMB by HRP. IC₅₀ graphs for representative non-biotinylated peptides are provided in Figures 8A-8D. IC₅₀ measurements of peptides JBT0303, JBT0120, and JBT0224 are set forth in Table 3.

TABLE 3

Peptide	IC ₅₀ [μ M]	n	SD	Tracer Peptide	Tracer Concentration [μ M]
JBT0303	0.119	2	0.064	JBT0131	0.0409
JBT0120	0.0189	3	0.0044	JBT0124	0.0718
JBT0224	n.a.	1		JBT0126	0.240

[00106] In addition to the competition ELISA (IC₅₀) assay, a screening assay was employed to measure higher numbers of peptides in parallel. The screening ELISA is similar to the competition IC₅₀ ELISA with the exception that only three different concentrations of the competitor were employed (300 nM, 100 nM and 33.3 nM for the JBT0047 class, and 50000 nM, 16667 nM and 5556 nM for the JBT0122 class). In some instances, screening results were expressed as percent inhibition of the tracer signal in relation to a competitive peptide (competitive peptide JBT0477 for the JBT0047 family, and competitive peptide JBT1697 for the JBT0122 family). The competition IC₅₀ assay results and the screening assay results of peptides prepared and screened in accordance with the methods set forth herein are provided in Figures 32-39. The mean IC₅₀ values presented in Figures 32-39 are based on a greater number of assays than the values presented in Table 3 and, therefore, the values may differ slightly. The results of the screening ELISA are presented as percent inhibition of tracer peptide JBT0131 binding. Several peptides that were analyzed using the

IC₅₀ ELISA are classified in Figures 32-39 according to their binding affinity as set forth in Table 4.

TABLE 4

TFPI competition ELISA IC ₅₀ [nM]	Group
< 50 nM	A
50 ≤ x < 100 nM	B
100 ≤ x < 250 nM	C
250 ≤ x < 1000 nM	D
1000 ≤ x < 5000 nM	E
5000 ≤ x < 10000 nM	F
10000 ≤ x < 50000 nM	G

[00107] Exemplary TFPI-binding peptides identified using the methods described herein are presented in Table 5. Some peptides were biotinylated, and many comprise N- and C-terminal lysines to promote solubility. Several peptides exhibited TFPI-inhibitory activity in model and/or plasmatic assay systems, as described below.

TABLE 5

Peptide	Parent	Sequence	SEQ ID
	JBT0047	QSKKNVFVFGYFERLRAK	1
JBT0047	JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2	253
JBT0051	JBT0047	Biotinyl-Ttds-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2	962
JBT0055	JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-Ttds-Lys(Biotinyl)-NH2	963
JBT0131	JBT0047	Biotinyl-Ttds-AFQSKKNVFVFGYFERLRAK-NH2	964
JBT0132	JBT0047	Biotinyl-Ttds-FQSKKNVFVFGYFERLRAKL-NH2	965
JBT0133	JBT0047	Biotinyl-Ttds-QSKKNVFVFGYFERLRAKL-NH2	966
JBT0155	JBT0047	Ac-KKSGVGRLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	8
JBT0158	JBT0047	Ac-KKSGVGRLQVAFQSKKNVFVFGYFERLRAKKK-NH2	9
JBT0162	JBT0047	Ac-KKGRLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	10
JBT0163	JBT0047	Ac-KKQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	11
JBT0164	JBT0047	Ac-KKFQSKKNVFVFGYFERLRAKLTSKK-NH2	12
JBT0166	JBT0047	Biotinyl-Ttds-KKFQSKKNVFVFGYFERLRAKLKK-NH2	968
JBT0169	JBT0047	Ac-KKAFQSKKNVFVFGYFERLRAKKK-NH2	254
JBT0170	JBT0047	Ac-KKFQSKKNVFVFGYFERLRAKLKK-NH2	13
JBT0171	JBT0047	Ac-KKQSKKNVFVFGYFERLRAKLTKK-NH2	255
JBT0174	JBT0047	Ac-KKAFQSKKNVFVFGYFERLRAKLKK-NH2	14
JBT0175	JBT0047	Ac-KKAFQSKKNVFVFGYFERLRAKLTKK-NH2	182
JBT0293	JBT0047	Ac-FQSKKNVFVFGYFERLRAKL-NH2	256
		X ₃ X ₄ X ₅ KX ₇ NVFX ₁₁ X ₁₂ GYX ₁₅ X ₁₆ RLRAKX ₂₂	2
JBT0294	JBT0047	Ac-YQSKKNVFVFGYFERLRAKL-NH2	257
JBT0295	JBT0047	Ac-FSSKKNVFVFGYFERLRAKL-NH2	713
JBT0296	JBT0047	Ac-FQNKKNVFVFGYFERLRAKL-NH2	407
JBT0297	JBT0047	Ac-FQSKNNVFVFGYFERLRAKL-NH2	183

JBT0298	JBT0047	Ac-FQSKQNVFVFGYFERLRACL-NH2	747
JBT0299	JBT0047	Ac-FQSKKNVFAFGYFERLRACL-NH2	408
JBT0300	JBT0047	Ac-FQSKKNVFSFGYFERLRACL-NH2	409
JBT0301	JBT0047	Ac-FQSKKNVFTFGYFERLRACL-NH2	470
JBT0302	JBT0047	Ac-FQSKKNVVFAGYFERLRACL-NH2	258
JBT0303	JBT0047	Ac-FQSKKNVFDGYFERLRACL-NH2	184
JBT0304	JBT0047	Ac-FQSKKNVFLGYFERLRACL-NH2	259
JBT0305	JBT0047	Ac-FQSKKNVVFQGYFERLRACL-NH2	260
JBT0306	JBT0047	Ac-FQSKKNVFSGYFERLRACL-NH2	185
JBT0307	JBT0047	Ac-FQSKKNVFVYGYFERLRACL-NH2	261
JBT0308	JBT0047	Ac-FQSKKNVVFVFGYKERLRACL-NH2	411
JBT0309	JBT0047	Ac-FQSKKNVVFVFGYYERLRACL-NH2	412
JBT0310	JBT0047	Ac-FQSKKNVVFVFGYFDRLRACL-NH2	262
JBT0311	JBT0047	Ac-FQSKKNVVFVFGYFERLRACN-NH2	748
		TFVDERLLYFLTIGNMGMYAAQLKF	3
JBT0049	JBT0049	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-NH2	3025
JBT0053	JBT0049	Biotinyl-Tds-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-NH2	3006
JBT0057	JBT0049	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-Tds-Lysin(biotin)-NH2	3018
JBT0190	JBT0049	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFRTSKK-NH2	3031
JBT0193	JBT0049	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFKK-NH2	3073
JBT0197	JBT0049	Ac-KKTFVDERLLYFLTIGNMGMYAAQLKFRTSKK-NH2	3076
		VIVFTRHNKLIGYERRY	4
JBT0050	JBT0050	Ac-SGRGCTKVIVFTRHNKLIGYERRYNCYS-NH2	3047
JBT0054	JBT0050	Biotinyl-Tds-SGRGCTKVIVFTRHNKLIGYERRYNCYS-NH2	3002
JBT0058	JBT0050	Ac-SGRGCTKVIVFTRHNKLIGYERRYNCYS-Tds-Lysin(biotin)-NH2	3003
JBT0129	JBT0050	Ac-SGRG[CTKVIVFTRHNKLIGYERRYNC]TS-NH2	3026
JBT0130	JBT0050	Biotinyl-Tds-SGRG[CTKVIVFTRHNKLIGYERRYNC]TS-NH2	3001
JBT0205	JBT0050	Ac-KKSGRGCTKVIVFTRHNKLIGYERRYNCYSK-NH2	3029
JBT0208	JBT0050	Ac-KKSGRGCTKVIVFTRHNKLIGYERRYNNK-NH2	3027
JBT0211	JBT0050	Ac-KKGCTKVIVFTRHNKLIGYERRYNCYSK-NH2	3032
JBT0212	JBT0050	Ac-KKKVIVFTRHNKLIGYERRYNCYSK-NH2	3033
JBT0217	JBT0050	Ac-KKTKVIVFTRHNKLIGYERRYKK-NH2	3062
JBT0218	JBT0050	Ac-KKKVIVFTRHNKLIGYERRYNNK-NH2	3063
JBT0219	JBT0050	Ac-KKVIVFTRHNKLIGYERRYNCCK-NH2	3030
		GVWQTHPRYFWTMWPDIKGEVIVLFGT	5
JBT0101	JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSK-NH2	3036
JBT0052	JBT0101	Biotinyl-Tds-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSK-NH2	3004
JBT0103	JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTS-Tds-KK-Lysin(biotinyl)-NH2	3005
JBT0178	JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTKK-NH2	3028
JBT0182	JBT0101	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGTSK-NH2	3037
		KWFCGMRDMKGTMSCVWVKF	6
JBT0120	JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1047
JBT0124		Biotinyl-Tds-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1290
JBT0247	JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1213
JBT0248	JBT0120	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSK-NH2	1001
JBT0251	JBT0120	Ac-KKKWFCGMRDMKGTMSCVWVKFKK-NH2	1202
JBT0252	JBT0120	Ac-KKCGMRDMKGTMSCVWVKFRYDKK-NH2	1215
		ASFPLAVQLHVSKRSKEMA	7
JBT0122	JBT0122	Ac-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2	2002
JBT0126	JBT0122	Biotinyl-Tds-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2	2498
JBT0221	JBT0122	Ac-KKSGYASFPLAVQLHVSKRSKEMALARLYYKTSK-NH2	2003
JBT0224	JBT0122	Ac-KKSGYASFPLAVQLHVSKRSKEMALARLYYKK-NH2	2298
JBT0225	JBT0122	Ac-KKSGYASFPLAVQLHVSKRSKEMALARLKK-NH2	2128
JBT0226	JBT0122	Ac-KKSGYASFPLAVQLHVSKRSKEMAKK-NH2	2299
JBT0228	JBT0122	Ac-KKASFPLAVQLHVSKRSKEMALARLYYKTSK-NH2	2016
JBT0232	JBT0122	Ac-KKGYASFPLAVQLHVSKRSKEMKK-NH2	2303
JBT0233	JBT0122	Ac-KKYASFPLAVQLHVSKRSKEMAKK-NH2	2304

[00108] This example provides exemplary methods of generating and characterizing TFPI-inhibitory peptides. All peptides in Table 5 were found to bind human TFPI-1 α . Mutation analysis demonstrated that at least one amino acid in a TFPI-binding peptide may be substituted while retaining affinity for TFPI. The peptides of Table 5 tested in ELISA assays bound TFPI-1 α with an EC₅₀ of less than 10 μ M (1×10^{-5} M) and an IC₅₀ of less than 50 μ M.

Example 2

[00109] Selected TFPI-binding peptides were further characterized in terms of “anti-target” binding. This example demonstrates that TFPI-inhibitory peptides exhibit reduced affinity for non-TFPI-1 proteins.

[00110] TFPI-2 was selected as an anti-target because of its similarity to TFPI-1. The binding kinetics of TFPI-binding peptides to human TFPI-1 (residues 29-282 fused at the C-terminus to a 10 His-tag; MW 41 kDa (R&D Systems, Minneapolis, MN; catalog number 2974-PI)) murine TFPI-1 (residues 29-289 fused at the C-terminus to a 10 His-tag; MW 41kDa (R&D Systems; catalogue number 2975-PI)), and TFPI-2 (R&D Systems, Minneapolis, MN) were studied using a BIAcore 3000™ surface plasmon resonance assay (GE Healthcare, Chalfont St. Giles, UK). TFPI proteins were immobilized on a C1 chip (GE Healthcare, Order Code: BR-1005-40) by amine coupling chemistry aiming for 500 RU. Several TFPI-binding peptides were employed as analytes for interacting with the immobilized TFPI proteins. A flow rate of 30 μ l/min was utilized. After 180 seconds, 180 μ l of peptide solution was injected at six different concentrations ranging from 3.84 nM to 656.25 nM, followed by a dissociation time of 480 seconds. The chip was regenerated with 45 μ l 10 mM NaOH. Each binding experiment was preceded and followed by four measurements with HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% P20) plus 1% DMSO and 0.8% P80. BIAevaluation® Version 4.1 software (GE Healthcare) was employed to analyze the data. Sensorgrams were fitted to a 1:1 Langmuir binding curve to determine k_{on} and k_{off} and calculate K_D .

[00111] Certain tested peptides, e.g., JBT0050, JBT0121, JBT0205 and JBT0211, bound to the blank cell and binding constants from those sensorgrams could not be determined. JBT0133 showed weak binding to TFPI-1. Sensorgrams from other peptides gave reliable binding constants. Results from BIAcore analysis of several TFPI-inhibitory peptides is

provided in Table 6 and Figures 19-21. Each of the peptides listed in Table 6 presented a K_D of less than 10 μ M. Sensorgrams of two of the peptides are provided as Figures 9A and 9B.

TABLE 6

Peptide	k_{on} (1/Ms)	k_{off} (1/s)	K_D (M)
JBT0047	4.0×10^5	1.9×10^{-2}	4.7×10^{-8}
JBT0120	1.17×10^6	4.78×10^{-2}	4.08×10^{-8}
JBT0131	1.4×10^5	6.0×10^{-2}	4.31×10^{-7}
JBT0132	3.55×10^4	3.26×10^{-2}	9.17×10^{-7}
JBT0224	6.39×10^4	1.95×10^{-2}	3.05×10^{-7}
JBT0293	6.0×10^5	5.6×10^{-2}	9.5×10^{-8}
JBT0297	5.0×10^5	1.4×10^{-2}	2.9×10^{-8}
JBT0303	8.13×10^5	2.75×10^{-2}	3.4×10^{-8}
JBT0305	7.5×10^5	3.1×10^{-2}	6.1×10^{-8}

[00112] Interaction with the TFPI-2 anti-target also was examined. The maximum signal generated from candidate peptide interaction with human TFPI-2 was much lower than the signals obtained with TFPI-1 as an interaction partner. Kinetic analysis of the low TFPI-2 binding signals was prone to error; therefore, visual comparison of sensorgrams was used to estimate binding affinity. A sensorgram illustrating JBT0120 binding to TFPI-1 and TFPI-2 is provided as Figures 10A and 10B. JBT0120 binds TFPI-2 with 10-fold lower affinity compared to its binding affinity for TFPI-1. JBT0132 also was found to exhibit at least 10-fold greater affinity for TFPI-1 than TFPI-2.

[00113] The data provided by this example confirm that TFPI-inhibitory peptides specifically bind TFPI-1.

Example 3

[00114] The following example describes the characterization of TFPI-inhibitory activity of select peptides identified in Example 1 using a FXa inhibition and extrinsic tenase inhibition assay. Both assays are predictive of activity in plasmatic systems. The extrinsic tenase assay gives insight into the influence of the peptides on (a) the interaction of FXa and TFPI and (b) the interaction of the FXa-TFPI complex with the TF-FVIIa complex. The FXa inhibition assay measures a peptide's influence on the interaction of FXa and TFPI only.

[00115] The extrinsic tenase complex is responsible for FX and FIX activation upon initiation of the coagulation process. The extrinsic complex is composed of FVIIa, Tissue Factor (TF), and FX substrate. To determine the influence of peptides on the TFPI-mediated

inhibition of the extrinsic tenase complex, a coupled enzyme assay was established. Peptides were diluted 1/6.25 from 10 mM stocks (in DMSO) and further diluted by serial 1/4 dilutions in DMSO to prevent unwanted precipitation. TFPI was diluted in HNaCa-HSA (25mM HEPES; 175mM NaCl; 5mM CaCl₂; 0.1% HSA; pH 7.35). FVIIa, lipidated TF, phospholipid vesicles (DOPC/ POPS 80/20), and chromogenic substrate specific for FXa (S-2222 (available from DiaPharma, West Chester, OH)), all diluted in HNaCa-HSA, were added to 96-well plates. After an incubation period, TFPI and peptide dilutions were added, resulting in a final concentration of 2.5% DMSO. FX activation was initiated by adding FX to the wells. FXa-mediated chromogenic substrate conversion was determined by observing an increase in absorbance using a micro-plate reader. The amount of FXa generated at certain time points was calculated from the OD readings. FXa generated at 20 minutes after start of the reaction was considered for calculation of EC₅₀ from plots of peptide concentration versus the inhibition of TFPI (%).

[00116] The functional inhibition of TFPI also was examined using a FXa inhibition assay. A FXa-specific chromogenic substrate (S-2222) and TFPI, both diluted in HNaCa-HSA, were added to 96 well plates. Peptides were diluted 1/6.25 from 10 mM stocks (in DMSO) and further diluted by serial 1/4 dilutions in DMSO to prevent unwanted precipitation. The peptide dilutions (2.5 μ l) were added to the 96 well plates, resulting in a final concentration of 2.5% DMSO. The conversion of chromogenic substrate was triggered by the addition of FXa, and the kinetics of the conversion were measured in a micro-plate reader. Because TFPI inhibits FXa slowly, OD readings after 115 minutes were considered for calculation of the EC₅₀ from plots of peptide concentration versus the inhibition of TFPI (%).

[00117] Results from the extrinsic tenase assay and FXa inhibition assay are provided in Table 7 and Figures 22-27.

TABLE 7

	FXa Inhibition Assay		Extrinsic Tenase Assay	
	EC ₅₀ [μ M]	% inhibition @ 2.5 μ M	EC ₅₀ [μ M]	% inhibition @ 2.5 μ M
JBT0120	0.9	45	0.9	45
JBT0132	1.2	36	0.1	10
JBT0224	n.a.	26	3.5	18
JBT0303	1.2	61	n.a.	8

[00118] Referring to Table 7, JBT0120, JBT0132, and JBT0224 restored extrinsic complex-mediated FX activation in the presence of TFPI-1 with an EC₅₀ of < 2 μ M, resulting in between about 20% to about 60% inhibition of TFPI activity. JBT0047 (EC₅₀=1.4 μ M),

JBT0131 ($EC_{50}=2.2\text{ }\mu\text{M}$), and JBT0293 ($EC_{50}=2.9\text{ }\mu\text{M}$) also restored extrinsic complex activity in the presence of TFPI-1. In addition, JBT0120, JBT0132, JBT0224, and JBT0303 restored FXa activity in the presence of TFPI-1 with an EC_{50} of $< 5\text{ }\mu\text{M}$, resulting in between about 5% to about 50% inhibition of TFPI activity, in the FXa inhibition assay. JBT0047 ($EC_{50}=0.7\text{ }\mu\text{M}$), JBT0131 ($EC_{50}=8.2\text{ }\mu\text{M}$), JBT0293 ($EC_{50}=1.3\text{ }\mu\text{M}$), JBT0297 ($EC_{50}=0.6\text{ }\mu\text{M}$), and JBT0305 ($EC_{50}=2.3\text{ }\mu\text{M}$) also restored activity of FXa in the presence of TFPI-1 in the FXa inhibition assay. This example confirms that peptides of the invention are TFPI antagonists.

Example 4

[00119] In this example, the TFPI inhibitory activity of peptides is established using a plasma-based assay.

[00120] The influence of peptides on thrombin generation was measured in duplicate via calibrated automated thrombography in a Fluoroskan Ascent® reader (Thermo Labsystems, Helsinki, Finland; filters 390 nm excitation and 460 nm emission) following the slow cleavage of the thrombin-specific fluorogenic substrate Z-Gly-Gly-Arg-AMC (Hemker, *Pathophysiol. Haemost. Thromb.*, 33, 4-15 (2003)). Plasma from patients with FVIII or FIX deficiency (George King Bio-Medical Inc., Overland Park, KN) was obtained for testing. The residual coagulation factor activity for each of the plasmas was lower than 1%. As a model for antibody-mediated FVIII deficiency, frozen pooled normal plasma (George King Bio-Medical Inc., Overland Park, KN) was incubated with high titer, heat inactivated, anti-human FVIII plasma raised in goat (4490 BU/ml; Baxter BioScience, Vienna, Austria) giving rise to 50 BU/mL. The plasmas were mixed with corn trypsin inhibitor (CTI) (Hematologic Technologies, Inc., Essex Junction, VT) to inhibit Factor XIIa contamination, resulting in a final concentration of 40 $\mu\text{g/mL}$.

[00121] Pre-warmed (37°C) plasma (80 μL) was added to each well of a 96 well microplate (Immulon 2HB, clear U-bottom; Thermo Electron, Waltham, MA). To trigger thrombin generation by Tissue Factor, 10 μL of PPP low reagent containing low amounts (12 pM) of recombinant human Tissue Factor and phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine (48 μM) (Thrombinoscope BV, Maastricht, The Netherlands) were added. Peptides were diluted 1/7.5 from 10 mM stocks with DMSO, and further diluted 1/8.33 with Aqua-Dest resulting in a DMSO concentration of 12%, providing a 0.5% DMSO concentration in the final assay mix.

Just prior putting the plate into the pre-warmed (37°C) reader, 5 µL of HEPES buffered saline with 5 mg/mL human serum albumin (Sigma-Aldrich Corporation, St. Louis, Missouri, USA) or 12% DMSO in Aqua-Dest was added, followed by addition of the peptide dilutions or reference proteins (FVIII Immunate reference standard (Baxter BioScience, Vienna, Austria); Factor VIII Inhibitor By-Passing Activity (FEIBA) reference standard (Baxter BioScience, Vienna, Austria); NovoSeven (Novo Nordisk, Denmark); and purified human plasma FIX (Enzyme Research Laboratories, South Bend, IL)). Thrombin generation was initiated by dispensing into each well 20 µL of FluCa reagent (Thrombinoscope BV, Maastricht, The Netherlands) containing a fluorogenic substrate and HEPES-buffered CaCl₂ (100 mM). Fluorescence intensity was recorded at 37°C.

[00122] The parameters of the resulting thrombin generation curves were calculated using Thrombinoscope™ software (Thrombinoscope BV, Maastricht, The Netherlands) and thrombin calibrator to correct for inner filter and substrate consumption effects (Hemker, *Pathophysiol. Haemost. Thromb.*, 33, 4-15 (2003)). For calculating the thrombin generating activity of certain peptide concentrations equivalent to the reference proteins (e.g., FVIII Immunate® reference standard, FEIBA reference standard), the thrombin amounts at the peak of each thrombin generation curve (peak thrombin, nM) were plotted against the standard concentrations, and fitted by a non-linear algorithm. Based on this calibration, FVIII Immunate, FIX, FEIBA or NovoSeven equivalent activities were calculated. Results for various peptides are provided in Figures 12-18 and 28-30. Representative results are provided in Table 8. (* denotes that FVIII deficient plasma was obtained from a different donor.)

TABLE 8

	% FVIII-equivalent activity in FVIII deficient plasma @ 10 µM peptide	FEIBA-equivalent activity in FVIII inhibited plasma @ 10 µM peptide [mU/ml]
JBT0120	37.4*	298
JBT0132	5.3	41
JBT0224	16.2	191
JBT0303	20.8	253

[00123] With reference to Table 8, JBT0120, JBT0132, JBT0224, and JBT0303 improved TFPI-dependent thrombin generation in FVIII-depleted plasma to levels exceeding 1% of the level of thrombin generation in plasma containing FVIII (% FVIII-equivalent activity). The tested peptides exhibited approximately 5%-40% FVIII-equivalent activity in FVIII-deficient

plasma. JBT0120 and JBT0132 improved peak thrombin and peak time, dose dependently, as illustrated in Figures 11A and 11B.

Example 5

[00124] The following example demonstrates that the peptides of the invention can be modified by the addition of moieties that enhance physicochemical or pharmacokinetic properties of the peptides. As illustrated below, the addition of 40 kDa PEG to peptides described herein dramatically improved the pharmacokinetic behavior of the peptides.

[00125] Methods of conjugating chemical or biological moieties to peptides are known in the art. To add PEG (polyethylene glycol) to the peptides describe herein, a functional group (AOA = aminooxy acetate) was added to the N-terminus of the peptides for coupling to aldehydes and ketones. Alternatively, a cysteine was added to the C-terminal part of the peptide for coupling with maleimid (Hermanson, *Bioconjugate Techniques*, Academic Press (1996)). The peptides (JBT1586) AOA-FQSKGNVFVDGYFERL-Aib-AKL-NH₂ (SEQ ID NO: 166) and (JBT1587) Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH₂ (SEQ ID NO: 167) were used for N-terminal and C-terminal modification with PEG, respectively. AOA-FQSKGNVFVDGYFERL-Aib-AKL-NH₂ (SEQ ID NO: 166) and Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH₂ (SEQ ID NO: 167) were incubated with excess 40 kDa mPEG-Propionaldehyde (SUNBRIGHT ME-400AL2, NOF, Japan) and 40 kDa mPEG-maleimide (SUNBRIGHT ME-400MA, NOF, Japan), respectively. The resulting PEGylated peptides, JBT1853 and JBT1855, show similar affinities compared to the starting structure Ac-FQSKGNVFVDGYFERL-Aib-AKL-NH₂ (JBT0740) (SEQ ID NO: 66).

[00126] The resulting PEGylated peptides demonstrated significantly increased plasma stability and prolonged plasma half-life in mice. Figure 31 illustrates the results from a pharmacokinetic analysis of the free peptide JBT0740 (Ac-FQSKGNVFVDGYFERL-Aib-AKL-NH₂) (SEQ ID NO: 66) compared to the C-terminally PEGylated peptide JBT1855 (Ac-FQSKGNVFVDGYFERL-Aib-AKLC(PEG(40kD))-NH₂) (SEQ ID NO: 252). In contrast to the unPEGylated peptide, the PEGylated peptide is present at high concentrations in mouse plasma at 100 minutes post-administration. The unPEGylated peptide is rapidly cleared from the plasma.

WHAT IS CLAIMED:

1. A peptide that binds TFPI, comprising the following structure of formula (I):

X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019-X1020 (I) (SEQ ID NO: 3116):

wherein X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

wherein X1002 is an amino acid selected from the group consisting of G, K and Q;

wherein X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

wherein X1004 is an amino acid selected from the group consisting of A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y;

wherein X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y;

wherein X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

wherein X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L, Nmv, P, Q, S, V, W and Y;

wherein X1008 is an amino acid selected from the group consisting of F, H, K, W and Y;

wherein X1009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V;

wherein X1010 is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y;

wherein X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg;

wherein X1012 is Y;

wherein X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y;

wherein X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

wherein X1015 is an amino acid selected from the group consisting of (omega-methyl)-R, D, E, K and R;

wherein X1016 is L;

wherein X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

wherein X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

wherein X1019 is an amino acid selected from the group consisting of Bhk, K, R and V; and

wherein X1020 is either present or absent, whereby in case X1020 is present it is an amino acid selected from the group consisting of Aib, Bhl, C, F, G, H, I, K, L, Nml, Q, R, S, T, V, W and Y.

2. The peptide according to claim 1,

wherein X1001 is an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M, W and Y;

wherein X1002 is Q;

wherein X1003 is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V;

wherein X1004 is an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y;

wherein X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y;

wherein X1006 is an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y;

wherein X1007 is an amino acid selected from the group consisting of I, K, L, Q, V and Y;

wherein X1008 is an amino acid selected from the group consisting of F, H and Y;

wherein X1009 is an amino acid selected from the group consisting of f, I and V;

wherein X1010 is an amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y;

wherein X1011 is an amino acid selected from the group consisting of G and Nmg;

wherein X1012 is Y;

wherein X1013 is an amino acid selected from the group consisting of Aib, C, F, H, L, W and Y;

wherein X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

wherein X1015 is an amino acid selected from the group consisting of E and R;

wherein X1016 is L;

wherein X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, R, S, T, V and Y;

wherein X1018 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W;

wherein X1019 is an amino acid selected from the group consisting of K and R; and

X1020 is either present or absent, whereby in case X1020 is present it is an amino acid selected from the group consisting of Aib, Bhl, F, K, L, R and W.

3. The peptide according to any of claims 1 to 2,

wherein X1001 is an amino acid selected from the group consisting of F, L, Y and M;

wherein X1002 is Q;

wherein X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C;

wherein X1004 is an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W;

wherein X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M;

wherein X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M;

wherein X1007 is an amino acid selected from the group consisting of I and V;

wherein X1008 is an amino acid selected from the group consisting of F, H and Y;

wherein X1009 is V;

wherein X1010 is an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y;

wherein X1011 is G;

wherein X1012 is Y;

wherein X1013 is an amino acid selected from the group consisting of C and F;

wherein X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib;

wherein X1015 is R;

wherein X1016 is L;

wherein X1017 is an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M;

wherein X1018 is an amino acid selected from the group consisting of A, L, N, M and R;

wherein X1019 is K; and

wherein X1020 is an amino acid selected from the group consisting of K and L.

4. The peptide according to any one of claims 1 to 3, comprising the following structure of formula (II):

X1000-X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019 (II) (SEQ ID NO: 3122)

wherein X1000 is an amino acid which is selected from the group consisting of A, E and P and wherein any one of X1001 to X1019 is as defined in any one of claims 1 to 3, preferably claim 2 and more preferably claim 3.

5. The peptide according to claim 4, wherein the peptide consists of the structure of formula (II).

6. The peptide according to any one of claims 1 to 5, wherein the IC_{50} of the peptide is less than 1000 nM.

7. The peptide according to any one of claims 2 to 5, wherein the IC_{50} of the peptide is less than 250 nM.

8. The peptide according to any one of claims 3 to 5, wherein the IC_{50} of the peptide is less than 50 nM.

9. The peptide according to any one of claims 6 to 8, wherein the IC_{50} is determined by competition enzyme-linked immunosorbent assay (ELISA).

10. A peptide that binds TFPI, comprising the following structure of formula (III):

X1001-Q-X1003-X1004-X1005-X1006-I/V-X1008-V-X1010-G-Y-C/F-X1014-R-L-X1017-X1018-K-K/L (III) (SEQ ID NO: 3117)

wherein X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 are each independently selected from any amino acid.

11. The peptide according to claim 10, wherein IC_{50} of the peptide is less than 1000 nM as determined by competition ELISA.

12. The peptide according to any one of claims 10 to 11, wherein

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

preferably X1001 is an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M, W and Y; and

more preferably X1001 is an amino acid selected from the group consisting of F, L, Y and M.

13. The peptide according to any one of claims 10 to 12, wherein

X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

preferably X1003 is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V; and

more preferably X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C.

14. The peptide according to any one of claims 10 to 13, wherein

X1004 is an amino acid selected from the group consisting of, A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y;

preferably X1004 is an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y; and

more preferably X1004 is an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W.

15. The peptide according to any one of claims 10 to 14, wherein

X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y;

preferably X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y; and

more preferably X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M.

16. The peptide according to any one of claims 10 to 15, wherein

X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

preferably X1006 is an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y; and

more preferably X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M.

17. The peptide according to any one of claims 10 to 16, wherein

X1008 is an amino acid selected from the group consisting of F, H, K, W and Y; and

preferably X1008 is an amino acid selected from the group consisting of F, H and Y.

18. The peptide according to any one of claims 10 to 17, wherein

X1010 is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y;

preferably X1010 is an amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y; and

more preferably X1010 is an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y.

19. The peptide according to any one of claims 10 to 18, wherein

X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

preferably X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y; and

more preferably X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib.

20. The peptide according to any one of claims 10 to 19, wherein

X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

preferably X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, R, S, T, V and Y; and

more preferably X1017 is an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M.

21. The peptide according to any one of claims 10 to 20, wherein

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

preferably X1018 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W; and

more preferably X1018 is an amino acid selected from the group consisting of A, L, N, M and R.

22. The peptide according to anyone of claims 1 to 21 further comprising one or more N-terminal amino acid(s) directly linked to X1001, wherein the N-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of

X1000,
 X999-X1000,
 X998-X999-X1000,
 X997-X998-X999-X1000 (SEQ ID NO: 3123),
 X996-X997-X998-X999-X1000 (SEQ ID NO: 3124),
 X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125),
 X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3126),
 X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127),
 X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO:
 3128),
 X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO:
 3129), and
 X990-X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ
 ID NO: 3130),

wherein X1000 is A or K, X999 is V or K, X998 is Q or K, X997 is L or K, X996 is R
 or K, X995 is G or K, X994 is V or K, X993 is G or K, X992 is S or K, X991 is K, and X990
 is K.

23. The peptide according to anyone of claims 1 to 22 further comprising one or more C-
 terminal amino acid(s) directly linked to X1020, wherein the C-terminal amino acid(s)
 comprise the amino acid sequence selected from the group consisting of X1021, X1021-
 X1022, X1021-X1022-X1023, and X1021-X1022-X1023-X1024 (SEQ ID NO: 3131),

wherein X1021 is T or K, X1022 is S or K, X1023 is K, and X1024 is K.

24. The peptide according to any one of claims 1 to 23, wherein the peptide contains at
 least two cysteine residues, preferably the peptide contains two cysteine residues, wherein the
 at least two cysteine residues are spaced apart by at least three amino acid residues of any of
 formulae (I) to (III) and wherein the at least two cysteine residues form together an
 intramolecular disulfide bond.

25. The peptide according to claim 24, wherein the at least two cysteine residues are
 spaced apart by more than three amino acid residues.

26. The peptide according to any one of claims 24 to 25, wherein any two of X1000, X1001, X1003, X1004, X1005, X1006, X1010, X1011, X1013, X1014, X1017, X1018, X1020 and X1021 is C.

27. The peptide according to any one of claims 24 to 26, wherein the peptide contains two cysteine residues,

wherein one of X1000, X1005, X1010 and X1014 is C; and

wherein one of X1006, X1010, X1017 and X1021 is C.

28. The peptide according to claim 27, wherein

X1000 and X1006 are C; or

X1000 and X1010 are C; or

X1000 and X1017 are C; or

X1005 and X1017 are C; or

X1010 and X1017 are C; or

X1010 and X1021 are C; or

X1014 and X1021 are C.

29. A peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence of formula IV:

Ac-FQSK-Nmg-NVFVDGYFERL-Aib-AKL-NH₂ (IV) (SEQ ID NO: 164)

30. The peptide according to claim 29, wherein the amino acid sequence identity is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95 % or 100%.

31. The peptide according to any one of claim 29 to 30, wherein the peptide comprises an amino acid sequence as defined in any of claims 1 to 21.

32. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 8-741, 744-968, and 971-978.

33. A peptide that binds TFPI, comprising the following structure of formula V:

X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V)
(SEQ ID NO: 3118)

wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;

wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;

wherein X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;

wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;

wherein X2005 is W;

wherein X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;

wherein X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;

wherein X2008 is an amino acid selected from the group consisting of A, G, R, S and T;

wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;

wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

wherein X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;

wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;

wherein X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;

wherein X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;

wherein X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;

wherein X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;

wherein X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

wherein X2018 is an amino acid selected from the group consisting of C and D, preferably C;

wherein X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;

wherein X2020 is an amino acid selected from the group consisting of F and W;

wherein X2021 is an amino acid selected from the group consisting of I, L and V;

wherein X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W;

wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.

34. The peptide according to claim 33,

wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S;

wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, M, P, R and S;

wherein X2003 is an amino acid selected from the group consisting of A, F, K, L, S and Y

wherein X2004 is an amino acid selected from the group consisting of A, D, F, G, K, L and S;

wherein X2005 is W;

wherein X2006 is an amino acid selected from the group consisting of F, H, K and L;

wherein X2007 is an amino acid selected from the group consisting of C and HcY;

wherein X2008 is an amino acid selected from the group consisting of A, G and S;

wherein X2009 is an amino acid selected from the group consisting of a, A, K, L, V, M, m, Nle, p and Sem;

wherein X2010 is an amino acid selected from the group consisting of A, G, K, L, P, R and S;

wherein X2011 is an amino acid selected from the group consisting of D, G and S;

wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, l, M, m, Nle, P, S, Sem and s;

wherein X2013 is an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s;

wherein X2014 is an amino acid selected from the group consisting of D, F, G, K, L and S;

wherein X2015 is an amino acid selected from the group consisting of A, D, F, G, I, K, L, M, Nle, S and T;

wherein X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem and Y;

wherein X2017 is an amino acid selected from the group consisting of A, D, F, G, K, L, S, T and Y;

wherein X2018 is C;

wherein X2019 is an amino acid selected from the group consisting of A, F, L, S and V;

wherein X2020 is an amino acid selected from the group consisting of F and W;

wherein X2021 is an amino acid selected from the group consisting of L and V;

wherein X2022 is an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W; and

wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y; and

wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.

35. The peptide according to any one of claims 33 to 34,

wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S;

wherein X2002 is an amino acid selected from the group consisting of A, F, H, K, L, M, R and S;

wherein X2003 is an amino acid selected from the group consisting of F, S and Y;

wherein X2004 is K;

wherein X2005 is W;

wherein X2006 is an amino acid selected from the group consisting of F, H, K and L;

wherein X2007 is C;

wherein X2008 is an amino acid selected from the group consisting of A, G and S;

wherein X2009 is an amino acid selected from the group consisting of M, Nle, p, Sem and V;

wherein X2010 is an amino acid selected from the group consisting of A, K, L, P, R and S;

wherein X2011 is an amino acid selected from the group consisting of D and S;

wherein X2012 is an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, Sem and S;

wherein X2013 is an amino acid selected from the group consisting of A, D, F, G, K, L and S;

wherein X2014 is an amino acid selected from the group consisting of D and G;

wherein X2015 is an amino acid selected from the group consisting of I and T;

wherein X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem and Y;

wherein X2017 is an amino acid selected from the group consisting of S and T;

wherein X2018 is C;

wherein X2019 is an amino acid selected from the group consisting of A, F, L, S and V;

wherein X2020 is W;

wherein X2021 is an amino acid selected from the group consisting of L and V;

wherein X2022 is an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W;

wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, L M, S and Y; and

wherein the peptide comprises a cyclic structure generated by a linkage between X2007 and X2018.

36. The peptide according to any one of claims 33 to 35,

wherein X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L and S;

wherein X2002 is an amino acid selected from the group consisting of H, F, M and R;

wherein X2003 is an amino acid selected from the group consisting of F and Y;

wherein X2004 is K;

wherein X2005 is W;

wherein X2006 is an amino acid selected from the group consisting of F and H;

wherein X2007 is C;

wherein X2008 is an amino acid selected from the group consisting of A, G and S;

wherein X2009 is an amino acid selected from the group consisting of M, Sem and V;

wherein X2010 is an amino acid selected from the group consisting of K, P and R;

wherein X2011 is D;

wherein X2012 is an amino acid selected from the group consisting of F, L, I, M and Sem;

wherein X2013 is an amino acid selected from the group consisting of D, G, K and S;

wherein X2014 is G;

wherein X2015 is an amino acid selected from the group consisting of I and T;

wherein X2016 is an amino acid selected from the group consisting of D, F, M, Sem and Y;

wherein X2017 is an amino acid selected from the group consisting of S and T;

wherein X2018 is C;

wherein X2019 is an amino acid selected from the group consisting of A and V;

wherein X2020 is W;

wherein X2021 is V;

wherein X2022 is an amino acid selected from the group consisting of F, L, K, R, P and W;

wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid sequence selected from the group consisting of A, D, F, M, S and Y; and

wherein the peptide comprises as a cyclic structure generated by a linkage between X2017 and X2018.

37. The peptide according to any one of claims 33 to 36, wherein the IC₅₀ of the peptide is less than 1000 nM.

38. The peptide according to any one of claims 34 to 36, wherein the IC₅₀ of the peptide is less than 250 nM.

39. The peptide according to any one of claims 35 to 36, wherein the IC₅₀ of the peptide is less than 50 nM.

40. The peptide according to any one of claims 37 to 39, wherein the IC₅₀ is determined by competition ELISA.

41. A peptide that binds TFPI, comprising the following structure of formula (VI):

X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V-X2010-D-X2012-X2013-G-I/T-X2016-S/T-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119)

wherein X2001, X2002 and X2023 are each independently present or absent, wherein, if any of X2001, X2002 and X2023 is present, any of X2001, X2002 and X2023 is independently selected from any amino acid; and

wherein X2008, X2010, X2012, X2013, X2016 and X2022 are each independently selected from any amino acid.

42. The peptide according to claim 41, wherein IC₅₀ of the peptide is less than 1000 nM, preferably as determined by competition ELISA.

43. The peptide according to any one of claims 41 to 42, wherein

X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;

preferably X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S; and

more preferably X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L and S.

44. The peptide according to any one of claims 41 to 43, wherein

X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;

preferably X2002 is an amino acid selected from the group consisting of A, D, F, G, H, K, L, M, P, R and S;

more preferably X2002 is an amino acid selected from the group consisting of A, F, H, K, L, M, R and S; and

most preferably X2002 is an amino acid selected from the group consisting of H, F, M and R.

45. The peptide according to any one of claims 41 to 44, wherein

X2008 is an amino acid selected from the group consisting of A, G, R, S and T; and

preferably X2008 is an amino acid selected from the group consisting of A, G and S.

46. The peptide according to any one of claims 41 to 45, wherein

X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

preferably X2010 is an amino acid selected from the group consisting of A, G, K, L, P, R and S;

more preferably X2010 is an amino acid selected from the group consisting of A, K, L, P, R and S; and

most preferably X2010 is an amino acid selected from the group consisting of K, P and R.

47. The peptide according to any one of claims 41 to 46, wherein

X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;
preferably X2012 is an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, l, M, m, Nle, P, S, Sem and s;
more preferably X2012 is an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, Sem and S; and
most preferably X2012 is an amino acid selected from the group consisting of F, L, l, M and Sem.

48. The peptide according to any one of claims 41 to 47, wherein

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;
preferably X2013 is an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s;
more preferably X2013 is an amino acid selected from the group consisting of A, D, F, G, K, L and S; and
most preferably X2013 is an amino acid selected from the group consisting of D, G, K and S.

49. The peptide according to any one of claims 41 to 48, wherein

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;
preferably X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem and Y;
more preferably X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, Sem and S; and
most preferably X2016 is an amino acid selected from the group consisting of F, Sem and M.

50. The peptide according to any one of claims 41 to 49, wherein

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W;
preferably X2022 is an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W;

more preferably X2022 is an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W; and

most preferably X2022 is an amino acid selected from the group consisting of F, L, K, R, P and W.

51. The peptide according to any one of claims 41 to 50, wherein

X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, M, S, T, V, W and Y;

preferably X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y;

more preferably X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, L M, S and Y; and

most preferably X2023 is either present or absent, whereby in case X2023 is present it is amino acid selected from the group consisting of A, D, F, M, S and Y.

52. A peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence of formula VII:

Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH₂ (VII) (SEQ ID NO: 1040)

53. The peptide according to claim 52, wherein the amino acid sequence identity is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

54. The peptide according to any one of claim 52 to 53, wherein the peptide comprises an amino acid sequence as defined in any of claims 41 to 51.

55. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1210 and 1213-1293.

56. A peptide that binds TFPI, comprising the following structure of formula (VIII):

X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120):

wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;

wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L;

wherein X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;

wherein X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

wherein X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;

wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

wherein X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

wherein X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

wherein X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

wherein X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;

wherein X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

wherein X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

wherein X3015 is an amino acid selected from the group consisting of A, K and R;

wherein X3016 is an amino acid selected from the group consisting of A, F, K and R;

wherein X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

wherein X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

wherein X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

wherein X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P; and

wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G.

57. The peptide according to claim 56,

wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;

wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L;

wherein X3003 is an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W;

wherein X3004 is an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P;

wherein X3005 is an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y;

wherein X3006 is an amino acid selected from the group consisting of P, H and A;

wherein X3007 is an amino acid selected from the group consisting of C, G, R, W, A and L;

wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I;

wherein X3009 is an amino acid selected from the group consisting of C, I, R, V and K;

wherein X3010 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R, S and T;

wherein X3011 is an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H;

wherein X3012 is an amino acid selected from the group consisting of H and R;

wherein X3013 is an amino acid selected from the group consisting of C, F, K, L, M, R, V and I;

wherein X3014 is an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K;

wherein X3015 is an amino acid selected from the group consisting of K and R;

wherein X3016 is K;

wherein X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M;

wherein X3018 is an amino acid selected from the group consisting of A, K, C, I, L, R and W;

wherein X3019 is an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I;

wherein X3020 is an amino acid selected from the group consisting of C, H, L, M, R, V, I and P;

wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, Y, F and G.

58. The peptide according to any one of claims 56 and 57,

wherein X3001 is an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y;

wherein X3002 is an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L;

wherein X3003 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W;

wherein X3004 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, N, R, S, T and P;

wherein X3005 is an amino acid selected from the group consisting of C, F, H, K, R and W;

wherein X3006 is an amino acid selected from the group consisting of A, P and H;

wherein X3007 is an amino acid selected from the group consisting of L, C, R and W;

wherein X3008 is an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I;

wherein X3009 is an amino acid selected from the group consisting of C, R, V and K;

wherein X3010 is an amino acid selected from the group consisting of A, C, K, L, Q, R and S;

wherein X3011 is an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H;

wherein X3012 is H;

wherein X3013 is an amino acid selected from the group consisting of C, K, R, V and I;

wherein X3014 is an amino acid selected from the group consisting of A, S, C, F, H, I, R and K;

wherein X3015 is an amino acid selected from the group consisting of K and R;

wherein X3016 is R;

wherein X3017 is an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M;

wherein X3018 is an amino acid selected from the group consisting of K, C, I, R and W;

wherein X3019 is an amino acid selected from the group consisting of C, E, H, K, R and I;

wherein X3020 is an amino acid selected from the group consisting of C, M, I and P;

wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G.

59. The peptide according to any one of claims 56 to 58, wherein the IC_{50} of the peptide is less than 50,000 nM.

60. The peptide according to any one of claims 57 to 58, wherein the IC_{50} of the peptide is less than 10,000 nM.

61. The peptide according to claim 58, wherein the IC_{50} of the peptide is less than 5,000 nM.

62. The peptide according to any one of claims 59 to 60, wherein the IC_{50} is determined by competition ELISA.

63. A peptide that binds TFPI, comprising the following structure of formula (IX):

X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H-
X3013-X3014-K/R-R-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121)

wherein X3001 and X3002 are independently either present or absent, wherein, if X3001 and/or X3002 are present, X3001 and/or X3002 are independently selected from any amino acid, and

wherein X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid.

64. The peptide according to claim 63, wherein

X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;

preferably X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y; and

more preferably X3001 is an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y.

65. The peptide according to any one of claims 63 to 64, wherein

X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L;

preferably X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L; and

more preferably X3002 is an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L.

66. The peptide according to any one of claims 63 to 65, wherein

X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, and Y;

preferably X3003 is an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W; and

more preferably X3003 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W.

67. The peptide according to any one of claims 63 to 66, wherein

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

preferably X3004 is an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P; and

more preferably X3004 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, N, R, S, T and P.

68. The peptide according to any one of claims 63 to 67, wherein

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

preferably X3005 is an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y; and

more preferably X3005 is an amino acid selected from the group consisting of C, F, H, K, R and W.

69. The peptide according to any one of claims 63 to 68, wherein

X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H; and

preferably X3006 is an amino acid selected from the group consisting of P, H and A.

70. The peptide according to any one of claims 63 to 69, wherein

X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

preferably X3007 is an amino acid selected from the group consisting of C, G, R, W, A and L; and

more preferably X3007 is an amino acid selected from the group consisting of L, C, R and W.

71. The peptide according to any one of claims 63 to 70, wherein

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

preferably X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I; and

more preferably X3008 is an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I.

72. The peptide according to any one of claims 63 to 71, wherein

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

preferably X3009 is an amino acid selected from the group consisting of C, I, R, V and K; and

more preferably X3009 is an amino acid selected from the group consisting of C, R, V and K.

73. The peptide according to any one of claims 63 to 72, wherein

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

preferably X3010 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R, S and T; and

more preferably X3010 is an amino acid selected from the group consisting of A, C, K, L, Q, R and S.

74. The peptide according to any one of claims 63 to 73, wherein

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

preferably X3011 is an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H; and

more preferably X3011 is an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H.

75. The peptide according to any one of claims 63 to 74, wherein

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

preferably X3013 is an amino acid selected from the group consisting of C, F, K, L, M, R, V, and I; and

more preferably X3013 is an amino acid selected from the group consisting of C, K, R, V and I.

76. The peptide according to any one of claims 63 to 75, wherein

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

preferably X3014 is an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K; and

more preferably X3014 is an amino acid selected from the group consisting of A, S, C, F, H, I, R and K.

77. The peptide according to any one of claims 63 to 76, wherein

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

preferably X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M; and

more preferably X3017 is an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M.

78. The peptide according to any one of claims 63 to 77, wherein

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

preferably X3018 is an amino acid selected from the group consisting of A, K, C, I, L, R and W; and

more preferably X3018 is an amino acid selected from the group consisting of K, C, I, R and W.

79. The peptide according to any one of claims 63 to 78, wherein

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

preferably X3019 is an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I; and

more preferably X3019 is an amino acid selected from the group consisting of C, E, H, K, R and I.

80. The peptide according to any one of claims 63 to 79, wherein

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P;

preferably X3020 is an amino acid selected from the group consisting of C, H, L, M, R, V, I and P; and

more preferably X3020 is an amino acid selected from the group consisting of C, M, I and P.

81. The peptide according to any one of claims 63 to 80, wherein

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G;

preferably X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, Y, F and G; and

more preferably X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G.

82. The peptide according to any one of claims 63 to 81, wherein the IC_{50} of the peptide is less than 50,000 nM, preferably less than 10,000 nM and more preferably less than 5,000 nM.

83. A peptide that binds TFPI, comprising an amino acid sequence of at least 60 % identity to the sequence of formula (X):

Ac-GYASFPWFVQLHVHKRSWEMA-NH₂ (X) (SEQ ID NO: 223).

84. The peptide according to claim 83, wherein the amino acid sequence identity is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

85. The peptide according to any one of claim 83 to 84, wherein the peptide comprises an amino acid sequence as defined in any of claims 56 to 82.

86. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2126, 2128-2296, and 2298-2498.

87. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3048, 3051-3053, 3055, 3057-3064, and 3066-3108.

88. The peptide according to any one of claims 1 to 87, wherein the peptide binds to TFPI.

89. The peptide according to any one of claims 1 to 88, wherein said peptide inhibits TFPI activity, whereby preferably the peptide binds to TFPI 1-alpha with a dissociation constant of less than 10 μ M.
90. The peptide according to any one of claims 1-89, wherein the peptide is conjugated to a polyethylene glycol (PEG) moiety.
91. A peptide according to any one of claims 1 to 90 for use in a method for the treatment of a subject.
92. The peptide according to claim 91, wherein the method is for the treatment of a blood coagulation disorder.
93. Use of a peptide according to any one of claims 1 to 90 for the manufacture of a medicament.
94. Use of a peptide according to any one of claims 1 to 90 for the manufacture of a medicament for the treatment of a blood coagulation disorder.
95. A method for treating a blood coagulation disorder in a subject, the method comprising administering to the subject a peptide that inhibits TFPI activity, wherein the peptide is administered in an amount sufficient to treat the blood coagulation disorder in the subject.
96. The method according to claim 95, wherein the peptide is different from a naturally occurring peptide which inhibits TFPI activity.
97. The method according to any one of claims 95 to 96, wherein the peptide is a peptide as defined in any one of claims 1 to 90.
98. The method according to any one of claims 95 to 96, wherein the peptide comprises 40 amino acids or less, preferably the peptide comprises 25 amino acids or less, and more preferably the peptide comprises 10 amino acids or less.

99. The method according to any one of claims 95 to 98, preferably claim 98, wherein the peptide comprises one or more D-amino acids.

100. The method according to any one of claims 95 to 99, preferably 98 to 99, wherein the peptide comprises one or more non-natural amino acids.

101. The method according to claim 100, wherein the one or more non-natural amino acids are selected from the group consisting of 2-aminobutyric acid, 2-amino-isobutyric acid, β -alanine, β -homoglutamic acid, β -homophenylalanine, β -homolysine, β -homoleucine, β -homoasparagine, β -homoglutamine, β -homoarginine, β -homoserine, β -homotyrosine, β -homoaspartic acid, β -homovaline, β -homoasparagin, (S)-cyclohexylalanine, (S)-citrullin, (S)-2,4-diaminobutyric acid, (S)-2,4-diaminobutyric acid, (S)-diaminopropionic acid, (S)-2-propargylglycine, (S)-N(omega)-nitro-arginine, L-homophenylalanine, S)-homo-arginine, (S)-homo-citrulline, (S)-homo-cysteine, (S)-2-amino-5-methyl-hexanoic acid, (S)-homolysine, (S)-norleucine, (S)-N-methylalanine, (S)-N-methyl-aspartic acid, (S)-N-methyl-glutamic acid, (S)-N-methyl-phenylalanine, N-methyl-glycine, (S)-N-methyl-lysine, (S)-N-methyl-leucine, (S)-N-methyl-arginine, (S)-N-methyl-serine, (S)-N-methyl-valine, (S)-N-methyl-tyrosine, (S)-2-amino-pentanoic acid, (S)-2-pyridyl-alanine, (S)-ornithine, L-phenylglycin, 4-phenyl-butyric acid and selenomethionine.

102. The method according to any one of claims 95 to 101, wherein the subject is Factor VIII or Factor IX deficient.

103. The method according to any one of claims 95 to 102, wherein the peptide binds to TFPI 1alpha with a dissociation constant of less than 10 μ m.

104. The method according to any one of claims 95 to 103, wherein the peptide is linked to an effector moiety.

105. The method according to any one of claims 95 to 103, wherein the peptide is linked to biotin.

106. A pharmaceutical composition comprising a peptide as defined any one of claims 1-90 and a pharmaceutical acceptable carrier.

107. The pharmaceutical composition according to claim 106, wherein the composition comprises a further pharmaceutically effective agent.

108. The pharmaceutical composition according to any one of claims 106 to 107, wherein the pharmaceutical composition is for use in a method as defined in any one of claims 94 to 106.

109. A method for targeting a cell displaying TFPI, wherein the method comprises contacting the cell with a peptide as defined in any one of claims 1 to 90.

110. The method of claim 109, wherein the cell is in a mammal, and contacting the cell comprises administering the peptide to the mammal.

111. The method according to any one of claims 109 to 110, wherein the further comprises detecting peptide binding to TFPI displayed on the cell.

112. The method according to any of claims 109 to 111, wherein the peptide is conjugated to a moiety, wherein such moiety is preferably selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

113. The method according to claim 111, wherein peptide-TFPI binding is detected by detecting an interaction partner complexed with the peptide or the moiety.

114. The method according to claim 113, wherein the interaction partner is selected from the group consisting of an antibody, an anticalin, an aptamer, and a spiegelmer.

115. The method according to any one of claims 113 to 114, wherein the interaction partner comprises a detection moiety.

116. The method according to claim 115, wherein the detection moiety is selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, and an enzyme.

117. A method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the method comprises administering to the subject a peptide as defined in any one of claims 1-90, wherein the peptide is conjugated to a therapeutic agent.

118. A method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the method comprises administering to the subject a peptide as defined in any one of claims 1-90, and administering to the subject an interaction partner that (a) binds the peptide and (b) is a therapeutically agent or is conjugated to a therapeutic agent.

119. The method according to claim 118, wherein the interaction partner is selected from the group consisting of an antibody, an anticalin, an aptamer and a spiegelmer.

120. The method according to any one of claims 117 to 119, wherein the therapeutically effective agent is selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

121. The method according to any one of claims 117 to 120, wherein the disease can be treated or the disease symptoms can be ameliorated by the inhibition of TFPI.

122. The method according to claim 121, wherein the disease is a blood coagulation disorder.

123. A method for diagnosing a subject suffering from a disease or being at risk of suffering from a disease, comprising

- (a) administering to the subject a peptide as defined in any one of claims 1-90 conjugated to a detectable moiety and
- (b) detecting the detectable moiety.

124. A method for diagnosing a subject suffering from a disease or being at risk of suffering from a disease, comprising

- (a) administering to the subject a peptide as defined in any one of claims 1-90,
- (b) administering to the subject an interaction partner conjugated to a detectable moiety, and
- (c) detecting the detectable moiety.

125. The method according to claim 124, wherein the interaction partner is selected from the group consisting of an antibody, an anticalin, an aptamer, and a spiegelmer.

126. The method according to any one of claims 123 to 125, wherein the detectable moiety is selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

127. The method according to any one of claims 123 to 126, wherein the disease is a disease which is associated with TFPI, which can be treated or the symptoms of which can be ameliorated by the inhibition of TFPI.

128. The method according to claim 127, wherein the disease is a blood coagulation disorder.

129. A method for purifying TFPI, wherein the method comprises

- a) contacting a sample containing TFPI with a peptide as defined in any one of claims 1-90 under conditions appropriate to form a complex between TFPI and the peptide;
- b) removing the complex from the sample; and, optionally,
- c) dissociating the complex to release TFPI.

130. The method according to claim 131, wherein the peptide is immobilized to a support, preferably a solid support.

131. The method according to any one of claims 129 to 130, wherein the peptide is immobilized to a chromatography stationary phase, and step (c) comprises eluting TFPI bound to the immobilized peptide.

133. The method according to claim 132, wherein the peptide is purified via affinity chromatography.






FIGURE 1

**FIGURE 2**

**FIGURE 3**

Base Sequence JBT0293	FQSKKNVFVFGYFERLRAKL	(SEQ ID NO: 256)
JBT0294	Ac- <u>Y</u> QSKKNVFVFGYFERLRAKL-NH ₂	(SEQ ID NO: 257)
JBT0295	Ac-F <u>S</u> SKKNVFVFGYFERLRAKL-NH ₂	(SEQ ID NO: 713)
JBT0296	Ac-FQ <u>N</u> KKNVFVFGYFERLRAKL-NH ₂	(SEQ ID NO: 407)
JBT0297	Ac-FQSK <u>N</u> NVFVFGYFERLRAKL-NH ₂	(SEQ ID NO: 183)
JBT0298	Ac-FQSK <u>Q</u> NVFVFGYFERLRAKL-NH ₂	(SEQ ID NO: 747)
JBT0299	Ac-FQSKKNVF <u>A</u> FGYFERLRAKL-NH ₂	(SEQ ID NO: 408)
JBT0300	Ac-FQSKKNVF <u>S</u> FGYFERLRAKL-NH ₂	(SEQ ID NO: 409)
JBT0301	Ac-FQSKKNVF <u>T</u> FGYFERLRAKL-NH ₂	(SEQ ID NO: 410)
JBT0302	Ac-FQSKKNVFV <u>A</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 258)
JBT0303	Ac-FQSKKNVFV <u>D</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 184)
JBT0304	Ac-FQSKKNVFV <u>L</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 259)
JBT0305	Ac-FQSKKNVFV <u>Q</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 260)
JBT0306	Ac-FQSKKNVFV <u>S</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 185)
JBT0307	Ac-FQSKKNVFV <u>Y</u> GYFERLRAKL-NH ₂	(SEQ ID NO: 261)
JBT0308	Ac-FQSKKNVFVFGY <u>K</u> ERLRAKL-NH ₂	(SEQ ID NO: 411)
JBT0309	Ac-FQSKKNVFVFGY <u>Y</u> ERLRAKL-NH ₂	(SEQ ID NO: 412)
JBT0310	Ac-FQSKKNVFVFGYF <u>D</u> RLRAKL-NH ₂	(SEQ ID NO: 262)
JBT0311	Ac-FQSKKNVFVFGYFERLRAK <u>N</u> -NH ₂	(SEQ ID NO: 748)

FIGURE 4




FIGURE 5




FIGURE 6A






FIGURE 6B

JBT-00000132:BATCH-02

+ EC50 Data

Binding %

**FIGURE 7**

**FIGURE 8A**

JBT-00000047:BATCH-01




FIGURE 8B

JBT-00000120:BATCH-03




FIGURE 8C

JBT-00000122:BATCH-01




FIGURE 8D




FIGURE 9A




FIGURE 9B




FIGURE 10A




FIGURE 10B




FIGURE 11A




FIGURE 11B

FIGURE 12

JBT-0047	SEQUENCE	Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
		EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM
JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 253)	---		NA	---	NA	123	122	
		---		NA	1.23	NA			
		---		NA	---	NA			
		---		NA	2.98	16			
		0.72	82.4	68					
				NA					
		---		49					
JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 253)	---		NA	1.37	20	128	289	68
		1.33	63.10	35	1.46	26			
							160		
							155		
JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2*HCL (SEQ ID NO: 253)								

FIGURE 12

JBT0051	Biotin-Ttds-SGVGRLLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 962)	---		NA	2.49	NA			
		0.53	86.9	66	1.04	19			
JBT0055	Ac-SGVGRLLQVAFQSKKNVFVFGYFERLRAKLTS-Ttds-Lysin(biotin)-NH2 (SEQ ID NO: 963)	---		NA	---	NA			
		---		NA	---	NA			
		---		NA		18			
		0.53	88.4	72	1.67	25			
		---		NA					
JBT0055	Ac-SGVGRLLQVAFQSKKNVFVFGYFERLRAKLTS-Ttds-Lysin(biotin)-NH2 (SEQ ID NO: 963)	---		NA					
JBT0131	Biotin-Ttds-AFQSKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 964)	---		NA	2.02	11	65	173	
		8.20	77.80	23					
JBT0131	Biotin-Ttds-AFQSKKNVFVFGYFERLRAK-NH2*HCl (SEQ ID NO: 964)	10.52	72.06	12	1.67	14	106	45	
		---		14	2.96	14			
JBT0132	Biotin-Ttds-FQSKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)	---		NA	0.06	10	41	102	
		---		44	---	16	28		
		1.15	49.37	36					
JBT0132	Biotin-Ttds-FQSKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)	---		23		11	109		

FIGURE 12

		---		27	---	13	123	53	
JBT0132	Biotin-Tids-FQSKKNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 965)	---		30	---	11	112		
JBT0133	Biotin-Tids-QSKKNVVFVGYFERLRAKL-T-NH2 (SEQ ID NO: 966)	---		NA	0.34	9	28	67	
JBT0134	Biotin-Tids-QSKKNVVFVGYFERLRAK-NH2 (SEQ ID NO: 967)	---		15	---	3	11	--	
JBT0155	Ac- KKS GVGRLQVAFQSKKNVVFVGYFERLRAKL TSKK-NH2 (SEQ ID NO: 8)	---		5					
JBT0156*	Ac- VVEKLTFVQLSFLNRRRFSQYAGFKGAGKV- NH2 (SEQ ID NO: 742)	0.97	77.70	54			67		
JBT0157*	Ac- RVFLYFSGKAGGLVKLVERQAFQTNVSKFR- NH2 (SEQ ID NO: 743)	---		0	---	12	--		
JBT0158	Ac- KKS GVGRLQVAFQSKKNVVFVGYFERLRAKK K-NH2 (SEQ ID NO: 9)	---		34	---	23	30		
JBT0159	Ac-	4.26	88.20	35					
		---		0	---	18	inhib		

FIGURE 12

[illegible]

FIGURE 12

JBT0299	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 408)	---		13	---	5	63		
		15.31	73.69	9	---	6			
JBT0300	Ac-FQSKKNVFSFGYFERLRAKL-NH2 (SEQ ID NO: 409)	---		7	---	3	40		
JBT0301	Ac-FQSKKNVFTFGYFERLRAKL-NH2 (SEQ ID NO: 410)	---		9	---	0	49		
JBT0302	Ac-FQSKKNVAVAGYFERLRAKL-NH2 (SEQ ID NO: 258)	---		55	---	3	220		
		2.10	90.94	47	---	6	249	185	
		2.6	68.2	33	---	8	218		
JBT0303	Ac-FQSKKNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 184)	---		61	---	7	253		
		1.16	93.12	61	---	8	250	218	
		0.92	78.01	54	---	7	244		
					11.16	7	239		
JBT0303	Ac-FQSKKNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 184)	1.76	77.5	45	8.8	9			
JBT0304	Ac-FQSKKNVFLGYFERLRAKL-NH2 (SEQ ID NO: 259)	---		35	---	7	138		
		2.95	75.15	32	12.87	7			
JBT0305	Ac-FQSKKNVVFQGYFERLRAKL-NH2 (SEQ ID NO: 260)	---		46	---	0	207		
		2.28	87.92	45	---	5	223	205	
		3.15	65.6	27	---	4	207		
JBT0306	Ac-FQSKKNVFSFGYFERLRAKL-NH2 (SEQ ID NO: 185)	---		42	---	3	197		
		3.56	94.28	37	---	2	204	174	

FIGURE 12

		3.89	71.4	28	---	5	247		
JBT0307	Ac-FQSKKNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 261)	---		38	---	7	151		
		3.42	85.15	34	8.72	4	182	168	
		3.01	60.2	26	---	9	182		
JBT0308	Ac-FQSKKNVVFVGYKERLRAKL-NH2 (SEQ ID NO: 411)	---		9	---	4	133		
JBT0309	Ac-FQSKKNVVFVGYERLRAKL-NH2 (SEQ ID NO: 412)	---		21	---	7	123		
		4.50	66.79	19	8.55	7			
JBT0310	Ac-FQSKKNVVFVGYFDRLRAKL-NH2 (SEQ ID NO: 262)	---		31	---	5	142		
		3.86	70.81	26	16.98	3	152		
		2.11	47.68	24	---	4	163		
		3.37	48.8	19	---	5			
JBT0311	Ac-FQSKKNVVFVGYFERLRAKN-NH2 (SEQ ID NO: 748)	---		5	---	5	27		
		44.92	68.81	5	3.72	10			
JBT0335	Ac-FQSKKNVVFVGYFERLRAK-NH2 (SEQ ID NO: 749)	6.2	16.4	2	10.48	5	28		
JBT0336	Ac-FQSKNNVVFVAGYFDRLRAKL-OH (SEQ ID NO: 263)	6.52	63	19	12.13	5	186		
JBT0337	Ac-FQSKNNVVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 16)	0.71	69.1	51	13.33	15	219		
JBT0338	Ac-FQSKNNVVFVQGYFDRLRAKL-NH2 (SEQ ID NO: 17)	1.12	60.9	40	8.42	9	197		
JBT0339	Ac-FQSKNNVVFVSGYFDRLRAKL-NH2 (SEQ ID NO: 17)	1.22	66.9	42	19.1	9	230		

FIGURE 12

JBT0379	Ac-FQSKKKNVVFVTGYFERLRAKL-NH2 (SEQ ID NO: 22)	---		31	---	6	226		
		3.13	81.8	36	47,85 ??	12			
JBT0380	Ac-FQSKKKNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 191)	---		27	---	6	199		
		2.59	73.1	34	7.58	10			
JBT0381	Ac-FQSPKKNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 265)	---		30	---	9	173		
		no fit		34	no fit	11			
JBT0385	Ac-FQSKKKNNFVFGYFERLRAKL-NH2 (SEQ ID NO: 672)	---		0	---	2	---		
JBT0386	Ac-FQSKKKNPFVFGYFERLRAKL-NH2 (SEQ ID NO: 415)	---		6	---	5	85		
JBT0388	Ac-FQSKKKNVHVFGYFERLRAKL-NH2 (SEQ ID NO: 192)	---		25	---	6	185		
		4.34	72.5	26	no fit	9			
JBT0389	Ac-FQSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 673)	---		0	---	8	34		
JBT0390	Ac-FQSKKKNVFQFGYFERLRAKL-NH2 (SEQ ID NO: 674)	---		0	---	5	28		
JBT0391	Ac-FQSKKKNVFGVGYFERLRAKL-NH2 (SEQ ID NO: 266)	---		12	---	1	178		
		7.02	73.8	18	---	1			
JBT0392	Ac-FQSKKKNVVFVHGYFERLRAKL-NH2 (SEQ ID NO: 23)	---		32	---	4	228		
		2.48	74.4	37	---	6			
JBT0393	Ac-FQSKKKNVFKGYFERLRAKL-NH2 (SEQ ID NO: 23)	---		20	---	3	268		

FIGURE 12

	NO: 193)		3.02	64.1	28	---	1				
JBT0394	Ac-FQSKKKNVFMGYFERLRAKL-NH2 (SEQ ID NO: 24)		---		10	---	7	115			
JBT0395	Ac-FQSKKKNVFNNGYFERLRAKL-NH2 (SEQ ID NO: 25)		6.83	57.3	12	---	8				
			---		28	---	7	235			
JBT0396	Ac-FQSKKKNVFPVPGYFERLRAKL-NH2 (SEQ ID NO: 194)		2.80	72.1	32	no fit	7				
			---		22	---	6	196			
JBT0397	Ac-FQSKKKNVFRVGYFERLRAKL-NH2 (SEQ ID NO: 195)		4.33	77.2	30	8.71	6				
			---		24	---	4	240			
JBT0398	Ac-FQSKKKNVVFVFGYFEELRAKL-NH2 (SEQ ID NO: 196)		5.09	72.3	23	9.80	0				
			---		4	---	8	--			
JBT0399	Ac-FQSKKKNVVFVFGYFELLRAKL-NH2 (SEQ ID NO: 750)		---		0	---	7	--			
JBT0400	Ac-FQSKKKNVVFVFGYFLRLRAKL-NH2 (SEQ ID NO: 267)		---		1	---	13	--			
JBT0401	Ac-FQSKKKNVVFVFGYFERLRAVL-NH2 (SEQ ID NO: 416)		---		0	---	4	--			
JBT0402	Biotin-Ttds-FQSKNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 973)		0.32	45.41	48	---	11	185			
JBT0403	Biotin-Ttds-FQSKKNVFDVGYFERLRAKL-NH2 (SEQ ID NO: 972)		0.49	64.39	59	---	9	253			
			---		62						
JBT0404	Biotin-Ttds-FQSKKKNVFVFGYFDRLRAKL-NH2		1.89	42.89	24	3.38	14	115			

FIGURE 12

	(SEQ ID NO: 974)																		
JBT0405	Biotin-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 975)	0.86	81.33	59	---	15	142												
JBT0406	Ac-Ttds-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 268)	---		28	---	9	114												

FIGURE 13

JBT-0049		Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
PEPTIDE	SEQUENCE	EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM
JBT0049	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFR _T S-NH ₂ (SEQ ID NO: 3025)	---		NA	---	NA		12	12
		---		NA	---	17	36	44	
		---		NA	---	11			
		---		NA					
		---		17					
JBT0049	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFR _T S-NH ₂ (SEQ ID NO: 3025)	---		10	---	13	49	17	
		---		19	---	8	42		
							53		
JBT0053	Biotin-T _{tds} -SGNTFVDERLLYFLTIGNMGMYAAQLKFR _T S-NH ₂ (SEQ ID NO: 3006)	---		NA	---	11			
		---		NA					
		---		18					
JBT0057	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFR _T S-T _{tds} -L-ysin(biotin)-NH ₂ (SEQ ID NO: 3018)	---		NA	---	15			
		---		NA					
		---		15					
JBT0135	Biotin-T _{tds} -LLYFLTIGNMGMYAAQLKFR-NH ₂ (SEQ ID NO: 3021)	---		NA	---	10 (0,625μ			

FIGURE 13

							M)			
JBT0136	Biotin-Ttds-LYFLTIGNMGMYAAQLKFR T-NH2 (SEQ ID NO: 3014)	---		0	---					
JBT0137	Biotin-Ttds-YFLTIGNMGMYAAQLKFR TS-NH2 (SEQ ID NO: 3013)	---		0	---		2			
JBT0138	Biotin-Ttds-YFLTIGNMGMYAAQLKFR -NH2 (SEQ ID NO: 3012)	---		0	---		4			
JBT0190	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFR TSKK-NH2 (SEQ ID NO: 3031)	---		21	0.49		32	80	72	
JBT0191*	Ac-MLGVLMRGISALTGDY TARFEFYLNKQTEN-NH2 (SEQ ID NO: 3054)	---		27				74		
JBT0192*										
JBT0193	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFK K-NH2 (SEQ ID NO: 3073)			51	1.26		38	140	114	
JBT0194	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQKK-NH2 (SEQ ID NO: 3074)	---		0	---		8			
JBT0195	Ac-KKSGNTFVDERLLYFLTIGNMGMYKK-NH2 (SEQ ID NO: 3075)	---		0	---		5			
JBT0196	Ac-KKSGNTFVDERLLYFLTIGNMCK-NH2 (SEQ ID NO: 3048)	---		0	---		12			
JBT0197	Ac-KKTFVDERLLYFLTIGNMGMYAAQLKFRTSK K-NH2 (SEQ ID NO: 3076)	---		38	0.38		35	146		
		0.91	57.40	39						

FIGURE 13

JBT0198	Ac- KKDERLLYFLTIGNMGMYAAQLKFRTSKK- NH2 (SEQ ID NO: 3077)	---		0	---	17			
JBT0199	Ac-KKLLYFLTIGNMGMYAAQLKFRTSKK- NH2 (SEQ ID NO: 3078)	---		0	---	20			
JBT0200	Ac-KKFLTIGNMGMYAAQLKFRTSKK-NH2 (SEQ ID NO: 3079)	---		0	---	9			
JBT0201	Ac-KKLLYFLTIGNMGMYAAQLKFRKK-NH2 (SEQ ID NO: 3080)	---		2	---	23			
JBT0202	Ac-KKLYFLTIGNMGMYAAQLKFRTKK-NH2 (SEQ ID NO: 3081)	---		0	---	15			
JBT0203	Ac-KKYFLTIGNMGMYAAQLKFRTSKK-NH2 (SEQ ID NO: 3082)	---		0	---	7			
JBT0204	Ac-KKSGNTFVDERLLYFLTIGNMGKK-NH2 (SEQ ID NO: 3060)	---		0	---	5			
JBT0243	Ac- SGDTFVDERLLYFLTIGNMRMYAVQLKRTS- NH2 (SEQ ID NO: 3085)			39	---	37			
JBT0244	Ac- SGDTFVDERLLYFLTIGNMRMYAVQLKRTS- NH2 (SEQ ID NO: 3086)	0.51	41.53	37					
JBT0245	Ac- SGDTFVDERLLYFLTIGDMRMYAVQLKRTS- NH2 (SEQ ID NO: 3087)	---		49					
		---		45	---	NA			
		0.44	50.53	44	---	21			
					---	24			
JBT0344	Ac-TFVDERLLYFLTIGNMGMYAAQLKF-NH2 (SEQ ID NO: 3038)	---		2	---	1	---		

FIGURE 13

JBT0345	Ac-FVDERLLYFLTIGNMGMYAAQLKF-NH2 (SEQ ID NO: 3039)	---		2	---	2	---			
JBT0346	Ac-VDERLLYFLTIGNMGMYAAQLKF-NH2 (SEQ ID NO: 3034)	---		0	---	2	---			
JBT0347	Ac-TFVDERLLYFLTIGNMGMYAAQLK-NH2 (SEQ ID NO: 3040)	---		2	---	4	---			
JBT0348	Ac-TFVDERLLYFLTIGNMGMYAAQ-NH2 (SEQ ID NO: 3084)	---		0	---	2	---			

FIGURE 14

JBT-0050		Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
PEPTIDE	SEQUENCE	EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM
JBT0050	Ac-SGRGCTKVIVFTFRHNKLGYYRRYNCTS-NH2 (SEQ ID NO: 3047)	---		NA	---	NA		81	21
		---			0.14	25	32	38	
		---		NA	---	NA	46		
		---		NA	---	NA	46		
		0.95	56.6	39	0.05	33	49		
		---		NA					
		1.14	58.99	35					
JBT0050	Ac-SGRGCTKVIVFTFRHNKLGYYRRYNCTS-NH2 (SEQ ID NO: 3047)	---		33	---	28	23		
JBT0054	Biotin-Ttds-SGRGCTKVIVFTFRHNKLGYYRRYNCTS-NH2 (SEQ ID NO: 3002)	1.07	35,,6	26	0.14	19	27	36	
		---		NA	0.16	NA			
JBT0058	Ac-SGRGCTKVIVFTFRHNKLGYYRRYNCTS-Ttds-Lysin(biotin)-NH2 (SEQ ID NO: 3003)	0.99	56.1	41	0.45	31			
		---		NA	---	NA			
JBT0129	Ac-SGRGCTKVIVFTFRHNKLGYYRRYNCTS-NH2; Cycl. C5-C27 (SEQ ID NO: 3026)	1.07	60.9	42	0.37	28			
		---		NA	0.16	21	27		

FIGURE 14

JBT0130	Biotin-Ttds- SGRGCTKVIVFTFRHNKLIYERRYNCT-S- NH2; cycl. C6-C28 (SEQ ID NO: 3001)	---		32	0.15	21	31	18	
JBT0139	Biotin-Ttds-GRGCTKVIVFTFRHNKLIY-NH2 (SEQ ID NO: 3008)	---		34	---	9	--	--	
JBT0140	Biotin-Ttds-GCTKVIVFTFRHNKLIYER-NH2 (SEQ ID NO: 3010)	---		7 (0,625μ M)	0.10	15			
JBT0141	Biotin-Ttds-CTKVIVFTFRHNKLIYERR-NH2 (SEQ ID NO: 3009)	---		0	---	10	18	25	
JBT0142	Biotin-Ttds-TKVIVFTFRHNKLIYERRY-NH2 (SEQ ID NO: 3022)	---		0	0.04	NA	12	--	
JBT0143	Biotin-Ttds-KVIVFTFRHNKLIYERRYN-NH2 (SEQ ID NO: 3023)	---		7	1.96	12	19	--	
JBT0144	Biotin-Ttds-VIVFTFRHNKLIYERRYN-NH2 (SEQ ID NO: 3011)	---		6	0.42	17	--	--	
JBT0145	Biotin-Ttds-VIVFTFRHNKLIYER-NH2 (SEQ ID NO: 3024)	---		0	0.03	---	--	--	
JBT0205	Ac- KKSGRGCTKVIVFTFRHNKLIYERRYNCTSK K-NH2 (SEQ ID NO: 3029)	---		40	---	34	134		
JBT0206*	Ac-TNYTGSEKCRFVTRRYLGVRINCFHKS-	1.64	87.46	49	0.11	36	--		
		---		0	---	22	--		

FIGURE 14

JBT0218	Ac-KKKVIVFTFRHNKLIgyerrYNKK-NH2 (SEQ ID NO: 3063)	---		4	1.18	12			
		---		12					
JBT0219	Ac-KKVIVFTFRHNKLIgyerrYNCKK-NH2 (SEQ ID NO: 3030)	---		8	---	17	29		
		---		22	0.10	17			
JBT0220	Ac-KKIVFTFRHNKLIgyerrYNCTKK-NH2 (SEQ ID NO: 3064)	---		0	---	15			
					---	16			
JBT0349	Ac-GCTKVIVFTFRHNKLIgyerrYNCTS-NH2 (SEQ ID NO: 3041)	---		19	---	28	54		
		1.63	27.6	17	0.18	13			
JBT0350	Ac-CTKVIVFTFRHNKLIgyerrYNCTS-NH2 (SEQ ID NO: 3042)	---		21	---	26	55		
		1.65	33.8	18	0.27	16			
JBT0351	Ac-TKVIVFTFRHNKLIgyerrYNCTS-NH2 (SEQ ID NO: 3043)	---		1	---	19	30		
		no fit		0	0.21	8			
JBT0352	Ac-GCTKVIVFTFRHNKLIgyerrYNCT-NH2 (SEQ ID NO: 3044)	---		24	---	24	65		
		1.34	26.3	19	0.35	18			
JBT0353	Ac-GCTKVIVFTFRHNKLIgyerrYNC-NH2 (SEQ ID NO: 3045)	---		28	---	30	76		
		0.72	24.5	21	0.61	20			

FIGURE 15

JBT-0101	SEQUENCE	Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
		EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM
JBT0052	Biotin-Ttds-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTS KK-NH2 (SEQ ID NO: 3004)	---		NA	0.22	20			
		---		NA	0.39	23			
		1.47	57.24	52					
JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTS KK-NH2 (SEQ ID NO: 3036)	---		NA	---	NA	65	164	40
		---		NA	1.42	22			
		2.25	50.13	26	0.24	21			
					---	20			
					0.17	22			
		2.01	45.27	26	---	19	68	38	
JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTS KK-NH2 (SEQ ID NO: 3036)	---		NA			60		
		---		NA					
		---		NA					
JBT0101	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTS KK-NH2 (SEQ ID NO: 3036)	1.51	44.8	31					
		---		29	---	19			

FIGURE 15

		---		18	0.25	14				
		1.94	37.47	19	0.61	19				
JBT0103	Ac- KKS ₆ GVWQTHPRYFWTMWPD ₁ IKGEVIVLFGTS -Ttds-KKL ₁ ysin(biotin)-NH ₂ (SEQ ID NO: 3005)	---		NA	0.19	21				
JBT0176*	Ac- KKVGSVTRWSMYGPIFIKFTWLTLEQPVGWDH KK-NH ₂ (SEQ ID NO: 3056)	1.69	38.91	24	0.17	17				
		---		0	---	17	150			
JBT0177*	Ac- KKLTGDW ₁ TYFWSKV ₁ WGPVIERQMPVSTFH KK-NH ₂ (SEQ ID NO: 3065)	---		4	---	15	--			
					---	10				
					---	10				
JBT0178	Ac- KKS ₆ GVWQTHPRYFWTMWPD ₁ IKGEVIVLFGTK K-NH ₂ (SEQ ID NO: 3028)			42	---	23	190	80		
		1.51	65.93	42	0.20	26	111			
JBT0179	Ac- KKS ₆ GVWQTHPRYFWTMWPD ₁ IKGEVIVLKK- NH ₂ (SEQ ID NO: 3066)	---		0	---	14				
JBT0180	Ac-KKS ₆ GVWQTHPRYFWTMWPD ₁ IKGEVKK- NH ₂ (SEQ ID NO: 3067)	---		0	---	5				
JBT0181	Ac-KKS ₆ GVWQTHPRYFWTMWPD ₁ IKKK-NH ₂ (SEQ ID NO: 3068)	---		0	---	2				
JBT0182	Ac- KKS ₆ GVWQTHPRYFWTMWPD ₁ IKGEVIVLFGTSK K-NH ₂ (SEQ ID NO: 3037)	---		39	0.26	27	146			
		0.62	52.16	40						
JBT0183	Ac- KKQTHPRYFWTMWPD ₁ IKGEVIVLFGTSKK- NH ₂ (SEQ ID NO: 3069)	---		0	---	19				

FIGURE 15

JBT0184	Ac-KKPRYFWTMWPDIKGEVIVLFGTSKK-NH2 (SEQ ID NO: 3070)	---		0	---	26				
JBT0185	Ac-KKFWTMWPDIKGEVIVLFGTSKK-NH2 (SEQ ID NO: 3057)	---		0	---	16				
JBT0186	Ac-KKSGVWQTHPRYFWTMWPDIKGKK-NH2 (SEQ ID NO: 3071)	---		0	---	3				
JBT0187	Ac-KKWQTHPRYFWTMWPDIKGEVIKK-NH2 (SEQ ID NO: 3072)	---		0	---	5				
JBT0188	Ac-KKHPRYFWTMWPDIKGEVIVLFGKK-NH2 (SEQ ID NO: 3058)	---		0	---	21				
					---	17				
JBT0189	Ac-KKYFWTMWPDIKGEVIVLFGTSKK-NH2 (SEQ ID NO: 3059)	---		0	---	19				
JBT0354	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGTK K-NH2 (SEQ ID NO: 3088)	---		26	0.62	14				
		2.25	50.46	25	0.56	18				
JBT0355	Ac-KKVWQTHPRYFWTMWPDIKGEVIVLFGTKK- NH2 (SEQ ID NO: 3089)	---		12	---	14				
JBT0356	Ac-KKWQTHPRYFWTMWPDIKGEVIVLFGTKK- NH2 (SEQ ID NO: 3090)	---		11	no fit	11				
JBT0357	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGKK- NH2 (SEQ ID NO: 3035)	---		30	---	25				
		2.51	55.65	26	0.58	20				
JBT0358	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGK- NH2 (SEQ ID NO: 3046)	---		19	---	27				
		3.26	41.21	15	0.46	16				

FIGURE 16

JBT-0120	SEQUENCE	Progress Curves of Inhibition of FXa				Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation			
		EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM		
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY DTS-NH2 (SEQ ID NO: 1047)	---		NA	0.94	35	298	374	162		
		0.90	85.30	58	1.84	31					
		1.50	88.65	48							
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY DTS-NH2 (SEQ ID NO: 1047)	1.50	74.75	43	0.86	45	355				
							258				
		1.29	69.17	43	0.88	45					
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY DTS-NH2 (SEQ ID NO: 1047)	1.18	50.68	34	1.18	46	326	288			
		---		37	---	48	383				
		---		38			299				
		1.26	46.06	32	0.38	40					
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY DTS-NH2*HCL (SEQ ID NO: 1047)	2.64	93.62	43	0.98	43					
JBT0124	Biotin-TTds-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYD TS-NH2 (SEQ ID NO: 1290)	1.59	73.59	41	1.26	36					
JBT0247	Ac-	---		43	---	44	273				

FIGURE 16

	SGASRYKWF CGMRDMKGTMSCVWVKFRYD TS-NH2 (SEQ ID NO: 1213)	0.79	50.9	42	0.61	42				
JBT0248	Ac- KKSASRYKWF[CGMRDMKGTMSC]VWVKF RYDTSKK-NH2 cyc. (SEQ ID NO: 1001)	---		54	---	60	164			
JBT0249	Ac-KKSASRYKWF CGMRDMKGTMSKK-NH2 (SEQ ID NO: 1214)	0.82	76.13	53	0.27	52				
		---		0	---	3	inhib			
					---	17				
					1.06	16				
JBT0250	Ac-KKSRYKWF CGMRDMKGTMSCVWKK- NH2 (SEQ ID NO: 1201)	---		0		15	inhib			
		---		11	---	20	inhib			
					0.61	19				
					---	17				
JBT0251	Ac-KKKWF CGMRDMKGTMSCVWVKFKK- NH2 (SEQ ID NO: 1202)	---		17	0.63	23	inhib			
		0.66	24.03	16			inhib			
		---		11	---	18				
JBT0252	Ac-KKCGMRDMKGTMSCVWVKFRYDKK- NH2 (SEQ ID NO: 1215)	---		13	1.02	18	inhib			
JBT0253	Ac-KKMRDMKGTMSCVWVKFRYDTSKK-NH2 (SEQ ID NO: 1216)	6.27	37.09	11						
		---		0	---	15	inhib			
					---	23				
					0.55	23				
JBT0319	Ac- SGASRYKWF CGMRDMKGTMSCVWVKFRY- NH2, cyc (SEQ ID NO: 1002)	0.51	71.07	59	---	56	383	293		
JBT0319	Ac- SGASRYKWF CGMRDMKGTMSCVWVKFRY-	0.30	82.38	72	---	60	294	466		

FIGURE 16

	NH2, cys (SEQ ID NO: 1002)	18.80	73.34	9	6.40					
JBT0320	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVK-NH2 (SEQ ID NO: 1103)	---		0	---	1	---	153		
JBT0321	Ac-SGASRYKWF[CGMRDMKGTMSCV-NH2 (SEQ ID NO: 1217)	---		0	---	5	---	--		
JBT0322	Ac-SGASRYKWF[CGMRDMKGTM-NH2 (SEQ ID NO: 1218)	---		0	---	3	---	--		
JBT0322	Ac-SGASRYKWF[CGMRDMKGTM-NH2 (SEQ ID NO: 1218)	---		0	---	48	0.77	355	314	
JBT0323	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1076)	0.72	51.55	42				285		
JBT0324	Ac-KWF[CGMRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1155)	---		0	2.44	18		91		
JBT0325	Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1219)	---		0	---	4	---	--		
JBT0326	Ac-RDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1220)	---		0	---	3	---	--		
JBT0326	Ac-RDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1220)							--		
JBT0327	Ac-SGASRYKWF[CGMRDMKGTMS-NH2 (SEQ ID NO: 1222)	---		0	---	0	---	--		
JBT0328	Ac-SRYKWF[CGMRDMKGTMSCVW-NH2 (SEQ ID NO: 1223)	---		0	---	1	---	--		
JBT0329	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1156)	---		2	---	8	---	70	66	
		---		4	---	13	---	40		
		no fit		7	3.53	6		84		
JBT0330	Ac-CGMRDMKGTMSCVWVKFRYD-NH2 (SEQ ID NO: 1224)	---		0	---	9	---	--		
JBT0330	Ac-[CGMRDMKGTMSC]VWVKFRYD-NH2 (SEQ ID NO: 1224)	---		0	---	7	---			
JBT0331	Ac-MRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1224)	---		0	---	5	---	--		

FIGURE 16

	ID NO: 1225)	---				---	0	---	5			
JBT0331	Ac-MRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1225)	---				---	0	---	5		--	
JBT0332	Ac-SRYKWF CGMRDMKGTMSCVW-NH2 (SEQ ID NO: 1206)	---				---	1	---	5		--	
JBT0333	Ac-KWFCGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1207)	---				---	3	---	12		40	--
											--	
JBT0333	Ac-KWFCGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1207)	---				---	4	---	11		114	
JBT0334	Ac-CGMRDMKGTMSCVWVKFRYD-NH2 (SEQ ID NO: 1227)	---				---	0	---	3		--	
JBT0409	Ac-SGASRYKWFSGMRDMKGTMSVWVKFRYDT S-NH2 (SEQ ID NO: 1204)	---				---	0	---	5		inhib	
JBT0410	Ac-SGASRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKFRYDTS-NH2 (SEQ ID NO: 1208)	---				---	0	---	7		inhib	
JBT0411	Ac-SGASRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKFRYDTS-NH2 (SEQ ID NO: 1104)	---				---	11	---	24		97	
JBT0412	Ac-KWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1209)	---				---	7	---	12		46	
JBT0413	Ac-KWFSGMRDMKGTMSVWVKF-NH2 (SEQ ID NO: 1228)	---				---	0	---	2		inhib	
JBT0414	Ac-KWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1205)	---				---	4	---	8		inhib	
JBT0415	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1003)	---				---	59	---	43		359	
		---					66					
		0.38	74.56	61	0.19		52					
JBT0416	Ac-SRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1077)	---				---	52	---	46		256	
JBT0417	Ac-SRYKWFSGMRDMKGTMSVWVKF-NH2 (SEQ ID NO: 1229)	---				---	2	---	11		inhib	
		no fit		0	no fit		6					

FIGURE 16

JBT0418	Ac-SRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1210)	---		4	---	11	inhib	
JBT0435*	Ac-RKRDVSGKM[CWSGFGSKWFRC]ADMMTYY SVT-NH2 (SEQ ID NO: 1211)	---		0	---	5		
JBT0436*	Ac-RWSGKSTYS[CDAMVRRMGMKC]FSFGWTDV YK-NH2 (SEQ ID NO: 1212)	---		0	---	0		

FIGURE 17

JBT- 0121	SEQUENCE	Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
		EC ₅₀ (μ M)	% Inhibit (Max)	% Inhibit (2.5 μ M)	EC ₅₀ (μ M)	% Inhibit (2.5 μ M)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10 μ M	FVIII Deficient (mU/mL) Conc: 10 μ M	FIX Deficient (mU/mL) Conc: 10 μ M
JBT0121	Ac-SGGRKKHKHFLRSNGKPSRALCSMHFWRWSTS-NH2 (SEQ ID NO: 3091)	---		NA	---	15	22	37	25
		0.08	14.44	14	0.17	11	inhib		
		---		8	---	19			
JBT0125	Biotin-Tids-SGGRKKHLHFLRSNGKPSRALCSMHFWRWSTS-NH2 (SEQ ID NO: 3092)	0.10	17.22	15	0.45	9			
JBT0419	Ac-SGGRKKHKHFLRSNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3093)	---		6	---	7			
JBT0420*	Ac-KGSSRSGHNALKTHSWMSPFRRRGWSLHFK-NH2 (SEQ ID NO: 3094)	---		3	---	10	inhib		
JBT0421*	Ac-KSRSGFWHAWSHRTRPMKSRLLHLGKFSNSSG-NH2 (SEQ ID NO: 3095)	---		3	---	5			
JBT0422	Ac-SGGRKKHKHFLRSNGKPSRALSSMHFWRW-NH2 (SEQ ID NO: 3096)	---		4	---	11	inhib		
JBT0423	Ac-SGGRKKHKHFLRSNGKPSRALSSMHF-NH2 (SEQ ID NO: 3097)	---		2	---	1	inhib		
JBT0424	Ac-SGGRKKHKHFLRSNGKPSRALSS-NH2 (SEQ	---		1	---	0	--		

FIGURE 17

	ID NO: 3098)								
JBT0425	Ac-SGGRKKHKHFLRSNGKPSRA-NH2 (SEQ ID NO: 3099)	---		3	---	0			
JBT0426	Ac-RKKHKHFLRSNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3100)	---		2	---	8	inhib		
JBT0427	Ac-KHFLRSNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3101)	---		0	---	0			
JBT0428	Ac-LRSNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3102)	---		2	---	1	--		
JBT0429	Ac-NGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3103)	---		0	---	0			
JBT0430	Ac-SGGRKKHKHFLRSNGKPSRAL-NH2 (SEQ ID NO: 3104)	---		0	---	0			
JBT0431	Ac-RKKHKHFLRSNGKPSRALSSM-NH2 (SEQ ID NO: 3105)	---		2	---	8			
JBT0432	Ac-KHFLRSNGKPSRALSSMHFW-NH2 (SEQ ID NO: 3106)	---		3	---	1	--		
JBT0433	Ac-LRSNGKPSRALSSMHFWRS-NH2 (SEQ ID NO: 3107)	---		0	---	1	--		
JBT0434	Ac-SNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 3108)	---		0	---	0			

FIGURE 18

JBT-0122	SEQUENCE	Progress Curves of Inhibition of FXa			Extrinsic Tenase Inhibition by TFPI		Factor IIa Generation		
		EC ₅₀ (μM)	% Inhibit (Max)	% Inhibit (2.5μM)	EC ₅₀ (μM)	% Inhibit (2.5μM)	Induced FVIII Deficiency FEIBA EA (mU/mL) Conc: 10μM	FVIII Deficient (mU/mL) Conc: 10μM	FIX Deficient (mU/mL) Conc: 10μM
JBT0122	Ac-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2 (SEQ ID NO: 2002)	---		NA	12.7	5	115	139	60
		15.5	93.8	15	39.5	8	175		
		7.92	78.52	23			183	160	
		---		9	---	9	210		
		---		11					
JBT0122	Ac-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2*HCL (SEQ ID NO: 2002)	15.81	64.12	6	6.70	7			
JBT0126	Biotin-Ttds-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2 (SEQ ID NO: 2498)	---		NA	5.05	5			
		14.1	88.4	17					
JBT0221	Ac-KKSGYASFPLAVQLHVSKRSKEMALARLYYKTSKK-NH2 (SEQ ID NO: 2003)	---		10	3.37	19	218		
		---		29					
JBT0222*	Ac-MKSRSLGLAYFAKHSSLEVLQTRKVAAPYY-NH2 (SEQ ID NO: 2127)	---		0	---	4	--		

FIGURE 18

		13.25	38.12	6					
JBT0233	Ac-KKYASFPLAVQLHVSKRSEKEMAKK-NH2 (SEQ ID NO: 2304)	---		6	---	6			
JBT0234	Ac-KKVQLHVSKRSEKEMALARLYYKKK-NH2 (SEQ ID NO: 2305)	---		8					
JBT0235	Ac-KKQLHVSKRSEKEMALARLYYKTKK-NH2 (SEQ ID NO: 2306)	---		0	---	3			
				0	---	0			
JBT0236	Ac-KKLHVSKRSEKEMALARLYYKTSKK-NH2 (SEQ ID NO: 2307)	---		0	---	0			
JBT0237	Ac-KKSGYASFPLAVQLHVSKRSEKKEK-NH2 (SEQ ID NO: 2308)	---		0	---	2			
JBT0359	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2309)	---		0	---	6	---		
JBT0360	Ac-SFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2310)	---		1	---	2	---		
JBT0361	Ac-FPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2311)	---		0	---	9	---		
JBT0362	Ac-ASFPLAVQLHVSKRSEKEM-NH2 (SEQ ID NO: 2312)	---		0	---	6	---		
JBT0363	Ac-ASFPLAVQLHVSKRSEKE-NH2 (SEQ ID NO: 2313)	---		0	---	9	---		
JBT0364	Ac-ASFPLAVQLHVSKRSEKEMAL-NH2 (SEQ ID NO: 2314)	---		2	---	12	---		
JBT0365	Ac-ASFPLAVQLHVSKRSEKEMALA-NH2 (SEQ ID NO: 2315)	---		0	---	9	---		
JBT0366	Ac-ASFPLAVQLHVSKRSEKEMALAR-NH2 (SEQ ID NO: 2316)	---		0	---	11	---		
JBT0367	Ac-ASFPLAVQLHVSKRSEKEMALARL-NH2 (SEQ ID NO: 2317)	---		2	---	10	28		
JBT0368	Ac-ASFPLAVQLHVSKRSEKEMALARLY-NH2 (SEQ ID NO: 2130)	---		0	---	8	36		
JBT0369	Ac-ASFPLAVQLHVSKRSEKEMALARLYY-NH2	---		2	---	9	68		

FIGURE 18

	(SEQ ID NO: 2017)																		
JBT0370	Ac-YASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2318)	---		2	---	0	39												
JBT0371	Ac-GYASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2319)	---		8	---	1	60												

FIGURE 19

JBT0047 class		BiaCore		
Peptide	Sequence	k_{on} (1/Ms)	k_{off} (1/s)	K_D (M)
JBT0047	Ac-SGVGRQLQVAFQSKKKNVFVFGYFERLRAKLT-S-NH2 (SEQ ID NO: 253)	3.98E+05	1.88E-02	4.72E-08
JBT0131	Biotin-Ttds-AFQSKKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 964)	1.38E+05	5.94E-02	4.31E-07
JBT0132	Biotin-Ttds-FQSKKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)	3.55E+04	3.26E-02	9.17E-07
JBT0155	Ac-KKSGVGRQLQVAFQSKKKNVFVFGYFERLRAKLT-SKK-NH2 (SEQ ID NO: 8)	1.64E+05	7.25E-03	4.41E-08
JBT0158	Ac-KKSGVGRQLQVAFQSKKKNVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 9)	4.49E+05	3.27E-02	7.29E-08
JBT0164	Ac-KKFQSKKKNVFVFGYFERLRAKLT-SKK-NH2 (SEQ ID NO: 12)	2.26E+05	1.05E-02	4.65E-08
JBT0170	Ac-KKFQSKKKNVFVFGYFERLRAKLT-SKK-NH2 (SEQ ID NO: 13)	4.09E+05	9.34E-03	2.28E-08
JBT0175	Ac-KKAFQSKKKNVFVFGYFERLRAKLT-SKK-NH2 (SEQ ID NO: 182)	2.70E+05	1.67E-02	6.18E-08
JBT0293	Ac-FQSKKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 256)	2.17E+05	2.12E-02	9.74E-08
JBT0294	Ac-YQSKKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 257)	5.69E+05	3.92E-02	6.90E-08
JBT0297	Ac-FQSKKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 183)	5.69E+05	3.92E-02	6.90E-08
JBT0302	Ac-FQSKKKNVFVAGYFERLRAKL-NH2 (SEQ ID NO: 258)	1.02E+06	8.47E-02	8.27E-08
JBT0303	Ac-FQSKKKNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 184)	8.13E+05	2.75E-02	3.38E-08
JBT0305	Ac-FQSKKKNVFVQGYFERLRAKL-NH2 (SEQ ID NO: 260)	7.45E+05	3.07E-02	4.11E-08
JBT0306	Ac-FQSKKKNVFVSGYFERLRAKL-NH2 (SEQ ID NO: 185)	6.56E+05	3.61E-02	5.50E-08
JBT0307	Ac-FQSKKKNVFVYGYFERLRAKL-NH2 (SEQ ID NO: 261)	5.95E+05	3.15E-02	5.30E-08
JBT0310	Ac-FQSKKKNVFVFGYFDRLRAKL-NH2 (SEQ ID NO: 262)	5.62E+04	1.05E-02	1.87E-07
JBT0337	Ac-FQSKKKNVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 16)	2.90E+05	5.30E-03	1.83E-08
JBT0342	Ac-FQSKKKNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 19)	3.92E+05	6.55E-03	1.67E-08
JBT0343	Ac-FQSKKKNVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 188)	3.28E+05	1.46E-02	4.46E-08
JBT0375	Ac-FQSKGNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 190)	4.00E+05	1.21E-02	3.04E-08
JBT0471	Ac-FQSKGNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 26)	7.03E+05	9.34E-03	1.33E-08
JBT0474	Ac-FQSKGNVFVKGYFERLRAKL-NH2 (SEQ ID NO: 29)	9.95E+05	1.49E-02	1.50E-08

FIGURE 19

JBT0477	Ac-FQSKGNVFDGYFERLRAKL-NH2 (SEQ ID NO: 32)	3.72E+05	3.02E-03	8.10E-09
JBT0500	Ac-FQSK-NmetGly-NVFGYFERLRAKL-NH2 (SEQ ID NO: 46)	2.52E+05	2.06E-03	8.19E-09
JBT0683	Ac-FQSK-Nmg-AVFVDGYFARLRAKL-NH2 (SEQ ID NO: 55)	1.00E+06	1.07E-03	1.07E-09
JBT0765	Ac-FQSKGNVFDGYFERL-Eew-AKL-NH2 (SEQ ID NO: 68)	2.31E+05	1.85E-03	8.00E-09
JBT0789	Ac-FQSK-Nmg-NVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 71)	1.92E+05	4.06E-04	2.12E-09
JBT1122	Ac-FQSK-Nmg-NVFDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 113)	6.99E+04	9.61E-04	1.38E-08
JBT1141	Ac-FQSKkAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 120)	1.36E+05	3.16E-03	2.33E-08
JBT1144	Ac-FQSKdAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 121)	3.05E+05	1.00E-02	3.28E-08

FIGURE 20

JBT0120 class		BiaCore		
Peptide	Sequence	k_{on} (1/Ms)	k_{off} (1/s)	K_D (M)
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1047)	1.17E+06	4.78E-02	4.08E-08
JBT0320	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVK-NH2 (SEQ ID NO: 1103)	1.78E+05	4.25E-02	2.38E-07
JBT0324	Ac-KWFCGMRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1155)	1.54E+04	6.36E-03	4.14E-07
JBT0415	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1003)	1.75E+05	2.24E-02	1.28E-07
JBT0444	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1004)	4.18E+05	1.21E-02	2.90E-08
JBT0447	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1158)	6.86E+03	5.60E-03	8.16E-07
JBT0455	Ac-SRYKWF[CGMRDMKGTMSC]AWVKF-NH2 (SEQ ID NO: 1049)	4.77E+05	3.03E-02	6.35E-08
JBT0643	Ac-SRYKWF[CGMPDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1006)	1.78E+05	3.22E-02	1.81E-07

FIGURE 21

JBT0122 class		BiaCore		
Peptide	Sequence	k _{on} (1/Ms)	k _{off} (1/s)	K _D (M)
JBT0122	AC-SGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2002)	1.13E+04	2.23E-02	1.97E-06
JBT0221	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARLYYKTSKK-NH2 (SEQ ID NO: 2003)	6.31E+04	1.19E-02	1.88E-07
JBT0224	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARLYYKK-NH2 (SEQ ID NO: 2298)	6.39E+04	1.95E-02	3.05E-07

FIGURE 22

JBT0047 class		FXa Inhibition assay			
Peptide	Sequence	EC50 (μM)	Maximal inhibition (%)	% Inhibition @ 2.5μM	% Inhibition @ 0.63μM
JBT0047	Ac-SGVGRQLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 253)	0.72		68	
JBT0051	Biotin-Ttds-SGVGRQLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 962)	0.53		66	
JBT0055	Ac-SGVGRQLQVAFQSKKNVFVFGYFERLRAKLTS-Ttds-Lysin(biotin)-NH2 (SEQ ID NO: 963)	0.53		72	
JBT0131	Biotin-Ttds-AFQSKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 964)	8.20		23	
JBT0132	Biotin-Ttds-FQSKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)	1.15		36	
JBT0133	Biotin-Ttds-QSKKNVFVFGYFERLRAKL-T-NH2 (SEQ ID NO: 966)			15	
JBT0134	Biotin-Ttds-QSKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 967)			5	
JBT0155	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 8)	0.97		54	
JBT0156*	Ac-VVEKLTFVQLSFLNRRFSQYAGFKGAGKV-NH2 (SEQ ID NO: 742)			0	
JBT0157*	Ac-RVFLYFSGKAGGLVKLVERQAFQTNVSKFR-NH2 (SEQ ID NO: 743)			0	
JBT0158	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 9)	4.26		35	
JBT0159	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLKK-NH2 (SEQ ID NO: 744)			0	
JBT0160	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFKK-NH2 (SEQ ID NO: 745)			0	
JBT0161	Ac-KKSGVGRQLQVAFQSKKNVFVFKK-NH2 (SEQ ID NO: 746)			0	
JBT0162	Ac-KKGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 10)	0.74		54	
JBT0163	Ac-KKQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 11)	1.54		48	
JBT0164	Ac-KKFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 12)	1.74		43	
JBT0165	Ac-KKKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 712)			0	
JBT0166	Biotinyl-Ttds-KKFQSKKNVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 968)	2.60		50	
JBT0167*	Biotinyl-Ttds-GKNAKFYLFESLRQVKFVFR-NH2 (SEQ ID NO: 969)			0	

FIGURE 22

JBT0168*	Biotinyl-Ttds-YKFSFNKELFKQARLRFVGV-NH2 (SEQ ID NO: 970)			0	
JBT0169	Ac-KKAFQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 254)			16	
JBT0170	Ac-KKQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 13)			61	
JBT0171	Ac-KKQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 255)			25	
JBT0172	Ac-KKQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 406)			7	
JBT0173	Biotinyl-Ttds-SGVGRQLQVAFQSKKNVVFVG-NH2 (SEQ ID NO: 971)			0	
JBT0174	Ac-KKAFQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 14)			47	
JBT0175	Ac-KKAFQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 182)	2.71		40	
JBT0293	Ac-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 256)	3.11	61	26	8
JBT0294	Ac-YQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 257)	4.07		40	
JBT0295	Ac-FSSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 713)			2	
JBT0296	Ac-FQNKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 407)	4.91		19	
JBT0297	Ac-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 183)	0.63		59	
JBT0298	Ac-FQSKQNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 747)	1.83		42	
JBT0299	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 408)	15.31		9	
JBT0300	Ac-FQSKKNVFSFGYFERLRAKL-NH2 (SEQ ID NO: 409)			7	
JBT0301	Ac-FQSKKNVFTFGYFERLRAKL-NH2 (SEQ ID NO: 410)			9	
JBT0302	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 258)	2.10		47	
JBT0303	Ac-FQSKKNVFDVFGYFERLRAKL-NH2 (SEQ ID NO: 184)	0.88	69	50	26
JBT0304	Ac-FQSKKNVFLVFGYFERLRAKL-NH2 (SEQ ID NO: 259)	2.95		32	
JBT0305	Ac-FQSKKNVQVFGYFERLRAKL-NH2 (SEQ ID NO: 260)	2.28		45	
JBT0306	Ac-FQSKKNVSVFGYFERLRAKL-NH2 (SEQ ID NO: 185)	3.56		37	
JBT0307	Ac-FQSKKNVVFVYGYFERLRAKL-NH2 (SEQ ID NO: 261)	3.42		34	
JBT0308	Ac-FQSKKNVVFVGYKERLRAKL-NH2 (SEQ ID NO: 411)			9	
JBT0309	Ac-FQSKKNVVFVGYERLRAKL-NH2 (SEQ ID NO: 412)	4.50		19	
JBT0310	Ac-FQSKKNVVFVGYFDRRAKL-NH2 (SEQ ID NO: 262)	3.86		26	
JBT0311	Ac-FQSKKNVVFVGYFERLRAKN-NH2 (SEQ ID NO: 748)			5	
JBT0335	Ac-FQSKKNVVFVGYFERLRAK-NH2 (SEQ ID NO: 749)	6.20		2	
JBT0336	Ac-FQSKNNVFAAGYFDRLRAKL-OH (SEQ ID NO: 263)	6.52		19	

FIGURE 22

JBT0337	Ac-FQSKNNVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 16)	0.71		51	
JBT0338	Ac-FQSKNNVFVQGYFDRLRAKL-NH2 (SEQ ID NO: 17)	1.12		40	
JBT0339	Ac-FQSKNNVFVSGYFDRLRAKL-NH2 (SEQ ID NO: 18)	1.22		42	
JBT0340	Ac-FQSKNNVFVGYFDRLRAKL-NH2 (SEQ ID NO: 186)	1.87		37	
JBT0341	Ac-FQSKNNVFVGYFDRLRAKL-NH2 (SEQ ID NO: 187)	1.08		38	
JBT0342	Ac-FQSKNNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 19)	0.38		58	
JBT0343	Ac-FQSKKNVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 188)	1.08		34	
JBT0374	Ac-FQSKDNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 20)	0.75	66	52	27
JBT0375	Ac-FQSKGNVFVGYFERLRAKL-NH2 (SEQ ID NO: 190)	0.41	73	65	40
JBT0376	Ac-FQSKKNVAFVGYFERLRAKL-NH2 (SEQ ID NO: 414)			11	
JBT0377	Ac-FQSKKNQVFVGYFERLRAKL-NH2 (SEQ ID NO: 264)			20	
JBT0378	Ac-FQSKKNVFVGYFERLRAKL-NH2 (SEQ ID NO: 21)	1.59	79	44	
JBT0379	Ac-FQSKKNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 22)	3.13	81	36	
JBT0380	Ac-FQSKKNVFVGYFERLRAKL-NH2 (SEQ ID NO: 191)	2.59	73	34	
JBT0381	Ac-FQSPKNVFVGYFERLRAKL-NH2 (SEQ ID NO: 265)	3.28	81	34	
JBT0385	Ac-FQSKKNVFVGYFERLRAKL-NH2 (SEQ ID NO: 672)			0	
JBT0386	Ac-FQSKKNPFVGYFERLRAKL-NH2 (SEQ ID NO: 415)			6	
JBT0388	Ac-FQSKKNVHVFGYFERLRAKL-NH2 (SEQ ID NO: 192)	4.34	73	26	
JBT0389	Ac-FQSKKNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 673)			0	
JBT0390	Ac-FQSKKNVFQGYFERLRAKL-NH2 (SEQ ID NO: 674)			0	
JBT0391	Ac-FQSKKNVFVGGYFERLRAKL-NH2 (SEQ ID NO: 266)	7.02	74	18	
JBT0392	Ac-FQSKKNVFVHGYFERLRAKL-NH2 (SEQ ID NO: 23)	2.48	74	37	
JBT0393	Ac-FQSKKNVFVKGYFERLRAKL-NH2 (SEQ ID NO: 193)	3.02	64	28	
JBT0394	Ac-FQSKKNVFVMGYFERLRAKL-NH2 (SEQ ID NO: 24)	6.83	57	12	
JBT0395	Ac-FQSKKNVFVNGYFERLRAKL-NH2 (SEQ ID NO: 25)	2.80	72	32	
JBT0396	Ac-FQSKKNVFVPGYFERLRAKL-NH2 (SEQ ID NO: 194)	4.33	77	30	
JBT0397	Ac-FQSKKNVFVRGYFERLRAKL-NH2 (SEQ ID NO: 195)	5.09	72	23	
JBT0398	Ac-FQSKKNVFVFGYFEELRAKL-NH2 (SEQ ID NO: 196)			4	
JBT0399	Ac-FQSKKNVFVFGYFELLRAKL-NH2 (SEQ ID NO: 750)			0	

FIGURE 22

JBT0400	Ac-FQSKKKNVVFVFGYFLRLRAKL-NH2 (SEQ ID NO: 267)			1	
JBT0401	Ac-FQSKKKNVVFVFGYFERLRAVL-NH2 (SEQ ID NO: 416)			0	
JBT0402	Biotin-Ttds-FQSKNNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 973)	0.32	45	48	
JBT0403	Biotin-Ttds-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 972)	0.49	64	59	
JBT0404	Biotin-Ttds-FQSKKKNVVFVFGYFDRLRAKL-NH2 (SEQ ID NO: 974)	1.89	43	24	
JBT0405	Biotin-FQSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 975)	0.86	81	59	
JBT0406	Ac-Ttds-FQSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 268)			28	
JBT0471	Ac-FQSKGNVVFVTGYFERLRAKL-NH2 (SEQ ID NO: 26)	0.41	77	64	45
JBT0472	Ac-FQSKGNVVFVNGYFERLRAKL-NH2 (SEQ ID NO: 27)	0.37	60	49	34
JBT0473	Ac-FQSKGNVVFVHGYFERLRAKL-NH2 (SEQ ID NO: 28)	0.25	47	45	31
JBT0474	Ac-FQSKGNVVFVKGYFERLRAKL-NH2 (SEQ ID NO: 29)	0.29	75	68	50
JBT0475	Ac-FQSKGNVVFVEGYFERLRAKL-NH2 (SEQ ID NO: 30)	0.25	60	50	37
JBT0476	Ac-FQSKGNVVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 31)	0.22	54	49	38
JBT0477	Ac-FQSKGNVVFVDGYFERLRAKL-NH2 (SEQ ID NO: 32)	0.23	72	68	51
JBT0478	Ac-FQSKDNNVVFVTGYFERLRAKL-NH2 (SEQ ID NO: 33)	0.76	51	39	21
JBT0479	Ac-FQSKDNNVVFVNGYFERLRAKL-NH2 (SEQ ID NO: 34)	1.10	58	40	21
JBT0480	Ac-FQSKDNNVVFVHGYFERLRAKL-NH2 (SEQ ID NO: 35)	1.11	65	42	24
JBT0481	Ac-FQSKDNNVVFVKGYFERLRAKL-NH2 (SEQ ID NO: 36)	0.77	53	41	23
JBT0482	Ac-FQSKDNNVVFVEGYFERLRAKL-NH2 (SEQ ID NO: 37)	0.53	86	69	43
JBT0483	Ac-FQSKDNNVFDGYFERLRAKL-NH2 (SEQ ID NO: 38)	0.53	84	68	41
JBT0484	Ac-FQSKDNNVFDGYFDRLRAKL-NH2 (SEQ ID NO: 976)	0.79	73	56	29
JBT0485	Ac-FQSKNNVVFVTGYFERLRAKL-NH2 (SEQ ID NO: 39)	0.75	86	63	38
JBT0486	Ac-FQSKNNVVFVNGYFERLRAKL-NH2 (SEQ ID NO: 40)			44	26
JBT0487	Ac-FQSKNNVVFVHGYFERLRAKL-NH2 (SEQ ID NO: 41)			58	36
JBT0488	Ac-FQSKNNVVFVKGYFERLRAKL-NH2 (SEQ ID NO: 42)	0.56	78	64	40
JBT0489	Ac-FQSKNNVVFVEGYFERLRAKL-NH2 (SEQ ID NO: 43)	0.42	78	68	48
JBT0490	Ac-FQSKQNNVVFVTGYFERLRAKL-NH2 (SEQ ID NO: 44)			53	25
JBT0491	Ac-FQSKQNNVVFVNGYFERLRAKL-NH2 (SEQ ID NO: 197)			53	29
JBT0492	Ac-FQSKQNNVVFVHGYFERLRAKL-NH2 (SEQ ID NO: 198)			45	24

FIGURE 22

JBT0493	Ac-FQSKQNVFVKGYFERLRAKL-NH2 (SEQ ID NO: 199)			45	21
JBT0494	Ac-FQSKQNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 45)			60	36
JBT0495	Ac-FQSKQNVFVEGYFERLRAKL-NH2 (SEQ ID NO: 200)			59	36
JBT0497	Ac-NmetPhe-QSKGNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 201)	0.47		40	24
JBT0498	Ac-FQ-NmetSer-KGNVVFVGYFERLRAKL-NH2 (SEQ ID NO: 675)			3	1
JBT0499	Ac-FQS-NmetLys-GNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 202)	0.83	75	56	30
JBT0500	Ac-FQSK-NmetGly-NVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 46)	0.13	71	70	60
JBT0501	Ac-FQSKGN-NmetV-FVFGYFERLRAKL-NH2 (SEQ ID NO: 417)			16	6
JBT0502	Ac-FQSKGNV-NmetPhe-VFGYFERLRAKL-NH2 (SEQ ID NO: 751)			0	0
JBT0503	Ac-FQSKGNVF-NmetV-FGYFERLRAKL-NH2 (SEQ ID NO: 676)			0	0
JBT0504	Ac-FQSKGNVVFV-NmetPhe-GYFERLRAKL-NH2 (SEQ ID NO: 418)			7	2
JBT0505	Ac-FQSKGNVVFV-NmetGly-YFERLRAKL-NH2 (SEQ ID NO: 269)			21	7
JBT0506	Ac-FQSKGNVVFVG-NmetTyr-FERLRAKL-NH2 (SEQ ID NO: 714)			0	0
JBT0507	Ac-FQSKGNVVFVFGY-NmetPhe-ERLRAKL-NH2 (SEQ ID NO: 677)			0	0
JBT0508	Ac-FQSKGNVVFVFGYF-NmetGlu-RLRAKL-NH2 (SEQ ID NO: 678)			0	0
JBT0509	Ac-FQSKGNVVFVFGYFE-Nmr-LRAKL-NH2 (SEQ ID NO: 752)			0	0
JBT0510	Ac-FQSKGNVVFVFGYFER-NmetLeu-RAKL-NH2 (SEQ ID NO: 753)			0	0
JBT0511	Ac-FQSKGNVVFVFGYFERL-Nmr-AKL-NH2 (SEQ ID NO: 754)			0	0
JBT0512	Ac-FQSKGNVVFVFGYFERLR-NmetAla-KL-NH2 (SEQ ID NO: 679)			0	0
JBT0513	Ac-FQSKGNVVFVFGYFERLRA-NmetLys-L-NH2 (SEQ ID NO: 755)			0	0
JBT0514	Ac-FQSKGNVVFVFGYFERLRAK-NmetLeu-NH2 (SEQ ID NO: 419)			1	0
JBT0515	Ac-bHomoPhe-QSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 420)			22	11
JBT0516	Ac-F-bHomoGln-SKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 680)			7	4
JBT0517	Ac-FQ-bHomoSer-KGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 421)			7	2
JBT0518	Ac-FQS-bHomoLys-GNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 422)			9	2
JBT0519	Ac-FQSK-bAla-NVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 270)			20	15
JBT0520	Ac-FQSKG-bGln-VFVFGYFERLRAKL-NH2 (SEQ ID NO: 271)			24	9
JBT0521	Ac-FQSKGN-bLeu-FVFGYFERLRAKL-NH2 (SEQ ID NO: 756)			3	3
JBT0522	Ac-FQSKGNV-bHomoPhe-VFGYFERLRAKL-NH2 (SEQ ID NO: 681)			5	3

FIGURE 22

JBT0523	Ac-FQSKGNV-bLeu-FGYFERLRAKL-NH2 (SEQ ID NO: 757)			1	2
JBT0524	Ac-FQSKGNV-bHomoPhe-GYFERLRAKL-NH2 (SEQ ID NO: 682)			0	4
JBT0525	Ac-FQSKGNV-bAla-YFERLRAKL-NH2 (SEQ ID NO: 758)			0	3
JBT0526	Ac-FQSKGNV-bHomoTyr-FERLRAKL-NH2 (SEQ ID NO: 759)			0	0
JBT0527	Ac-FQSKGNV-bHomoPhe-ERLRAKL-NH2 (SEQ ID NO: 683)			9	2
JBT0528	Ac-FQSKGNV-bE-RLRAKL-NH2 (SEQ ID NO: 272)			25	20
JBT0529	Ac-FQSKGNV-bHomoArg-LRAKL-NH2 (SEQ ID NO: 760)			0	1
JBT0530	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 684)			3	0
JBT0532	Ac-FQSKGNV-bAla-KL-NH2 (SEQ ID NO: 423)			14	7
JBT0533	Ac-FQSKGNV-bHomoK-L-NH2 (SEQ ID NO: 424)			17	4
JBT0534	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 204)	0.47	48	39	28
JBT0535	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 685)			13	5
JBT0536	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 273)			52	32
JBT0537	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 761)			0	0
JBT0538	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 425)			16	20
JBT0564	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 205)	4.12	54	19	6
JBT0578	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 441)			1	0
JBT0613	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 283)			21	8
JBT0614	NH2-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 720)			3	0
JBT0615	NH2-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 284)			14	5
JBT0616	NH2-GSFQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 285)	0.85	30	25	
JBT0636	Ac-FQSK-Nimg-NVVDGYFARLRAKL-NH2 (SEQ ID NO: 47)	0.10	90	86	76
JBT0651	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 48)	0.59	50	40	26
JBT0652	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 49)	0.34	52	48	34
JBT0653	Ac-FQSPGNV-bIle-LRAKL-NH2 (SEQ ID NO: 50)	0.44	57	47	33
JBT0654	Ac-FQSPGNV-bIle-LRAKL-NH2 (SEQ ID NO: 51)	0.37	60	50	36
JBT0655	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 52)	1.32	65	41	22
JBT0656	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 286)			21	10
JBT0657	Ac-FQSKGNV-bIle-LRAKL-NH2 (SEQ ID NO: 287)			24	10

FIGURE 22

JBT0658	Ac-FQSKGNVFLFGYFERLRAKL-NH2 (SEQ ID NO: 694)			6	3
JBT0663	Ac-FQSKaNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 53)	0.29	86	81	60
JBT0668	Ac-FQSKaNVFVTGYFARLRAKL-NH2 (SEQ ID NO: 54)	0.52	84	70	43
JBT0681	Ac-FQSK-Nmg-AVFVFGYFARLRAKL-NH2 (SEQ ID NO: 206)			52	52
JBT0683	Ac-FQSK-Nmg-AVFVDGYFARLRAKL-NH2 (SEQ ID NO: 55)	0.13	91	86	74
JBT0696	Ac-FQSKKAVFVFGYFERLRAKL-NH2 (SEQ ID NO: 288)	0.71	56	48	26
JBT0697	Ac-FQSKGNVFDGYFERL-Dap-AKL-NH2 (SEQ ID NO: 56)	0.50	89	73	52
JBT0699	Ac-FQSKGNVFDGYFERL-Orn-AKL-NH2 (SEQ ID NO: 57)	0.41	89	76	57
JBT0700	Ac-FQSKGNVFDGYFERL-Nva-AKL-NH2 (SEQ ID NO: 58)	0.19	83	77	64
JBT0704	Ac-FQSKKKNVFGYFARLRAKL-NH2 (SEQ ID NO: 289)			19	8
JBT0708	Ac-FQSKaNVFVAGYFERLRAKL-NH2 (SEQ ID NO: 59)	0.25	89	77	59
JBT0714	Ac-FQSKaNVFVDGYFARLRAKL-NH2 (SEQ ID NO: 60)	0.18	81	75	59
JBT0717	Ac-FQSK-Nmg-NVFDGYFERLRAKL-NH2 (SEQ ID NO: 61)	0.06	91	87	84
JBT0720	Ac-FQSK-Nmg-NVFTGYFARLRAKL-NH2 (SEQ ID NO: 62)	0.22	85	77	62
JBT0732	Ac-FQSKGNVFDGYFERL-Hci-AKL-NH2 (SEQ ID NO: 63)	0.18	83	75	62
JBT0733	Ac-FQSKGNVFDGYFERL-Har-AKL-NH2 (SEQ ID NO: 64)	0.18	81	75	62
JBT0739	Ac-FQSKGNVFDGYFERL-Opa-AKL-NH2 (SEQ ID NO: 65)	0.28	82	74	51
JBT0740	Ac-FQSKGNVFDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 66)	0.09	87	84	78
JBT0754	Ac-FQSK-Nmg-AVFVTGYFARLRAKL-NH2 (SEQ ID NO: 67)	0.24	80	74	57
JBT0757	Ac-FQSKKKNVFTGYFERLRAKL-NH2 (SEQ ID NO: 699)			3	1
JBT0759	Ac-FQSKkNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 207)	0.65	60	53	29
JBT0765	Ac-FQSKGNVFDGYFERL-Eew-AKL-NH2 (SEQ ID NO: 68)	0.16	95	87	73
JBT0775	Ac-FQSKGNVFTGYFDRLRAKL-NH2 (SEQ ID NO: 69)	0.77	77	57	34
JBT0778	Ac-FQSKGNVFKGYFDRLRAKL-NH2 (SEQ ID NO: 209)	1.48	77	46	23
JBT0779	Ac-FQSKGNVFEVGYFDRLRAKL-NH2 (SEQ ID NO: 210)	0.77	82	59	37
JBT0780	Ac-FQSK-Nmg-NVFGYFARLRAKL-NH2 (SEQ ID NO: 70)			45	54
JBT0781	Ac-FQSKGNVFDGYFKRLRAKL-NH2 (SEQ ID NO: 211)	1.25	81	48	25
JBT0789	Ac-FQSK-Nmg-NVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 71)	0.06	86	84	77
JBT0806	Ac-FQSK-Nmg-NVFGYFARLRAKL-NH2 (SEQ ID NO: 74)	0.13	79	75	65

FIGURE 22

JBT0837	Ac-FQSK-Nmg-NVFVTGYFERL-Nle-AKL-NH2 (SEQ ID NO: 213)	0.20	76	70	54
JBT0844	Ac-FQSKaNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 300)	0.32	84	72	51
JBT0850	Ac-FQSKaAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 302)	0.19	75	70	55
JBT0854	Ac-FQSKaAVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 490)	0.29	49	47	36
JBT0870	Ac-FQSKaAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 214)	0.31	84	80	57
JBT0886	Ac-FQSKaNVFVDGYFARLRAKL-NH2 (SEQ ID NO: 215)	0.36	83	71	48
JBT0894	Ac-FQSKGNVFDGYFERLHAKL-NH2 (SEQ ID NO: 76)	0.39	95	80	56
JBT0919	Ac-FQSKaNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 79)	0.36	86	74	51
JBT0931	Ac-FQSKGNVFDGYFERL-Eag-AKL-NH2 (SEQ ID NO: 879)	0.42	91	75	52
JBT0946	Ac-FQSKGNVFDGYFERL-Dab-AKL-NH2 (SEQ ID NO: 85)	0.27	85	74	56
JBT0950	Ac-FQSKaNVFVFGYFARLRAKL-NH2 (SEQ ID NO: 217)			47	31
JBT0973	Ac-FQSKGNVFDGYFERL-Cha-AKL-NH2 (SEQ ID NO: 92)	0.16	70	65	58
JBT1006	Ac-FQSKGNVFDGYFERL-Hle-AKL-NH2 (SEQ ID NO: 96)	0.17	77	71	61
JBT1035	Ac-FQSK-Nmg-AVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 218)				53
JBT1037	Ac-FQSKGNVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 104)	0.22	74	68	55
JBT1043	Ac-FQSKaNVFVDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 106)	0.30	80	70	51
JBT1082	Ac-FQSKaAVFVFGYFARLRAKL-NH2 (SEQ ID NO: 565)	0.20	47	45	38
JBT1084	Ac-FQSK-Nmg-AVFVAGYFARLRAKL-NH2 (SEQ ID NO: 109)	0.21	66	62	51
JBT1106	Ac-FQSKGNVFDGYFWRLRAKL-NH2 (SEQ ID NO: 220)	0.28	94	79	65
JBT1122	Ac-FQSK-Nmg-NVFVDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 113)			67	65
JBT1131	Biotin-Ttds-FQSKGNVFDGYFERLRAKL-NH2 (SEQ ID NO: 977)	0.20	94	86	69
JBT1133	Ac-FQSKaAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 115)	0.22	80	72	57
JBT1134	Ac-FQSKGAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 116)	0.24	72	66	54
JBT1135	Ac-FQSKDAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 221)	0.39	68	61	38
JBT1136	Ac-FQSKdAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 117)	0.17	77	72	58
JBT1137	Ac-FQSKaAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 118)	0.32	71	58	40
JBT1138	Ac-FQSKGAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 222)	0.25	50	47	38
JBT1139	Ac-FQSKDAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 223)			48	26
JBT1140	Ac-FQSKdAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 119)	0.21	62	58	47

FIGURE 22

JBT1141	Ac-FQSKkAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 120)	0.37	62	54	38
JBT1142	Ac-FQSKGAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 224)	0.39	49	47	32
JBT1143	Ac-FQSKDAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 225)	0.84	54	40	19
JBT1144	Ac-FQSKdAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 121)	0.32	63	57	38
JBT1145	Ac-FQSKkAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 122)	0.39	66	60	38
JBT1146	Ac-FQSKGAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 226)			41	28
JBT1147	Ac-FQSKDAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 227)			48	24
JBT1148	Ac-FQSKdAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 123)	0.33	68	61	44
JBT1149	Ac-FQSKGNVvFGYFERLRAKL-NH2 (SEQ ID NO: 936)			0	0
JBT1151	Ac-FQSKKNVvFGYFERLRAKL-NH2 (SEQ ID NO: 937)			0	0
JBT1152	Ac-FQSKKNVFFFYFERLRAKL-NH2 (SEQ ID NO: 735)			0	0
JBT1153	Ac-FQSKKNVvFGYFERLRAKL-NH2 (SEQ ID NO: 705)	5.25	51	12	0
JBT1155	Ac-FQSK-Nmg-NVvFGYFERLRAKL-NH2 (SEQ ID NO: 125)	0.21	87	77	61
JBT1156	Ac-FQSKaNVFVDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 126)			67	44
JBT1157	Ac-FQSKaNVFVAGYFARLRAKL-NH2 (SEQ ID NO: 127)	0.27	77	69	51
JBT1158	Ac-FQSKGNVvFGYFERLRAKL-N-methyl (SEQ ID NO: 228)			73	45
JBT1159	Ac-FQSKGNVvFGYFERLRAKL-N-ethyl (SEQ ID NO: 128)			71	41
JBT1160	Ac-FQSKGNVvFGYFERLRAKL-N-propyl (SEQ ID NO: 978)			76	54
JBT1161	Ac-FQSK-Aib-NVvFGYFERLRAKL-NH2 (SEQ ID NO: 338)			71	46
JBT1162	Ac-FQSKpNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 129)	0.03	94	92	90
JBT1396	Ac-FQSK-Nmg-NVvFVAGYFERLRAKL-NH2 (SEQ ID NO: 161)	0.05	95	93	87
JBT1584	Ac-FQSK-Nmg-NVvVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 164)	0.02	93	93	92
JBT1585	Ac-FQSK-Nmg-NVvVTGYFERL-Aib-AKL-NH2 (SEQ ID NO: 165)	0.04	90	90	89
JBT1587	Ac-FQSKGNVvVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167)	0.05	90	88	83
JBT1590	Ac-FQSKGNVvV[CGYFERL-Aib-AKLC]-NH2 (SEQ ID NO: 401)			53	21
JBT1591	Ac-FQSKGNVvVDGYF[CRL-Aib-AKLC]-NH2 (SEQ ID NO: 168)	0.67	81	72	41
JBT1592	Ac-[CFQSKGNVvVDGYFERL]AKL-NH2 (SEQ ID NO: 402)	1.55	86	54	24
JBT1593	Ac-FQSK[CNVvVDGYFERL]AKL-NH2 (SEQ ID NO: 670)			43	18
JBT1594	Ac-FQSKGNVvV[CGYFERL]AKL-NH2 (SEQ ID NO: 671)			9	5

FIGURE 22

JBT1595	Ac-[CFQSKGNVFC]GYFERL-Aib-AKL-NH2 (SEQ ID NO: 403)				32		14
JBT1596	Ac-[CFQSKGC]FVEGYFERL-Aib-AKL-NH2 (SEQ ID NO: 404)				52		24
JBT1597	Ac-DGYFERLRAKL-NH2 (SEQ ID NO: 960)				0		0
JBT1598	Ac-FQSKKNV-NH2 (SEQ ID NO: 961)				0		0
JBT1843	Ac-FQSKGNIFVDGYFERLHAKL-NH2 (SEQ ID NO: 169)	0.81	94		70		42
JBT1844	Ac-FQSKNNVFVDGYFKRLRAKL-NH2 (SEQ ID NO: 170)	0.73	91		70		42
JBT1845	Ac-FQSYKHVFVDGYFERLRAKL-NH2 (SEQ ID NO: 249)	1.24	94		61		33
JBT1846	Ac-FQSKGIVFDGYFKRLRAKL-NH2 (SEQ ID NO: 250)	0.87	91		65		38
JBT1847	Ac-YQTKGNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 171)	0.12	87		82		73
JBT1852	PEG(1kD)-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 174)	0.11	93		88		76
JBT1853	PEG(40kD)-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 175)	0.17	99		91		75
JBT1854	Ac-FQSKGNVFVDGYFERL-Aib-AKLC(PEG1kD)-NH2 (SEQ ID NO: 176)	0.07	93		90		83
JBT1855	Ac-FQSKGNVFVDGYFERL-Aib-AKLC(PEG40kD)-NH2 (SEQ ID NO: 252)	0.10	97		91		79

FIGURE 23

Peptide	Sequence	FXa Inhibition assay			% Inhibition @ 2.5μM	% Inhibition @ 0.63μM
		EC50 (μM)	Maximal inhibition (%)			
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1047)	1.21	75		47	26
JBT0124	Biotin-Tds-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1290)	1.59			41	
JBT0247	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1213)	0.79			42	
JBT0248	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1001)	0.82			53	
JBT0249	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1214)				0	
JBT0250	Ac-KKSRYSKWF[CGMRDMKGTMSC]VWKK-NH2 (SEQ ID NO: 1201)				11	
JBT0251	Ac-KKKWF[CGMRDMKGTMSC]VWVKFKK-NH2 (SEQ ID NO: 1202)				17	
JBT0252	Ac-KK[CGMRDMKGTMSC]VWVKFRYDKK-NH2 (SEQ ID NO: 1215)				13	
JBT0253	Ac-KKMRDMKGTMSCVWVKFRYDTSK-NH2 (SEQ ID NO: 1216)				0	
JBT0319	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY-NH2 (SEQ ID NO: 1002)	0.30			72	
JBT0320	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVK-NH2 (SEQ ID NO: 1103)				9	
JBT0321	Ac-SGASRYKWF[CGMRDMKGTMSC]V-NH2 (SEQ ID NO: 1217)				0	
JBT0322	Ac-SGASRYKWF[CGMRDMKGTMSC]V-NH2 (SEQ ID NO: 1218)				0	
JBT0322	Ac-SGASRYKWF[CGMRDMKGTMSC]V-NH2 (SEQ ID NO: 1218)				0	
JBT0323	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1076)	0.72			42	
JBT0324	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1155)				0	
JBT0325	Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1219)				0	
JBT0326	Ac-RDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1220)				0	
JBT0327	Ac-SGASRYKWF[CGMRDMKGTMSC]VW-NH2 (SEQ ID NO: 1222)				0	
JBT0328	Ac-SRYKWF[CGMRDMKGTMSC]VW-NH2 (SEQ ID NO: 1223)				0	

FIGURE 23

JBT0329	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1156)				2	
JBT0330	Ac-[CGMRDMKGTMSC]VWVKFRYD-NH2 (SEQ ID NO: 1224)				0	
JBT0331	Ac-MRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1225)				0	
JBT0332	Ac-SRYKWF[CGMRDMKGTMSC]VW-NH2 (SEQ ID NO: 1206)				1	
JBT0333	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1207)				4	
JBT0334	Ac-CGMRDMKGTMSCVWVKFRYD-NH2 (SEQ ID NO: 1227)				0	
JBT0409	Ac-SGASRYKWFSGMRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1204)				0	
JBT0410	Ac-SGASRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKFRYDTS-NH2 (SEQ ID NO: 1208)				0	
JBT0411	Ac-SGASRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKFRYDTS-NH2 (SEQ ID NO: 1104)				11	
JBT0412	Ac-KWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1209)				7	
JBT0413	Ac-KWFSGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1228)				0	
JBT0414	Ac-KWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1205)				4	
JBT0415	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1003)	0.52	73		59	39
JBT0416	Ac-SRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1077)				52	
JBT0417	Ac-SRYKWFSGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1229)				0	
JBT0418	Ac-SRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1210)				4	
JBT0419	Ac-SGGRKKHFLRSNGKPSRALSSMHFWRWSTS-NH2 (SEQ ID NO: 1293)				6	
JBT0435	Ac-RKRDVSGKM[CWSGFGSKWFC]ADMMTYYSVT-NH2 (SEQ ID NO: 1211)				0	
JBT0436	Ac-RWSGKSTYS[CDAMVRRMGMKC]FSFGWTDVYK-NH2 (SEQ ID NO: 1212)				0	
JBT0437	Ac-ARYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1048)				71	
JBT0438	Ac-SAYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1078)				54	
JBT0439	Ac-SRAKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1105)				35	
JBT0440	Ac-SRYAWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1106)				37	
JBT0441	Ac-SRYKAF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1230)				0	
JBT0442	Ac-SRYKWA[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1231)				8	
JBT0443	Ac-SRYKWFAGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1157)				0	
JBT0444	Ac-SRYKWF[CAMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1004)	0.24	90		80	62

FIGURE 23

JBT0445	Ac-SRYKWF[CGARDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1107)			18		
JBT0446	Ac-SRYKWF[CGMADMGTMSC]VWVKF-NH2 (SEQ ID NO: 1079)			50		
JBT0447	Ac-SRYKWF[CGMRAMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1158)			11		
JBT0448	Ac-SRYKWF[CGMRDAKGTMSC]VWVKF-NH2 (SEQ ID NO: 1108)			44		
JBT0449	Ac-SRYKWF[CGMRDMAGTMSC]VWVKF-NH2 (SEQ ID NO: 1080)	1.26	82	46		30
JBT0450	Ac-SRYKWF[CGMRDMKATMSC]VWVKF-NH2 (SEQ ID NO: 1159)			33		
JBT0451	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1081)			54		
JBT0452	Ac-SRYKWF[CGMRDMKGTASC]VWVKF-NH2 (SEQ ID NO: 1109)			39		
JBT0453	Ac-SRYKWF[CGMRDMKGTMAC]VWVKF-NH2 (SEQ ID NO: 1110)	1.18	62	38		23
JBT0454	Ac-SRYKWF[CGMRDMKGTMSAVWVKF-NH2 (SEQ ID NO: 1160)			0		
JBT0455	Ac-SRYKWF[CGMRDMKGTMSC]AWVKF-NH2 (SEQ ID NO: 1049)	1.02	65	40		26
JBT0456	Ac-SRYKWF[CGMRDMKGTMSCVAVKF-NH2 (SEQ ID NO: 1232)			3		
JBT0457	Ac-SRYKWF[CGMRDMKGTMSC]VWAKF-NH2 (SEQ ID NO: 1161)			16		
JBT0458	Ac-SRYKWF[CGMRDMKGTMSC]VWVAF-NH2 (SEQ ID NO: 1082)	1.34	66	39		24
JBT0459	Ac-SRYKWF[CGMRDMKGTMSC]VWVKA-NH2 (SEQ ID NO: 1083)			47		
JBT0460	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1050)			57		
JBT0461	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1111)			32		
JBT0462	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1233)			0		
JBT0463	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1234)			0		
JBT0464	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1235)			0		
JBT0465	Ac-SRYKWF[CGMRDMKGTMSC]MSVWVKF-NH2 (SEQ ID NO: 1236)			0		
JBT0466	Ac-SRYKWF[CGMRDMKGTMSC]GTMSVWVKF-NH2 (SEQ ID NO: 1237)			0		
JBT0467	Ac-SRYKWF[CGMRDMKGTMSC]MSVWVKF-NH2 (SEQ ID NO: 1238)			0		
JBT0468	Ac-SRYKWF[CGMRDMKGTMSC]SVWVKF-NH2 (SEQ ID NO: 1239)			2		
JBT0469	Ac-SRYKWF[CGMRDMKGTMSC]MSVWVKF-NH2 (SEQ ID NO: 1240)			5		
JBT0470	Ac-SRYKWF[CGMRDMKGTMSC]TMSVWVKF-NH2 (SEQ ID NO: 1162)			0		
JBT0617	Ac-SRYKWF[homoC-GMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1112)	1.91	35	18		8
JBT0618	Ac-SRYKWF[CGMRDMKGTMS-homoC]VWVKF-NH2 (SEQ ID NO: 1163)	3.44	18	5		1
JBT0619	Ac-SRYKWF[homoC-GMRDMKGTMS-homoC]VWVKF-NH2 (SEQ ID NO: 1241)			0		0

FIGURE 23

JBT0620	Ac-SRYKWF[Dap-GMRDMKGTMS-D]VWVKF-NH2 (SEQ ID NO: 1242)				0	0
JBT0623	Ac-SRYKWF[KGMRDMKGTMSD]VWVKF-NH2 (SEQ ID NO: 1243)				3	2
JBT0625	Ac-SRYKWF[CMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1244)				0	0
JBT0626	Ac-SRYKWF[CGMRDKGTMSC]VWVKF-NH2 (SEQ ID NO: 1164)				3	0
JBT0627	Ac-SRYKWF[CGMRDMGTMSC]VWVKF-NH2 (SEQ ID NO: 1165)				2	0
JBT0628	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1166)				0	0
JBT0629	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1167)				0	0
JBT0631	Ac-SRYKWF[CGmRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1113)	1.89	62		33	15
JBT0632	Ac-SRYKWF[CGMRdMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1245)				0	0
JBT0633	Ac-SRYKWF[CGMRdMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1168)				0	0
JBT0634	Ac-SRYKWF[CGMRDmKGTMSC]VWVKF-NH2 (SEQ ID NO: 1051)	0.69	63		47	26
JBT0635	Ac-SRYKWF[CGMRDMkGTMSC]VWVKF-NH2 (SEQ ID NO: 1114)	5.14	48		13	2
JBT0637	Ac-SRYKWF[CGMRDMKGaMSC]VWVKF-NH2 (SEQ ID NO: 1169)				0	0
JBT0638	Ac-SRYKWF[CGMRDMKGTmSC]VWVKF-NH2 (SEQ ID NO: 1246)				0	0
JBT0639	Ac-SRYKWF[CGMRDMKGTMsC]VWVKF-NH2 (SEQ ID NO: 1170)				2	0
JBT0640	Ac-SRYKWF[CGMRDMKGTMSc]VWVKF-NH2 (SEQ ID NO: 1171)				3	0
JBT0641	Ac-SRYKWF[CPMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1247)				4	2
JBT0642	Ac-SRYKWF[CGPRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1248)				2	1
JBT0643	Ac-SRYKWF[CGMPDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1006)				45	26
JBT0644	Ac-SRYKWF[CGMRPmKGTMSC]VWVKF-NH2 (SEQ ID NO: 1172)	4.55	35		12	3
JBT0645	Ac-SRYKWF[CGMRDPKGTMSC]VWVKF-NH2 (SEQ ID NO: 1084)	3.79	62		27	12
JBT0646	Ac-SRYKWF[CGMRDMPGTMSC]VWVKF-NH2 (SEQ ID NO: 1173)				4	1
JBT0647	Ac-SRYKWF[CGMRDMKPTMSC]VWVKF-NH2 (SEQ ID NO: 1249)				4	2
JBT0648	Ac-SRYKWF[CGMRDMKGPmSC]VWVKF-NH2 (SEQ ID NO: 1174)				4	0
JBT0649	Ac-SRYKWF[CGMRDMKGTpSC]VWVKF-NH2 (SEQ ID NO: 1175)				5	2
JBT0650	Ac-SRYKWF[CGMRDMKGTmPC]VWVKF-NH2 (SEQ ID NO: 1250)				0	0
JBT0659	Biotinyl-Ttds-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1291)				63	38
JBT0787	Ac-SRYKWF[CG-SeMet-RD-SeMet-KGT-SeMet-SC]VWVKF-NH2 (SEQ ID NO: 1292)				68	56

FIGURE 23

JBT1416	Ac-DRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1007)	0.58	93	68	46
JBT1417	Ac-SDYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1116)			34	13
JBT1418	Ac-SRDYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1176)			15	5
JBT1419	Ac-SRYDWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1117)			31	10
JBT1420	Ac-SRYKDF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1251)			0	0
JBT1421	Ac-SRYKWD[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1252)			2	2
JBT1422	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1253)			0	0
JBT1423	Ac-SRYKWF[CGDRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1177)			1	0
JBT1424	Ac-SRYKWF[CGMDDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1254)			4	1
JBT1425	Ac-SRYKWF[CGMRDDKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1085)			53	28
JBT1426	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1008)	0.19	96	81	66
JBT1427	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1052)			57	31
JBT1428	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1118)			28	6
JBT1429	Ac-SRYKWF[CGMRDMKGMTDSC]VWVKF-NH2 (SEQ ID NO: 1086)			49	21
JBT1430	Ac-SRYKWF[CGMRDMKGMTDC]VWVKF-NH2 (SEQ ID NO: 1119)			37	15
JBT1431	Ac-SRYKWF[CGMRDMKGMTMSC]DWVKF-NH2 (SEQ ID NO: 1255)			0	0
JBT1432	Ac-SRYKWF[CGMRDMKGMTMSC]VDVKF-NH2 (SEQ ID NO: 1256)			0	0
JBT1433	Ac-SRYKWF[CGMRDMKGMTMSC]VWDKF-NH2 (SEQ ID NO: 1257)			0	0
JBT1434	Ac-SRYKWF[CGMRDMKGMTMSC]VWVDF-NH2 (SEQ ID NO: 1120)			28	9
JBT1435	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKD-NH2 (SEQ ID NO: 1009)			61	34
JBT1436	Ac-FRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1053)	0.68	95	71	45
JBT1437	Ac-SFYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1010)	0.27	95	80	64
JBT1438	Ac-SRFKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1011)	0.69	88	64	43
JBT1439	Ac-SRYFWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1121)			35	14
JBT1440	Ac-SRYKFF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1258)			3	2
JBT1441	Ac-SRYKWF[CFMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1259)			7	4
JBT1442	Ac-SRYKWF[CGFRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1778)			10	3
JBT1443	Ac-SRYKWF[CGMFDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1779)			22	7
JBT1444	Ac-SRYKWF[CGMRFMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1260)			7	5

FIGURE 23

JBT1445	Ac-SRYKWF[CGMRDFKGTMSC]VWVKF-NH2 (SEQ ID NO: 1012)	0.77	89	64	41
JBT1446	Ac-SRYKWF[CGMRDMFGTMS]VWVKF-NH2 (SEQ ID NO: 1054)	0.68	93	69	45
JBT1447	Ac-SRYKWF[CGMRDMKFTMSC]VWVKF-NH2 (SEQ ID NO: 1227)			46	21
JBT1448	Ac-SRYKWF[CGMRDMKGFMS]VWVKF-NH2 (SEQ ID NO: 1123)	0.99	86	60	34
JBT1449	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1013)	0.40	89	74	53
JBT1450	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1124)			44	17
JBT1451	Ac-SRYKWF[CGMRDMKGTMSC]FWVKF-NH2 (SEQ ID NO: 1087)			34	11
JBT1452	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1125)			27	5
JBT1453	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1261)			6	1
JBT1454	Ac-SRYKWF[CGMRDMKGTMSC]VWVFF-NH2 (SEQ ID NO: 1262)			47	22
JBT1455	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1014)	0.79	87	62	40
JBT1456	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1126)			41	15
JBT1457	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1180)			15	4
JBT1458	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1127)			32	10
JBT1459	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1263)			0	0
JBT1460	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1264)			0	0
JBT1461	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1181)			8	0
JBT1462	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1128)			33	15
JBT1463	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1129)			23	10
JBT1464	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1088)			50	25
JBT1465	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1015)	0.84	92	60	41
JBT1466	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1055)			53	26
JBT1467	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1130)			27	11
JBT1468	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1131)			25	9
JBT1469	Ac-SRYKWF[CGMRDMKGTMSC]GWVKF-NH2 (SEQ ID NO: 1182)			4	0
JBT1470	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1265)			0	0
JBT1471	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1266)			4	0
JBT1472	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1089)			48	21
JBT1473	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1090)			40	16

FIGURE 23

JBT1474	Ac-KRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1016)	0.37	90	75	55
JBT1475	Ac-SKYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1056)			63	37
JBT1476	Ac-SRKKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1132)			31	11
JBT1477	Ac-SRYKKF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1267)			0	0
JBT1478	Ac-SRYKWK[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1091)			45	18
JBT1479	Ac-SRYKWF[CKMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1183)			14	2
JBT1480	Ac-SRYKWF[CGKRDMMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1133)			27	9
JBT1481	Ac-SRYKWF[CGMKDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1017)	0.37	88	71	54
JBT1482	Ac-SRYKWF[CGMRKMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1184)			9	1
JBT1483	Ac-SRYKWF[CGMRDKKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1057)	0.99	83	60	32
JBT1484	Ac-SRYKWF[CGMRDMKKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1134)			30	10
JBT1485	Ac-SRYKWF[CGMRDMKGMKMSC]VWVKF-NH2 (SEQ ID NO: 1058)			56	32
JBT1486	Ac-SRYKWF[CGMRDMKGTKSC]VWVKF-NH2 (SEQ ID NO: 1059)			58	34
JBT1487	Ac-SRYKWF[CGMRDMKGMTMKC]VWVKF-NH2 (SEQ ID NO: 1135)			30	9
JBT1488	Ac-SRYKWF[CGMRDMKGMTMSC]KWVKF-NH2 (SEQ ID NO: 1268)			3	0
JBT1489	Ac-SRYKWF[CGMRDMKGMTMSC]VKVKF-NH2 (SEQ ID NO: 1269)			0	0
JBT1490	Ac-SRYKWF[CGMRDMKGMTMSC]VWKKF-NH2 (SEQ ID NO: 1270)			0	1
JBT1491	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKK-NH2 (SEQ ID NO: 1136)			26	6
JBT1492	Ac-LRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1018)	0.47	91	72	52
JBT1493	Ac-SLYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1060)	0.48	96	74	54
JBT1494	Ac-SRLKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1137)			22	6
JBT1495	Ac-SRYLWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1138)			30	10
JBT1496	Ac-SRYKLF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1271)			0	0
JBT1497	Ac-SRYKWL[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1061)			58	33
JBT1498	Ac-SRYKWF[CLMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1272)			3	1
JBT1499	Ac-SRYKWF[CGLRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1139)			21	7
JBT1500	Ac-SRYKWF[CGMLDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1062)			60	34
JBT1501	Ac-SRYKWF[CGMRLMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1185)			14	3
JBT1502	Ac-SRYKWF[CGMRDLKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1019)	0.33	93	76	59

FIGURE 23

JBT1503	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1063)	0.53	83	66	44
JBT1504	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1140)			37	13
JBT1505	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1092)			66	42
JBT1506	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1064)	0.89	91	63	39
JBT1507	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 10141)			35	11
JBT1508	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1093)			52	27
JBT1509	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1273)			3	0
JBT1510	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1094)			51	27
JBT1511	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1142)			52	27
JBT1512	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1020)	0.37	91	72	55
JBT1513	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1065)			63	40
JBT1514	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1066)			51	27
JBT1515	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1143)			32	11
JBT1516	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1274)			0	0
JBT1517	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1275)			1	0
JBT1518	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1021)			62	39
JBT1519	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1186)			11	3
JBT1520	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1095)			45	20
JBT1521	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1096)			44	21
JBT1522	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1067)			56	32
JBT1523	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1022)	0.50	91	70	51
JBT1524	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1144)			39	16
JBT1525	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1068)			68	46
JBT1526	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1069)			53	32
JBT1527	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1097)			43	20
JBT1528	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1276)			2	0
JBT1529	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1277)			1	0
JBT1530	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1070)			54	31
JBT1531	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1071)			50	28

FIGURE 23

JBT1532	Ac-PRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1072)			62	38
JBT1533	Ac-SPYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1145)			31	10
JBT1534	Ac-SRPKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1187)			2	0
JBT1535	Ac-SRYPWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1278)			0	1
JBT1536	Ac-SRYKPF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1279)			0	0
JBT1537	Ac-SRYKWP[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1280)			0	0
JBT1538	Ac-SRYKWF[CGMRDMKGMTMSC]PWVKF-NH2 (SEQ ID NO: 1281)			2	2
JBT1539	Ac-SRYKWF[CGMRDMKGMTMSC]VPVKF-NH2 (SEQ ID NO: 1282)			0	0
JBT1540	Ac-SRYKWF[CGMRDMKGMTMSC]VWPKF-NH2 (SEQ ID NO: 1283)			0	0
JBT1541	Ac-SRYKWF[CGMRDMKGMTMSC]VWVPF-NH2 (SEQ ID NO: 1023)	0.47	89	69	49
JBT1542	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKP-NH2 (SEQ ID NO: 1188)			15	3
JBT1543	Ac-SRYKWF[CGMRDMKGMTMSC]VWVKF-OH (SEQ ID NO: 1098)			44	20
JBT1544	H-SRYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1024)	0.64	88	67	44
JBT1545	H-SRYKWF[CGMRDMKGMTMSC]VWVKF-OH (SEQ ID NO: 1099)			40	20
JBT1546	Ac-SRYKWF[CEMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1284)			3	2
JBT1547	Ac-SRYKWF[CHMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1285)			2	0
JBT1548	Ac-SRYKWF[CIMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1286)			6	3
JBT1549	Ac-SRYKWF[CMMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1189)			9	3
JBT1550	Ac-SRYKWF[CNMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1190)			20	10
JBT1551	Ac-SRYKWF[CQMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1146)			31	13
JBT1552	Ac-SRYKWF[CRMMDKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1147)			32	12
JBT1553	Ac-SRYKWF[CTMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1148)			36	15
JBT1554	Ac-SRYKWF[CVMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1287)			6	2
JBT1555	Ac-SRYKWF[CWMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1191)			8	2
JBT1556	Ac-SRYKWF[CYMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1288)			5	0
JBT1557	H-RYKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 173)			53	27
JBT1558	H-YKWF[CGMRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1149)			17	3
JBT1559	Ac-SRYKWF[CGaRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1150)			29	10
JBT1560	Ac-SRYKWF[CGdRDMKGMTMSC]VWVKF-NH2 (SEQ ID NO: 1289)			1	1

FIGURE 23

JBT1561	Ac-SRYKWF[CGfRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1192)			9	1
JBT1562	Ac-SRYKWF[CGkRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1193)			5	1
JBT1563	Ac-SRYKWF[CGIRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1194)			14	6
JBT1564	Ac-SRYKWF[CGpRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1100)			65	40
JBT1565	Ac-SRYKWF[CGsRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1195)			13	3
JBT1566	Ac-SRYKWF[CGMRDaKGTMSC]VWVKF-NH2 (SEQ ID NO: 1151)			33	13
JBT1567	Ac-SRYKWF[CGMRDdKGTMSC]VWVKF-NH2 (SEQ ID NO: 1101)			45	21
JBT1568	Ac-SRYKWF[CGMRDfKGTMSC]VWVKF-NH2 (SEQ ID NO: 1074)			63	38
JBT1569	Ac-SRYKWF[CGMRDkKGTMSC]VWVKF-NH2 (SEQ ID NO: 1102)			50	23
JBT1570	Ac-SRYKWF[CGMRDIKGTMSC]VWVKF-NH2 (SEQ ID NO: 1025)	0.74	88	62	43
JBT1571	Ac-SRYKWF[CGMRDpKGTMSC]VWVKF-NH2 (SEQ ID NO: 1196)			15	5
JBT1572	Ac-SRYKWF[CGMRDsKGTMSC]VWVKF-NH2 (SEQ ID NO: 1152)			28	9
JBT1573	Ac-SRYKWF[CGMRDMaGTMSC]VWVKF-NH2 (SEQ ID NO: 1197)			20	4
JBT1574	Ac-SRYKWF[CGMRDMdGTMSC]VWVKF-NH2 (SEQ ID NO: 1153)			39	15
JBT1575	Ac-SRYKWF[CGMRDMfGTMSC]VWVKF-NH2 (SEQ ID NO: 1198)			18	3
JBT1576	Ac-SRYKWF[CGMRDMiGTMSC]VWVKF-NH2 (SEQ ID NO: 1199)			19	6
JBT1577	Ac-SRYKWF[CGMRDMpGTMSC]VWVKF-NH2 (SEQ ID NO: 1200)			14	2
JBT1578	Ac-SRYKWF[CGMRDMsGTMSC]VWVKF-NH2 (SEQ ID NO: 1154)			30	10

FIGURE 24

Peptide	Sequence	FXa Inhibition assay		% Inhibition @ 2.5μM	% Inhibition @ 0.63μM
		EC50 (μM)	Maximal inhibition (%)		
JBT0122	AC-SGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2 (SEQ ID NO: 2002)	7.92		23	
JBT0126	Biotin-Ttds-SGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2 (SEQ ID NO: 2498)	14.10		17	
JBT0221	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2003)			29	
JBT0222*	Ac-MKSRSLGLAYFAKHSSLEVLRKVAAPYY-NH2 (SEQ ID NO: 2127)			0	
JBT0223*	Ac-KMQLRVYASTAHSRYLLGSSLPKYAEVKA-NH2 (SEQ ID NO: 2297)			0	
JBT0224	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKK-NH2 (SEQ ID NO: 2298)			26	
JBT0225	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARKK-NH2 (SEQ ID NO: 2128)			12	
JBT0226	Ac-KKSGYASFPLAVQLHVSKRSEKEMAKK-NH2 (SEQ ID NO: 2299)			6	
JBT0227	Ac-KKSGYASFPLAVQLHVSKRSEKKN-NH2 (SEQ ID NO: 2300)			0	
JBT0228	Ac-KKASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2016)			21	
JBT0229	Ac-KKPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2129)			0	
JBT0230	Ac-KKVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2301)			0	
JBT0231	Ac-KKHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2302)			0	
JBT0232	Ac-KKGYASFPLAVQLHVSKRSEKMKK-NH2 (SEQ ID NO: 2303)			6	
JBT0233	Ac-KKYASFPLAVQLHVSKRSEKEMAKK-NH2 (SEQ ID NO: 2304)			8	
JBT0234	Ac-KKVQLHVSKRSEKEMALARYYKKK-NH2 (SEQ ID NO: 2305)			0	
JBT0235	Ac-KKQLHVSKRSEKEMALARYYKTKK-NH2 (SEQ ID NO: 2306)			0	
JBT0236	Ac-KKLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2307)			0	
JBT0237	Ac-KKSGYASFPLAVQLHVSKRSEKKN-NH2 (SEQ ID NO: 2308)			0	
JBT0359	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2309)			0	

FIGURE 24

JBT0360	Ac-SFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2310)			1	
JBT0361	Ac-FPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2311)			0	
JBT0362	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2312)			0	
JBT0363	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2313)			0	
JBT0364	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2314)			2	
JBT0365	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2315)			0	
JBT0366	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2316)			0	
JBT0367	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2317)			2	
JBT0368	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2130)			0	
JBT0369	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2017)			2	
JBT0370	Ac-YASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2318)			2	
JBT0371	Ac-GYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2319)			8	
JBT0660	Ac-AGYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2004)			5	2
JBT0661	Ac-SAYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2005)			13	5
JBT0662	Ac-SGAASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2131)			4	0
JBT0664	Ac-SGYAAFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2006)			7	2
JBT0665	Ac-SGYASAPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2132)			2	0
JBT0666	Ac-SGYASFALAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2001)			12	6
JBT0667	Ac-SGYASFPAAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2018)			2	0
JBT0669	Ac-SGYASFPLAAQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2133)			0	0
JBT0670	Ac-SGYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2007)			6	0
JBT0671	Ac-SGYASFPLAVQAHVSKRSEKEMA-NH2 (SEQ ID NO: 2019)			4	1
JBT0672	Ac-SGYASFPLAVQLAVSKRSEKEMA-NH2 (SEQ ID NO: 2134)			2	0
JBT0673	Ac-SGYASFPLAVQLHASKRSEKEMA-NH2 (SEQ ID NO: 2135)			0	0
JBT0674	Ac-SGYASFPLAVQLHVAKRSEKEMA-NH2 (SEQ ID NO: 2008)			10	3
JBT0675	Ac-SGYASFPLAVQLHVSARSKEMA-NH2 (SEQ ID NO: 2136)			0	0
JBT0676	Ac-SGYASFPLAVQLHVSASKEMA-NH2 (SEQ ID NO: 2137)			0	0
JBT0677	Ac-SGYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2009)			4	0
JBT0678	Ac-SGYASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2010)			6	2

FIGURE 24

JBT0679	Ac-SGYASFPPLAVQLHVSKRSKAMALARLYYKTS-NH2 (SEQ ID NO: 2020)			2	0
JBT0680	Ac-SGYASFPPLAVQLHVSKRSKAAALARLYYKTS-NH2 (SEQ ID NO: 2138)			0	0
JBT0682	Ac-SGYASFPPLAVQLHVSKRSKEMAAARLYYKTS-NH2 (SEQ ID NO: 2139)			2	0
JBT0684	Ac-SGYASFPPLAVQLHVSKRSKEMALAAALYKTS-NH2 (SEQ ID NO: 2011)			5	1
JBT0685	Ac-SGYASFPPLAVQLHVSKRSKEMALARAYYKTS-NH2 (SEQ ID NO: 2021)			4	0
JBT0686	Ac-SGYASFPPLAVQLHVSKRSKEMALARLAYKTS-NH2 (SEQ ID NO: 2140)			3	0
JBT0687	Ac-SGYASFPPLAVQLHVSKRSKEMALARLAYKTS-NH2 (SEQ ID NO: 2141)			3	0
JBT0688	Ac-SGYASFPPLAVQLHVSKRSKEMALARLYYATS-NH2 (SEQ ID NO: 2012)			8	2
JBT0689	Ac-SGYASFPPLAVQLHVSKRSKEMALARLYYKAS-NH2 (SEQ ID NO: 2013)			10	3
JBT0690	Ac-SGYASFPPLAVQLHVSKRSKEMALARLYYKTA-NH2 (SEQ ID NO: 2014)			10	3
JBT1579	Ac-GYASFPPLAVQLHVAKRSKEMA-NH2 (SEQ ID NO: 2015)			9	4
JBT1580	Ac-GYASFALSVQLHVSKRSKEMA-NH2 (SEQ ID NO: 2320)			3	1
JBT1581	Ac-GYASFALAVQLHVAKRSKEMA-NH2 (SEQ ID NO: 2321)			11	4
JBT1582	Ac-GYASFPPLAVQLHVMKRSKEMA-NH2 (SEQ ID NO: 2022)			10	3
JBT1583	Ac-GYASFALAVQLHVMKRSKEMA-NH2 (SEQ ID NO: 2322)			18	5
JBT1599	Ac-FPLAVQLHVSKRSKEMALA-NH2 (SEQ ID NO: 2323)			0	0
JBT1600	Ac-QLHVSKRSKEMALA-NH2 (SEQ ID NO: 2324)			0	0
JBT1601	Ac-SGYASFP-NH2 (SEQ ID NO: 2325)			0	0
JBT1602	Ac-LAVQLHVSKRSKEMALARL-NH2 (SEQ ID NO: 2326)			0	0

FIGURE 25

JBT0047 class		Extrinsic Tenase Inhibition assay	
Peptide	Sequence	EC50 (μM)	% Inhibition @ 2.5μM
JBT0047	Ac-SGVGRLQVAFQSKKNVVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 253)	1.37	20
JBT0051	Biotin-Ttds-SGVGRLQVAFQSKKNVVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 962)	1.04	19
JBT0055	Ac-SGVGRLQVAFQSKKNVVFVFGYFERLRAKLTS-Ttds-Lysin(biotin)-NH2 (SEQ ID NO: 963)	1.67	25
JBT0131	Biotin-Ttds-AFQSKKNVVFVFGYFERLRAK-NH2 (SEQ ID NO: 964)	2.02	11
JBT0132	Biotin-Ttds-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)		11
JBT0133	Biotin-Ttds-QSKKNVVFVFGYFERLRAKL-T-NH2 (SEQ ID NO: 966)		9
JBT0134	Biotin-Ttds-QSKKNVVFVFGYFERLRAK-NH2 (SEQ ID NO: 967)		3
JBT0155	Ac-KKSGVGRLQVAFQSKKNVVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 8)	0.38	33
JBT0158	Ac-KKSGVGRLQVAFQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 9)		23
JBT0159	Ac-KKSGVGRLQVAFQSKKNVVFVFGYFERLKK-NH2 (SEQ ID NO: 744)		18
JBT0160	Ac-KKSGVGRLQVAFQSKKNVVFVFGYFKK-NH2 (SEQ ID NO: 745)		22
JBT0161	Ac-KKSGVGRLQVAFQSKKNVVFVFKK-NH2 (SEQ ID NO: 746)		6
JBT0162	Ac-KKGRQLQVAFQSKKNVVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 10)	0.28	34
JBT0163	Ac-KKQVAFQSKKNVVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 11)	0.89	31
JBT0164	Ac-KKFQSKKNVVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 12)	2.68	24
JBT0165	Ac-KKKKNVVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 712)		15
JBT0166	Biotinyl-Ttds-KKFQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 968)	1.95	36
JBT0169	Ac-KKAFQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 254)	2.35	20
JBT0170	Ac-KKFQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 13)	1.90	30

FIGURE 25

JBT0171	Ac-KKQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 255)	4.12	13
JBT0172	Ac-KKQSKKNVVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 406)	3.98	8
JBT0173	Biotinyl-Ttds-SGVGRLQVAFQSKKNVVFVFG-NH2 (SEQ ID NO: 971)		3
JBT0174	Ac-KKAFQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 14)	2.90	26
JBT0175	Ac-KKAFQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 182)	2.29	26
JBT0293	Ac-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 256)	1.62	16
JBT0294	Ac-YQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 257)	5.31	9
JBT0295	Ac-FSSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 713)	1.80	10
JBT0296	Ac-FQNKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 407)	7.83	10
JBT0297	Ac-FQSKNNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 183)		13
JBT0298	Ac-FQSKQNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 747)		15
JBT0299	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 408)		5
JBT0300	Ac-FQSKKNVFSFGYFERLRAKL-NH2 (SEQ ID NO: 409)		3
JBT0301	Ac-FQSKKNVFTFGYFERLRAKL-NH2 (SEQ ID NO: 410)		0
JBT0302	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 258)		3
JBT0303	Ac-FQSKKNVFDGYFERLRAKL-NH2 (SEQ ID NO: 184)	8.80	9
JBT0304	Ac-FQSKKNVFLGYFERLRAKL-NH2 (SEQ ID NO: 259)		7
JBT0305	Ac-FQSKKNVVFVQGYFERLRAKL-NH2 (SEQ ID NO: 260)		0
JBT0306	Ac-FQSKKNVVFVSGYFERLRAKL-NH2 (SEQ ID NO: 185)		3
JBT0307	Ac-FQSKKNVVFVYGYFERLRAKL-NH2 (SEQ ID NO: 261)	8.72	4
JBT0308	Ac-FQSKKNVVFVFGYKERLRAKL-NH2 (SEQ ID NO: 411)		4
JBT0309	Ac-FQSKKNVVFVFGYERLRAKL-NH2 (SEQ ID NO: 412)	8.55	7
JBT0310	Ac-FQSKKNVVFVFGYFDRLRAKL-NH2 (SEQ ID NO: 262)		5
JBT0311	Ac-FQSKKNVVFVFGYFERLRAKN-NH2 (SEQ ID NO: 748)	3.72	10
JBT0335	Ac-FQSKKNVVFVFGYFERLRAK-NH2 (SEQ ID NO: 749)	10.48	5
JBT0336	Ac-FQSKNNVFAAGYFDRLRAKL-OH (SEQ ID NO: 263)	12.13	5

FIGURE 25

JBT0337	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 16)	13.33	15
JBT0338	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 17)	8.42	9
JBT0339	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 18)		9
JBT0340	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 186)		9
JBT0341	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 187)	8.68	10
JBT0342	Ac-FQSKNNVFDGYFERRAKL-NH2 (SEQ ID NO: 19)	7.15	18
JBT0343	Ac-FQSKNNVFDGYFDRRAKL-NH2 (SEQ ID NO: 188)		8
JBT0374	Ac-FQSKDNNVFDGYFERRAKL-NH2 (SEQ ID NO: 20)		19
JBT0375	Ac-FQSKGNVFDGYFERRAKL-NH2 (SEQ ID NO: 190)	2.93	30
JBT0376	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 414)		3
JBT0377	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 264)		8
JBT0378	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 21)	9.03	12
JBT0379	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 22)		6
JBT0380	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 191)	7.58	10
JBT0381	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 265)		9
JBT0385	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 672)		2
JBT0386	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 415)		5
JBT0388	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 192)		6
JBT0389	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 673)		8
JBT0390	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 674)		5
JBT0391	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 266)		1
JBT0392	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 23)		4
JBT0393	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 193)		3
JBT0394	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 24)	4.38	8
JBT0395	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 25)		7
JBT0396	Ac-FQSKKNVFDGYFERRAKL-NH2 (SEQ ID NO: 194)	8.71	6

FIGURE 25

JBT0397	Ac-FQSKKKNVVRGYFERLRAKL-NH2 (SEQ ID NO: 195)		4
JBT0398	Ac-FQSKKKNVVFVFGYFEELRAKL-NH2 (SEQ ID NO: 196)		8
JBT0399	Ac-FQSKKKNVVFVFGYFELLRAKL-NH2 (SEQ ID NO: 750)		7
JBT0400	Ac-FQSKKKNVVFVFGYFLRLRAKL-NH2 (SEQ ID NO: 267)		13
JBT0401	Ac-FQSKKKNVVFVFGYFERLRAVL-NH2 (SEQ ID NO: 416)		4
JBT0402	Biotin-Ttds-FQSKNNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 973)		11
JBT0403	Biotin-Ttds-FQSKKKNVVDVFGYFERLRAKL-NH2 (SEQ ID NO: 972)		9
JBT0404	Biotin-Ttds-FQSKKKNVVFVFGYFDRRLRAKL-NH2 (SEQ ID NO: 974)	3.38	14
JBT0405	Biotin-FQSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 975)		15
JBT0406	Ac-Ttds-FQSKKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 268)		9
JBT0471	Ac-FQSKGNVFTGYFERLRAKL-NH2 (SEQ ID NO: 26)		32
JBT0472	Ac-FQSKGNVFNFGYFERLRAKL-NH2 (SEQ ID NO: 27)		22
JBT0473	Ac-FQSKGNVFNHGYFERLRAKL-NH2 (SEQ ID NO: 28)		24
JBT0474	Ac-FQSKGNVFNKGYFERLRAKL-NH2 (SEQ ID NO: 29)		33
JBT0475	Ac-FQSKGNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 30)		30
JBT0476	Ac-FQSKGNVFDVGYFDRRLRAKL-NH2 (SEQ ID NO: 31)		33
JBT0477	Ac-FQSKGNVFDVGYFERLRAKL-NH2 (SEQ ID NO: 32)	2.22	36
JBT0478	Ac-FQSKDNNVFTGYFERLRAKL-NH2 (SEQ ID NO: 33)		19
JBT0479	Ac-FQSKDNNVFNFGYFERLRAKL-NH2 (SEQ ID NO: 34)		18
JBT0480	Ac-FQSKDNNVFNHGYFERLRAKL-NH2 (SEQ ID NO: 35)		16
JBT0481	Ac-FQSKDNNVFNKGYFERLRAKL-NH2 (SEQ ID NO: 36)		15
JBT0482	Ac-FQSKDNNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 37)		23
JBT0483	Ac-FQSKDNNVFDVGYFERLRAKL-NH2 (SEQ ID NO: 38)		24
JBT0484	Ac-FQSKDNNVFDVGYFDRRLRAKL-NH2 (SEQ ID NO: 976)	4.89	19
JBT0485	Ac-FQSKNNVFTGYFERLRAKL-NH2 (SEQ ID NO: 39)		21
JBT0486	Ac-FQSKNNVFNFGYFERLRAKL-NH2 (SEQ ID NO: 40)		19

FIGURE 25

JBT0487	Ac-FQSKNNVVFVHG YFERLRAKL-NH2 (SEQ ID NO: 41)		19
JBT0488	Ac-FQSKNNVVFVKGYFERLRAKL-NH2 (SEQ ID NO: 42)		18
JBT0489	Ac-FQSKNNVVFVEGYFERLRAKL-NH2 (SEQ ID NO: 43)		21
JBT0490	Ac-FQSKQN VFVTGYFERLRAKL-NH2 (SEQ ID NO: 44)		9
JBT0491	Ac-FQSKQN VFVNGYFERLRAKL-NH2 (SEQ ID NO: 197)		10
JBT0492	Ac-FQSKQN VFVHG YFERLRAKL-NH2 (SEQ ID NO: 198)		7
JBT0493	Ac-FQSKQN VFVKGYFERLRAKL-NH2 (SEQ ID NO: 199)		7
JBT0494	Ac-FQSKQN VFVDGYFERLRAKL-NH2 (SEQ ID NO: 45)		15
JBT0495	Ac-FQSKQN VFVEGYFERLRAKL-NH2 (SEQ ID NO: 200)		15
JBT0497	Ac-NmetPhe-QSKGNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 201)	1.13	15
JBT0498	Ac-FQ-NmetSer-KGNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 675)		9
JBT0499	Ac-FQS-NmetLys-GNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 202)		11
JBT0500	Ac-FQSK-NmetGly-NVFVFGYFERLRAKL-NH2 (SEQ ID NO: 46)	1.11	45
JBT0501	Ac-FQSKGN-NmetV-FVFGYFERLRAKL-NH2 (SEQ ID NO: 417)		0
JBT0502	Ac-FQSKGNV-NmetPhe-VFGYFERLRAKL-NH2 (SEQ ID NO: 751)		1
JBT0503	Ac-FQSKGNVF-NmetV-FGYFERLRAKL-NH2 (SEQ ID NO: 676)		0
JBT0504	Ac-FQSKGNVFV-NmetPhe-GYFERLRAKL-NH2 (SEQ ID NO: 418)		5
JBT0505	Ac-FQSKGNVFVF-NmetGly-YFERLRAKL-NH2 (SEQ ID NO: 269)		9
JBT0506	Ac-FQSKGNVFVFG-NmetTyr-FERLRAKL-NH2 (SEQ ID NO: 714)		0
JBT0507	Ac-FQSKGNVFVFGY-NmetPhe-ERLRAKL-NH2 (SEQ ID NO: 677)		0
JBT0508	Ac-FQSKGNVFVFGYF-NmetGlu-RLRAKL-NH2 (SEQ ID NO: 678)		2
JBT0509	Ac-FQSKGNVFVFGYFE-Nmr-LRAKL-NH2 (SEQ ID NO: 752)		2
JBT0510	Ac-FQSKGNVFVFGYFER-NmetLeu-RAKL-NH2 (SEQ ID NO: 753)		3
JBT0511	Ac-FQSKGNVFVFGYFERL-Nmr-AKL-NH2 (SEQ ID NO: 754)		7
JBT0512	Ac-FQSKGNVFVFGYFERLR-NmetAla-KL-NH2 (SEQ ID NO: 679)		1
JBT0513	Ac-FQSKGNVFVFGYFERLRA-NmetLys-L-NH2 (SEQ ID NO: 755)		3

FIGURE 25

JBT0514	Ac-FQSKGNVVFVFGYFERLRAK-NmetLeu-NH2 (SEQ ID NO: 419)	5
JBT0515	Ac-bHomoPhe-QSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 420)	0
JBT0516	Ac-F-bHomoGln-SKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 680)	0
JBT0517	Ac-FQ-bHomoSer-KGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 421)	0
JBT0518	Ac-FQS-bHomoLys-GNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 422)	0
JBT0519	Ac-FQSK-bAla-NVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 270)	0
JBT0520	Ac-FQSKG-bGln-VFVFGYFERLRAKL-NH2 (SEQ ID NO: 271)	0
JBT0521	Ac-FQSKGN-bLeu-FVFGYFERLRAKL-NH2 (SEQ ID NO: 756)	0
JBT0522	Ac-FQSKGNV-bHomoPhe-VFVFGYFERLRAKL-NH2 (SEQ ID NO: 681)	0
JBT0523	Ac-FQSKGNVF-bLeu-FGYFERLRAKL-NH2 (SEQ ID NO: 757)	0
JBT0524	Ac-FQSKGNV-bHomoPhe-GYFERLRAKL-NH2 (SEQ ID NO: 682)	0
JBT0525	Ac-FQSKGNVVF-bAla-YFERLRAKL-NH2 (SEQ ID NO: 758)	0
JBT0526	Ac-FQSKGNVVFVFG-bHomoTyr-FERLRAKL-NH2 (SEQ ID NO: 759)	0
JBT0527	Ac-FQSKGNVVFVFGY-bHomoPhe-ERLRAKL-NH2 (SEQ ID NO: 683)	0
JBT0528	Ac-FQSKGNVVFVFGYF-bE-RLRAKL-NH2 (SEQ ID NO: 272)	8
JBT0529	Ac-FQSKGNVVFVFGYFE-bHomoArg-LRAKL-NH2 (SEQ ID NO: 760)	0
JBT0530	Ac-FQSKGNVVFVFGYFER-Btl-RAKL-NH2 (SEQ ID NO: 684)	0
JBT0531	Ac-FQSKGNVVFVFGYFERL-bHomoArg-AKL-NH2 (SEQ ID NO: 203)	0
JBT0532	Ac-FQSKGNVVFVFGYFERLR-bAla-KL-NH2 (SEQ ID NO: 423)	0
JBT0533	Ac-FQSKGNVVFVFGYFERLRA-bHomoK-L-NH2 (SEQ ID NO: 424)	0
JBT0534	Ac-FQSKGNVVFVFGYFERLRAK-Btl-NH2 (SEQ ID NO: 204)	8
JBT0535	Ac-FQSKGNVVFVFGYFE-Cit-LRAKL-NH2 (SEQ ID NO: 685)	1
JBT0536	Ac-FQSKGNVVFVFGYFERL-Cit-AKL-NH2 (SEQ ID NO: 273)	11
JBT0537	Ac-FQSKGNVVFVFGYFE-Nle-LRAKL-NH2 (SEQ ID NO: 761)	7
JBT0538	Ac-FQSKGNVVFVFGYFERL-Nle-AKL-NH2 (SEQ ID NO: 425)	15
JBT0564	Ac-FQSKKNVVFVFGYFKRLRAKL-NH2 (SEQ ID NO: 205)	0

FIGURE 25

JBT0578	Ac-FQSKKNVVFVFGYFFRLRAKL-NH2 (SEQ ID NO: 441)		0
JBT0613	Ac-FQSKGNVVFVFGYFERLRAKL-OH (SEQ ID NO: 283)		6
JBT0614	NH2-FQSKGNVVFVFGYFERLRAKL-OH (SEQ ID NO: 720)		4
JBT0615	NH2-FQSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 284)		6
JBT0651	Ac-FQSKGNVHVKGYFERLRAKL-NH2 (SEQ ID NO: 48)		6
JBT0652	Ac-FQSKGNVHVDGYFERLRAKL-NH2 (SEQ ID NO: 49)		8
JBT0653	Ac-FQSPGNVHVKGYFERLRAKL-NH2 (SEQ ID NO: 50)		9
JBT0654	Ac-FQSPGNVHVDGYFERLRAKL-NH2 (SEQ ID NO: 51)		11
JBT0655	Ac-FQSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 52)		9
JBT0656	Ac-FQSKGNLFFVFGYFERLRAKL-NH2 (SEQ ID NO: 286)		5
JBT0657	Ac-FQSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 287)		8
JBT0658	Ac-FQSKGNVFLFVFGYFERLRAKL-NH2 (SEQ ID NO: 694)		3
JBT0663	Ac-FQSKaNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 53)		22
JBT0668	Ac-FQSKaNVFVTGYFARLRAKL-NH2 (SEQ ID NO: 54)		16
JBT0681	Ac-FQSK-Nmg-AVFVFGYFARLRAKL-NH2 (SEQ ID NO: 206)		25
JBT0683	Ac-FQSK-Nmg-AVFVDGYFARLRAKL-NH2 (SEQ ID NO: 55)		38
JBT0708	Ac-FQSKaNVFVAGYFERLRAKL-NH2 (SEQ ID NO: 59)		25
JBT0714	Ac-FQSKaAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 60)		29
JBT0717	Ac-FQSK-Nmg-NVFDGYFERLRAKL-NH2 (SEQ ID NO: 61)		50
JBT0720	Ac-FQSK-Nmg-NVFTGYFARLRAKL-NH2 (SEQ ID NO: 62)		30
JBT0740	Ac-FQSKGNVFDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 66)		36
JBT0754	Ac-FQSK-Nmg-AVFVTGYFARLRAKL-NH2 (SEQ ID NO: 67)		27
JBT0765	Ac-FQSKGNVFDGYFERL-Eew-AKL-NH2 (SEQ ID NO: 68)		37
JBT0780	Ac-FQSK-Nmg-NVFDGYFERLRAKL-NH2 (SEQ ID NO: 70)	1.92	35
JBT0789	Ac-FQSK-Nmg-NVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 71)	0.79	51
JBT0806	Ac-FQSK-Nmg-NVFDGYFARLRAKL-NH2 (SEQ ID NO: 74)	2.42	38

FIGURE 25

JBT0837	Ac-FQSK-Nmg-NVFTGYFERL-Nle-AKL-NH2 (SEQ ID NO: 213)		33
JBT0844	Ac-FQSKaNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 300)		23
JBT0850	Ac-FQSKaAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 302)		24
JBT0854	Ac-FQSKaAVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 490)		14
JBT0870	Ac-FQSKaAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 214)		20
JBT0886	Ac-FQSKaNVFVDGYFARLRAKL-NH2 (SEQ ID NO: 215)		21
JBT0919	Ac-FQSKaNVFTGYFERLRAKL-NH2 (SEQ ID NO: 79)		24
JBT0931	Ac-FQSKGNVFDGYFERL-Eag-AKL-NH2 (SEQ ID NO: 82)		24
JBT0946	Ac-FQSKGNVFDGYFERL-Dab-AKL-NH2 (SEQ ID NO: 85)		29
JBT0950	Ac-FQSKaNVFVFGYFARLRAKL-NH2 (SEQ ID NO: 217)		14
JBT0973	Ac-FQSKGNVFDGYFERL-Cha-AKL-NH2 (SEQ ID NO: 92)	1.21	32
JBT1006	Ac-FQSKGNVFDGYFERL-Hle-AKL-NH2 (SEQ ID NO: 96)	1.35	35
JBT1035	Ac-FQSK-Nmg-AVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 218)		25
JBT1037	Ac-FQSKGNVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 104)		30
JBT1043	Ac-FQSKaNVFVDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 106)		27
JBT1082	Ac-FQSKaAVFVFGYFARLRAKL-NH2 (SEQ ID NO: 565)		16
JBT1084	Ac-FQSK-Nmg-AVFVAGYFARLRAKL-NH2 (SEQ ID NO: 109)		28
JBT1122	Ac-FQSK-Nmg-NVFDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 113)	0.81	43
JBT1133	Ac-FQSKkAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 115)		31
JBT1134	Ac-FQSKGAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 116)		28
JBT1135	Ac-FQSKDAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 221)		22
JBT1136	Ac-FQSKdAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 117)		36
JBT1137	Ac-FQSKkAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 118)		23
JBT1138	Ac-FQSKGAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 222)		19
JBT1139	Ac-FQSKDAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 223)		16
JBT1140	Ac-FQSKdAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 119)		29

FIGURE 25

JBT1141	Ac-FQSKkAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 120)	13
JBT1142	Ac-FQSKGAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 224)	11
JBT1143	Ac-FQSKDAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 225)	6
JBT1144	Ac-FQSKdAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 121)	15
JBT1145	Ac-FQSKkAVFTGYFARLRAKL-NH2 (SEQ ID NO: 122)	13
JBT1146	Ac-FQSKGAVFTGYFARLRAKL-NH2 (SEQ ID NO: 226)	12
JBT1147	Ac-FQSKDAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 227)	14
JBT1148	Ac-FQSKdAVFTGYFARLRAKL-NH2 (SEQ ID NO: 123)	27
JBT1149	Ac-FQSKGNVFvFGYFERLRAKL-NH2 (SEQ ID NO: 936)	0
JBT1151	Ac-FQSKKNVFvFGYFERLRAKL-NH2 (SEQ ID NO: 937)	0
JBT1152	Ac-FQSKKNVFFFGYFERLRAKL-NH2 (SEQ ID NO: 735)	0
JBT1153	Ac-FQSKKNVFvFGYFERLRAKL-NH2 (SEQ ID NO: 705)	4
JBT1155	Ac-FQSK-Nmg-NVFTGYFERLRAKL-NH2 (SEQ ID NO: 125)	32
JBT1156	Ac-FQSKaNVFDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 126)	22
JBT1157	Ac-FQSKaNVFVAGYFARLRAKL-NH2 (SEQ ID NO: 127)	22
JBT1162	Ac-FQSKpNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 129)	51
JBT1396	Ac-FQSK-Nmg-NVFAVGYFERLRAKL-NH2 (SEQ ID NO: 161)	34
JBT1584	Ac-FQSK-Nmg-NVFDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 164)	57
JBT1585	Ac-FQSK-Nmg-NVFTGYFERL-Aib-AKL-NH2 (SEQ ID NO: 165)	48
JBT1590	Ac-FQSKGNVFV[CGYFERL-Aib-AKLC]-NH2 (SEQ ID NO: 401)	22
JBT1591	Ac-FQSKGNVFVDGYF[CRL-Aib-AKLC]-NH2 (SEQ ID NO: 168)	23
JBT1592	Ac-[CFQSKGNVFVDGYFERLC]AKL-NH2 (SEQ ID NO: 402)	11
JBT1593	Ac-FQSK[CNVFVDGYFERLC]AKL-NH2 (SEQ ID NO: 670)	13
JBT1594	Ac-FQSKGNVFV[CGYFERLC]AKL-NH2 (SEQ ID NO: 671)	5
JBT1595	Ac-[CFQSKGNVFVCGYFERL-Aib-AKL-NH2 (SEQ ID NO: 403)	12
JBT1596	Ac-[CFQSKGC]VFVEGYFERL-Aib-AKL-NH2 (SEQ ID NO: 404)	13

FIGURE 25

JBT1843	Ac-FQSKGNIFVVDGYFERLHAKL-NH2 (SEQ ID NO: 169)		7
JBT1844	Ac-FQSKNNVFVDGYFKRLRAKL-NH2 (SEQ ID NO: 170)		6
JBT1845	Ac-FQSYKHHVFVDGYFERLRAKL-NH2 (SEQ ID NO: 249)		6
JBT1846	Ac-FQSKGIVFVDGYFKRLRAKL-NH2 (SEQ ID NO: 250)		7
JBT1847	Ac-YQTKGNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 171)		16
JBT1853	PEG(40kD)-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 175)		56
JBT1855	Ac-FQSKGNVFVDGYFERL-Aib-AKL.C(PEG40kD)-NH2 (SEQ ID NO: 252)		59

FIGURE 26

JBT0120 class		Extrinsic Tenase Inhibition assay	
Peptide	Sequence	EC50 (μM)	% Inhibition @ 2.5μM
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1047)	0.88	45
JBT0124	Biotin-Ttds-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1290)	1.26	36
JBT0247	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1213)	0.61	42
JBT0248	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSK-NH2 (SEQ ID NO: 1001)	0.27	52
JBT0249	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1214)	1.06	16
JBT0250	Ac-KKSRYSYKWF[CGMRDMKGTMSC]VWKK-NH2 (SEQ ID NO: 1201)	0.61	19
JBT0251	Ac-KKKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1202)	0.63	23
JBT0252	Ac-KK[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1215)	1.02	18
JBT0253	Ac-KKMRDMKGTMSCVWVKFRYDTSK-NH2 (SEQ ID NO: 1216)	0.55	23
JBT0319	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY-NH2 (SEQ ID NO: 1002)		60
JBT0320	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVK-NH2 (SEQ ID NO: 1103)	6.40	7
JBT0321	Ac-SGASRYKWF[CGMRDMKGTMSC]V-NH2 (SEQ ID NO: 1217)		1
JBT0322	Ac-SGASRYKWF[CGMRDMKGTMSC]V-NH2 (SEQ ID NO: 1218)		3
JBT0323	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1076)	0.77	48
JBT0324	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1155)	2.44	18
JBT0325	Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1219)		4
JBT0326	Ac-RDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1220)		3
JBT0327	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1222)		0
JBT0328	Ac-SRYKWF[CGMRDMKGTMSC]VW-NH2 (SEQ ID NO: 1223)		1
JBT0329	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1156)		8
JBT0330	Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1224)		7

FIGURE 26

JBT0331	Ac-MRDMKGTMSCVWVKFRYDTS-NH2 (SEQ ID NO: 1225)		5
JBT0332	Ac-SRYKWF CGMRDMKGTMSCVW-NH2 (SEQ ID NO: 1206)		5
JBT0333	Ac-KWFCGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1207)		11
JBT0334	Ac-CGMRDMKGTMSCVWVKFRYD-NH2 (SEQ ID NO: 1227)		3
JBT0409	Ac-SGASRYKWFSGMRDMKGTMSVWVKFRYDTS-NH2 (SEQ ID NO: 1204)		5
JBT0410	Ac-SGASRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKFRYDTS-NH2 (SEQ ID NO: 1208)		7
JBT0411	Ac-SGASRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKFRYDTS-NH2 (SEQ ID NO: 1104)		24
JBT0412	Ac-KWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1209)		12
JBT0413	Ac-KWFSGMRDMKGTMSVWVKF-NH2 (SEQ ID NO: 1228)		2
JBT0414	Ac-KWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1205)		8
JBT0415	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1003)	0.19	52
JBT0416	Ac-SRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1077)		46
JBT0417	Ac-SRYKWFSGMRDMKGTMSVWVKF-NH2 (SEQ ID NO: 1229)		11
JBT0418	Ac-SRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2 (SEQ ID NO: 1210)		11
JBT0419	Ac-SGGRKHKHLRSNGKPSRALSSMHFWRWST-NH2 (SEQ ID NO: 1293)		7
JBT0435*	Ac-RKRDDVSGKM[CWSGFGSKWFC]ADMMTYYSVT-NH2 (SEQ ID NO: 1211)		5
JBT0436*	Ac-RWSGKSTYS[CDAMVRRMGMKC]FSFGWTDVYK-NH2 (SEQ ID NO: 1212)		0
JBT0437	Ac-ARYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1048)		52
JBT0438	Ac-SAYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1078)		46
JBT0439	Ac-SRAKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1105)		38
JBT0440	Ac-SRYAWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1106)		34
JBT0441	Ac-SRYKAF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1230)		1
JBT0442	Ac-SRYKWA[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1231)		17
JBT0443	Ac-SRYKWFAGMRDMKGTMSCVWVKF-NH2 (SEQ ID NO: 1157)		7
JBT0444	Ac-SRYKWF[CAMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1004)		63
JBT0445	Ac-SRYKWF[CGARDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1107)		12
JBT0446	Ac-SRYKWF[CGMADMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1079)		46
JBT0447	Ac-SRYKWF[CGMRAMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1158)		15
JBT0448	Ac-SRYKWF[CGMRDAKGTMSC]VWVKF-NH2 (SEQ ID NO: 1108)		33

FIGURE 26

JBT0449	Ac-SRYKWF[CGMRDMAGTMS]VWVKF-NH2 (SEQ ID NO: 1080)		55
JBT0450	Ac-SRYKWF[CGMRDMKATMS]VWVKF-NH2 (SEQ ID NO: 1159)		34
JBT0451	Ac-SRYKWF[CGMRDMKGAMSC]VWVKF-NH2 (SEQ ID NO: 1081)		46
JBT0452	Ac-SRYKWF[CGMRDMKGTASC]VWVKF-NH2 (SEQ ID NO: 1109)		31
JBT0453	Ac-SRYKWF[CGMRDMKGTMAC]VWVKF-NH2 (SEQ ID NO: 1110)	0.97	40
JBT0454	Ac-SRYKWF[CGMRDMKGTMSAVWVKF-NH2 (SEQ ID NO: 1160)		0
JBT0455	Ac-SRYKWF[CGMRDMKGTMS]AWVKF-NH2 (SEQ ID NO: 1049)	0.95	30
JBT0456	Ac-SRYKWF[CGMRDMKGTMSCAVKF-NH2 (SEQ ID NO: 1232)		0
JBT0457	Ac-SRYKWF[CGMRDMKGTMS]VWAKF-NH2 (SEQ ID NO: 1161)		17
JBT0458	Ac-SRYKWF[CGMRDMKGTMS]VWVAF-NH2 (SEQ ID NO: 1082)		52
JBT0459	Ac-SRYKWF[CGMRDMKGTMS]VWVKA-NH2 (SEQ ID NO: 1083)		38
JBT0460	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1050)		51
JBT0461	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1111)		40
JBT0462	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1233)		0
JBT0463	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1234)		11
JBT0464	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1235)		10
JBT0465	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1236)		7
JBT0466	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1237)		11
JBT0467	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1238)		11
JBT0468	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1239)		7
JBT0469	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1240)		11
JBT0470	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1162)		2
JBT0617	Ac-SRYKWF[homoC-GMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1112)		21
JBT0618	Ac-SRYKWF[CGMRDMKGTMS-homoC]VWVKF-NH2 (SEQ ID NO: 1163)		11
JBT0619	Ac-SRYKWF[homoC-GMRDMKGTMS-homoC]VWVKF-NH2 (SEQ ID NO: 1241)		1
JBT0620	Ac-SRYKWF[Dap-GMRDMKGTMS-D]VWVKF-NH2 (SEQ ID NO: 1242)		0
JBT0625	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1244)		0
JBT0626	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1164)		7
JBT0627	Ac-SRYKWF[CGMRDMKGTMS]VWVKF-NH2 (SEQ ID NO: 1165)		3

FIGURE 26

JBT0628	Ac-SRYKWF[CGMRDMKGMSC]VWVKF-NH2 (SEQ ID NO: 1166)		0
JBT0629	Ac-SRYKWF[cGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1167)		3
JBT0631	Ac-SRYKWF[CGmRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1113)		18
JBT0632	Ac-SRYKWF[CGMrDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1245)		0
JBT0633	Ac-SRYKWF[CGMRdMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1168)		2
JBT0634	Ac-SRYKWF[CGMRDmKGTMSC]VWVKF-NH2 (SEQ ID NO: 1051)	0.47	44
JBT0635	Ac-SRYKWF[CGMRDMkGTMSC]VWVKF-NH2 (SEQ ID NO: 1114)		10
JBT0637	Ac-SRYKWF[CGMRDMKGmMSC]VWVKF-NH2 (SEQ ID NO: 1169)		0
JBT0638	Ac-SRYKWF[CGMRDMKGTmSC]VWVKF-NH2 (SEQ ID NO: 1246)		0
JBT0639	Ac-SRYKWF[CGMRDMKGTMsC]VWVKF-NH2 (SEQ ID NO: 1170)		3
JBT0640	Ac-SRYKWF[CGMRDMKGTMSc]VWVKF-NH2 (SEQ ID NO: 1171)		1
JBT0641	Ac-SRYKWF[CPMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1247)		0
JBT0642	Ac-SRYKWF[CGPRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1248)		0
JBT0643	Ac-SRYKWF[CGMPDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1006)		31
JBT0644	Ac-SRYKWF[CGMRPMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1172)		17
JBT0645	Ac-SRYKWF[CGMRDPKGTMSC]VWVKF-NH2 (SEQ ID NO: 1084)		23
JBT0646	Ac-SRYKWF[CGMRDMPGTMSC]VWVKF-NH2 (SEQ ID NO: 1173)		2
JBT0647	Ac-SRYKWF[CGMRDMKPTMSC]VWVKF-NH2 (SEQ ID NO: 1249)		0
JBT0648	Ac-SRYKWF[CGMRDMKGP MSC]VWVKF-NH2 (SEQ ID NO: 1174)		3
JBT0649	Ac-SRYKWF[CGMRDMKGT PSC]VWVKF-NH2 (SEQ ID NO: 1175)		2
JBT0650	Ac-SRYKWF[CGMRDMKGT MPC]VWVKF-NH2 (SEQ ID NO: 1250)		0
JBT0787	Ac-SRYKWF[CG-SeMet-RD-SeMet-KGT-SeMet-SC]VWVKF-NH2 (SEQ ID NO: 1292)		55
JBT1416	Ac-DRYKWF[CGMRDMKGT MSC]VWVKF-NH2 (SEQ ID NO: 1007)		47
JBT1426	Ac-SRYKWF[CGMRDMDGT MSC]VWVKF-NH2 (SEQ ID NO: 1008)		40
JBT1436	Ac-FRYKWF[CGMRDMKGT MSC]VWVKF-NH2 (SEQ ID NO: 1053)		51
JBT1437	Ac-SFYKWF[CGMRDMKGT MSC]VWVKF-NH2 (SEQ ID NO: 1010)		53
JBT1438	Ac-SRFKWF[CGMRDMKGT MSC]VWVKF-NH2 (SEQ ID NO: 1011)		49
JBT1445	Ac-SRYKWF[CGMRDFKGT MSC]VWVKF-NH2 (SEQ ID NO: 1012)		39
JBT1446	Ac-SRYKWF[CGMRDMFGT MSC]VWVKF-NH2 (SEQ ID NO: 1054)		46

FIGURE 26

JBT1448	Ac-SRYKWF[CGMRDMKGFMSC]VWVKF-NH2 (SEQ ID NO: 1123)		47
JBT1449	Ac-SRYKWF[CGMRDMKGTFC]VWVKF-NH2 (SEQ ID NO: 1013)		55
JBT1455	Ac-GRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1014)		49
JBT1474	Ac-KRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1016)		59
JBT1481	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1017)		55
JBT1483	Ac-SRYKWF[CGMRDKKGTMSC]VWVKF-NH2 (SEQ ID NO: 1057)		50
JBT1492	Ac-LRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1018)		52
JBT1493	Ac-SLYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1060)		43
JBT1502	Ac-SRYKWF[CGMRDLKGTMSC]VWVKF-NH2 (SEQ ID NO: 1019)		46
JBT1506	Ac-SRYKWF[CGMRDMKGTLC]VWVKF-NH2 (SEQ ID NO: 1064)		45
JBT1512	Ac-SRYKWF[CGMRDMKGTMSC]VWVKL-NH2 (SEQ ID NO: 1020)		44
JBT1541	Ac-SRYKWF[CGMRDMKGTMSC]VWVPF-NH2 (SEQ ID NO: 1023)		41
JBT1544	H-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1024)		59
JBT1570	Ac-SRYKWF[CGMRDIKGTMSC]VWVKF-NH2 (SEQ ID NO: 1025)		41

FIGURE 27

JBT0122 class		Extrinsic Tenase Inhibition assay	
Peptide	Sequence	EC50 (μM)	% Inhibition @ 2.5μM
JBT0122	Ac-SGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2 (SEQ ID NO: 2002)	6.70	7
JBT0126	Biotin-Ttds-SGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2 (SEQ ID NO: 2498)	5.05	5
JBT0221	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2003)	3.37	19
JBT0222	Ac-MKSRSLGLAYFAKHSSLEVLRKVAAPYY-NH2 (SEQ ID NO: 2127)		4
JBT0223	Ac-KMQLRVYASTAHSRYLLGSSLPKYAEVKA-NH2 (SEQ ID NO: 2297)		4
JBT0224	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKK-NH2 (SEQ ID NO: 2298)	3.49	18
JBT0225	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARKK-NH2 (SEQ ID NO: 2128)		0
JBT0226	Ac-KKSGYASFPLAVQLHVSKRSEKEMAKK-NH2 (SEQ ID NO: 2299)		0
JBT0227	Ac-KKSGYASFPLAVQLHVSKRSEKKN-NH2 (SEQ ID NO: 2300)		5
JBT0228	Ac-KKASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2016)	6.93	9
JBT0229	Ac-KKPLAVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2129)		0
JBT0230	Ac-KKVQLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2301)		0
JBT0231	Ac-KKHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2302)		0
JBT0232	Ac-KKGYASFPLAVQLHVSKRSEKMKK-NH2 (SEQ ID NO: 2303)		2
JBT0233	Ac-KKYASFPLAVQLHVSKRSEKMAKK-NH2 (SEQ ID NO: 2304)		6
JBT0234	Ac-KKVQLHVSKRSEKEMALARYYKKK-NH2 (SEQ ID NO: 2305)		3
JBT0235	Ac-KKQLHVSKRSEKEMALARYYKTKK-NH2 (SEQ ID NO: 2306)		0
JBT0236	Ac-KKLHVSKRSEKEMALARYYKTSKK-NH2 (SEQ ID NO: 2307)		0
JBT0237	Ac-KKSGYASFPLAVQLHVSKRSEKK-NH2 (SEQ ID NO: 2308)		2
JBT0359	Ac-ASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2309)		6
JBT0360	Ac-SFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2310)		2

FIGURE 27

JBT0361	Ac-FPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2311)		9
JBT0362	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2312)		6
JBT0363	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2313)		9
JBT0364	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2314)		12
JBT0365	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2315)		9
JBT0366	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2316)		11
JBT0367	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2317)		10
JBT0368	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2130)		8
JBT0369	Ac-ASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2017)		9
JBT0370	Ac-YASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2318)		0
JBT0371	Ac-GYASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2319)		5
JBT0660	Ac-AGYASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2004)		0
JBT0661	Ac-SAYASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2005)		3
JBT0662	Ac-SGAAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2131)		0
JBT0664	Ac-SGYAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2006)		3
JBT0665	Ac-SGYAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2132)		0
JBT0666	Ac-SGYAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2001)		5
JBT0667	Ac-SGYAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2018)		0
JBT0669	Ac-SGYAASFPLAAQLHVSKRSEMA-NH2 (SEQ ID NO: 2133)		0
JBT0670	Ac-SGYAASFPLAVQLHVSKRSEMA-NH2 (SEQ ID NO: 2007)		2
JBT0671	Ac-SGYAASFPLAVQAHVSKRSEMA-NH2 (SEQ ID NO: 2019)		7
JBT0672	Ac-SGYAASFPLAVQLAVSKRSEMA-NH2 (SEQ ID NO: 2134)		3
JBT0673	Ac-SGYAASFPLAVQLHASKRSEMA-NH2 (SEQ ID NO: 2135)		5
JBT0674	Ac-SGYAASFPLAVQLHVAKRSEMA-NH2 (SEQ ID NO: 2008)		5
JBT0675	Ac-SGYAASFPLAVQLHVSARSKRSEMA-NH2 (SEQ ID NO: 2136)		7
JBT0676	Ac-SGYAASFPLAVQLHVSASKRSEMA-NH2 (SEQ ID NO: 2137)		1
JBT0677	Ac-SGYAASFPLAVQLHVSRAKRSEMA-NH2 (SEQ ID NO: 2009)		2
JBT0678	Ac-SGYAASFPLAVQLHVSARSKRSEMA-NH2 (SEQ ID NO: 2010)		2
JBT0679	Ac-SGYAASFPLAVQLHVSRAKRSEMA-NH2 (SEQ ID NO: 2020)		3

FIGURE 27

JBT0680	Ac-SGYASFPLAVQLHVSKRSEAAALARYYKTS-NH2 (SEQ ID NO: 2138)	3
JBT0682	Ac-SGYASFPLAVQLHVSKRSEMAAARLYYKTS-NH2 (SEQ ID NO: 2139)	0
JBT0684	Ac-SGYASFPLAVQLHVSKRSEKEMALAAALYYKTS-NH2 (SEQ ID NO: 2011)	2
JBT0685	Ac-SGYASFPLAVQLHVSKRSEKEMALARAYYKTS-NH2 (SEQ ID NO: 2021)	1
JBT0686	Ac-SGYASFPLAVQLHVSKRSEKEMALARAYKTS-NH2 (SEQ ID NO: 2140)	1
JBT0687	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYAKTS-NH2 (SEQ ID NO: 2141)	0
JBT0688	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYATS-NH2 (SEQ ID NO: 2012)	2
JBT0689	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKAS-NH2 (SEQ ID NO: 2013)	2
JBT0690	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKTA-NH2 (SEQ ID NO: 2014)	3
JBT1579	Ac-GYASFPLAVQLHVAKRSEKEMA-NH2 (SEQ ID NO: 2015)	5
JBT1580	Ac-GYASFALSVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2320)	6
JBT1581	Ac-GYASFALAVQLHVAKRSEKEMA-NH2 (SEQ ID NO: 2321)	13
JBT1582	Ac-GYASFPLAVQLHVMKRSEKEMA-NH2 (SEQ ID NO: 2022)	7
JBT1583	Ac-GYASFALAVQLHVMKRSEKEMA-NH2 (SEQ ID NO: 2322)	12
JBT1602	Ac-LAVQLHVSKRSEKEMALARL-NH2 (SEQ ID NO: 2326)	0

FIGURE 28

Peptide	Sequence	Thrombin generation assay						
		FEIBA-equivalent activity in FVIII-inhibited plasma @ 10μM peptide [mU/mL]	FEIBA-equivalent activity in FVIII-inhibited plasma @ 1.1μM peptide [mU/mL]	EC ₅₀ (μM), FVIII-inhibited plasma	% FVIII-equivalent activity in deficient plasma @ 10μM peptide	% FVIII-equivalent activity in deficient plasma @ 1.1μM peptide		
JBT0047	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 (SEQ ID NO: 253)	156	87	0.89	24.6	20.0		
JBT0131	Biotin-Ttds-AFQSKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 964)	106			4.5			
JBT0132	Biotin-Ttds-FQSKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 965)	123			5.3			
JBT0133	Biotin-Ttds-QSKKNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 966)	28			6.7			
JBT0134	Biotin-Ttds-QSKKNVFVFGYFERLRAK-NH2 (SEQ ID NO: 967)	11						
JBT0155	Ac-KKSGVGRLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 8)	49						
JBT0158	Ac-KKSGVGRLQVAFQSKKNVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 9)	30						
JBT0162	Ac-KKGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 10)	54						
JBT0163	Ac-KKQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 11)	69						
JBT0164	Ac-KKFQSKKNVFVFGYFERLRAKLTSKK-NH2 (SEQ ID NO: 12)	39						
JBT0169	Ac-KKAFQSKKNVFVFGYFERLRAKKK-NH2 (SEQ ID NO: 254)	21						

FIGURE 28

JBT0170	Ac-KKFQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 13)	68				
JBT0171	Ac-KKQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 255)	33				
JBT0174	Ac-KKAFQSKKNVVFVFGYFERLRAKLKK-NH2 (SEQ ID NO: 14)	49				
JBT0175	Ac-KKAFQSKKNVVFVFGYFERLRAKLTKK-NH2 (SEQ ID NO: 182)	49				
JBT0293	Ac-FQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 256)	106	34	1.60	7.1	
JBT0294	Ac-YQSKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 257)	122			8.2	
JBT0296	Ac-FQNKKNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 407)	79				
JBT0297	Ac-FQSKNNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 183)	147			11.3	
JBT0298	Ac-FQSKQNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 747)	109				
JBT0299	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 408)	63				
JBT0300	Ac-FQSKKNVFSFGYFERLRAKL-NH2 (SEQ ID NO: 409)	40				
JBT0301	Ac-FQSKKNVFTFGYFERLRAKL-NH2 (SEQ ID NO: 410)	49				
JBT0302	Ac-FQSKKNVFAFGYFERLRAKL-NH2 (SEQ ID NO: 258)	220			18.5	
JBT0303	Ac-FQSKKNVVDGTYFERLRAKL-NH2 (SEQ ID NO: 184)	220	126	0.85	21.8	
JBT0304	Ac-FQSKKNVFLGYFERLRAKL-NH2 (SEQ ID NO: 259)	138				
JBT0305	Ac-FQSKKNVVFQGYFERLRAKL-NH2 (SEQ ID NO: 260)	207	113		20.5	
JBT0306	Ac-FQSKKNVVFSGYFERLRAKL-NH2 (SEQ ID NO: 185)	247	113		17.4	
JBT0307	Ac-FQSKKNVVFYGYFERLRAKL-NH2 (SEQ ID NO: 261)	182	81		16.8	
JBT0308	Ac-FQSKKNVVFVFGYKERLRAKL-NH2 (SEQ ID NO: 411)	133				
JBT0309	Ac-FQSKKNVVFVFGYERLRAKL-NH2 (SEQ ID NO: 412)	123				
JBT0310	Ac-FQSKKNVVFVFGYFDRRAKL-NH2 (SEQ ID NO: 262)	163	50			
JBT0311	Ac-FQSKKNVVFVFGYFERLRAKN-NH2 (SEQ ID NO: 748)	27				
JBT0335	Ac-FQSKKNVVFVFGYFERLRAK-NH2 (SEQ ID NO: 749)	28				
JBT0336	Ac-FQSKNNVFAAGYFDRRAKL-OH (SEQ ID NO: 263)	186	62			
JBT0337	Ac-FQSKNNVVDGYFDRRAKL-NH2 (SEQ ID NO: 16)	219	144			
JBT0338	Ac-FQSKNNVVFQGYFDRRAKL-NH2 (SEQ ID NO: 17)	197	133			
JBT0339	Ac-FQSKNNVVFSGYFDRRAKL-NH2 (SEQ ID NO: 18)	230	136			
JBT0340	Ac-FQSKNNVVFYGYFDRRAKL-NH2 (SEQ ID NO: 186)	197	122			
JBT0341	Ac-FQSKNNVVFVFGYFDRRAKL-NH2 (SEQ ID NO: 187)	193	100			

FIGURE 28

JBT0342	Ac-FQSKKNNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 19)	244	178		29.7	28.1
JBT0343	Ac-FQSKKNNVFVDGYFDRLRAKL-NH2 (SEQ ID NO: 188)	239	126			
JBT0374	Ac-FQSKDNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 20)	216	128			
JBT0375	Ac-FQSKGNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 190)	180	140	0.47	22.9	22.9
JBT0376	Ac-FQSKKNAFVFGYFERLRAKL-NH2 (SEQ ID NO: 414)	101	22			
JBT0377	Ac-FQSKKKNQFVFGYFERLRAKL-NH2 (SEQ ID NO: 264)	180	75			
JBT0378	Ac-FQSKKNNVFVEGYFERLRAKL-NH2 (SEQ ID NO: 21)	245	148		30.7	21.2
JBT0379	Ac-FQSKKNNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 22)	226	123			
JBT0380	Ac-FQSKKNNVFVVG YFERLRAKL-NH2 (SEQ ID NO: 191)	199	102			
JBT0381	Ac-FQSPKNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 265)	173	76			
JBT0386	Ac-FQSKKKNPFVFGYFERLRAKL-NH2 (SEQ ID NO: 415)	85				
JBT0388	Ac-FQSKKNNVHVFGYFERLRAKL-NH2 (SEQ ID NO: 192)	185	82			
JBT0389	Ac-FQSKKNNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 673)	34				
JBT0390	Ac-FQSKKNNVFQGYFERLRAKL-NH2 (SEQ ID NO: 674)	28				
JBT0391	Ac-FQSKKNNVFVGGYFERLRAKL-NH2 (SEQ ID NO: 266)	178	62			
JBT0392	Ac-FQSKKNNVFVHGYFERLRAKL-NH2 (SEQ ID NO: 23)	228	112			
JBT0393	Ac-FQSKKNNVFVKGYFERLRAKL-NH2 (SEQ ID NO: 193)	268	161		38.8	30.1
JBT0394	Ac-FQSKKNNVFVMGYFERLRAKL-NH2 (SEQ ID NO: 24)	115	43			
JBT0395	Ac-FQSKKNNVFVNGYFERLRAKL-NH2 (SEQ ID NO: 25)	235	107			
JBT0396	Ac-FQSKKNNVFVPGYFERLRAKL-NH2 (SEQ ID NO: 194)	196	85			
JBT0397	Ac-FQSKKNNVFVRGYFERLRAKL-NH2 (SEQ ID NO: 195)	240	128			
JBT0402	Biotin-Ttds-FQSKNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 973)	185	159			
JBT0403	Biotin-Ttds-FQSKKNNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 972)	253	188			
JBT0404	Biotin-Ttds-FQSKKNNVFVFGYFDRLRAKL-NH2 (SEQ ID NO: 974)	115	52			
JBT0405	Biotin-FQSKKNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 975)	142	152			
JBT0406	Ac-Ttds-FQSKKNNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 268)	114	63			
JBT0471	Ac-FQSKGNNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 26)	193	164		42.5	34.7
JBT0472	Ac-FQSKGNNVFVNGYFERLRAKL-NH2 (SEQ ID NO: 27)	197	159			
JBT0473	Ac-FQSKGNNVFVHGYFERLRAKL-NH2 (SEQ ID NO: 28)	188	145			

FIGURE 28

JBT0474	Ac-FQSKGNVVFVKGYFERLRAKL-NH2 (SEQ ID NO: 29)	200	191		50.5	45.2
JBT0475	Ac-FQSKGNVVFVEGYFERLRAKL-NH2 (SEQ ID NO: 30)	202	165			
JBT0476	Ac-FQSKGNVFDGYFDRRAKL-NH2 (SEQ ID NO: 31)	202	164		43.2	41.5
JBT0477	Ac-FQSKGNVFDGYFERLRAKL-NH2 (SEQ ID NO: 32)	231	194	0.26	47.2	41.3
JBT0478	Ac-FQSKDNVFTGYFERLRAKL-NH2 (SEQ ID NO: 33)	161	104			
JBT0479	Ac-FQSKDNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 34)	161	105			
JBT0480	Ac-FQSKDNVFNHGYFERLRAKL-NH2 (SEQ ID NO: 35)	180	125			
JBT0481	Ac-FQSKDNVFNKGYFERLRAKL-NH2 (SEQ ID NO: 36)	168	124			
JBT0482	Ac-FQSKDNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 37)	183	133			
JBT0483	Ac-FQSKDNVFDGYFERLRAKL-NH2 (SEQ ID NO: 38)	191	136			
JBT0484	Ac-FQSKDNVFDGYFDRRAKL-NH2 (SEQ ID NO: 976)	178	111			
JBT0485	Ac-FQSKNNVFTGYFERLRAKL-NH2 (SEQ ID NO: 39)	186	150			
JBT0486	Ac-FQSKNNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 40)	171	112			
JBT0487	Ac-FQSKNNVFNHGYFERLRAKL-NH2 (SEQ ID NO: 41)	178	138			
JBT0488	Ac-FQSKNNVFNKGYFERLRAKL-NH2 (SEQ ID NO: 42)	193	153			
JBT0489	Ac-FQSKNNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 43)	185	148			
JBT0490	Ac-FQSKQNVFTGYFERLRAKL-NH2 (SEQ ID NO: 44)	162	79			
JBT0491	Ac-FQSKQNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 197)	169	96			
JBT0492	Ac-FQSKQNVFNHGYFERLRAKL-NH2 (SEQ ID NO: 198)	124	69			
JBT0493	Ac-FQSKQNVFNKGYFERLRAKL-NH2 (SEQ ID NO: 199)	151	92			
JBT0494	Ac-FQSKQNVFDGYFERLRAKL-NH2 (SEQ ID NO: 45)	163	102			
JBT0495	Ac-FQSKQNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 200)	156	93			
JBT0497	Ac-NmetPhe-QSKGNVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 201)	165	106			
JBT0499	Ac-FQS-NmetLys-GNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 202)	192	129			
JBT0500	Ac-FQSK-NmetGly-NVFNVEGYFERLRAKL-NH2 (SEQ ID NO: 46)	254	239	0.17		51.1
JBT0501	Ac-FQSKGN-NmetV-FVFGYFERLRAKL-NH2 (SEQ ID NO: 417)	95	21			
JBT0504	Ac-FQSKGNVFN-NmetPhe-GYFERLRAKL-NH2 (SEQ ID NO: 418)	62				
JBT0505	Ac-FQSKGNVFN-NmetGly-YFERLRAKL-NH2 (SEQ ID NO: 269)	204	90			
JBT0508	Ac-FQSKGNVFNVEGYF-NmetGlu-RLRAKL-NH2 (SEQ ID NO: 678)	82				

FIGURE 28

JBT0514	Ac-FQSKGNVVFVFGYFERLRAK-NmetLeu-NH2 (SEQ ID NO: 419)	69			
JBT0515	Ac-bHomoPhe-QSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 420)	86	31		
JBT0517	Ac-FQ-bHomoSer-KGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 421)	34			
JBT0518	Ac-FQS-bHomoLys-GNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 422)	38			
JBT0519	Ac-FQSK-bAla-NVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 270)	105	37		
JBT0520	Ac-FQSKG-bGln-VFVFGYFERLRAKL-NH2 (SEQ ID NO: 271)	100	42		
JBT0522	Ac-FQSKGNV-bHomoPhe-VFGYFERLRAKL-NH2 (SEQ ID NO: 681)	40			
JBT0524	Ac-FQSKGNV-bHomoPhe-GYFERLRAKL-NH2 (SEQ ID NO: 682)	36			
JBT0527	Ac-FQSKGNVVFVFGY-bHomoPhe-ERLRAKL-NH2 (SEQ ID NO: 683)	44			
JBT0528	Ac-FQSKGNVVFVFGYF-bE-RLRAKL-NH2 (SEQ ID NO: 272)	151	100		
JBT0531	Ac-FQSKGNVVFVFGYFERL-bHomoArg-AKL-NH2 (SEQ ID NO: 203)	170	99		
JBT0532	Ac-FQSKGNVVFVFGYFERL-bAla-KL-NH2 (SEQ ID NO: 423)	118	53		
JBT0533	Ac-FQSKGNVVFVFGYFERLRA-bHomoK-L-NH2 (SEQ ID NO: 424)	97	29		
JBT0534	Ac-FQSKGNVVFVFGYFERLRAK-Btl-NH2 (SEQ ID NO: 204)	156	130		
JBT0535	Ac-FQSKGNVVFVFGYFE-Cit-LRAKL-NH2 (SEQ ID NO: 685)	97	28		
JBT0536	Ac-FQSKGNVVFVFGYFERL-Cit-AKL-NH2 (SEQ ID NO: 273)	196	133		
JBT0538	Ac-FQSKGNVVFVFGYFERL-Nle-AKL-NH2 (SEQ ID NO: 425)	118	59		
JBT0564	Ac-FQSKKNVVFVFGYFKRLRAKL-NH2 (SEQ ID NO: 205)	120	61		
JBT0613	Ac-FQSKGNVVFVFGYFERLRAKL-OH (SEQ ID NO: 283)	156	55		
JBT0614	NH2-FQSKGNVVFVFGYFERLRAKL-OH (SEQ ID NO: 720)	54			
JBT0615	NH2-FQSKGNVVFVFGYFERLRAKL-NH2 (SEQ ID NO: 284)	105	33		
JBT0616	NH2-GSFQSKKNVFDGYFERLRAKL-OH (SEQ ID NO: 285)	162	77		
JBT0616	NH2-GSFQSKKNVFDGYFERLRAKL-OH (SEQ ID NO: 285)	147	29		
JBT0651	Ac-FQSKGNVHVKGYFERLRAKL-NH2 (SEQ ID NO: 48)	250	216		
JBT0652	Ac-FQSKGNVHVVDGYFERLRAKL-NH2 (SEQ ID NO: 49)		207		
JBT0653	Ac-FQSPGNVHVKGYFERLRAKL-NH2 (SEQ ID NO: 50)		237		
JBT0654	Ac-FQSPGNVHVVDGYFERLRAKL-NH2 (SEQ ID NO: 51)		214		
JBT0655	Ac-FQSKGNIFVFGYFERLRAKL-NH2 (SEQ ID NO: 52)	150	120		
JBT0656	Ac-FQSKGNLIFVFGYFERLRAKL-NH2 (SEQ ID NO: 286)	86	42		

FIGURE 28

JBT0657	Ac-FQSKGNVFIIFGYFERLRAKL-NH2 (SEQ ID NO: 287)	92	47			
JBT0663	Ac-FQSKaNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 53)		180			
JBT0668	Ac-FQSKaNVFVTGYFARLRAKL-NH2 (SEQ ID NO: 54)		167			
JBT0681	Ac-FQSK-Nmg-AVFVFGYFARLRAKL-NH2 (SEQ ID NO: 206)		158			
JBT0683	Ac-FQSK-Nmg-AVFVDGYFARLRAKL-NH2 (SEQ ID NO: 55)		228			
JBT0696	Ac-FQSKKA VFVFGYFERLRAKL-NH2 (SEQ ID NO: 288)	64	60			
JBT0697	Ac-FQSKGNVFDGYFERL-Dap-AKL-NH2 (SEQ ID NO: 56)		188			
JBT0699	Ac-FQSKGNVFDGYFERL-Om-AKL-NH2 (SEQ ID NO: 57)		207			
JBT0700	Ac-FQSKGNVFDGYFERL-Nva-AKL-NH2 (SEQ ID NO: 58)		218			
JBT0704	Ac-FQSKKNVVFVFGYFARLRAKL-NH2 (SEQ ID NO: 289)	96	35			
JBT0708	Ac-FQSKaNVFVAGYFERLRAKL-NH2 (SEQ ID NO: 59)		200			
JBT0714	Ac-FQSKaNVFVDGYFARLRAKL-NH2 (SEQ ID NO: 60)		209			
JBT0717	Ac-FQSK-Nmg-NVFDGYFERLRAKL-NH2 (SEQ ID NO: 61)	271	241	0.11		42.1
JBT0720	Ac-FQSK-Nmg-NVFTGYFARLRAKL-NH2 (SEQ ID NO: 62)		271			
JBT0732	Ac-FQSKGNVFDGYFERL-Hci-AKL-NH2 (SEQ ID NO: 63)		258			
JBT0733	Ac-FQSKGNVFDGYFERL-Har-AKL-NH2 (SEQ ID NO: 64)		213			
JBT0739	Ac-FQSKGNVFDGYFERL-Opa-AKL-NH2 (SEQ ID NO: 65)		193			
JBT0740	Ac-FQSKGNVFDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 66)	236	184	0.29		33.3
JBT0754	Ac-FQSK-Nmg-AVFVTGYFARLRAKL-NH2 (SEQ ID NO: 67)		224			
JBT0759	Ac-FQSKkNVFVFGYFERLRAKL-NH2 (SEQ ID NO: 207)	159	131			
JBT0765	Ac-FQSKGNVFDGYFERL-Eew-AKL-NH2 (SEQ ID NO: 68)		205			
JBT0775	Ac-FQSKGNVFTGYFDRLRAKL-NH2 (SEQ ID NO: 69)		157			
JBT0778	Ac-FQSKGNVFKGYFDRLRAKL-NH2 (SEQ ID NO: 209)		176			
JBT0779	Ac-FQSKGNVVEGYFDRLRAKL-NH2 (SEQ ID NO: 210)		145			
JBT0780	Ac-FQSK-Nmg-NVFTGYFARLRAKL-NH2 (SEQ ID NO: 70)		227			
JBT0781	Ac-FQSKGNVFDGYFKRLRAKL-NH2 (SEQ ID NO: 211)		156			
JBT0789	Ac-FQSK-Nmg-NVFDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 71)	266	230	0.26		
JBT0806	Ac-FQSK-Nmg-NVFAVAGYFARLRAKL-NH2 (SEQ ID NO: 74)		281			
JBT0837	Ac-FQSK-Nmg-NVFTGYFERL-Nle-AKL-NH2 (SEQ ID NO: 213)		259			

FIGURE 28

JBT0844	Ac-FQSKaNVFVDGYFERLRAKL-NH2 (SEQ ID NO: 300)	195			
JBT0850	Ac-FQSKaAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 302)	174			
JBT0854	Ac-FQSKaAVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 490)	34			
JBT0870	Ac-FQSKaAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 214)	167			
JBT0886	Ac-FQSKaNVFVDGYFARLRAKL-NH2 (SEQ ID NO: 215)	186			
JBT0919	Ac-FQSKaNVFVTGYFERLRAKL-NH2 (SEQ ID NO: 79)	204			
JBT0931	Ac-FQSKGNVVDGYFERL-Eag-AKL-NH2 (SEQ ID NO: 82)	172			
JBT0946	Ac-FQSKGNVVDGYFERL-Dab-AKL-NH2 (SEQ ID NO: 85)	177			
JBT0950	Ac-FQSKaNVFVFGYFARLRAKL-NH2 (SEQ ID NO: 217)	115			
JBT0973	Ac-FQSKGNVVDGYFERL-Cha-AKL-NH2 (SEQ ID NO: 92)	193			
JBT1006	Ac-FQSKGNVVDGYFERL-Hle-AKL-NH2 (SEQ ID NO: 96)	210			
JBT1035	Ac-FQSK-Nmg-AVFVAGYFARL-Nle-AKL-NH2 (SEQ ID NO: 218)	172			
JBT1037	Ac-FQSKGNVVDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 104)	192			
JBT1043	Ac-FQSKaNVFVDGYFERL-Nle-AKL-NH2 (SEQ ID NO: 106)	203			
JBT1082	Ac-FQSKaAVFVFGYFARLRAKL-NH2 (SEQ ID NO: 565)	90			
JBT1084	Ac-FQSK-Nmg-AVFVAGYFARLRAKL-NH2 (SEQ ID NO: 109)	192			
JBT1122	Ac-FQSK-Nmg-NVVDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 113)	353			
JBT1133	Ac-FQSKkAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 115)	233			
JBT1134	Ac-FQSKGAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 116)	240			
JBT1135	Ac-FQSKDAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 221)	227			
JBT1136	Ac-FQSKdAVFVDGYFARLRAKL-NH2 (SEQ ID NO: 117)	283			
JBT1137	Ac-FQSKkAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 118)	218			
JBT1138	Ac-FQSKGAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 222)	185			
JBT1139	Ac-FQSKDAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 223)	205			
JBT1140	Ac-FQSKdAVFVAGYFARLRAKL-NH2 (SEQ ID NO: 119)	203			
JBT1141	Ac-FQSKkAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 120)	223			0.12
JBT1142	Ac-FQSKGAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 224)	299			
JBT1143	Ac-FQSKDAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 225)	214			
JBT1144	Ac-FQSKdAVFVKGYFARLRAKL-NH2 (SEQ ID NO: 121)	200			0.21

FIGURE 28

JBT1145	Ac-FQSKkAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 122)	274	243			
JBT1146	Ac-FQSKGAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 226)	231	185			
JBT1147	Ac-FQSKDAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 227)	230	146			
JBT1148	Ac-FQSKdAVFVTGYFARLRAKL-NH2 (SEQ ID NO: 123)	231	185			
JBT1151	Ac-FQSKKNVFVFGYFERLRAKD-NH2 (SEQ ID NO: 937)	27				
JBT1153	Ac-FQSKKNVFVFGYFERLGAKL-NH2 (SEQ ID NO: 705)	125	45			
JBT1155	Ac-FQSK-Nmg-NVFVTGYFERLRAKL-NH2 (SEQ ID NO: 125)		258			
JBT1156	Ac-FQSKaNVFVDGYFARL-Nle-AKL-NH2 (SEQ ID NO: 126)		173			
JBT1157	Ac-FQSKaNVFVAGYFARLRAKL-NH2 (SEQ ID NO: 127)		178			
JBT1584	Ac-FQSK-Nmg-NVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 164)	330	301	0.16		48.6
JBT1585	Ac-FQSK-Nmg-NVFVTGYFERL-Aib-AKL-NH2 (SEQ ID NO: 165)	300	269	0.13		
JBT1587	Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167)		189	0.32		
JBT1590	Ac-FQSKGNVFV[CGYFERL-Aib-AKLC]-NH2 (SEQ ID NO: 401)	35				
JBT1591	Ac-FQSKGNVFVDGYF[CRL-Aib-AKLC]-NH2 (SEQ ID NO: 168)	148	75			
JBT1592	Ac-[CFQSKGNVFVDGYFERLC]AKL-NH2 (SEQ ID NO: 402)	138	46			
JBT1593	Ac-FQSK[CNVFVDGYFERLC]AKL-NH2 (SEQ ID NO: 670)	110	39			
JBT1594	Ac-FQSKGNVFV[CGYFERLC]AKL-NH2 (SEQ ID NO: 671)	35				
JBT1595	Ac-[CFQSKGNVFVC]GYFERL-Aib-AKL-NH2 (SEQ ID NO: 403)	82	22			
JBT1596	Ac-[CFQSKGC]VFVEGYFERL-Aib-AKL-NH2 (SEQ ID NO: 404)	116	36			
JBT1853	PEG(40kD)-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 175)		605			
JBT1855	Ac-FQSKGNVFVDGYFERL-Aib-AKLC(PEG40kD)-NH2 (SEQ ID NO: 252)		642			

FIGURE 29

JBT0120 class		Thrombin generation assay					
Peptide	Sequence	FEIBA-equivalent activity in FVIII-inhibited plasma @ 10 μ M peptide [mU/mL]	FEIBA-equivalent activity in FVIII-inhibited plasma @ 1.1 μ M peptide [mU/mL]	EC ₅₀ (μ M), FVIII-inhibited plasma	% FVIII-equivalent activity in FVIII deficient plasma @ 10 μ M peptide	% FVIII-equivalent activity in FVIII deficient plasma @ 1.1 μ M peptide	
JBT0120	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1047)	269	95	2.78	28.8	8.6	
JBT0247	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1213)	273					
JBT0248	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSK-NH2 (SEQ ID NO: 1001)	164					
JBT0319	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRY-NH2 (SEQ ID NO: 1075)	383	187		29.3		
JBT0320	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVK-NH2 (SEQ ID NO: 1103)	153	21				
JBT0323	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1076)	355	142		31.4		
JBT0324	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2 (SEQ ID NO: 1155)	91					
JBT0329	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1156)	70			6.6		
JBT0333	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1207)	40					
JBT0333	Ac-KWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1207)	114					
JBT0411	Ac-SGASRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKFRYDTS-NH2 (SEQ ID NO: 1104)	97					

FIGURE 29

JBT0412	Ac-KWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1209)	46					
JBT0415	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1003)	291	182	0.57	47.2	36.5	
JBT0416	Ac-SRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2 (SEQ ID NO: 1077)	256	95		36.6	22.3	
JBT0437	Ac-ARYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1048)	362	225				
JBT0438	Ac-SAYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1078)	300	137				
JBT0439	Ac-SRAKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1105)	266	88				
JBT0440	Ac-SRYAWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1106)	175	33				
JBT0441	Ac-SRYKAF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1230)	18	5				
JBT0442	Ac-SRYKWA[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1231)	53	8				
JBT0444	Ac-SRYKWF[CAMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1004)	331	229	0.42	53.4	45.7	
JBT0445	Ac-SRYKWF[CGARDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1107)	157	40				
JBT0446	Ac-SRYKWF[CGMADMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1079)	287	140				
JBT0447	Ac-SRYKWF[CGMRAMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1158)	101					
JBT0448	Ac-SRYKWF[CGMRDAKGTMSC]VWVKF-NH2 (SEQ ID NO: 1108)	324	138				
JBT0449	Ac-SRYKWF[CGMRDMAGTMS]VWVKF-NH2 (SEQ ID NO: 1080)	362	217		54.1	34.2	
JBT0450	Ac-SRYKWF[CGMRDMKATMSC]VWVKF-NH2 (SEQ ID NO: 1159)	232	68				
JBT0451	Ac-SRYKWF[CGMRDMKGAMSC]VWVKF-NH2 (SEQ ID NO: 1081)	339	189				
JBT0452	Ac-SRYKWF[CGMRDMKGTASC]VWVKF-NH2 (SEQ ID NO: 1109)	265	119				
JBT0453	Ac-SRYKWF[CGMRDMKGTMAC]VWVKF-NH2 (SEQ ID NO: 1110)	282	111				
JBT0455	Ac-SRYKWF[CGMRDMKGTMSC]AWVKF-NH2 (SEQ ID NO: 1049)	316	203				
JBT0456	Ac-SRYKWF[CGMRDMKGTMSC]AVKF-NH2 (SEQ ID NO: 1232)	16					
JBT0457	Ac-SRYKWF[CGMRDMKGTMSC]VWAKF-NH2 (SEQ ID NO: 1161)	76					
JBT0458	Ac-SRYKWF[CGMRDMKGTMSC]VWVAF-NH2 (SEQ ID NO: 1082)	292	161				
JBT0459	Ac-SRYKWF[CGMRDMKGTMSC]VWVKA-NH2 (SEQ ID NO: 1083)	266	137				
JBT0460	Ac-RYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1050)	262	138				
JBT0461	Ac-YKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1111)	197	47				
JBT0625	Ac-SRYKWF[CMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1244)	5	3				
JBT0626	Ac-SRYKWF[CGMRDKGTMSC]VWVKF-NH2 (SEQ ID NO: 1164)	81	10				

FIGURE 29

JBT0627	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1165)	62	15		
JBT0628	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1166)	54	16		
JBT0631	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1113)	171	60		
JBT0634	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1051)	311	156		
JBT0635	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1114)	123			
JBT0641	Ac-SRYKWF[CPMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1247)	21			
JBT0642	Ac-SRYKWF[CGPRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1248)	32			
JBT0643	Ac-SRYKWF[CGMPDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1006)	289	192	0.63	
JBT0644	Ac-SRYKWF[CGMRPMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1172)	31			
JBT0645	Ac-SRYKWF[CGMRDPKGTMSC]VWVKF-NH2 (SEQ ID NO: 1084)		109		
JBT0646	Ac-SRYKWF[CGMRDMPGTMSC]VWVKF-NH2 (SEQ ID NO: 1173)	84			
JBT0648	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1174)	42			
JBT0649	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1175)	64			
JBT1416	Ac-DRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1007)	253	102	1.38	
JBT1417	Ac-SDYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1116)	140	30	4.79	
JBT1418	Ac-SRDYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1176)	67		3.15	
JBT1419	Ac-SRYDWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1117)	120		3.80	
JBT1426	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1008)	287	135	0.94	
JBT1436	Ac-FRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1053)	228	72	2.54	
JBT1437	Ac-SFYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1010)	284	157	0.85	
JBT1438	Ac-SRFKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1011)	218	81	1.63	
JBT1445	Ac-SRYKWF[CGMRDFKGTMSC]VWVKF-NH2 (SEQ ID NO: 1012)	213	89	1.75	
JBT1446	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1054)	169	64	1.53	
JBT1448	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1123)	184	34		
JBT1449	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1013)	276	116	1.45	
JBT1455	Ac-GRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1014)	226	66	2.50	
JBT1465	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1015)	235	74	2.46	
JBT1474	Ac-KRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1016)	275	136	1.06	
JBT1481	Ac-SRYKWF[CGMKDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1017)	303	123	1.48	

FIGURE 29

JBT1483	Ac-SRYKWF[CGMRDkKGTMSC]VWVKF-NH2 (SEQ ID NO: 1057)	275	88		
JBT1492	Ac-LRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1018)	239	100	1.55	
JBT1493	Ac-SLYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1060)	261	122	1.17	
JBT1502	Ac-SRYKWF[CGMRDLKGTMSC]VWVKF-NH2 (SEQ ID NO: 1019)	307	175	0.77	
JBT1503	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2 (SEQ ID NO: 1063)	202	105	0.95	
JBT1506	Ac-SRYKWF[CGMRDMKGTLSL]VWVKF-NH2 (SEQ ID NO: 1064)	191	49	2.99	
JBT1512	Ac-SRYKWF[CGMRDMKGTMSC]VWVKL-NH2 (SEQ ID NO: 1020)	294	152	0.89	
JBT1523	Ac-SRYKWF[CGMRDMSGTMSL]VWVKF-NH2 (SEQ ID NO: 1022)	255	115	1.30	
JBT1541	Ac-SRYKWF[CGMRDMKGTMSC]VWVPF-NH2 (SEQ ID NO: 1023)	291	155	0.82	
JBT1543	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-OH (SEQ ID NO: 1098)	192	39	3.10	
JBT1544	H-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1024)	235	98		
JBT1545	H-SRYKWF[CGMRDMKGTMSC]VWVKF-OH (SEQ ID NO: 1099)	152	21	7.92	
JBT1557	H-RYKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 173)	208	91		
JBT1558	H-YKWF[CGMRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1149)	115	20		
JBT1559	Ac-SRYKWF[CGaRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1150)	131	42		
JBT1562	Ac-SRYKWF[CGkRDMKGTMSC]VWVKF-NH2 (SEQ ID NO: 1193)	54			
JBT1567	Ac-SRYKWF[CGMRDdKGTMSC]VWVKF-NH2 (SEQ ID NO: 1101)	226	76		
JBT1570	Ac-SRYKWF[CGMRDIKGTMSC]VWVKF-NH2 (SEQ ID NO: 1025)	250	76		
JBT1574	Ac-SRYKWF[CGMRDMdGTMSC]VWVKF-NH2 (SEQ ID NO: 1153)	173	34		

FIGURE 30

JBT0122 class		Thrombin generation assay				
Peptide	Sequence	FEIBA-equivalent activity in FVIII-inhibited plasma @ 10μM [mU/mL]	FEIBA-equivalent activity in FVIII-inhibited plasma @ 1.1μM [mU/mL]	EC ₅₀ (μM), FVIII-inhibited plasma	% FVIII-equivalent activity in FVIII-deficient plasma @ 10μM peptide	% FVIII-equivalent activity in FVIII-deficient plasma @ 1.1μM peptide
JBT0122	AC-SGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2002)	170	31		160	
JBT0221	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARLYYKTSKK-NH2 (SEQ ID NO: 2003)	206	150			
JBT0224	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARLYYKK-NH2 (SEQ ID NO: 2298)	152	58	1.10	162	
JBT0225	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARKK-NH2 (SEQ ID NO: 2128)	55				
JBT0367	Ac-ASFPLAVQLHVSKRSEKEMALARL-NH2 (SEQ ID NO: 2317)	28				
JBT0368	Ac-ASFPLAVQLHVSKRSEKEMALARLY-NH2 (SEQ ID NO: 2130)	36				
JBT0369	Ac-ASFPLAVQLHVSKRSEKEMALARLYY-NH2 (SEQ ID NO: 2017)	68				
JBT0370	Ac-YASFPLAVQLHVSKRSEKEMA-NH2 (SEQ ID NO: 2318)	39				
JBT0371	Ac-GYASFPLAVQLHVSKRSEKEMA-NH2(SEQ ID NO: 2319)	25				
JBT0660	Ac-AGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2004)	141	27			
JBT0661	Ac-SAYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2004)	215	49			

FIGURE 30

JBT0662	2005) Ac-SGAASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2131)	43					
JBT0664	Ac-SGYAAFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2006)	178	26				
JBT0665	Ac-SGYASAPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2132)	49					
JBT0666	Ac-SGYASFALAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2001)	99	23				
JBT0667	Ac-SGYASFPAAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2018)	95					
JBT0669	Ac-SGYASFPLAAQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2133)	20					
JBT0670	Ac-SGYASFPLAVALHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2007)	101					
JBT0671	Ac-SGYASFPLAVQAHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2019)	120					
JBT0673	Ac-SGYASFPLAVQLHASKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2135)	39					
JBT0674	Ac-SGYASFPLAVQLHVAKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2008)	234	90				
JBT0675	Ac-SGYASFPLAVQLHVSARSKEMALARLYYKTS-NH2 (SEQ ID NO: 2136)	20					
JBT0677	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2009)	178	37				
JBT0678	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2010)	153	23				
JBT0679	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2 (SEQ ID NO: 2020)	20					
JBT0682	Ac-SGYASFPLAVQLHVSKRSEKEMAAAARLYYKTS-NH2 (SEQ ID NO: 105/178)	133	27				

FIGURE 30

	2139)								
JBT0684	Ac-SGYASFPLAVQLHVSKRSEKEMALAAALYYKTS-NH2 (SEQ ID NO: 2011)	159	28						
JBT0685	Ac-SGYASFPLAVQLHVSKRSEKEMALARAYYKTS-NH2 (SEQ ID NO: 2021)	131	21						
JBT0686	Ac-SGYASFPLAVQLHVSKRSEKEMALARLAYKTS-NH2 (SEQ ID NO: 2140)	109							
JBT0687	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYAKTS-NH2 (SEQ ID NO: 2141)	124							
JBT0688	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYATS-NH2 (SEQ ID NO: 2012)	148	29						
JBT0689	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKAS-NH2 (SEQ ID NO: 2013)	184	40						
JBT0690	Ac-SGYASFPLAVQLHVSKRSEKEMALARLYYKTA-NH2 (SEQ ID NO: 2014)	187	41						
JBT1579	Ac-GYASFPLAVQLHVAKRSEMA-NH2 (SEQ ID NO: 2015)	66							
JBT1581	Ac-GYASFALAVQLHVAKRSEMA-NH2 (SEQ ID NO: 2321)	67							
JBT1582	Ac-GYASFPLAVQLHVMKRSEMA-NH2 (SEQ ID NO: 2022)	73							
JBT1583	Ac-GYASFALAVQLHVMKRSEMA-NH2 (SEQ ID NO: 2322)	68							

FIGURE 31




FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0047		115	C	Ac-SGVGRQLQVAFQSKKNVFVFGYFERLRAKLTS-NH2	253
JBT0155		30	A	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	8
JBT0156*		>4170		Ac-VVEKLTFVQLSFLNRRRFSQYAGFKGAGKV-NH2	742
JBT0157*		>4170		Ac-RVFLYFSGKAGGLVKLVERQAFQTNVSKFR-NH2	743
JBT0158		41	A	Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLRAKKK-NH2	9
JBT0159		>8300		Ac-KKSGVGRQLQVAFQSKKNVFVFGYFERLKK-NH2	744
JBT0160		>8300		Ac-KKSGVGRQLQVAFQSKKNVFVFGYFKK-NH2	745
JBT0161		>8300		Ac-KKSGVGRQLQVAFQSKKNVFVFKK-NH2	746
JBT0162		36	A	Ac-KKGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	10
JBT0163		18	A	Ac-KKQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	11
JBT0164		43	A	Ac-KKFQSKKNVFVFGYFERLRAKLTSKK-NH2	12
JBT0165		6134	F	Ac-KKKKNVFVFGYFERLRAKLTSKK-NH2	712
JBT0169		120	C	Ac-KKAFQSKKNVFVFGYFERLRAKKK-NH2	254
JBT0170		39	A	Ac-KKFQSKKNVFVFGYFERLRAKLKK-NH2	13
JBT0171		123	C	Ac-KKQSKKNVFVFGYFERLRAKLTKK-NH2	255
JBT0172		295	D	Ac-KKQSKKNVFVFGYFERLRAKKK-NH2	406
JBT0174		44	A	Ac-KKAFQSKKNVFVFGYFERLRAKLKK-NH2	14
JBT0175		65	B	Ac-KKAFQSKKNVFVFGYFERLRAKLTKK-NH2	182
JBT0291		46	A	Ac-K(FAM)KSGVGRQLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2	15
JBT0293	61	179	C	Ac-FQSKKNVFVFGYFERLRAKL-NH2	256
JBT0294		188	C	Ac-YQSKKNVFVFGYFERLRAKL-NH2	257
JBT0295	37	2777	F	Ac-FSSKKNVFVFGYFERLRAKL-NH2	713
JBT0296		575	D	Ac-FQNKKNVFVFGYFERLRAKL-NH2	407
JBT0297		63	B	Ac-FQSKNNVFVFGYFERLRAKL-NH2	183

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0298		>206		Ac-FQSKQN VFVFGYFERLRAKL-NH2	747
JBT0299	25	446	D	Ac-FQSKKN VFVAFGYFERLRAKL-NH2	408
JBT0300		943	D	Ac-FQSKKN VFSFGYFERLRAKL-NH2	409
JBT0301		671	D	Ac-FQSKKN VFTFGYFERLRAKL-NH2	410
JBT0302	55	133	C	Ac-FQSKKN VFVAGYFERLRAKL-NH2	258
JBT0303	66	85	B	Ac-FQSKKN VFVDGYFERLRAKL-NH2	184
JBT0304	54	231	C	Ac-FQSKKN VFVLGYFERLRAKL-NH2	259
JBT0305		154	C	Ac-FQSKKN VFVQGYFERLRAKL-NH2	260
JBT0306	50	89	B	Ac-FQSKKN VFVSGYFERLRAKL-NH2	185
JBT0307		108	C	Ac-FQSKKN VFVYGYFERLRAKL-NH2	261
JBT0308		736	D	Ac-FQSKKN VFVFGYKERLRAKL-NH2	411
JBT0309		565	D	Ac-FQSKKN VFVFGYERLRAKL-NH2	412
JBT0310	66	146	C	Ac-FQSKKN VFVFGYFDRLRAKL-NH2	262
JBT0311		>50000		Ac-FQSKKN VFVFGYFERLRAKN-NH2	748
JBT0335		>50000		Ac-FQSKKN VFVFGYFERLRAK-NH2	749
JBT0336		232	C	Ac-FQSKNN VFVAGYFDRLRAKL-OH	263
JBT0337		32	A	Ac-FQSKNN VFVDGYFDRLRAKL-NH2	16
JBT0338		32	A	Ac-FQSKNN VFVQGYFDRLRAKL-NH2	17
JBT0339		46	A	Ac-FQSKNN VFVSGYFDRLRAKL-NH2	18
JBT0340		68	B	Ac-FQSKNN VFVYGYFDRLRAKL-NH2	186
JBT0341		75	B	Ac-FQSKNN VFVFGYFDRLRAKL-NH2	187
JBT0342	90	47	A	Ac-FQSKNN VFVDGYFERLRAKL-NH2	19
JBT0343		83	B	Ac-FQSKKN VFVDGYFDRLRAKL-NH2	188
JBT0372		313	D	Fam-Ttds-AFQSKKN VFVFGYFERLRAK-NH2	413
JBT0373		97	B	Fam-AFQSKKN VFVFGYFERLRAK-NH2	189

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0374		25	A	Ac-FQSKDNVVFVFGYFERLRAKL-NH2	20
JBT0375	101	56	B	Ac-FQSKGNVVFVFGYFERLRAKL-NH2	190
JBT0376	32	254	D	Ac-FQSKKNAFVVFVFGYFERLRAKL-NH2	414
JBT0377		146	C	Ac-FQSKKNQFVVFVFGYFERLRAKL-NH2	264
JBT0378		39	A	Ac-FQSKKNVVFVFGYFERLRAKL-NH2	21
JBT0379		27	A	Ac-FQSKKNVVFVTGYFERLRAKL-NH2	22
JBT0380		81	B	Ac-FQSKKNVVFVFGYFERLRAKL-NH2	191
JBT0381	40	154	C	Ac-FQSPKNVVFVFGYFERLRAKL-NH2	265
JBT0385		1765	E	Ac-FQSKKNVVFVFGYFERLRAKL-NH2	672
JBT0386	42	526	D	Ac-FQSKKNPFVVFVFGYFERLRAKL-NH2	415
JBT0388		51	B	Ac-FQSKKNVHVFGYFERLRAKL-NH2	192
JBT0389		1165	E	Ac-FQSKKNVVFVFGYFERLRAKL-NH2	673
JBT0390		1393	E	Ac-FQSKKNVVFQFGYFERLRAKL-NH2	674
JBT0391	22	107	C	Ac-FQSKKNVVFVGGYFERLRAKL-NH2	266
JBT0392		32	A	Ac-FQSKKNVVFVHGYFERLRAKL-NH2	23
JBT0393	87	56	B	Ac-FQSKKNVVFVKGYFERLRAKL-NH2	193
JBT0394		48	A	Ac-FQSKKNVVFVMGYFERLRAKL-NH2	24
JBT0395		31	A	Ac-FQSKKNVVFVNGYFERLRAKL-NH2	25
JBT0396	28	80	B	Ac-FQSKKNVFPVPGYFERLRAKL-NH2	194
JBT0397		69	B	Ac-FQSKKNVFPVRGYFERLRAKL-NH2	195
JBT0398		69	B	Ac-FQSKKNVFPVFGYFEELRAKL-NH2	196
JBT0399	-24	>185 >5000.000 >5000.000 >5000.000		Ac-FQSKKNVFPVFGYFELLRAKL-NH2	750

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0400	40	216	C	Ac-FQSKKNVVFVFGYFLRLAKL-NH2	267
JBT0401		359	D	Ac-FQSKKNVVFVFGYFERLRAVL-NH2	416
JBT0406		210	C	Ac-Ttds-FQSKKNVVFVFGYFERLRAKL-NH2	268
JBT0471	93	29	A	Ac-FQSKGNVVFVTGYFERLRAKL-NH2	26
JBT0472	96	38	A	Ac-FQSKGNVVFVNGYFERLRAKL-NH2	27
JBT0473	106	39	A	Ac-FQSKGNVVFVHGYFERLRAKL-NH2	28
JBT0474	100	27	A	Ac-FQSKGNVVFVKGYFERLRAKL-NH2	29
JBT0475	106	25	A	Ac-FQSKGNVVFVEGYFERLRAKL-NH2	30
JBT0476	56	23	A	Ac-FQSKGNVVFVDGYFDRRAKL-NH2	31
JBT0477	99	32	A	Ac-FQSKGNVVFVDGYFERLRAKL-NH2	32
JBT0478		29	A	Ac-FQSKDNVVFVTGYFERLRAKL-NH2	33
JBT0479		48	A	Ac-FQSKDNVVFVNGYFERLRAKL-NH2	34
JBT0480		35	A	Ac-FQSKDNVVFVHGYFERLRAKL-NH2	35
JBT0481		49	A	Ac-FQSKDNVVFVKGYFERLRAKL-NH2	36
JBT0482		38	A	Ac-FQSKDNVVFVEGYFERLRAKL-NH2	37
JBT0483	74	39	A	Ac-FQSKDNVVFVDGYFERLRAKL-NH2	38
JBT0485		23	A	Ac-FQSKNNVVFVTGYFERLRAKL-NH2	39
JBT0486		40	A	Ac-FQSKNNVVFVNGYFERLRAKL-NH2	40
JBT0487		40	A	Ac-FQSKNNVVFVHGYFERLRAKL-NH2	41
JBT0488		29	A	Ac-FQSKNNVVFVKGYFERLRAKL-NH2	42
JBT0489		30	A	Ac-FQSKNNVVFVEGYFERLRAKL-NH2	43
JBT0490		42	A	Ac-FQSKQNVVFVTGYFERLRAKL-NH2	44
JBT0491		59	B	Ac-FQSKQNVVFVNGYFERLRAKL-NH2	197
JBT0492		68	B	Ac-FQSKQNVVFVHGYFERLRAKL-NH2	198
JBT0493		86	B	Ac-FQSKQNVVFVKGYFERLRAKL-NH2	199

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0494	74	48	A	Ac-FQSKQN VFVDGYFERLRAKL-NH2	45
JBT0495		52	B	Ac-FQSKQN VFVEGYFERLRAKL-NH2	200
JBT0497		100	B	Ac-Nmf-QSKGN VFVFGYFERLRAKL-NH2	201
JBT0498		1512	E	Ac-FQ-Nms-KGN VFVFGYFERLRAKL-NH2	675
JBT0499		74	B	Ac-FQS-Nmk-GNV VFVFGYFERLRAKL-NH2	202
JBT0500		24	A	Ac-FQSK-Nmg-NV VFVFGYFERLRAKL-NH2	46
JBT0501		267	D	Ac-FQSKGN-Nmv-FV FG YFERLRAKL-NH2	417
JBT0502		>5000		Ac-FQSKGNV-Nmf-VF FG YFERLRAKL-NH2	751
JBT0503		2038	E	Ac-FQSKGNVF-Nmv-FG YFERLRAKL-NH2	676
JBT0504		861	D	Ac-FQSKGNVFV-Nmf-GYFERLRAKL-NH2	418
JBT0505		118	C	Ac-FQSKGNVFVF-Nmg-YFERLRAKL-NH2	269
JBT0506		3106	F	Ac-FQSKGNVFVFG-Nmy-FERLRAKL-NH2	714
JBT0507		2091	E	Ac-FQSKGNVFVFGY-Nmf-ERLRAKL-NH2	677
JBT0508		1192	E	Ac-FQSKGNVFVFGYF-Nme-RLRAKL-NH2	678
JBT0509		>5000		Ac-FQSKGNVFVFGYFE-Nmr-LRAKL-NH2	752
JBT0510		>5000		Ac-FQSKGNVFVFGYFER-Nml-RAKL-NH2	753
JBT0511		>5000		Ac-FQSKGNVFVFGYFERL-Nmr-AKL-NH2	754
JBT0512		2218	E	Ac-FQSKGNVFVFGYFERL R-Nma-KL-NH2	679
JBT0513		>5000		Ac-FQSKGNVFVFGYFERLRA-Nmk-L-NH2	755
JBT0514		891	D	Ac-FQSKGNVFVFGYFERLRAK-Nml-NH2	419
JBT0515		366	D	Ac-Bhf-QSKGN VFVFGYFERLRAKL-NH2	420
JBT0516		1191	E	Ac-F-Bhq-SKGN VFVFGYFERLRAKL-NH2	680
JBT0517		781	D	Ac-FQ-Bhs-KGN VFVFGYFERLRAKL-NH2	421
JBT0518		767	D	Ac-FQS-Bhk-GNV VFVFGYFERLRAKL-NH2	422
JBT0519		207	C	Ac-FQSK-Bal-NV VFVFGYFERLRAKL-NH2	270

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0520		188	C	Ac-FQSKG-Btg-VFVFGYFERLRAKL-NH2	271
JBT0521		>5000		Ac-FQSKGN-Btl-FVFGYFERLRAKL-NH2	756
JBT0522		1424	E	Ac-FQSKGNV-Bhf-VFVFGYFERLRAKL-NH2	681
JBT0523		>5000		Ac-FQSKGNVF-Btl-FGYFERLRAKL-NH2	757
JBT0524		1573	E	Ac-FQSKGNFV-Bhf-GYFERLRAKL-NH2	682
JBT0525		>5000		Ac-FQSKGNFVF-Bal-YFERLRAKL-NH2	758
JBT0526		>5000		Ac-FQSKGNFVFG-Bhy-FERLRAKL-NH2	759
JBT0527		1348	E	Ac-FQSKGNFVFGY-Bhf-ERLRAKL-NH2	683
JBT0528		107	C	Ac-FQSKGNFVFGYF-Bte-RLRAKL-NH2	272
JBT0529		>5000		Ac-FQSKGNFVFGYFE-Bhr-LRAKL-NH2	760
JBT0530		1684	E	Ac-FQSKGNFVFGYFER-Bhl-RAKL-NH2	684
JBT0531		93	B	Ac-FQSKGNFVFGYFERL-Bhr-AKL-NH2	203
JBT0532		334	D	Ac-FQSKGNFVFGYFERLR-Bal-KL-NH2	423
JBT0533		756	D	Ac-FQSKGNFVFGYFERLRA-Bhk-L-NH2	424
JBT0534		84	B	Ac-FQSKGNFVFGYFERLRAK-Bhl-NH2	204
JBT0535		1779	E	Ac-FQSKGNFVFGYFE-Cit-LRAKL-NH2	685
JBT0536		229	C	Ac-FQSKGNFVFGYFERL-Cit-AKL-NH2	273
JBT0537		>5000		Ac-FQSKGNFVFGYFE-Nle-LRAKL-NH2	761
JBT0538		534	D	Ac-FQSKGNFVFGYFERL-Nle-AKL-NH2	425
JBT0539	-1	542	D	Ac-GQSKKNFVFGYFERLRAKL-NH2	426
JBT0540	3	479	D	Ac-FGSKKNFVFGYFERLRAKL-NH2	427
JBT0541	14	292	D	Ac-FQGGKNFVFGYFERLRAKL-NH2	428
JBT0542	14	129	C	Ac-FQSGKNFVFGYFERLRAKL-NH2	274
JBT0543	67	184	C	Ac-FQSKKGVFVFGYFERLRAKL-NH2	275
JBT0544	-7	746	D	Ac-FQSKKNGFVFGYFERLRAKL-NH2	429

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0545	-19	1780	E	Ac-FQSKKKNVGVFGYFERLRAKL-NH2	686
JBT0546	-15	>5000		Ac-FQSKKKNVFGYFERLRAKL-NH2	762
JBT0547	-18	>5000		Ac-FQSKKKNVVFVGGFERLRAKL-NH2	763
JBT0548	4	885	D	Ac-FQSKKKNVVFVFGYGERLRAKL-NH2	430
JBT0549	35	572	D	Ac-FQSKKKNVVFVFGYFGRRAKL-NH2	431
JBT0550	-14	>5000		Ac-FQSKKKNVVFVFGYFEGRAKL-NH2	764
JBT0551	-22	1640	E	Ac-FQSKKKNVVFVFGYFERGRAKL-NH2	687
JBT0552	10	591	D	Ac-FQSKKKNVVFVFGYFERLRGKL-NH2	432
JBT0553	-19	1101	E	Ac-FQSKKKNVVFVFGYFERLRAGL-NH2	688
JBT0554	-5	314	D	Ac-FQSKKKNVVFVFGYFERLRAG-NH2	433
JBT0555	8	350	D	Ac-KQSKKKNVVFVFGYFERLRAKL-NH2	434
JBT0556	2	336	D	Ac-FKSKKKNVVFVFGYFERLRAKL-NH2	435
JBT0557	27	245	C	Ac-FQKKKKNVVFVFGYFERLRAKL-NH2	276
JBT0558	44	125	C	Ac-FQSKKKKVVFVFGYFERLRAKL-NH2	277
JBT0559	23	203	C	Ac-FQSKKKNKFVFGYFERLRAKL-NH2	278
JBT0560	2	688	D	Ac-FQSKKKNVKVFGYFERLRAKL-NH2	436
JBT0561	7	653	D	Ac-FQSKKKNVFKHGYFERLRAKL-NH2	437
JBT0562	10	413	D	Ac-FQSKKKNVVFVKYFERLRAKL-NH2	438
JBT0563	-6	1151	E	Ac-FQSKKKNVVFVGKFERLRAKL-NH2	689
JBT0564	69	95	B	Ac-FQSKKKNVVFVGYFKRLRAKL-NH2	205
JBT0565	-5	383	D	Ac-FQSKKKNVVFVGYFEKRLRAKL-NH2	439
JBT0566	-7	3310	F	Ac-FQSKKKNVVFVGYFERKRAKL-NH2	715
JBT0567	51	225	C	Ac-FQSKKKNVVFVGYFERLAKL-NH2	279
JBT0568	49	147	C	Ac-FQSKKKNVVFVGYFERLRKKL-NH2	280
JBT0569	13			Ac-FQSKKKNVVFVGYFERLRAKK-NH2	765

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0570	4	>5000		Ac-FFSKKNVFVFGYFERLRAKL-NH2	766
JBT0571	4	>5000		Ac-FQFKKNVFVFGYFERLRAKL-NH2	767
JBT0572	12	>5000		Ac-FQSFKNVFVFGYFERLRAKL-NH2	768
JBT0573	5	1370	E	Ac-FQSKFNVFVFGYFERLRAKL-NH2	690
JBT0574	-8	>5000		Ac-FQSKKFVFVFGYFERLRAKL-NH2	769
JBT0575	3	578	D	Ac-FQSKKNFFVFGYFERLRAKL-NH2	440
JBT0576	12	>1666		Ac-FQSKKNVFVFYFERLRAKL-NH2	770
JBT0577	14	>5000		Ac-FQSKKNVFVFGFFERLRAKL-NH2	771
JBT0578	58	292	D	Ac-FQSKKNVFVFGYFFERLRAKL-NH2	441
JBT0579	4	>5000		Ac-FQSKKNVFVFGYFEFLRAKL-NH2	772
JBT0580	12	>5000		Ac-FQSKKNVFVFGYFERFRAKL-NH2	773
JBT0581	17	>5000		Ac-FQSKKNVFVFGYFERLFAKL-NH2	774
JBT0582	45	>5000	E	Ac-FQSKKNVFVFGYFERLRFKL-NH2	691
JBT0583	13	>5000		Ac-FQSKKNVFVFGYFERLRAFL-NH2	775
JBT0584	50	401	D	Ac-FQSKKNVFVFGYFERLRAKF-NH2	442
JBT0585	10	609	D	Ac-DQSKKNVFVFGYFERLRAKL-NH2	443
JBT0586	5	>1667		Ac-FDSKKNVFVFGYFERLRAKL-NH2	776
JBT0587	50	172	C	Ac-FQDKKNVFVFGYFERLRAKL-NH2	281
JBT0588	5	>5000		Ac-FQSDKNVFVFGYFERLRAKL-NH2	777
JBT0589	58	241	C	Ac-FQSKKDVFVFGYFERLRAKL-NH2	282
JBT0590	2	>5000		Ac-FQSKKNDFVFGYFERLRAKL-NH2	778
JBT0591	1	>5000		Ac-FQSKKNVDVFVFGYFERLRAKL-NH2	779
JBT0592	-1	>5000		Ac-FQSKKNVDFVFGYFERLRAKL-NH2	780
JBT0593	6	2982	F	Ac-FQSKKNVFVDYFERLRAKL-NH2	716
JBT0594	-1	>5000		Ac-FQSKKNVFVFGDFERLRAKL-NH2	781

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0595	10	3557	F	Ac-FQSKKNVFVFGYDERLRAKL-NH2	717
JBT0596	1	549	D	Ac-FQSKKNVFVFGYFEDLRAKL-NH2	444
JBT0597	-5	>5000		Ac-FQSKKNVFVFGYFERDRAKL-NH2	782
JBT0598	-2	>5000		Ac-FQSKKNVFVFGYFERLDACL-NH2	783
JBT0599	30	301	D	Ac-FQSKKNVFVFGYFERLDKL-NH2	445
JBT0600	-12	3232	F	Ac-FQSKKNVFVFGYFERLRADL-NH2	718
JBT0601	-1	1531	E	Ac-LQSKKNVFVFGYFERLRAKL-NH2	692
JBT0602	8	>1000 >1000 >5000.000		Ac-FLSKKNVFVFGYFERLRAKL-NH2	784
JBT0603	4	>5000		Ac-FQLKKNVFVFGYFERLRAKL-NH2	785
JBT0604	11	>1668		Ac-FQSLKNVFVFGYFERLRAKL-NH2	786
JBT0605	18	>1669		Ac-FQSKLNVFVFGYFERLRAKL-NH2	787
JBT0606	1	>5000		Ac-FQSKKLNVFVFGYFERLRAKL-NH2	788
JBT0607	19	718	D	Ac-FQSKKNLNVFVFGYFERLRAKL-NH2	446
JBT0608	4	2673	F	Ac-FQSKKNLVFVFGYFERLRAKL-NH2	719
JBT0609	0	>5000		Ac-FQSKKNVFLVFGYFERLRAKL-NH2	789
JBT0610	-4	>5000		Ac-FQSKKNVFVFLVFGYFERLRAKL-NH2	790
JBT0611	-5	>5000		Ac-FQSKKNVFVFGYFERLRAKL-NH2	791
JBT0612	9	1378	E	Ac-FQSKKNVFVFGYLERLRAKL-NH2	693
JBT0613		237	C	Ac-FQSKGNVFVFGYFERLRAKL-OH	283
JBT0614		2575	F	H-FQSKGNVFVFGYFERLRAKL-OH	720
JBT0615		249	C	H-FQSKGNVFVFGYFERLRAKL-NH2	284
JBT0616		124	C	H-GSFQSKKNVFVDGYFERLRAKL-OH	285
JBT0636		24	A	Ac-FQSK-Nmg-NVFDGYFARLRAKL-NH2	47

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0651		18	A	Ac-FQSKGNVHVKG YFERLRAKL-NH2	48
JBT0652	103	36	A	Ac-FQSKGNVHVDG YFERLRAKL-NH2	49
JBT0653		23	A	Ac-FQSPGNVHVKG YFERLRAKL-NH2	50
JBT0654		16	A	Ac-FQSPGNVHVDG YFERLRAKL-NH2	51
JBT0655		38	A	Ac-FQSKGNIFVFG YFERLRAKL-NH2	52
JBT0656		155	C	Ac-FQSKGNL FVFG YFERLRAKL-NH2	286
JBT0657		142	C	Ac-FQSKGNVFI FGYFERLRAKL-NH2	287
JBT0658		1062	E	Ac-FQSKGNVFLFG YFERLRAKL-NH2	694
JBT0663		45	A	Ac-FQSKaNVFVFG YFERLRAKL-NH2	53
JBT0668		49	A	Ac-FQSKaNVFVTG YFARLRAKL-NH2	54
JBT0681		68	B	Ac-FQSK-Nmg-AVFVFG YFARLRAKL-NH2	206
JBT0683		25	A	Ac-FQSK-Nmg-AVFVDG YFARLRAKL-NH2	55
JBT0691	32		F	Ac-AQSKKNV FVFG YFERLRAKL-NH2	721
JBT0692	49		E	Ac-FASKKNV FVFG YFERLRAKL-NH2	695
JBT0693	60		D	Ac-FQAKKNV FVFG YFERLRAKL-NH2	447
JBT0694	58		D	Ac-FQSAKNV FVFG YFERLRAKL-NH2	448
JBT0695	52		D	Ac-FQSKANV FVFG YFERLRAKL-NH2	449
JBT0696	94	101	C	Ac-FQSKKA V FVFG YFERLRAKL-NH2	288
JBT0697		47	A	Ac-FQSKGNV FVDG YFERL-Dap-AKL-NH2	56
JBT0698	-1			Ac-FQSKKNV A VFG YFERLRAKL-NH2	792
JBT0699		37	A	Ac-FQSKGNV FVDG YFERL-Om-AKL-NH2	57
JBT0700		26	A	Ac-FQSKGNV FVDG YFERL-Nva-AKL-NH2	58
JBT0701	29			Ac-FQSKKNV FVFA YFERLRAKL-NH2	793
JBT0702	10			Ac-FQSKKNV FVFGA FERLRAKL-NH2	794
JBT0703	22			Ac-FQSKKNV FVFGYA ERLRAKL-NH2	795

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0704	96	116	C	Ac-FQSKKNVVFVFGYFARLRAKL-NH2	289
JBT0705	22			Ac-FQSKKNVVFVFGYFEALRAKL-NH2	796
JBT0706	10			Ac-FQSKKNVVFVFGYFERARAKL-NH2	797
JBT0707	50	502	D	Ac-FQSKKNVVFVFGYFERLAALKL-NH2	450
JBT0708		30	A	Ac-FQSKaNVFVAGYFERLRAKL-NH2	59
JBT0709	6			Ac-FQSKKNVVFVFGYFERLRAAL-NH2	798
JBT0710	-2			Ac-FQSKKNVVFVFGYFERLRAKA-NH2	799
JBT0711	2			Ac-PQSKKNVVFVFGYFERLRAKL-NH2	800
JBT0712	19			Ac-FPSKKNVVFVFGYFERLRAKL-NH2	801
JBT0713	5	679	D	Ac-FQPKKNVVFVFGYFERLRAKL-NH2	451
JBT0714		23	A	Ac-FQSKaVFDGYFARLRAKL-NH2	60
JBT0715	40		F	Ac-FQSKPNVVFVFGYFERLRAKL-NH2	722
JBT0716	42		E	Ac-FQSKKPVFVFGYFERLRAKL-NH2	696
JBT0717		24	A	Ac-FQSK-Nmg-NVFDGYFERLRAKL-NH2	61
JBT0718	14			Ac-FQSKKNVPVFGYFERLRAKL-NH2	802
JBT0719	31		F	Ac-FQSKKNVPFVFGYFERLRAKL-NH2	723
JBT0720		27	A	Ac-FQSK-Nmg-NVFTGYFARLRAKL-NH2	62
JBT0721	29			Ac-FQSKKNVVFVFPYFERLRAKL-NH2	803
JBT0722	12			Ac-FQSKKNVVFVGPFERLRAKL-NH2	804
JBT0723	3			Ac-FQSKKNVVFVGYPERLRAKL-NH2	805
JBT0724	50		D	Ac-FQSKKNVVFVGYFPRLRAKL-NH2	452
JBT0725	21			Ac-FQSKKNVVFVGYFEPLRAKL-NH2	806
JBT0726	2		D	Ac-FQSKKNVVFVGYFERPRRAKL-NH2	453
JBT0727	-1			Ac-FQSKKNVVFVGYFERLPAKL-NH2	807
JBT0728	12			Ac-FQSKKNVVFVGYFERLRPKL-NH2	808

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0729	4			Ac-FQSKKNVFVFGYFERLRAPL-NH2	809
JBT0730	3		D	Ac-FQSKKNVFVFGYFERLRACP-NH2	454
JBT0731	21			Ac-SQSKKNVFVFGYFERLRACL-NH2	810
JBT0732		20	A	Ac-FQSKGNVVDGYFERL-Hci-AKL-NH2	63
JBT0733		26	A	Ac-FQSKGNVVDGYFERL-Har-AKL-NH2	64
JBT0734	26		D	Ac-FQSSKNVFVFGYFERLRACL-NH2	455
JBT0735	19			Ac-FQSKSNVFVFGYFERLRACL-NH2	811
JBT0736	68		D	Ac-FQSKKS VFVFGYFERLRACL-NH2	456
JBT0737	34		F	Ac-FQSKKNS VFVFGYFERLRACL-NH2	724
JBT0738	20			Ac-FQSKKNVSVFGYFERLRACL-NH2	812
JBT0739		31	A	Ac-FQSKGNVVDGYFERL-Opa-AKL-NH2	65
JBT0740	113	18	A	Ac-FQSKGNVVDGYFERL-Aib-AKL-NH2	66
JBT0741	44		E	Ac-FQSKKNVFVFSYFERLRACL-NH2	697
JBT0742	12			Ac-FQSKKNVFVFGSFERLRACL-NH2	813
JBT0743	5			Ac-FQSKKNVFVFGYSERLRACL-NH2	814
JBT0744	66		D	Ac-FQSKKNVFVFGYFSRLACL-NH2	457
JBT0745	9			Ac-FQSKKNVFVFGYFESLRACL-NH2	815
JBT0746	-1			Ac-FQSKKNVFVFGYFERSRACL-NH2	816
JBT0747	19			Ac-FQSKKNVFVFGYFERLSAKL-NH2	817
JBT0748	43		D	Ac-FQSKKNVFVFGYFERLSKL-NH2	458
JBT0749	19		D	Ac-FQSKKNVFVFGYFERLRASL-NH2	459
JBT0750	10			Ac-FQSKKNVFVFGYFERLRAS-NH2	818
JBT0751	33		F	Ac-FQSKKNVFVFGYFERLLAKL-NH2	725
JBT0752	46		E	Ac-FQSKKNVFVFGYFERLRKL-NH2	698
JBT0753	26		D	Ac-FQSKKNVFVFGYFERLRALL-NH2	460

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0754		33	A	Ac-FQSK-Nmg-AVFVTGYFARLRAKL-NH2	67
JBT0755	34	>5000	F	Ac-fQSKKNVFVFGYFERLRAKL-NH2	726
JBT0756	35	>5000	F	Ac-FqSKKNVFVFGYFERLRAKL-NH2	727
JBT0757		2212	E	Ac-FQsKKNVFVFGYFERLRAKL-NH2	699
JBT0758	52	101	C	Ac-FQSkKNVFVFGYFERLRAKL-NH2	290
JBT0759	78	52	B	Ac-FQSKknVFVFGYFERLRAKL-NH2	207
JBT0760	37		F	Ac-FQSKKnVFVFGYFERLRAKL-NH2	728
JBT0761	35		F	Ac-FQSKKNvVFVFGYFERLRAKL-NH2	729
JBT0762	37		F	Ac-FQSKKNVFVFGYFERLRAKL-NH2	730
JBT0763	58	129	C	Ac-FQSKKNVFVFGYFERLRAKL-NH2	291
JBT0764	53	296	D	Ac-FQSKKNVFVfGYFERLRAKL-NH2	461
JBT0765		26	A	Ac-FQSKGNVFVDGYFERL-Eew-AKL-NH2	68
JBT0766	32		D	Ac-FQSKKNVFVFGyFERLRAKL-NH2	462
JBT0767	40		E	Ac-FQSKKNVFVFGYfERLRAKL-NH2	700
JBT0768	27		D	Ac-FQSKKNVFVFGYFeRLRAKL-NH2	463
JBT0769	22		D	Ac-FQSKKNVFVFGYFeRLRAKL-NH2	464
JBT0770	20			Ac-FQSKKNVFVFGYFERLRAKL-NH2	819
JBT0771	29	423	D	Ac-FQSKKNVFVFGYFERLrAKL-NH2	465
JBT0772	21			Ac-FQSKKNVFVFGYFERLaKL-NH2	820
JBT0773	21			Ac-FQSKKNVFVFGYFERLAKL-NH2	821
JBT0774	26			Ac-FQSKKNVFVFGYFERLAKL-NH2	822
JBT0775	73	22	A	Ac-FQSKGNVFVTGYFDRLRAKL-NH2	69
JBT0776	51	82	B	Ac-FQSKGNVFVNGYFDRLRAKL-NH2	208
JBT0777	49	101	C	Ac-FQSKGNVFVHGyFDRLRAKL-NH2	292
JBT0778	68	66	B	Ac-FQSKGNVFVKGYFDRLRAKL-NH2	209

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0779	51	71	B	Ac-FQSKGNVFVEGYFDRRAKL-NH2	210
JBT0780		44	A	Ac-FQSK-Nmg-NVVFVGYFARLRAKL-NH2	70
JBT0781	82	63	B	Ac-FQSKGNVFVDGYFKRLRAKL-NH2	211
JBT0782	44	>556 >555,556	D	Ac-fqskknvfvfyferlrakl-NH2	466
JBT0783	39	>556 >1666,670	D	Ac-lkarlrefygvfnkksqf-NH2	467
JBT0784		>5000		Ac-FQSKKKNVFVFGYFE-(omega-methyl-L)-(omega-methyl-L)-AKL-NH2	823
JBT0785		163	C	Ac-FQSKKKNVFVFGYFERL-(omega-methyl-R)-AKL-NH2	293
JBT0786		616	D	Ac-FQSKKKNVFVFGYFE-(omega-methyl-R)-LRAKL-NH2	468
JBT0789		20	A	Ac-FQSK-Nmg-NVFDGYFERL-Nle-AKL-NH2	71
JBT0791	42		D	Ac-AQSKGNVFVDGYFERLRAKL-NH2	469
JBT0792	5		D	Ac-FASKGNVFVDGYFERLRAKL-NH2	470
JBT0793	88		C	Ac-FQAKGNVFVDGYFERLRAKL-NH2	294
JBT0794	90	156	C	Ac-FQSAGNVFVDGYFERLRAKL-NH2	295
JBT0795	92	34	A	Ac-FQSKGAVFVDGYFERLRAKL-NH2	72
JBT0796	70		D	Ac-FQSKGNAFVDGYFERLRAKL-NH2	471
JBT0797	-2			Ac-FQSKGNVAVDGYFERLRAKL-NH2	824
JBT0798	39		F	Ac-FQSKGNVFADGYFERLRAKL-NH2	731
JBT0799	8			Ac-FQSKGNVFVDGYFERLRAKL-NH2	825
JBT0800	-2			Ac-FQSKGNVFVDGAFERLRAKL-NH2	826
JBT0801	64		D	Ac-FQSKGNVFVDGYAERLRAKL-NH2	472
JBT0802	101	35	A	Ac-FQSKGNVFVDGYFARLRAKL-NH2	73
JBT0803	7		D	Ac-FQSKGNVFVDGYFEALRAKL-NH2	473
JBT0804	10			Ac-FQSKGNVFVDGYFERARAKL-NH2	827

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0805	98	64	B	Ac-FQSKGNVFVDGYFERLAAKL-NH2	212
JBT0806		42	A	Ac-FQSK-Nmg-NVFVAGYFARLRAKL-NH2	74
JBT0807	-6			Ac-FQSKGNVFVDGYFERLRAAL-NH2	828
JBT0808	39		F	Ac-FQSKGNVFVDGYFERLRAKA-NH2	732
JBT0809	10			Ac-DQSKGNVFVDGYFERLRAKL-NH2	829
JBT0810	-1			Ac-FDSKGNVFVDGYFERLRAKL-NH2	830
JBT0811	69		D	Ac-FQDKGNVFVDGYFERLRAKL-NH2	474
JBT0812	81		C	Ac-FQSDGNVFVDGYFERLRAKL-NH2	296
JBT0813	76		D	Ac-FQSKGDNVFVDGYFERLRAKL-NH2	475
JBT0814	4			Ac-FQSKGDNVFVDGYFERLRAKL-NH2	831
JBT0815	2			Ac-FQSKGNVDVDGYFERLRAKL-NH2	832
JBT0816	1			Ac-FQSKGNVFDDGYFERLRAKL-NH2	833
JBT0817	5			Ac-FQSKGNVFVDDYFERLRAKL-NH2	834
JBT0818	3		D	Ac-FQSKGNVFVDGDFERLRAKL-NH2	476
JBT0819	31		D	Ac-FQSKGNVFVDGYDERLRAKL-NH2	477
JBT0820	0			Ac-FQSKGNVFVDGYFEDLRAKL-NH2	835
JBT0821	-3			Ac-FQSKGNVFVDGYFERDRAKL-NH2	836
JBT0822	51		D	Ac-FQSKGNVFVDGYFERLDAKL-NH2	478
JBT0823	82		C	Ac-FQSKGNVFVDGYFERLRDKL-NH2	297
JBT0824	3			Ac-FQSKGNVFVDGYFERLRADL-NH2	837
JBT0825	9			Ac-FQSKGNVFVDGYFERLRAKD-NH2	838
JBT0826	22		D	Ac-EQSKGNVFVDGYFERLRAKL-NH2	479
JBT0827	-3			Ac-FESKGNVFVDGYFERLRAKL-NH2	839
JBT0828	90		C	Ac-FQEKGNVFVDGYFERLRAKL-NH2	298
JBT0829	104		A	Ac-FQSEGNVFVDGYFERLRAKL-NH2	75

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0830	75		D	Ac-FQSKGEVFVDGYFERLRAKL-NH2	480
JBT0831	18		D	Ac-FQSKGNEFVDGYFERLRAKL-NH2	481
JBT0832	-5			Ac-FQSKGNVEVDGYFERLRAKL-NH2	840
JBT0833	11			Ac-FQSKGNVFEDGYFERLRAKL-NH2	841
JBT0834	13			Ac-FQSKGNVFVDEYFERLRAKL-NH2	842
JBT0835	5			Ac-FQSKGNVFVDGEFERLRAKL-NH2	843
JBT0836	51		D	Ac-FQSKGNVFVDGYEERLRAKL-NH2	482
JBT0837		87	B	Ac-FQSK-Nmg-NVFVTGYFERL-Nle-AKL-NH2	213
JBT0838	4		D	Ac-FQSKGNVFVDGYFEELRAKL-NH2	483
JBT0839	4			Ac-FQSKGNVFVDGYFERERAKL-NH2	844
JBT0840	71		D	Ac-FQSKGNVFVDGYFERLEAKL-NH2	484
JBT0841	82		C	Ac-FQSKGNVFVDGYFERLREKL-NH2	299
JBT0842	3			Ac-FQSKGNVFVDGYFERLRAEL-NH2	845
JBT0843	21			Ac-FQSKGNVFVDGYFERLRAKE-NH2	846
JBT0844		112	C	Ac-FQSKaNVFVDGYFERLRAKL-NH2	300
JBT0845	5		D	Ac-FFSKGNVFVDGYFERLRAKL-NH2	485
JBT0846	66		D	Ac-FQFKGNVFVDGYFERLRAKL-NH2	486
JBT0847	82		C	Ac-FQSFGNVFVDGYFERLRAKL-NH2	301
JBT0848	69		D	Ac-FQSKGFVFVDGYFERLRAKL-NH2	487
JBT0849	48		D	Ac-FQSKGNFFVDGYFERLRAKL-NH2	488
JBT0850		150	C	Ac-FQSKaAVFVAGYFARLRAKL-NH2	302
JBT0851	6		D	Ac-FQSKGNVFVDGYFERLRAKL-NH2	489
JBT0852	18			Ac-FQSKGNVFVDGYFERLRAKL-NH2	847
JBT0853	13			Ac-FQSKGNVFVDGYFERLRAKL-NH2	848
JBT0854		593	D	Ac-FQSKaAVFVAGYFARL-Nle-AKL-NH2	490

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0855	57		D	Ac-FQSKGNVFVDGYFFERLAKL-NH2	491
JBT0856	4		D	Ac-FQSKGNVFVDGYFFERLAKL-NH2	492
JBT0857	13			Ac-FQSKGNVFVDGYFFERLAKL-NH2	849
JBT0858	85		C	Ac-FQSKGNVFVDGYFFERLAKL-NH2	303
JBT0859	81		C	Ac-FQSKGNVFVDGYFFERLAKL-NH2	304
JBT0860	1			Ac-FQSKGNVFVDGYFFERLAKL-NH2	850
JBT0861	94		C	Ac-FQSKGNVFVDGYFFERLAKL-NH2	305
JBT0862	23			Ac-GQSKGNVFVDGYFFERLAKL-NH2	851
JBT0863	7		D	Ac-FGSKGNVFVDGYFFERLAKL-NH2	493
JBT0864	60		D	Ac-FQGGKGNVFVDGYFFERLAKL-NH2	494
JBT0865	69		D	Ac-FQSGGNVFVDGYFFERLAKL-NH2	495
JBT0866	79		D	Ac-FQSKGGVFVDGYFFERLAKL-NH2	496
JBT0867	2			Ac-FQSKGNVFVDGYFFERLAKL-NH2	852
JBT0868	4			Ac-FQSKGNVFVDGYFFERLAKL-NH2	853
JBT0869	-1			Ac-FQSKGNVFVDGYFFERLAKL-NH2	854
JBT0870		57	B	Ac-FQSKaAVFTGYFARLAKL-NH2	214
JBT0871	1			Ac-FQSKGNVFVDGGFERLAKL-NH2	855
JBT0872	24		D	Ac-FQSKGNVFVDGYGERLAKL-NH2	497
JBT0873	64		D	Ac-FQSKGNVFVDGYFGRLAKL-NH2	498
JBT0874	1		D	Ac-FQSKGNVFVDGYFEGRLAKL-NH2	499
JBT0875	-5			Ac-FQSKGNVFVDGYFFERGRAL-NH2	856
JBT0876	75		D	Ac-FQSKGNVFVDGYFFERLAKL-NH2	500
JBT0877	50		E	Ac-FQSKGNVFVDGYFFERLGRKL-NH2	701
JBT0878	9			Ac-FQSKGNVFVDGYFFERLAKL-NH2	857
JBT0879	29			Ac-FQSKGNVFVDGYFFERLAKG-NH2	858

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0880	56		D	Ac-HQSKGNVFVDGYFERLRAKL-NH2	501
JBT0881	-2			Ac-FHSGKNVFVDGYFERLRAKL-NH2	859
JBT0882	85		C	Ac-FQHKGNVFVDGYFERLRAKL-NH2	306
JBT0883	93		C	Ac-FQSHGNVFVDGYFERLRAKL-NH2	307
JBT0884	71		D	Ac-FQSKGHHVFVDGYFERLRAKL-NH2	502
JBT0885	50		D	Ac-FQSKGNHFVDGYFERLRAKL-NH2	503
JBT0886		50	B	Ac-FQSKaNVFVDGYFARLRAKL-NH2	215
JBT0887	0			Ac-FQSKGNVFHDGYFERLRAKL-NH2	860
JBT0888	35		D	Ac-FQSKGNVFVDHYFERLRAKL-NH2	504
JBT0889	-8			Ac-FQSKGNVFVDGHFERLRAKL-NH2	861
JBT0890	71		D	Ac-FQSKGNVFVDGYHERLRAKL-NH2	505
JBT0891	93		C	Ac-FQSKGNVFVDGYFHRRAKL-NH2	308
JBT0892	-8			Ac-FQSKGNVFVDGYFEHLRAKL-NH2	862
JBT0893	-10			Ac-FQSKGNVFVDGYFERHRAKL-NH2	863
JBT0894	103	42	A	Ac-FQSKGNVFVDGYFERLHAKL-NH2	76
JBT0895	69		D	Ac-FQSKGNVFVDGYFERLRHKL-NH2	506
JBT0896	-12			Ac-FQSKGNVFVDGYFERLRAHL-NH2	864
JBT0897	71		D	Ac-FQSKGNVFVDGYFERLRAKH-NH2	507
JBT0898	87		C	Ac-IQSKGNVFVDGYFERLRAKL-NH2	309
JBT0899	7		D	Ac-FISKGNVFVDGYFERLRAKL-NH2	508
JBT0900	88		C	Ac-FQIKGNVFVDGYFERLRAKL-NH2	310
JBT0901	96		A	Ac-FQSIGNVFVDGYFERLRAKL-NH2	77
JBT0902	94		C	Ac-FQSKGIVFVDGYFERLRAKL-NH2	311
JBT0903	97		A	Ac-FQSKGNIFVDGYFERLRAKL-NH2	78
JBT0904	2			Ac-FQSKGNVIVDGYFERLRAKL-NH2	865

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0905	58		D	Ac-FQSKGNVFIDGYFERLRAKL-NH2	509
JBT0906	-2			Ac-FQSKGNVFVDIYFERLRAKL-NH2	866
JBT0907	1			Ac-FQSKGNVFVDGIFERLRAKL-NH2	867
JBT0908	39		D	Ac-FQSKGNVFVDGYIERLRAKL-NH2	510
JBT0909	92		C	Ac-FQSKGNVFVDGYFRLRAKL-NH2	312
JBT0910	0			Ac-FQSKGNVFVDGYFEILRAKL-NH2	868
JBT0911	15			Ac-FQSKGNVFVDGYFERIRAKL-NH2	869
JBT0912	104	57	B	Ac-FQSKGNVFVDGYFERLIAKL-NH2	216
JBT0913	65		D	Ac-FQSKGNVFVDGYFERLRIKL-NH2	511
JBT0914	-7			Ac-FQSKGNVFVDGYFERLAIL-NH2	870
JBT0915	80		D	Ac-FQSKGNVFVDGYFERLRAKI-NH2	512
JBT0916	59		D	Ac-KQSKGNVFVDGYFERLRAKL-NH2	513
JBT0917	-3			Ac-FKSKGNVFVDGYFERLRAKL-NH2	871
JBT0918	65		D	Ac-FQKKGNVFVDGYFERLRAKL-NH2	514
JBT0919		42	A	Ac-FQSKaNVFVTGYFERLRAKL-NH2	79
JBT0920	115	23	A	Ac-FQSKGKVFVDGYFERLRAKL-NH2	80
JBT0921	11			Ac-FQSKGNKFVDGYFERLRAKL-NH2	872
JBT0922	-4			Ac-FQSKGNVKVDGYFERLRAKL-NH2	873
JBT0923	3		D	Ac-FQSKGNVFKDGYFERLRAKL-NH2	515
JBT0924	17			Ac-FQSKGNVFVDKYFERLRAKL-NH2	874
JBT0925	-6			Ac-FQSKGNVFVDGKFERLRAKL-NH2	875
JBT0926	20		D	Ac-FQSKGNVFVDGYKERLRAKL-NH2	516
JBT0927	-8			Ac-FQSKGNVFVDGYFEKRAKL-NH2	876
JBT0928	4			Ac-FQSKGNVFVDGYFERKRAKL-NH2	877
JBT0929	107	29	A	Ac-FQSKGNVFVDGYFERLKAKL-NH2	81

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0930	44		E	Ac-FQSKGNVFVDGYFERLRKKL-NH2	702
JBT0931		33	A	Ac-FQSKGNVFVDGYFERL-Eag-AKL-NH2	82
JBT0932	47		E	Ac-FQSKGNVFVDGYFERLRACK-NH2	703
JBT0933	75		D	Ac-LQSKGNVFVDGYFERLRACL-NH2	517
JBT0934	-7			Ac-FLSKGNVFVDGYFERLRACL-NH2	878
JBT0935	72		D	Ac-FQLKGNVFVDGYFERLRACL-NH2	518
JBT0936	97	41	A	Ac-FQSLGNVFVDGYFERLRACL-NH2	83
JBT0937	90		C	Ac-FQSKGLVFVDGYFERLRACL-NH2	313
JBT0938	44		D	Ac-FQSKGNLFVDGYFERLRACL-NH2	519
JBT0939	27			Ac-FQSKGNLVVDGYFERLRACL-NH2	879
JBT0940	4			Ac-FQSKGNVFLDGYFERLRACL-NH2	880
JBT0941	28		D	Ac-FQSKGNVFVDLYFERLRACL-NH2	520
JBT0942	4		D	Ac-FQSKGNVFVDGLFERLRACL-NH2	521
JBT0943	83		C	Ac-FQSKGNVFVDGYLERLRACL-NH2	314
JBT0944	103		A	Ac-FQSKGNVFVDGYFLRLRACL-NH2	84
JBT0945	1		D	Ac-FQSKGNVFVDGYFELLRACL-NH2	522
JBT0946		38	A	Ac-FQSKGNVFVDGYFERL-Dab-AKL-NH2	85
JBT0947	105		A	Ac-FQSKGNVFVDGYFERLLAKL-NH2	86
JBT0948	108	46	A	Ac-FQSKGNVFVDGYFERLRLKL-NH2	87
JBT0949	2			Ac-FQSKGNVFVDGYFERLALL-NH2	881
JBT0950		73	B	Ac-FQSKaNVFVGyFARLRACL-NH2	217
JBT0951	97		A	Ac-MQSKGNVFVDGYFERLRACL-NH2	88
JBT0953	109	43	A	Ac-FQMKGNVFVDGYFERLRACL-NH2	89
JBT0956	27			Ac-FQSKGNMFVDGYFERLRACL-NH2	882
JBT0961	77		D	Ac-FQSKGNVFVDGYMERLRACL-NH2	523

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0962	107	40	A	Ac-FQSKGNVFVDGYFMRLRAKL-NH2	90
JBT0964	28			Ac-FQSKGNVFVDGYFERMRRAKL-NH2	883
JBT0966	100		A	Ac-FQSKGNVFVDGYFERLRMKL-NH2	91
JBT0969	65		D	Ac-NQSKGNVFVDGYFERLRRAKL-NH2	524
JBT0970	7		D	Ac-FNSKGNVFVDGYFERLRRAKL-NH2	525
JBT0971	83		C	Ac-FQNKGNVFVDGYFERLRRAKL-NH2	315
JBT0972	94		C	Ac-FQSNGNVFVDGYFERLRRAKL-NH2	316
JBT0973		37	A	Ac-FQSKGNVFVDGYFERL-Cha-AKL-NH2	92
JBT0974	29			Ac-FQSKGNVFVDGYFERLRRAKL-NH2	884
JBT0975	-3			Ac-FQSKGNVFVDGYFERLRRAKL-NH2	885
JBT0976	-2			Ac-FQSKGNVFVDGYFERLRRAKL-NH2	886
JBT0977	15			Ac-FQSKGNVFVDNYFERLRRAKL-NH2	887
JBT0978	-10			Ac-FQSKGNVFVDGNFERLRRAKL-NH2	888
JBT0979	44		D	Ac-FQSKGNVFVDGYNERLRRAKL-NH2	526
JBT0980	93	40	A	Ac-FQSKGNVFVDGYFNRLRAKL-NH2	93
JBT0982	-2			Ac-FQSKGNVFVDGYFERNRAKL-NH2	889
JBT0983	81		C	Ac-FQSKGNVFVDGYFERLNAKL-NH2	317
JBT0984	100	34	A	Ac-FQSKGNVFVDGYFERLRNKL-NH2	94
JBT0985	4			Ac-FQSKGNVFVDGYFERLRANL-NH2	890
JBT0986	32		F	Ac-FQSKGNVFVDGYFERLRAKN-NH2	733
JBT0987	27			Ac-PQSKGNVFVDGYFERLRRAKL-NH2	891
JBT0988	0			Ac-FPSKGNVFVDGYFERLRRAKL-NH2	892
JBT0989	5			Ac-FQPKGNVFVDGYFERLRRAKL-NH2	893
JBT0990	106	33	A	Ac-FQSPGNVFVDGYFERLRRAKL-NH2	95
JBT0991	5			Ac-FQSKGPVFVDGYFERLRRAKL-NH2	894

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0992	65		D	Ac-FQSKGNPFVDGYFERLRAKL-NH2	527
JBT0993	1			Ac-FQSKGNVPVDGYFERLRAKL-NH2	895
JBT0994	2			Ac-FQSKGNVPDGYFERLRAKL-NH2	896
JBT0995	4		D	Ac-FQSKGNVFVDGYFERLRAKL-NH2	528
JBT0996	3			Ac-FQSKGNVFVDGYFERLRAKL-NH2	897
JBT0997	8		D	Ac-FQSKGNVFVDGYFERLRAKL-NH2	529
JBT0998	48		D	Ac-FQSKGNVFVDGYFERLRAKL-NH2	530
JBT0999	3		D	Ac-FQSKGNVFVDGYFERLRAKL-NH2	531
JBT1000	3			Ac-FQSKGNVFVDGYFERLRAKL-NH2	898
JBT1001	1			Ac-FQSKGNVFVDGYFERLPAKL-NH2	899
JBT1002	15			Ac-FQSKGNVFVDGYFERLRPKL-NH2	900
JBT1003	4			Ac-FQSKGNVFVDGYFERLRAPL-NH2	901
JBT1004	8			Ac-FQSKGNVFVDGYFERLRAP-NH2	902
JBT1005	55		D	Ac-QQSKGNVFVDGYFERLRAKL-NH2	532
JBT1006		28	A	Ac-FQSKGNVFVDGYFERL-Hle-AKL-NH2	96
JBT1007	98	28	A	Ac-FQQKGNVFVDGYFERLRAKL-NH2	97
JBT1008	83		C	Ac-FQSQGNVFVDGYFERLRAKL-NH2	318
JBT1009	99	38	A	Ac-FQSKGQVFVDGYFERLRAKL-NH2	98
JBT1010	46		D	Ac-FQSKGNQVFVDGYFERLRAKL-NH2	533
JBT1011	8			Ac-FQSKGNVQVFVDGYFERLRAKL-NH2	903
JBT1012	14		D	Ac-FQSKGNVFQDGYFERLRAKL-NH2	534
JBT1013	23		D	Ac-FQSKGNVFVDQYFERLRAKL-NH2	535
JBT1014	4			Ac-FQSKGNVFVDGQYFERLRAKL-NH2	904
JBT1015	55		D	Ac-FQSKGNVFVDGYQYERLRAKL-NH2	536
JBT1016	102	27	A	Ac-FQSKGNVFVDGYFQYERLRAKL-NH2	99

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1017	8		D	Ac-FQSKGNVFVDGYFEQLRAKL-NH2	537
JBT1018	12			Ac-FQSKGNVFVDGYFERQRAKL-NH2	905
JBT1019	76		D	Ac-FQSKGNVFVDGYFERLQAKL-NH2	538
JBT1020	88		C	Ac-FQSKGNVFVDGYFERLRQKL-NH2	319
JBT1021	2			Ac-FQSKGNVFVDGYFERLRAQL-NH2	906
JBT1022	55		D	Ac-FQSKGNVFVDGYFERLRAKQ-NH2	539
JBT1023	60		D	Ac-RQSKGNVFVDGYFERLRAKL-NH2	540
JBT1024	11		D	Ac-FRQSKGNVFVDGYFERLRAKL-NH2	541
JBT1025	93	46	A	Ac-FQSKGNVFVDGYFERLRAKL-NH2	100
JBT1026	102	38	A	Ac-FQSKGNVFVDGYFERLRAKL-NH2	101
JBT1027	110	29	A	Ac-FQSKGRVFVDGYFERLRAKL-NH2	102
JBT1028	15		D	Ac-FQSKGNRFVDGYFERLRAKL-NH2	542
JBT1029	18		D	Ac-FQSKGNVRVDGYFERLRAKL-NH2	543
JBT1030	18		D	Ac-FQSKGNVFRDGYFERLRAKL-NH2	544
JBT1031	27			Ac-FQSKGNVFVDGYFERLRAKL-NH2	907
JBT1032	6			Ac-FQSKGNVFVDGRFERLRAKL-NH2	908
JBT1033	60		D	Ac-FQSKGNVFVDGYRERLRAKL-NH2	545
JBT1034	103	36	A	Ac-FQSKGNVFVDGYFRRLRAKL-NH2	103
JBT1035		92	B	Ac-FQSK-Nimg-AVFVAGYFARL-Nie-AKL-NH2	218
JBT1036	29		D	Ac-FQSKGNVFVDGYFERRRAKL-NH2	546
JBT1037		27	A	Ac-FQSKGNVFVDGYFERL-Nie-AKL-NH2	104
JBT1038	107		A	Ac-FQSKGNVFVDGYFERLRRKL-NH2	105
JBT1039	95		C	Ac-FQSKGNVFVDGYFERLRARL-NH2	320
JBT1040	84		C	Ac-FQSKGNVFVDGYFERLRAKR-NH2	321
JBT1041	37		F	Ac-SQSKGNVFVDGYFERLRAKL-NH2	734

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1042	2		D	Ac-FSSKGNVFVDGYFERLRAKL-NH2	547
JBT1043		40	A	Ac-FQSKaNVFVDGYFERL-Nle-AKL-NH2	106
JBT1044	78		D	Ac-FQSSGNVFVDGYFERLRAKL-NH2	548
JBT1045	109	50	A	Ac-FQSKGSVFVDGYFERLRAKL-NH2	107
JBT1046	57		D	Ac-FQSKGNSFVDGYFERLRAKL-NH2	549
JBT1047	5			Ac-FQSKGNVSVDGYFERLRAKL-NH2	909
JBT1048	38		D	Ac-FQSKGNVFSVDGYFERLRAKL-NH2	550
JBT1049	18		D	Ac-FQSKGNVFVDSYFERLRAKL-NH2	551
JBT1050	2			Ac-FQSKGNVFVDGSEFERLRAKL-NH2	910
JBT1051	47		D	Ac-FQSKGNVFVDGYSERLRAKL-NH2	552
JBT1052	84		C	Ac-FQSKGNVFVDGYFSRLRAKL-NH2	322
JBT1053	-7			Ac-FQSKGNVFVDGYFESLRAKL-NH2	911
JBT1054	1			Ac-FQSKGNVFVDGYFERSRAKL-NH2	912
JBT1055	78		D	Ac-FQSKGNVFVDGYFERLSAKL-NH2	553
JBT1056	78		D	Ac-FQSKGNVFVDGYFERLRSL-NH2	554
JBT1057	-9			Ac-FQSKGNVFVDGYFERLRASL-NH2	913
JBT1058	58		D	Ac-FQSKGNVFVDGYFERLRAKS-NH2	555
JBT1059	69		D	Ac-TQSKGNVFVDGYFERLRAKL-NH2	556
JBT1060	-1			Ac-FTSKGNVFVDGYFERLRAKL-NH2	914
JBT1061	73		D	Ac-FQTKGNVFVDGYFERLRAKL-NH2	557
JBT1062	51		D	Ac-FQSTGNVFVDGYFERLRAKL-NH2	558
JBT1063	72		D	Ac-FQSKGTVFVDGYFERLRAKL-NH2	559
JBT1064	49		D	Ac-FQSKGNTFVDGYFERLRAKL-NH2	560
JBT1065	-12			Ac-FQSKGNVTVDGYFERLRAKL-NH2	915
JBT1066	24		D	Ac-FQSKGNVFTDGYFERLRAKL-NH2	561

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1067	-2			Ac-FQSKGNVFVDITYFERLRAKL-NH2	916
JBT1068	-10			Ac-FQSKGNVFVDGTFERLRAKL-NH2	917
JBT1069	46		D	Ac-FQSKGNVFVDGYTERLRAKL-NH2	562
JBT1070	97		A	Ac-FQSKGNVFVDGYFTRLRAKL-NH2	108
JBT1071	-9			Ac-FQSKGNVFVDGYFETLRAKL-NH2	918
JBT1072	9			Ac-FQSKGNVFVDGYFERTRAKL-NH2	919
JBT1073	82		C	Ac-FQSKGNVFVDGYFERLTAKL-NH2	323
JBT1074	71		D	Ac-FQSKGNVFVDGYFERLRTKL-NH2	563
JBT1075	-15			Ac-FQSKGNVFVDGYFERLRATL-NH2	920
JBT1076	69		D	Ac-FQSKGNVFVDGYFERLRAKT-NH2	564
JBT1077	81		C	Ac-VQSKGNVFVDGYFERLRAKL-NH2	324
JBT1078	-3			Ac-FVSKGNVFVDGYFERLRAKL-NH2	921
JBT1079	93		C	Ac-FQVKGNVFVDGYFERLRAKL-NH2	325
JBT1080	92		C	Ac-FQSVGNVFVDGYFERLRAKL-NH2	326
JBT1081	95		C	Ac-FQSKGVVFVDGYFERLRAKL-NH2	327
JBT1082		250	D	Ac-FQSKaAVFVGYYFARLRAKL-NH2	565
JBT1083	17			Ac-FQSKGNVVVDGYFERLRAKL-NH2	922
JBT1084		45	A	Ac-FQSK-Nmg-AVFVAGYFARLRAKL-NH2	109
JBT1085	-10			Ac-FQSKGNVFVDVYFERLRAKL-NH2	923
JBT1086	-15			Ac-FQSKGNVFVDGVFERLRAKL-NH2	924
JBT1087	40		D	Ac-FQSKGNVFVDGYVERLRAKL-NH2	566
JBT1088	99		A	Ac-FQSKGNVFVDGYFVRLRAKL-NH2	110
JBT1089	-4			Ac-FQSKGNVFVDGYFEVRLRAKL-NH2	925
JBT1090	37		D	Ac-FQSKGNVFVDGYFERVRAKL-NH2	567
JBT1091	91	53	B	Ac-FQSKGNVFVDGYFERLVAKL-NH2	219

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1092	85		C	Ac-FQSKGNVFVDGYFERLRV KL-NH2	328
JBT1093	6			Ac-FQSKGNVFVDGYFERLR V L-NH2	926
JBT1094	68		D	Ac-FQSKGNVFVDGYFERLR A K V-NH2	568
JBT1095	92		C	Ac-WQSKGNVFVDGYFERLR A K L-NH2	329
JBT1096	-3			Ac-FWQSKGNVFVDGYFERLR A K L-NH2	927
JBT1097	55		D	Ac-FQWKGNVFVDGYFERLR A K L-NH2	569
JBT1099	58		D	Ac-FQSKGWVFVDGYFERLR A K L-NH2	570
JBT1100	45		D	Ac-FQSKGNVFVDGYFERLR A K L-NH2	571
JBT1101	55		D	Ac-FQSKGNVWVDGYFERLR A K L-NH2	572
JBT1102	4		D	Ac-FQSKGNVFWDGYFERLR A K L-NH2	573
JBT1103	15		D	Ac-FQSKGNVFVDWYFERLR A K L-NH2	574
JBT1104	0			Ac-FQSKGNVFVDGWYFERLR A K L-NH2	928
JBT1105	85		C	Ac-FQSKGNVFVDGYWERLR A K L-NH2	330
JBT1106	82	59	B	Ac-FQSKGNVFVDGYFWRL A K L-NH2	220
JBT1107	-7			Ac-FQSKGNVFVDGYFEWL A K L-NH2	929
JBT1108	9		D	Ac-FQSKGNVFVDGYFERWR A K L-NH2	575
JBT1109	78		D	Ac-FQSKGNVFVDGYFERLW A K L-NH2	576
JBT1110	93		C	Ac-FQSKGNVFVDGYFERLRW K L-NH2	331
JBT1111	-6			Ac-FQSKGNVFVDGYFERLR A W L-NH2	930
JBT1112	87		C	Ac-FQSKGNVFVDGYFERLR A K W-NH2	332
JBT1113	101		A	Ac-YQSKGNVFVDGYFERLR A K L-NH2	111
JBT1114	12			Ac-FYQSKGNVFVDGYFERLR A K L-NH2	931
JBT1115	75		D	Ac-FQYKGNVFVDGYFERLR A K L-NH2	577
JBT1117	83		C	Ac-FQSKGYVFVDGYFERLR A K L-NH2	333
JBT1118	82		C	Ac-FQSKGNVFVDGYFERLR A K L-NH2	334

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1119	99		A	Ac-FQSKGNVYVDGYFERLRAKL-NH2	112
JBT1120	11		D	Ac-FQSKGNVFYDGYFERLRAKL-NH2	578
JBT1121	12			Ac-FQSKGNVFVDYFYFERLRAKL-NH2	932
JBT1122		33	A	Ac-FQSK-Nmg-NVFDGYFARL-Nle-AKL-NH2	113
JBT1123	84		C	Ac-FQSKGNVFVDGYFERLRAKL-NH2	335
JBT1124	85		C	Ac-FQSKGNVFVDGYFYRLRAKL-NH2	336
JBT1125	8			Ac-FQSKGNVFVDGYFEYLRACL-NH2	933
JBT1126	11			Ac-FQSKGNVFVDGYFYERYRAKL-NH2	934
JBT1127	92		C	Ac-FQSKGNVFVDGYFERLYAKL-NH2	337
JBT1128	65		D	Ac-FQSKGNVFVDGYFERLRYKL-NH2	579
JBT1129	-7			Ac-FQSKGNVFVDGYFERLAYL-NH2	935
JBT1130	76		D	Ac-FQSKGNVFVDGYFERLRAKY-NH2	580
JBT1132		20	A	Fam-FQSKGNVFVDGYFERLRAKL-NH2	114
JBT1133		31	A	Ac-FQSKkAVFDGYFARLRAKL-NH2	115
JBT1134		39	A	Ac-FQSKGAVFDGYFARLRAKL-NH2	116
JBT1135		82	B	Ac-FQSKDAVFDGYFARLRAKL-NH2	221
JBT1136		40	A	Ac-FQSKdAVFDGYFARLRAKL-NH2	117
JBT1137		40	A	Ac-FQSKkAVFVAGYFARLRAKL-NH2	118
JBT1138		64	B	Ac-FQSKGAVFVAGYFARLRAKL-NH2	222
JBT1139		87	B	Ac-FQSKDAVFVAGYFARLRAKL-NH2	223
JBT1140		36	A	Ac-FQSKdAVFVAGYFARLRAKL-NH2	119
JBT1141		34	A	Ac-FQSKkAVFVKGYFARLRAKL-NH2	120
JBT1142		53	B	Ac-FQSKGAVFVKGYFARLRAKL-NH2	224
JBT1143		58	B	Ac-FQSKDAVFVKGYFARLRAKL-NH2	225
JBT1144		34	A	Ac-FQSKdAVFVKGYFARLRAKL-NH2	121

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1145		45	A	Ac-FQSKkAVFVTGYFARLRAKL-NH2	122
JBT1146		65	B	Ac-FQSKGAVFVTGYFARLRAKL-NH2	226
JBT1147		95	B	Ac-FQSKDAVFVTGYFARLRAKL-NH2	227
JBT1148		46	A	Ac-FQSKdAVFVTGYFARLRAKL-NH2	123
JBT1149		>5000		Ac-FQSKGNVfVFGYFERLRAKL-NH2	936
JBT1150		1154	E	Ac-FQSKaNVFVTGYFERL-Nle-AKL-NH2	704
JBT1151		>5000		Ac-FQSKKNVfVFGYFERLRAKD-NH2	937
JBT1152		4119	F	Ac-FQSKKNVFFFGYFERLRAKL-NH2	735
JBT1153		1294	E	Ac-FQSKKNVfVFGYFERLGAKL-NH2	705
JBT1154		27	A	Fam-Ttds-FQSKGNVfVDGYFERLRAKL-NH2	124
JBT1155		31	A	Ac-FQSK-Nmg-NVfVTGYFERLRAKL-NH2	125
JBT1156		41	A	Ac-FQSKaNVfVDGYFARL-Nle-AKL-NH2	126
JBT1157		34	A	Ac-FQSKaNVfVAGYFARLRAKL-NH2	127
JBT1158		51	B	Ac-FQSKGNVfVFGYFERLRAKL-N-methyl	228
JBT1159		38	A	Ac-FQSKGNVfVFGYFERLRAKL-N-ethyl	128
JBT1161		122	C	Ac-FQSK-Aib-NVfVFGYFERLRAKL-NH2	338
JBT1162		28	A	Ac-FQSKpNVfVFGYFERLRAKL-NH2	129
JBT1164		28	A	Ac-FQSKGNVfVDGYFERLRAKLC-NH2	130
JBT1166	70	129	C	Ac-FQSKANVfVDGYFERLRAKL-NH2	339
JBT1167	57		D	Ac-FQSKENVfVDGYFERLRAKL-NH2	581
JBT1168	86	94	B	Ac-FQSKfNVfVDGYFERLRAKL-NH2	229
JBT1169	70	127	C	Ac-FQSKHNVfVDGYFERLRAKL-NH2	340
JBT1170	37		D	Ac-FQSKINVfVDGYFERLRAKL-NH2	582
JBT1171	81		C	Ac-FQSKLVfVDGYFERLRAKL-NH2	341
JBT1173	11		D	Ac-FQSKPNVfVDGYFERLRAKL-NH2	583

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1174	83	115	C	Ac-FQSKRNVFVDGYFERLRAKL-NH2	342
JBT1175	63		D	Ac-FQSKSNVFVDGYFERLRAKL-NH2	584
JBT1176	79		D	Ac-FQSKTNVFVDGYFERLRAKL-NH2	585
JBT1177	61		D	Ac-FQSKVNVFVDGYFERLRAKL-NH2	586
JBT1178	54		D	Ac-FQSKWNVFVDGYFERLRAKL-NH2	587
JBT1179	86	100	C	Ac-FQSKYNVFVDGYFERLRAKL-NH2	343
JBT1180	101	98	B	Ac-FQSKGNVFVAGYFERLRAKL-NH2	230
JBT1181	86	107	C	Ac-FQSKGNVFVGGYFERLRAKL-NH2	344
JBT1182	71		D	Ac-FQSKGNVFVIGYFERLRAKL-NH2	588
JBT1183	52		D	Ac-FQSKGNVFVLGYFERLRAKL-NH2	589
JBT1184	97	52	B	Ac-FQSKGNVFVMGYFERLRAKL-NH2	231
JBT1185	105	50	B	Ac-FQSKGNVFVPGYFERLRAKL-NH2	232
JBT1186	60		D	Ac-FQSKGNVFVQGYFERLRAKL-NH2	590
JBT1188	104		A	Ac-FQSKGNVFVSGYFERLRAKL-NH2	131
JBT1189	124	48	A	Ac-FQSKGNVFVVGYYFERLRAKL-NH2	132
JBT1190	116	101	C	Ac-FQSKGNVFVWGYFERLRAKL-NH2	345
JBT1191	112	158	C	Ac-FQSKGNVFVYGYFERLRAKL-NH2	346
JBT1192	81	113	C	Ac-FQSKANVFVDGYFERLAAKL-NH2	347
JBT1193	73		D	Ac-FQSKFNVFVDGYFERLAAKL-NH2	591
JBT1194	65		D	Ac-FQSKYNVFVDGYHERLAAKL-NH2	592
JBT1195	44		D	Ac-FQSSHNVFVDGYFERLAAKL-NH2	593
JBT1196	85		C	Ac-FQSRNVFVDGYFERLAAKL-NH2	348
JBT1197	100	63	B	Ac-FQSKGNVFVDGYFMRLAAKL-NH2	233
JBT1198	60		D	Ac-FQSAKNVFVDGYFERLRAKL-NH2	594
JBT1199	62		D	Ac-FQSFKNVFVDGYFERLAAKL-NH2	595

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1200	53	226	C	Ac-FQSKDNVVFVHGYFERLAAKL-NH2	349
JBT1201	44		D	Ac-FQDPKNVFDVGYFERLAAKL-NH2	596
JBT1202	34		D	Ac-FQSKVNVFVDVGYFERLAAKL-NH2	597
JBT1203	50		D	Ac-FQSIKNVFDVGYFERLAAKL-NH2	598
JBT1204	106	98	B	Ac-YQSKNNVFDVGYFERLAAKL-NH2	234
JBT1205	85	128	C	Ac-FQSKERVFDVGYFERLAAKL-NH2	350
JBT1206	104	74	B	Ac-FQSKGHVFDVGYFERLAAKL-NH2	235
JBT1207	48		D	Ac-FQSKTNIFVDVGYFERLAAKL-NH2	599
JBT1208	37		D	Ac-FQSHYNVFDVGYFERLAAKL-NH2	600
JBT1209	32		D	Ac-FQSKENVFDVGYFDRLAAKL-NH2	601
JBT1210	61	137	C	Ac-FQSKQNVFDVGYFERLAIKL-NH2	351
JBT1211	79	105	C	Ac-FQSKYNVFDVGYFERLAVKL-NH2	352
JBT1212	86		C	Ac-FQSRNNVFDVGYFERLAAKL-NH2	353
JBT1213	64	122	C	Ac-FQSRQNVFDVGYFERLAAKL-NH2	354
JBT1214	64	132	C	Ac-FQSKQNVFDVGYFERLAAKL-NH2	355
JBT1215	72	171	C	Ac-FQSSKNVFDVGYFERLAAKL-NH2	356
JBT1216	70	117	C	Ac-FQSKENVFDVGYFERLAAKL-NH2	357
JBT1217	63		D	Ac-FQSHHNVFDVGYFERLAAKL-NH2	602
JBT1218	72		D	Ac-FQSYKNVFDVGYFERLAAKL-NH2	603
JBT1219	76	90	B	Ac-FQSKKNVFDVGYFERLAAKL-NH2	236
JBT1220	85	85	B	Ac-FQTKHNVFDVGYFERLAAKL-NH2	237
JBT1221	67		D	Ac-FQSKHNVFDVGYFERLAFKL-NH2	604
JBT1222	85	82	B	Ac-FQSKYNVFDVGYFERLAAKL-NH2	238
JBT1223	54		D	Ac-FQSFKNVFDVGYFERLAAKL-NH2	605
JBT1224	57		D	Ac-FQSKANVHVDVGYFERLAAKL-NH2	606

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1225	77	107	C	Ac-FQSKDNNVFVDGYFERLAAKL-NH2	358
JBT1226	26			Ac-LQSKTNVFVDGYFERLAAKL-NH2	938
JBT1227	99	76	B	Ac-FQSKNNVFVDGYFERLAAKL-NH2	239
JBT1228	99	55	B	Ac-FQSKDHHVFVDGYFERLAAKL-NH2	240
JBT1229	93	92	B	Ac-FQSKHNVFVDGYFERLARKL-NH2	241
JBT1230	52		D	Ac-FQSKSNVFVDGYFERLAAKL-NH2	607
JBT1231	68	92	B	Ac-FQSKHNVFVDGYFERLAAKL-NH2	242
JBT1232	47		D	Ac-FQSKHNVFVDGYFERLAAKL-NH2	608
JBT1233	11			Ac-FQSKFNVFVDGYTERLAAKL-NH2	939
JBT1234	63		D	Ac-FQSKDNNVFVDGYFERLAAKL-NH2	609
JBT1235	65		D	Ac-FQSKMNVFVDGYFERLAAKL-NH2	610
JBT1236	41		E	Ac-FQSVKNVFVDGYFERLAAKL-NH2	706
JBT1238	14			Ac-FQSKHNVFVDGHHFERLAAKL-NH2	940
JBT1240	61		D	Ac-FQSAYNVFVDGYFERLAAKL-NH2	611
JBT1241	53		D	Ac-FQSKGNVFVDGYFERLAAKL-NH2	612
JBT1242	49		E	Ac-FQSKVAVFVDGYFERLAAKL-NH2	707
JBT1243	59		D	Ac-FQSAKNVFVDGYFVRLRAKL-NH2	613
JBT1244	62		D	Ac-FQSKTNVFVDGYFERLAAKL-NH2	614
JBT1245	34		F	Ac-FQSKKDVFDGYFERLAAKL-NH2	736
JBT1246	68		D	Ac-FQSKHNVFVDGYFERLAAKL-NH2	615
JBT1247	39		F	Ac-FQSKSNVFVDGYFERLAARL-NH2	737
JBT1248	6			Ac-FQSVHNVFVDGYFERPAAKL-NH2	941
JBT1249	7			Ac-FQSKYNVFVDEYFERLAAKL-NH2	942
JBT1250	66	216	C	Ac-FQSKDNNVFVDGYFERLAARL-NH2	359
JBT1251	60		D	Ac-FQSKKHVFVDGYFERLAAKL-NH2	616

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1252	37		F	Ac-FQSTKNVFVDGYFERLAAKL-NH2	738
JBT1253	30		D	Ac-FQSDKNVFVDGYFERLAAKL-NH2	617
JBT1254	93	47	A	Ac-FQSKHHVFVDGYFERLAAKL-NH2	133
JBT1255	41		D	Ac-FQSNKNVFVDGYFERLAAKL-NH2	618
JBT1256	88	125	C	Ac-FQSKHNVFVDGYFERLAAKL-NH2	360
JBT1257	40		D	Ac-FQSHKNVFVEGYFERLAAKL-NH2	619
JBT1258	13			Ac-FQSKPNVFVDGYFERLAAKL-NH2	943
JBT1259	23		D	Ac-FQSYKDVFDGYFERLATKL-NH2	620
JBT1260	113	50	A	Ac-FQSRRGVFVDGYFERLAAKL-NH2	134
JBT1261	81	98	B	Ac-FQSKLVNFVDGYFERLAAKL-NH2	243
JBT1262	15		D	Ac-FQSKNNVFVDGYFERLAARL-NH2	621
JBT1263	78	152	C	Ac-FQSKYNVFVDGYFERLAAKL-NH2	361
JBT1264	39		F	Ac-YQSKQNVFVDGYFERLAAKL-NH2	739
JBT1265	58		D	Ac-FQSEQNVFVDGYFERLAAKL-NH2	622
JBT1266	53		D	Ac-FQSEHNVFVDGYFERLAAKL-NH2	623
JBT1267	55	219	C	Ac-FQSKNDVFVDGYFERLAAKL-NH2	362
JBT1268	-8			Ac-HQQFKNVFVDGYFERLAAKL-NH2	944
JBT1269	58	155	C	Ac-FQSGGNVFVDGYFERLAAKL-NH2	363
JBT1270	61		D	Ac-FQSEKNVFVDGYFERLAAKL-NH2	624
JBT1271	21		D	Ac-FQSKKNVFVDGYFERLAFKL-NH2	625
JBT1272	58		D	Ac-FQSKRNVFVDGYFERLAAKL-NH2	626
JBT1273	74	106	C	Ac-FQSPKNVFVDGYFERLAAKL-NH2	364
JBT1274	28		D	Ac-FQSGKNVFVDGYFERLAAKL-NH2	627
JBT1275	68	123	C	Ac-FQSPKNVFVDGYFERLAAKL-NH2	365
JBT1277	-4			Ac-FQSKHNVFVDGYFERLAAKL-NH2	945

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1278	74	73	B	Ac-FQSVGNVFVDGYFERLSAKL-NH2	244
JBT1279	13		D	Ac-FQSYKKNVFVDGYFERLFAKL-NH2	628
JBT1280	56	160	C	Ac-FQSRKNVFVDGYFERLRAKL-NH2	366
JBT1281	-5			Ac-FQSKKKNVFVDGYSERLRAKL-NH2	946
JBT1282	52	176	C	Ac-FQSKKRVFVDGYFERLRAKL-NH2	367
JBT1283	36		F	Ac-FQSFENVFVDGYFERLHAKL-NH2	740
JBT1285	100	186	C	Ac-FQSIKNVFVDGYFERLRAKL-NH2	368
JBT1286	113	69	B	Ac-FQSYKKNVFVDGYFERLRAKL-NH2	245
JBT1287	86		C	Ac-CQSKGNVFVDGYFERLRAKL-NH2	369
JBT1288	32		D	Ac-FCSKGNVFVDGYFERLRAKL-NH2	629
JBT1289	96		A	Ac-FQCKGNVFVDGYFERLRAKL-NH2	135
JBT1290	64		D	Ac-FQSCGNVFVDGYFERLRAKL-NH2	630
JBT1292	109	30	A	Ac-FQSKGCVFVDGYFERLRAKL-NH2	136
JBT1293	17		D	Ac-FQSKGNCVFVDGYFERLRAKL-NH2	631
JBT1294	-6			Ac-FQSKGNVCVDGYFERLRAKL-NH2	947
JBT1295	1			Ac-FQSKGNVFCVDGYFERLRAKL-NH2	948
JBT1296	65		D	Ac-FQSKGNVFVCGYFERLRAKL-NH2	632
JBT1297	66		D	Ac-FQSKGNVFVDCYFERLRAKL-NH2	633
JBT1298	-20			Ac-FQSKGNVFVDGCGYFERLRAKL-NH2	949
JBT1299	111	28	A	Ac-FQSKGNVFVDGYCERLRAKL-NH2	137
JBT1300	113		A	Ac-FQSKGNVFVDGYFCRLRAKL-NH2	138
JBT1301	-18			Ac-FQSKGNVFVDGYFECRLRAKL-NH2	950
JBT1302	27		D	Ac-FQSKGNVFVDGYFERCRAKL-NH2	634
JBT1303	97		A	Ac-FQSKGNVFVDGYFERLCAKL-NH2	139
JBT1304	85		C	Ac-FQSKGNVFVDGYFERLRCKL-NH2	370

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1305	-6			Ac-FQSKGNVFVDGYFERLRACL-NH2	951
JBT1306	65		D	Ac-FQSKGNVFVDGYFERLRAC-NH2	635
JBT1307	103		A	Ac-FQSKANVFVDGYFERLCAKL-NH2	140
JBT1308	86		C	Ac-FQSKFNVFVDGYFERLCAKL-NH2	371
JBT1309	92		C	Ac-FQSKYNVFVDGYHERLCAKL-NH2	372
JBT1310	95		C	Ac-FQSSHNVFVDGYFERLCAKL-NH2	373
JBT1311	83		C	Ac-FQSRNVFVDGYFERLCAKL-NH2	374
JBT1312	99		A	Ac-FQSKGNVFVDGYFMRLCAKL-NH2	141
JBT1313	87		C	Ac-FQSKCNVFVDGYFERLRACL-NH2	375
JBT1314	55		D	Ac-FQSFKNVFVDGYFERLCAKL-NH2	636
JBT1315	95	35	A	Ac-FQSKDNVFVHGYFERLCAKL-NH2	142
JBT1316	90		C	Ac-FQDPKNVFVDGYFERLCAKL-NH2	376
JBT1317	76		D	Ac-FQSKVNVFVDGYFERLCAKL-NH2	637
JBT1318	73		D	Ac-FQSIKNVFVDGYFERLCAKL-NH2	638
JBT1319	108	20	A	Ac-YQSKNNVFVDGYFERLCAKL-NH2	143
JBT1320	110	271	D	Ac-FQSKERVVDGYFERLCAKL-NH2	639
JBT1321	117	31	A	Ac-FQSKGHVFVDGYFERLCAKL-NH2	144
JBT1322	89		C	Ac-FQSKTNVFVDGYFERLCAKL-NH2	377
JBT1323	87	171	C	Ac-FQSHYNVFVDGYFERLCAKL-NH2	378
JBT1324	92	424	D	Ac-FQSKENVVDGYFDRLCAKL-NH2	640
JBT1325	62		D	Ac-FQSKQNVFVDGYFERLCIKL-NH2	641
JBT1326	61		D	Ac-FQSKYNVFVDGYFERLCVKL-NH2	642
JBT1328	93		C	Ac-FQSRQNVFVDGYFERLCAKL-NH2	379
JBT1329	96	20	A	Ac-FQSKQNVFVDGYFERLCAKL-NH2	145
JBT1330	86		C	Ac-FQSSKNVFVDGYFERLCAKL-NH2	380

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1331	100		A	Ac-FQSKENVFVDGYFERLCAKL-NH2	146
JBT1332	87		C	Ac-FQSHHNVFVDGYFERLCAKL-NH2	381
JBT1333	72		D	Ac-FQSYKKNVFVDGYFERLCAKL-NH2	643
JBT1334	103	23	A	Ac-FQSKKKNVFVDGYFERLCAKL-NH2	147
JBT1335	111	247	C	Ac-FQTKHNVFVDGYFERLCAKL-NH2	382
JBT1336	61		D	Ac-FQSKHNVFVDGYFERLCAKL-NH2	644
JBT1337	74		D	Ac-FQSKYNVFVDGYFERLCAKL-NH2	645
JBT1338	46		D	Ac-FQSFKHVFVDGYFERLCAKL-NH2	646
JBT1339	88		C	Ac-FQSKANVHVDGYFERLCAKL-NH2	383
JBT1340	7			Ac-FQSCKNVFVDGYFERLCAKL-NH2	952
JBT1341	98	49	A	Ac-FQSKDNVFVDGYFERLCAKL-NH2	148
JBT1342	75		D	Ac-LQSKTNVFVDGYFERLCAKL-NH2	647
JBT1343	99		A	Ac-FQSKNNVFVDGYFERLCAKL-NH2	149
JBT1344	95		A	Ac-FQSKDHFVDGYFERLCAKL-NH2	150
JBT1345	91		C	Ac-FQSKHNVFVDGYFERLCAKL-NH2	384
JBT1346	20		D	Ac-FQSKCNVFVDGYFERLCAKL-NH2	648
JBT1347	95	24	A	Ac-FQSKHNVFVDGYFERLCAKL-NH2	151
JBT1348	91		C	Ac-FQSKSNVFVDGYFERLCAKL-NH2	385
JBT1349	82		C	Ac-FQSHKNVFVDGYFERLCAKL-NH2	386
JBT1350	35		D	Ac-FQSKFNVFVDGYTERLCAKL-NH2	649
JBT1351	85		C	Ac-FQSKDNVFVDGYFERLCAKL-NH2	387
JBT1352	85		C	Ac-FQSKMNVFVDGYFERLCAKL-NH2	388
JBT1353	51		D	Ac-FQSVKNVFVDGYFERLCAKL-NH2	650
JBT1354	86		C	Ac-FQSAKNVFVDGYFERLCAKL-NH2	389
JBT1356	49		E	Ac-FQSKENVFVDGYFERLCYKL-NH2	708

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1357	52		D	Ac-FQSKGNWFVDGYFERLCAKL-NH2	651
JBT1358	20		D	Ac-FQSKVAVFVDGYFERLCAKL-NH2	652
JBT1359	24			Ac-FQSAYNVFVDGYFERLCAKL-NH2	953
JBT1360	25		D	Ac-FQSCKNVFVDGYFVRLRAKL-NH2	653
JBT1361	75		D	Ac-FQSKTNVFVDGYFERLCAKL-NH2	654
JBT1362	76		D	Ac-FQSKKDVFDGYFERLCAKL-NH2	655
JBT1363	88		C	Ac-FQSKHVVFVDGYFERLCAKL-NH2	390
JBT1364	64		D	Ac-FQSKSNVFVDGYFERLCARL-NH2	656
JBT1365	-4			Ac-FQSVHNVFVDGYFERPCAKL-NH2	954
JBT1366	21			Ac-FQSKYNVFVDEYFERLCAKL-NH2	955
JBT1367	83		C	Ac-FQSKDNVFVDGYFERLCARL-NH2	391
JBT1368	89		C	Ac-FQSKKHVFVDGYFERLCAKL-NH2	392
JBT1369	40		E	Ac-FQSTKNVFVDGYFERLCAKL-NH2	709
JBT1370	52		D	Ac-FQSDKNVFVDGYFERLCAKL-NH2	657
JBT1371	96		A	Ac-FQSKHHVFVDGYFERLCAKL-NH2	152
JBT1372	83		C	Ac-FQSNKNVFVDGYFERLCAKL-NH2	393
JBT1373	96		A	Ac-FQSKHNVFVDGYFERLCAKL-NH2	153
JBT1374	71		D	Ac-FQSHKNVFVEGYFERLCAKL-NH2	658
JBT1375	45		D	Ac-FQSKPNVFVDGYFERLCAKL-NH2	659
JBT1376	47		D	Ac-FQSYKDVFDGYFERLCTKL-NH2	660
JBT1377	101		A	Ac-FQSRG VFVDGYFERLCAKL-NH2	154
JBT1378	70		D	Ac-FQSKLNVFVDGYFERLCAKL-NH2	661
JBT1379	40		D	Ac-FQSKNNFFVDGYFERLCARL-NH2	662
JBT1380	66		D	Ac-FQSKYNVFVDGYFERLCAKL-NH2	663
JBT1381	106	19	A	Ac-YQSKQNVFDGYFERLCAKL-NH2	155

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1383	103		A	Ac-FQSEHNVFVDGYFERLCAKL-NH2	156
JBT1384	105	23	A	Ac-FQSKNDVFVDGYFERLCAKL-NH2	157
JBT1385	54		D	Ac-HQQFKNVFVDGYFERLCAKL-NH2	664
JBT1386	107	76	B	Ac-FQSGGNVFVDGYFERLCAKL-NH2	246
JBT1387	92		C	Ac-FQSEKNVFVDGYFERLCAKL-NH2	394
JBT1388	90		C	Ac-FQSKKNVFVDGYFERLCAKL-NH2	395
JBT1389	106	23	A	Ac-FQSKRNVFVDGYFERLCAKL-NH2	158
JBT1390	96		A	Ac-FQSPKNVFVDGYFERLCAKL-NH2	159
JBT1391	99		A	Ac-FQSGKNVFVDGYFERLCAKL-NH2	160
JBT1392	68	235	C	Ac-FQSKQNVFVDGYFERLSAKL-NH2	396
JBT1393	67	205	C	Ac-FQSKKNVFVDGYFERLSAKL-NH2	397
JBT1394	88	191	C	Ac-FQSKDNVFVDGYFERLSAKL-NH2	398
JBT1395	100	173	C	Ac-FQSKHNVFVDGYFERLSAKL-NH2	399
JBT1396		29	A	Ac-FQSK-Nmg-NVFVAGYFERLRAKL-NH2	161
JBT1397	5	1569	E	Ac-F-Aib-SKGNVFVDGYFERL-Aib-AKL-NH2	710
JBT1398	5	660	D	Ac-FQ-Aib-KGNVFVDGYFERL-Aib-AKL-NH2	665
JBT1399	109	40	A	Ac-FQS-Aib-GNVFVDGYFERL-Aib-AKL-NH2	162
JBT1400	92	46	A	Ac-FQSK-Aib-NVFVDGYFERL-Aib-AKL-NH2	163
JBT1401	-7	913	D	Ac-FQSKG-Aib-VFVDGYFERL-Aib-AKL-NH2	666
JBT1402	-8	1144	E	Ac-FQSKGN-Aib-FVDGYFERL-Aib-AKL-NH2	711
JBT1403	-6	>5000		Ac-FQSKGNV-Aib-VDGYFERL-Aib-AKL-NH2	956
JBT1404	13	329	D	Ac-FQSKGNVF-Aib-DGYFERL-Aib-AKL-NH2	667
JBT1405	6	313	D	Ac-FQSKGNVFV-Aib-GYFERL-Aib-AKL-NH2	668
JBT1406	3	610	D	Ac-FQSKGNVFVD-Aib-YFERL-Aib-AKL-NH2	669
JBT1407	6	>5000		Ac-FQSKGNVFVDG-Aib- -Aib-AKL-NH2	957

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1408	78	92	B	Ac-FQSKGNVFVDGY-Aib-ERL-Aib-AKL-NH2	247
JBT1409	104	65	B	Ac-FQSKGNVFVDGYF-Aib-RL-Aib-AKL-NH2	248
JBT1410	-3	>5000		Ac-FQSKGNVFVDGYFE-Aib-L-Aib-AKL-NH2	958
JBT1413	-1	>5000		Ac-FQSKGNVFVDGYFERL-Aib-A-Aib-L-NH2	959
JBT1414	86	119	C	Ac-FQSKGNVFVDGYFERL-Aib-AK-Aib-NH2	400
JBT1415	5	3668	F	Ac-Aib-QSKGNVFVDGYFERL-Aib-AKL-NH2	741
JBT1584		9	A	Ac-FQSK-Nmg-NVFVDGYFERL-Aib-AKL-NH2	164
JBT1585		12	A	Ac-FQSK-Nmg-NVFVTGYFERL-Aib-AKL-NH2	165
JBT1586		25	A	AO-FQSKGNVFVDGYFERL-Aib-AKL-NH2	166
JBT1587		45	A	Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH2	167
JBT1590		106	C	Ac-FQSKGNVFV[CGYFERL-Aib-AKLC]-NH2	401
JBT1591		40	A	Ac-FQSKGNVFVDGYF[CRL-Aib-AKLC]-NH2	168
JBT1592		105	C	Ac-[CFQSKGNVFVDGYFERLC]AKL-NH2	402
JBT1593		462	D	Ac-FQSK[CNVFVDGYFERLC]AKL-NH2	670
JBT1594		952	D	Ac-FQSKGNVFV[CGYFERLC]AKL-NH2	671
JBT1595		249	C	Ac-[CFQSKGNVFC]GYFERL-Aib-AKL-NH2	403
JBT1596		129	C	Ac-[CFQSKGC]VFEVGYFERL-Aib-AKL-NH2	404
JBT1597		>5000		Ac-DGYFERLRAKL-NH2	960
JBT1598		>5000		Ac-FQSKKNV-NH2	961
JBT1843		35	A	Ac-FQSKGNVFVDGYFERLHAKL-NH2	169
JBT1844		41	A	Ac-FQSKNNVFVDGYFKRLRAKL-NH2	170
JBT1845		89	B	Ac-FQSKYKHVFVDGYFERLRAKL-NH2	249
JBT1846		54	B	Ac-FQSKGNVFVDGYFKRLRAKL-NH2	250
JBT1847		30	A	Ac-YQTKGNVFVDGYFERLRAKL-NH2	171
JBT1848		112	C	Ac-FQSKYNNVFVDGYFERLFAKL-NH2	405

FIGURE 32

Object ID	% Inhibition (relative to JBT-0477)	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT1849		44	A	Ac-FQTKDNNVHVDGYFERLRAKL-NH2	172
JBT1850		56	B	Ac-FQSYKRNVFVDGYFERLRAKL-NH2	251
JBT1851		49	A	Ac-LQKGNVFDGYFERLRAKL-NH2	173
JBT1852		19	A	PEG-FQSKGNVFDGYFERL-Aib-AKL-NH2	174
JBT1853		42	A	PEG-FQSKGNVFDGYFERL-Aib-AKL-NH2	175
JBT1854		16	A	Ac-FQSKGNVFDGYFERL-Aib-AKLC(PEG)-NH2	176
JBT1855		96	B	Ac-FQSKGNVFDGYFERL-Aib-AKLC(PEG)-NH2	252
JBT1856		17	A	Ac-FQSKpNVFDGYFERL-Aib-AKL-NH2	177
JBT1857		14	A	Ac-FQSKpNVHVDGYFERL-Aib-AKL-NH2	178
JBT2266		20	A	Ac-PFQSKGNVFDGYFERLRAKL-NH2	179
JBT2267		19	A	Ac-PEFQSKGNVFDGYFERLRAKL-NH2	180
JBT2268		18	A	Ac-PFQSK-Nme-NVFDGYFERL-Aib-AKL-NH2	181

FIGURE 33

Object ID	EC50 (nM)	Sequence	SEQ ID NO:
JBT0051	1.0	Biotinyl-Ttds-SGVGRLQVAFQSKKNVFVFGYFERLRAKLT-S-NH2	962
JBT0055	1.7	Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLT-S-Ttds-Lysin(biotin)-NH2	963
JBT0131	16.8	Biotinyl-Ttds-AFQSKKNVFVFGYFERLRAK-NH2	964
JBT0132	2.2	Biotinyl-Ttds-FQSKKNVFVFGYFERLRAKL-NH2	965
JBT0133	>25000	Biotinyl-Ttds-Ttds-QSKKNVFVFGYFERLRAKL-T-NH2	966
JBT0134	>1000	Biotinyl-Ttds-QSKKNVFVFGYFERLRAK-NH2	967
JBT0166	0.9	Biotinyl-Ttds-KKFQSKKNVFVFGYFERLRAKLKK-NH2	968
JBT0167*	574.8	Biotinyl-Ttds-GKNAKFYLFESLRQVKFVFR-NH2	969
JBT0168*	152.3	Biotinyl-Ttds-YKFSFNKELFKQARLRFVGV-NH2	970
JBT0173	>5000	Biotinyl-Ttds-SGVGRLQVAFQSKKNVFVFG-NH2	971
JBT0403	1.4	Biotinyl-Ttds-FQSKKNVFVDGYFERLRAKL-NH2	972

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT0120	59	B	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1047
JBT0247	>206		Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1213
JBT0248	30	A	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1001
JBT0249	>50000		Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1214
JBT0250	8766	F	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1201
JBT0251	5207	F	Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1202
JBT0252	>50000		Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1215
JBT0253	>207		Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2	1216
JBT0319	32	A	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1002
JBT0319	109	C	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1075
JBT0320	977	D	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1103
JBT0321	>50000		Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1217
JBT0322	>50000		Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1218
JBT0323	118	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1076
JBT0324	1931	E	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1155
JBT0325	>50000		Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1219
JBT0326	>10000		Ac-RDMKGTMSCVWVKFRYDTS-NH2	1220
JBT0326	>50000		Ac-RDMKGTMSCVWVKFRYDTS-NH2	1221
JBT0327	>50000		Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1222
JBT0328	>50000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1223
JBT0329	4574	E	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1156
JBT0329	9396	F	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1203
JBT0330	>50000		Ac-[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1224
JBT0331	>10001		Ac-MRDMKGTMSCVWVKFRYDTS-NH2	1225
JBT0331	>50000		Ac-MRDMKGTMSCVWVKFRYDTS-NH2	1226
JBT0332	29746	G	Ac-SRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1206
JBT0333	18840	G	Ac-KWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1207
JBT0334	>10002		Ac-CGMRDMKGTMSCVWVKFRYDTS-NH2	1227
JBT0409	6413	F	Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1204

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT0410	24801	G	Ac-SGASRYKWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKFRYDTS-NH2	1208
JBT0411	685	D	Ac-SGASRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKFRYDTS-NH2	1104
JBT0412	16103	G	Ac-KWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2	1209
JBT0413	>50000		Ac-KWFSGMRDMKGTMSVWVKF-NH2	1228
JBT0414	5693	F	Ac-KWFSG-Nle-RD-Nle-KGT-Nle-SSVWVKF-NH2	1205
JBT0415	50	A	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1003
JBT0416	187	C	Ac-SRYKWF[CG-Nle-RD-Nle-KGT-Nle-SC]VWVKF-NH2	1077
JBT0417	>50000		Ac-SRYKWFSGMRDMKGTMSVWVKF-NH2	1229
JBT0418	43941	G	Ac-SRYKWF SG-Nle-RD-Nle-KGT-Nle-SS VVVKF-NH2	1210
JBT0435*	31732	G	Ac-RKRDVSGKM[CW-SGFGSKWFRCA]ADMMTYYSVT-NH2	1211
JBT0436*	45925	G	Ac-RWSGKSTYS[CDAMVRRMGMKC]FSFGWTDVYK-NH2	1212
JBT0437	60	B	Ac-ARYKWF[CGMRDMKGTMSC]VWVKF-NH2	1048
JBT0438	194	C	Ac-SAYKWF[CGMRDMKGTMSC]VWVKF-NH2	1078
JBT0439	291	D	Ac-SRAKWF[CGMRDMKGTMSC]VWVKF-NH2	1105
JBT0440	393	D	Ac-SRYAWF[CGMRDMKGTMSC]VWVKF-NH2	1106
JBT0441	>5000		Ac-SRYKAF[CGMRDMKGTMSC]VWVKF-NH2	1230
JBT0442	>5000		Ac-SRYKWA[CGMRDMKGTMSC]VWVKF-NH2	1231
JBT0443	2861	E	Ac-SRYKWF AGMRDMKGTMSC VVVKF-NH2	1157
JBT0444	18	A	Ac-SRYKWF[CAMRDMKGTMSC]VWVKF-NH2	1004
JBT0444	31	A	Ac-SRYKWF[CAMRDMKGTMSC]VWVKF-NH2	1005
JBT0445	760	D	Ac-SRYKWF[CGARDMKGTMSC]VWVKF-NH2	1107
JBT0446	152	C	Ac-SRYKWF[CGMADMKGTMSC]VWVKF-NH2	1079
JBT0447	3249	E	Ac-SRYKWF[CGMRAMKGTMSC]VWVKF-NH2	1158
JBT0448	315	D	Ac-SRYKWF[CGMRDAKGTMSC]VWVKF-NH2	1108
JBT0449	104	C	Ac-SRYKWF[CGMRDMAGTMSC]VWVKF-NH2	1080
JBT0450	1061	E	Ac-SRYKWF[CGMRDMKATMSC]VWVKF-NH2	1159
JBT0451	131	C	Ac-SRYKWF[CGMRDMKGMAMSC]VWVKF-NH2	1081
JBT0452	313	D	Ac-SRYKWF[CGMRDMKGTASC]VWVKF-NH2	1109
JBT0453	343	D	Ac-SRYKWF[CGMRDMKGTMAC]VWVKF-NH2	1110
JBT0454	4963	E	Ac-SRYKWF CGMRDMKGTMSA VVVKF-NH2	1160
JBT0455	99	B	Ac-SRYKWF[CGMRDMKGTMSC]AWVKF-NH2	1049
JBT0456	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VAVKF-NH2	1232

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT0457	2896	E	Ac-SRYKWF[CGMRDMKGTMSC]VWAKF-NH2	1161
JBT0458	148	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVAF-NH2	1082
JBT0459	150	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVKA-NH2	1083
JBT0460	88	B	Ac-RYKWF[CGMRDMKGTMSC]VWVKF-NH2	1050
JBT0461	503	D	Ac-YKWF[CGMRDMKGTMSC]VWVKF-NH2	1111
JBT0462	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1233
JBT0463	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1234
JBT0464	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1235
JBT0465	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1236
JBT0466	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1237
JBT0467	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1238
JBT0468	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1239
JBT0469	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1240
JBT0470	1472	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1162
JBT0617	489	D	Ac-SRYKWF[homoC-GMRDMKGTMSC]VWVKF-NH2	1112
JBT0618	2073	E	Ac-SRYKWF[CGMRDMKGTMSC-homoC]VWVKF-NH2	1163
JBT0619	>5000		Ac-SRYKWF[homoC-GMRDMKGTMSC-homoC]VWVKF-NH2	1241
JBT0620	>5000		Ac-SRYKWF[Dap-GMRDMKGTMSC-D]VWVKF-NH2	1242
JBT0623	>5000		Ac-SRYKWF[K-GMRDMKGTMSC-D]VWVKF-NH2	1243
JBT0625	>5000		Ac-SRYKWF[CMRDMKGTMSC]VWVKF-NH2	1244
JBT0626	1078	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1164
JBT0627	2169	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1165
JBT0628	3611	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1166
JBT0629	4076	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1167
JBT0631	343	D	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1113
JBT0632	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1245
JBT0633	2131	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1168
JBT0634	61	B	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1051
JBT0635	433	D	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1114
JBT0637	3590	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1169
JBT0638	>5000		Ac-SRYKWF[CGMRDMKGTmSC]VWVKF-NH2	1246
JBT0639	1220	E	Ac-SRYKWF[CGMRDMKGTmSC]VWVKF-NH2	1170

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT0640	3470	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1171
JBT0641	>5000		Ac-SRYKWF[CPMRDMKGTMSC]VWVKF-NH2	1247
JBT0642	>5000		Ac-SRYKWF[CGPRDMKGTMSC]VWVKF-NH2	1248
JBT0643	23	A	Ac-SRYKWF[CGMPDMKGTMSC]VWVKF-NH2	1006
JBT0644	2873	E	Ac-SRYKWF[CGMRPMKGTMSC]VWVKF-NH2	1172
JBT0645	165	C	Ac-SRYKWF[CGMRDPKGTMSC]VWVKF-NH2	1084
JBT0646	3169	E	Ac-SRYKWF[CGMRDMPGTMSC]VWVKF-NH2	1173
JBT0647	>5000		Ac-SRYKWF[CGMRDMKPTMSC]VWVKF-NH2	1249
JBT0648	3682	E	Ac-SRYKWF[CGMRDMKGPMSC]VWVKF-NH2	1174
JBT0649	2989	E	Ac-SRYKWF[CGMRDMKGTTPSC]VWVKF-NH2	1175
JBT0650	>5000		Ac-SRYKWF[CGMRDMKGTMPSC]VWVKF-NH2	1250
JBT0790	255	D	H-GSSRYKWF[CGMRDMKGTMSC]VWVKF-OH	1115
JBT1416	39	A	Ac-DRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1007
JBT1417	344	D	Ac-SDYKWF[CGMRDMKGTMSC]VWVKF-NH2	1116
JBT1418	1469	E	Ac-SRDKWF[CGMRDMKGTMSC]VWVKF-NH2	1176
JBT1419	536	D	Ac-SRYDWF[CGMRDMKGTMSC]VWVKF-NH2	1117
JBT1420	>5000		Ac-SRYKDF[CGMRDMKGTMSC]VWVKF-NH2	1251
JBT1421	>5000		Ac-SRYKWD[CGMRDMKGTMSC]VWVKF-NH2	1252
JBT1422	>5000		Ac-SRYKWF[CDMRDMKGTMSC]VWVKF-NH2	1253
JBT1423	4671	E	Ac-SRYKWF[CGDRDMKGTMSC]VWVKF-NH2	1177
JBT1424	>5000		Ac-SRYKWF[CGMDDMKGTMSC]VWVKF-NH2	1254
JBT1425	101	C	Ac-SRYKWF[CGMRDDKGTMSC]VWVKF-NH2	1085
JBT1426	17	A	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1008
JBT1427	87	B	Ac-SRYKWF[CGMRDMKDTMSC]VWVKF-NH2	1052
JBT1428	478	D	Ac-SRYKWF[CGMRDMKGDMS]VWVKF-NH2	1118
JBT1429	107	C	Ac-SRYKWF[CGMRDMKGTDS]VWVKF-NH2	1086
JBT1430	265	D	Ac-SRYKWF[CGMRDMKGTMD]VWVKF-NH2	1119
JBT1431	>5000		Ac-SRYKWF[CGMRDMKGTMSC]DWVKF-NH2	1255
JBT1432	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VDVKF-NH2	1256
JBT1433	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWDKF-NH2	1257
JBT1434	515	D	Ac-SRYKWF[CGMRDMKGTMSC]VWVDF-NH2	1120
JBT1435	34	A	Ac-SRYKWF[CGMRDMKGTMSC]VWVKD-NH2	1009

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1436	54	B	Ac-FRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1053
JBT1437	33	A	Ac-SFYKWF[CGMRDMKGTMSC]VWVKF-NH2	1010
JBT1438	40	A	Ac-SRFKWF[CGMRDMKGTMSC]VWVKF-NH2	1011
JBT1439	572	D	Ac-SRYFWF[CGMRDMKGTMSC]VWVKF-NH2	1121
JBT1440	>5000		Ac-SRYKFF[CGMRDMKGTMSC]VWVKF-NH2	1258
JBT1441	>5000		Ac-SRYKWF[CEMRDMKGTMSC]VWVKF-NH2	1259
JBT1442	2701	E	Ac-SRYKWF[CGFRDMKGTMSC]VWVKF-NH2	1178
JBT1443	1218	E	Ac-SRYKWF[CGMFDMKGTMSC]VWVKF-NH2	1179
JBT1444	>5000		Ac-SRYKWF[CGMRFMKGTMSC]VWVKF-NH2	1260
JBT1445	43	A	Ac-SRYKWF[CGMRDFKGTMSC]VWVKF-NH2	1012
JBT1446	69	B	Ac-SRYKWF[CGMRDMFGTMSC]VWVKF-NH2	1054
JBT1447	344	D	Ac-SRYKWF[CGMRDMKFTMSC]VWVKF-NH2	1122
JBT1448	296	D	Ac-SRYKWF[CGMRDMKGFMSC]VWVKF-NH2	1123
JBT1449	23	A	Ac-SRYKWF[CGMRDMKGTFC]VWVKF-NH2	1013
JBT1450	475	D	Ac-SRYKWF[CGMRDMKGTMC]VWVKF-NH2	1124
JBT1451	236	C	Ac-SRYKWF[CGMRDMKGTMSC]FWVKF-NH2	1087
JBT1452	546	D	Ac-SRYKWF[CGMRDMKGTMSC]VFVKF-NH2	1125
JBT1453	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWFKF-NH2	1261
JBT1454	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVFF-NH2	1262
JBT1455	39	A	Ac-GRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1014
JBT1456	265	D	Ac-SGYKWF[CGMRDMKGTMSC]VWVKF-NH2	1126
JBT1457	1866	E	Ac-SRGKWF[CGMRDMKGTMSC]VWVKF-NH2	1180
JBT1458	430	D	Ac-SRYGWF[CGMRDMKGTMSC]VWVKF-NH2	1127
JBT1459	>5000		Ac-SRYKGF[CGMRDMKGTMSC]VWVKF-NH2	1263
JBT1460	>5000		Ac-SRYKWG[CGMRDMKGTMSC]VWVKF-NH2	1264
JBT1461	2099	E	Ac-SRYKWF[CGGRDMKGTMSC]VWVKF-NH2	1181
JBT1462	370	D	Ac-SRYKWF[CGMGDMKGTMSC]VWVKF-NH2	1128
JBT1463	682	D	Ac-SRYKWF[CGMRGMKGTMSC]VWVKF-NH2	1129
JBT1464	150	C	Ac-SRYKWF[CGMRDGKGTMSC]VWVKF-NH2	1088
JBT1465	50	A	Ac-SRYKWF[CGMRDMGGTMSC]VWVKF-NH2	1015
JBT1466	85	B	Ac-SRYKWF[CGMRDMKGGMSC]VWVKF-NH2	1055
JBT1467	290	D	Ac-SRYKWF[CGMRDMKGTGSC]VWVKF-NH2	1130

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1468	778	D	Ac-SRYKWF[CGMRDMKGTMG]VWVKF-NH2	1131
JBT1469	2366	E	Ac-SRYKWF[CGMRDMKGTMSC]GWVKF-NH2	1182
JBT1470	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VGVKF-NH2	1265
JBT1471	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWGKF-NH2	1266
JBT1472	158	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVGf-NH2	1089
JBT1473	176	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVKG-NH2	1090
JBT1474	31	A	Ac-KRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1016
JBT1475	69	B	Ac-SKYKWF[CGMRDMKGTMSC]VWVKF-NH2	1056
JBT1476	282	D	Ac-SRKKWF[CGMRDMKGTMSC]VWVKF-NH2	1132
JBT1477	>5000		Ac-SRYKKF[CGMRDMKGTMSC]VWVKF-NH2	1267
JBT1478	162	C	Ac-SRYKWK[CGMRDMKGTMSC]VWVKF-NH2	1091
JBT1479	1110	E	Ac-SRYKWF[CKMRDMKGTMSC]VWVKF-NH2	1183
JBT1480	392	D	Ac-SRYKWF[CGKRDMKGTMSC]VWVKF-NH2	1133
JBT1481	20	A	Ac-SRYKWF[CGMKDMKGTMSC]VWVKF-NH2	1017
JBT1482	1354	E	Ac-SRYKWF[CGMRKMGTMSC]VWVKF-NH2	1184
JBT1483	59	B	Ac-SRYKWF[CGMRDKKGTMSC]VWVKF-NH2	1057
JBT1484	520	D	Ac-SRYKWF[CGMRDMKKTMSC]VWVKF-NH2	1134
JBT1485	67	B	Ac-SRYKWF[CGMRDMKGMSC]VWVKF-NH2	1058
JBT1486	54	B	Ac-SRYKWF[CGMRDMKGTKSC]VWVKF-NH2	1059
JBT1487	434	D	Ac-SRYKWF[CGMRDMKGTMC]VWVKF-NH2	1135
JBT1488	>5000		Ac-SRYKWF[CGMRDMKGTMSC]KWVKF-NH2	1268
JBT1489	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VKVKF-NH2	1269
JBT1490	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWKKF-NH2	1270
JBT1491	335	D	Ac-SRYKWF[CGMRDMKGTMSC]VWVK-NH2	1136
JBT1492	38	A	Ac-LRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1018
JBT1493	51	B	Ac-SLYKWF[CGMRDMKGTMSC]VWVKF-NH2	1060
JBT1494	679	D	Ac-SRLKWF[CGMRDMKGTMSC]VWVKF-NH2	1137
JBT1495	729	D	Ac-SRYLWF[CGMRDMKGTMSC]VWVKF-NH2	1138
JBT1496	>5000		Ac-SRYKLF[CGMRDMKGTMSC]VWVKF-NH2	1271
JBT1497	72	B	Ac-SRYKWL[CGMRDMKGTMSC]VWVKF-NH2	1061
JBT1498	>5000		Ac-SRYKWF[CLMRDMKGTMSC]VWVKF-NH2	1272
JBT1499	636	D	Ac-SRYKWF[CGLRDMKGTMSC]VWVKF-NH2	1139

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1500	68	B	Ac-SRYKWF[CGMLDMKGTMSC]VWVKF-NH2	1062
JBT1501	3449	E	Ac-SRYKWF[CGMRMLKGTMSC]VWVKF-NH2	1185
JBT1502	38	A	Ac-SRYKWF[CGMRDLKGTMSC]VWVKF-NH2	1019
JBT1503	54	B	Ac-SRYKWF[CGMRDMLGTMSC]VWVKF-NH2	1063
JBT1504	757	D	Ac-SRYKWF[CGMRDMLKLTMSC]VWVKF-NH2	1140
JBT1505	155	C	Ac-SRYKWF[CGMRDMLKGLMSC]VWVKF-NH2	1092
JBT1506	57	B	Ac-SRYKWF[CGMRDMLKGTLS]VWVKF-NH2	1064
JBT1507	411	D	Ac-SRYKWF[CGMRDMLKGTMLC]VWVKF-NH2	10141
JBT1508	216	C	Ac-SRYKWF[CGMRDMLKGTMSC]LWVKF-NH2	1093
JBT1509	>5000		Ac-SRYKWF[CGMRDMLKGTMSC]VLVKF-NH2	1273
JBT1510	221	C	Ac-SRYKWF[CGMRDMLKGTMSC]VWLKF-NH2	1094
JBT1511	330	D	Ac-SRYKWF[CGMRDMLKGTMSC]VWVLF-NH2	1142
JBT1512	18	A	Ac-SRYKWF[CGMRDMLKGTMSC]VWVKL-NH2	1020
JBT1513	56	B	Ac-SSYKWF[CGMRDMLKGTMSC]VWVKF-NH2	1065
JBT1514	92	B	Ac-SRSKWF[CGMRDMLKGTMSC]VWVKF-NH2	1066
JBT1515	411	D	Ac-SRYSWF[CGMRDMLKGTMSC]VWVKF-NH2	1143
JBT1516	>5000		Ac-SRYKSF[CGMRDMLKGTMSC]VWVKF-NH2	1274
JBT1517	>5000		Ac-SRYKWS[CGMRDMLKGTMSC]VWVKF-NH2	1275
JBT1518	50	A	Ac-SRYKWF[CSMRDMLKGTMSC]VWVKF-NH2	1021
JBT1519	1825	E	Ac-SRYKWF[CGSRDMLKGTMSC]VWVKF-NH2	1186
JBT1520	202	C	Ac-SRYKWF[CGMSDMLKGTMSC]VWVKF-NH2	1095
JBT1521	226	C	Ac-SRYKWF[CGMRSMKGTMSC]VWVKF-NH2	1096
JBT1522	92	B	Ac-SRYKWF[CGMRDSKGTMSC]VWVKF-NH2	1067
JBT1523	35	A	Ac-SRYKWF[CGMRDMSGTMSC]VWVKF-NH2	1022
JBT1524	512	D	Ac-SRYKWF[CGMRDMLKSTMSC]VWVKF-NH2	1144
JBT1525	56	B	Ac-SRYKWF[CGMRDMLKGSMSC]VWVKF-NH2	1068
JBT1526	80	B	Ac-SRYKWF[CGMRDMLKGTSSC]VWVKF-NH2	1069
JBT1527	190	C	Ac-SRYKWF[CGMRDMLKGTMSC]SWVKF-NH2	1097
JBT1528	>5000		Ac-SRYKWF[CGMRDMLKGTMSC]VSVKF-NH2	1276
JBT1529	>5000		Ac-SRYKWF[CGMRDMLKGTMSC]VWSKF-NH2	1277
JBT1530	83	B	Ac-SRYKWF[CGMRDMLKGTMSC]VWVSF-NH2	1070
JBT1531	63	B	Ac-SRYKWF[CGMRDMLKGTMSC]VWVKS-NH2	1071

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1532	54	B	Ac-PRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1072
JBT1533	263	D	Ac-SPYKWF[CGMRDMKGTMSC]VWVKF-NH2	1145
JBT1534	2398	E	Ac-SRPKWF[CGMRDMKGTMSC]VWVKF-NH2	1187
JBT1535	>5000		Ac-SRYPWF[CGMRDMKGTMSC]VWVKF-NH2	1278
JBT1536	>5000		Ac-SRYKPF[CGMRDMKGTMSC]VWVKF-NH2	1279
JBT1537	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1280
JBT1538	>5000		Ac-SRYKWF[CGMRDMKGTMSC]PWVKF-NH2	1281
JBT1539	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VPVKF-NH2	1282
JBT1540	>5000		Ac-SRYKWF[CGMRDMKGTMSC]VWPKF-NH2	1283
JBT1541	29	A	Ac-SRYKWF[CGMRDMKGTMSC]VWVPF-NH2	1023
JBT1542	1052	E	Ac-SRYKWF[CGMRDMKGTMSC]VWVKP-NH2	1188
JBT1543	202	C	Ac-SRYKWF[CGMRDMKGTMSC]VWVKF-OH	1098
JBT1544	40	A	H-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1024
JBT1545	239	C	H-SRYKWF[CGMRDMKGTMSC]VWVKF-OH	1099
JBT1546	>5000		Ac-SRYKWF[CEMRDMKGTMSC]VWVKF-NH2	1284
JBT1547	>5000		Ac-SRYKWF[CHMRDMKGTMSC]VWVKF-NH2	1285
JBT1548	>5000		Ac-SRYKWF[CIMRDMKGTMSC]VWVKF-NH2	1286
JBT1549	1736	E	Ac-SRYKWF[CMMRDMKGTMSC]VWVKF-NH2	1189
JBT1550	1086	E	Ac-SRYKWF[CNMRDMKGTMSC]VWVKF-NH2	1190
JBT1551	682	D	Ac-SRYKWF[CQMRDMKGTMSC]VWVKF-NH2	1146
JBT1552	400	D	Ac-SRYKWF[CRMrdMKGTMSC]VWVKF-NH2	1147
JBT1553	292	D	Ac-SRYKWF[CTMRDMKGTMSC]VWVKF-NH2	1148
JBT1554	>5000		Ac-SRYKWF[CVMRDMKGTMSC]VWVKF-NH2	1287
JBT1555	3382	E	Ac-SRYKWF[CWMrdMKGTMSC]VWVKF-NH2	1191
JBT1556	>5000		Ac-SRYKWF[CVMrdMKGTMSC]VWVKF-NH2	1288
JBT1557	60	B	H-RYKWF[CGMRDMKGTMSC]VWVKF-NH2	173
JBT1558	975	D	H-YKWF[CGMRDMKGTMSC]VWVKF-NH2	1149
JBT1559	286	D	Ac-SRYKWF[CGArDMKGTMSC]VWVKF-NH2	1150
JBT1560	>5000		Ac-SRYKWF[CGdRDMKGTMSC]VWVKF-NH2	1289
JBT1561	3031	E	Ac-SRYKWF[CGIRDMKGTMSC]VWVKF-NH2	1192
JBT1562	1783	E	Ac-SRYKWF[CGkrDMKGTMSC]VWVKF-NH2	1193
JBT1563	1821	E	Ac-SRYKWF[CGIRDmkGTMSC]VWVKF-NH2	1194

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1564	170	C	Ac-SRYKWF[CGpRDMKGTMSC]VWVKF-NH2	1100
JBT1565	1712	E	Ac-SRYKWF[CGsRDMKGTMSC]VWVKF-NH2	1195
JBT1566	367	D	Ac-SRYKWF[CGMRDaKGTMSC]VWVKF-NH2	1151
JBT1567	212	C	Ac-SRYKWF[CGMRDdKGTMSC]VWVKF-NH2	1101
JBT1568	73	B	Ac-SRYKWF[CGMRDfKGTMSC]VWVKF-NH2	1074
JBT1569	155	C	Ac-SRYKWF[CGMRDkKGTMSC]VWVKF-NH2	1102
JBT1570	47	A	Ac-SRYKWF[CGMRDlKGTMSC]VWVKF-NH2	1025
JBT1571	1320	E	Ac-SRYKWF[CGMRDpKGTMSC]VWVKF-NH2	1196
JBT1572	650	D	Ac-SRYKWF[CGMRDsKGTMSC]VWVKF-NH2	1152
JBT1573	1154	E	Ac-SRYKWF[CGMRDmaGTMSC]VWVKF-NH2	1197
JBT1574	350	D	Ac-SRYKWF[CGMRDmGTMSC]VWVKF-NH2	1153
JBT1575	2377	E	Ac-SRYKWF[CGMRDmGTMSC]VWVKF-NH2	1198
JBT1576	1004	E	Ac-SRYKWF[CGMRDMiGTMSC]VWVKF-NH2	1199
JBT1577	1121	E	Ac-SRYKWF[CGMRDMpGTMSC]VWVKF-NH2	1200
JBT1578	633	D	Ac-SRYKWF[CGMRDMsGTMSC]VWVKF-NH2	1154
JBT1735	9	A	Ac-SMYKWH[CGMRDMKGTYS]VWVKF-NH2	1026
JBT1772	11	A	Ac-FHYKWH[CGMRDMKGTYS]VWVKF-NH2	1027
JBT1808	12	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKF-NH2	1028
JBT1811	11	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKY-NH2	1029
JBT1812	11	A	Ac-SYYKWH[CGMRDMKGTYS]VWVRF-NH2	1030
JBT1813	9	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKA-NH2	1031
JBT1815	10	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKF-NH2	1032
JBT1816	9	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKS-NH2	1033
JBT1817	9	A	Ac-SHYKWH[CGMRDMKGTYS]VWVKF-NH2	1034
JBT1821	11	A	Ac-SYYKWH[CGVRDMKGTYS]VWVKS-NH2	1035
JBT1822	18	A	Ac-GHYKWH[CGMRDMKGTYS]VWVVF-NH2	1036
JBT1825	11	A	Ac-AYYKWH[CGMRDLKGTYS]VWVKS-NH2	1037
JBT1826	11	A	Ac-SYYKWH[CGMRDMKGTYS]VWVKM-NH2	1038
JBT1828	22	A	Ac-SHYKWH[CGMRDMKGTYS]VWVVF-NH2	1039
JBT1829	8	A	Ac-FYYKWH[CGMRDMKGTYS]VWVKF-NH2	1040
JBT1830	10	A	Ac-SYYKWH[CGMRDMKGTYS]VWVWY-NH2	1041
JBT1831	13	A	Ac-SHYKWH[CGMRDMKGTYS]VWVKF-NH2	1042

FIGURE 34

Object ID	IC50 [nm]	Affinity Class	Sequence	SEQ ID NO:
JBT1832	11	A	Ac-HYYKWH[CGMRDMKGTMSC]VWVKS-NH2	1043
JBT1837	10	A	Ac-SYYKWH[CAMRDMKGTMTCTC]VWVKF-NH2	1044
JBT1840	11	A	Ac-SYYKWH[CGMRDMKGTMSC]VWVLF-NH2	1045
JBT1842	9	A	Ac-SHYKWH[CAMRDMKGTMSC]AWVKF-NH2	1046

FIGURE 35

Object ID	EC50(nM)	Sequence	SEQ ID NO:
JBT0124	1.8	Biotinyl-Ttds-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NH2	1290
JBT0659	2.1	Biotinyl-Ttds-SRYKWF[CGMRDMKGTMSC]VWVKF-NH2	1291

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT0122	3084	E	Ac-SGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2	2002
JBT0221	1412	E	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2	2003
JBT0222*	36272	G	Ac-MKSRSLGLAYFAKHSSLEVLQTRKVAAPYY-NH2	2127
JBT0223*	>50000		Ac-KMQLRVYASTAHSRYLLGSSLFPKYAEVKA-NH2	2297
JBT0224	>50000		Ac-KKSGYASFPLAVQLHVSKRSEKEMALARYYKK-NH2	2298
JBT0225	25395	G	Ac-KKSGYASFPLAVQLHVSKRSEKEMALARKK-NH2	2128
JBT0226	>50000		Ac-KKSGYASFPLAVQLHVSKRSEKEMAKK-NH2	2299
JBT0227	>50000		Ac-KKSGYASFPLAVQLHVSKRSEKKNH2	2300
JBT0228	5436	F	Ac-KKASFPLAVQLHVSKRSEKEMALARYYKTSKK-NH2	2016
JBT0229	16971	G	Ac-KKPLAVQLHVSKRSEKEMALARYYKTSKK-NH2	2129
JBT0230	>50000		Ac-KKVQLHVSKRSEKEMALARYYKTSKK-NH2	2301
JBT0231	>50000		Ac-KKHVSKRSEKEMALARYYKTSKK-NH2	2302
JBT0232	>50000		Ac-KKGYASFPLAVQLHVSKRSEKMKK-NH2	2303
JBT0233	>50000		Ac-KKYASFPLAVQLHVSKRSEKMAKK-NH2	2304
JBT0234	>50000		Ac-KKVQLHVSKRSEKEMALARYYKKK-NH2	2305
JBT0235	>50000		Ac-KKQLHVSKRSEKEMALARYYKTKK-NH2	2306
JBT0236	>50000		Ac-KKLHVSKRSEKEMALARYYKTSKK-NH2	2307
JBT0237	>50000		Ac-KKSGYASFPLAVQLHVSKRSEKKNH2	2308
JBT0359	>50000		Ac-ASFPLAVQLHVSKRSEMA-NH2	2309
JBT0360	>50000		Ac-SFPLAVQLHVSKRSEMA-NH2	2310
JBT0361	>50000		Ac-FPLAVQLHVSKRSEMA-NH2	2311
JBT0362	>50000		Ac-ASFPLAVQLHVSKRSEMA-NH2	2312
JBT0363	>50000		Ac-ASFPLAVQLHVSKRSE-NH2	2313
JBT0364	>50000		Ac-ASFPLAVQLHVSKRSEMA-NH2	2314
JBT0365	>50000		Ac-ASFPLAVQLHVSKRSEMAA-NH2	2315
JBT0366	>50000		Ac-ASFPLAVQLHVSKRSEKEMALAR-NH2	2316
JBT0367	>50000		Ac-ASFPLAVQLHVSKRSEKEMALARL-NH2	2317
JBT0368	27346	G	Ac-ASFPLAVQLHVSKRSEKEMALARLY-NH2	2130
JBT0369	5107	F	Ac-ASFPLAVQLHVSKRSEKEMALARLYY-NH2	2017
JBT0370	>50000		Ac-YASFPLAVQLHVSKRSEMA-NH2	2318
JBT0371	>50000		Ac-GYASFPLAVQLHVSKRSEMA-NH2	2319
JBT0660	2645	E	Ac-AGYASFPLAVQLHVSKRSEKEMALARYYKTS-NH2	2004

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT0661	1383	E	Ac-SAYASFPPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2005
JBT0662	13759	G	Ac-SGAASFPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2131
JBT0664	2739	E	Ac-SGYAAFPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2006
JBT0665	25704	G	Ac-SGYASAPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2132
JBT0666	915	D	Ac-SGYASFALAVQLHVSKRSEKEMALARLYYKTS-NH2	2001
JBT0667	9314	F	Ac-SGYASFPAAVQLHVSKRSEKEMALARLYYKTS-NH2	2018
JBT0669	33021	G	Ac-SGYASFPPLAAQLHVSKRSEKEMALARLYYKTS-NH2	2133
JBT0670	2506	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2007
JBT0671	5836	F	Ac-SGYASFPPLAVQAHVSKRSEKEMALARLYYKTS-NH2	2019
JBT0672	38327	G	Ac-SGYASFPPLAVQLAVSKRSEKEMALARLYYKTS-NH2	2134
JBT0673	16425	G	Ac-SGYASFPPLAVQLHASKRSEKEMALARLYYKTS-NH2	2135
JBT0674	1173	E	Ac-SGYASFPPLAVQLHVAKRSEKEMALARLYYKTS-NH2	2008
JBT0675	18317	G	Ac-SGYASFPPLAVQLHVSARSKEMALARLYYKTS-NH2	2136
JBT0676	37412	G	Ac-SGYASFPPLAVQLHVSASKEMALARLYYKTS-NH2	2137
JBT0677	1905	E	Ac-SGYASFPPLAVQLHVSRAKEMALARLYYKTS-NH2	2009
JBT0678	4071	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2010
JBT0679	6196	F	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2020
JBT0680	20935	G	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKTS-NH2	2138
JBT0682	10271	G	Ac-SGYASFPPLAVQLHVSKRSEKEMAAARLYYKTS-NH2	2139
JBT0684	4567	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALAAALYKTS-NH2	2011
JBT0685	9134	F	Ac-SGYASFPPLAVQLHVSKRSEKEMALARAAYKTS-NH2	2021
JBT0686	13474	G	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLAYKTS-NH2	2140
JBT0687	11783	G	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYAKTS-NH2	2141
JBT0688	4196	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYATS-NH2	2012
JBT0689	3127	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKAS-NH2	2013
JBT0690	3000	E	Ac-SGYASFPPLAVQLHVSKRSEKEMALARLYYKTA-NH2	2014
JBT0788	16205	G	H-GSSGYASFPLAVQLHVSKRSEKEMALARLYYKTS-OH	2142
JBT1579	2593	E	Ac-GYASFPPLAVQLHVAKRSEKEMA-NH2	2015
JBT1580	>50000		Ac-GYASFALSVQLHVSKRSEKEMA-NH2	2320
JBT1581	>50000		Ac-GYASFALAVQLHVAKRSEKEMA-NH2	2321
JBT1582	5841	F	Ac-GYASFPPLAVQLHVMKRSEKEMA-NH2	2022
JBT1583	>50000		Ac-GYASFALAVQLHVMKRSEKEMA-NH2	2322

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1599	>50000		Ac-FPLAVQLHVSKRSEKEMALA-NH2	2323
JBT1600	>50000		Ac-QLHVSKRSEKEMALA-NH2	2324
JBT1601	>50000		Ac-SGYASFP-NH2	2325
JBT1602	>50000		Ac-LAVQLHVSKRSEKEMAL-ARL-NH2	2326
JBT1644			Ac-VYASFFLTVQLHVSKRSEKEMA-NH2	2327
JBT1645			Ac-GYWSPFPQAVQLHVSKRSEKEMA-NH2	2328
JBT1646			Ac-GYASFILAVQLHVSKRSEKEMA-NH2	2329
JBT1647			Ac-GYWSFYLAVALHVSKRSEKEMA-NH2	2330
JBT1648			Ac-SYASFFLAVALHVSKRSEKEMA-NH2	2331
JBT1649	10282	G	Ac-GYWSPFHAVVHHVSKRSEKEMA-NH2	2143
JBT1650			Ac-GYASFILAVQLHHSKRSEKEMA-NH2	2332
JBT1651			Ac-GMASFFLARLDLHWSKVFEKEMA-NH2	2333
JBT1653			Ac-EYAQFWLAVQLHVSKRSEKEMA-NH2	2334
JBT1654			Ac-GYASFFLIVQLHVSKRSEKEMA-NH2	2335
JBT1655			Ac-GYASFPPIHVQHHSKRSEKEMA-NH2	2336
JBT1656			Ac-GYASFALMVQLHVSKRSEKEMA-NH2	2337
JBT1657			Ac-GYASFHQAQRHVSKRSEKEMA-NH2	2338
JBT1658			Ac-GYASFALMVQHHSKRSEKEMA-NH2	2339
JBT1659	14473	G	Ac-GYASFWQAVQLHVWKRSEIA-NH2	2144
JBT1660	14063	G	Ac-GYASFPPLIVWLHVSKRSEKEMA-NH2	2145
JBT1661			Ac-GYASFLAVQLHVSKRSEKEMA-NH2	2340
JBT1662			Ac-GYHSFKLAVQLHVSKRSEKEMA-NH2	2341
JBT1663	12912	G	Ac-GYASFWQAVQLHVSKRSEKEMA-NH2	2146
JBT1664			Ac-GYASYVLAVALHVSWSRSEKEMA-NH2	2342
JBT1665			Ac-HYHSLPKQVQLHVSKRSEKEMA-NH2	2343
JBT1666			Ac-GYASFLAVQLHVSKRSEKEMA-NH2	2344
JBT1668			Ac-GYASFELLVQLHVSKRSEKEMA-NH2	2345
JBT1669			Ac-SYSSFKLAVQLHVSKRSEKEMA-NH2	2346
JBT1670			Ac-GYAWFPPLNVWLHVSKRSEKEMA-NH2	2347
JBT1671			Ac-GYASFWLSVQTHVSKRSEKEMA-NH2	2348

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1672			Ac-GYASFPLMVQLHVIKRSKEMA-NH2	2349
JBT1673			Ac-GYWSEFNLVVQLHVSKRSEKEMA-NH2	2350
JBT1674			Ac-GYASFHLAVQLHVWKRSEKEMA-NH2	2351
JBT1675			Ac-GYASFVLVVQLHVSKRSEKEMA-NH2	2352
JBT1676			Ac-GYWSEPLAVQLHVWKRSEWEMA-NH2	2353
JBT1677			Ac-GYASFPPWYVQLHVSKRSEKEMA-NH2	2354
JBT1678			Ac-GYTSEFQLAVQLHVSKRSEKEMA-NH2	2355
JBT1679			Ac-RYASFPLAVYLVTKRSEKEMA-NH2	2356
JBT1680			Ac-GYWSEPLAVQLHVSKRRLKEMA-NH2	2357
JBT1681			Ac-GHASFQTAVQQHVSKRSEKEMA-NH2	2358
JBT1682			Ac-FHVSKRSEKEMA-NH2	2359
JBT1683			Ac-GYASFWHAVQLHVSKRSEKEMA-NH2	2360
JBT1684			Ac-GIASFILAVQLHVYKRSEKEMA-NH2	2361
JBT1685			Ac-GYTSEFMQAVQHHVSKRSEKEMA-NH2	2362
JBT1686			Ac-HYHSFYLAVALHVWERSYEMA-NH2	2363
JBT1687			Ac-GYASFWHAVQHHVTKRSEKEMA-NH2	2364
JBT1688			Ac-GYASFILTVQLHVSKRSEKEMA-NH2	2365
JBT1689			Ac-GYASFILTVQLHVSKRSEKEMA-NH2	2366
JBT1690			Ac-GYASFVLAVALHVSKRSEKEMA-NH2	2367
JBT1691			Ac-GYASFILAVQHHVSKRSEKEMA-NH2	2368
JBT1692			Ac-SYASFPPAVMLHVWKRSEYEMA-NH2	2369
JBT1693			Ac-GYASENLAVQLHVSKRSEKEMA-NH2	2370
JBT1694			Ac-GYWSEFNLAVQLHVSKRSEKEMA-NH2	2371
JBT1695			Ac-GYASFELAVQLHVSKRSEKEMA-NH2	2372
JBT1696			Ac-GYASFVLAVALHVWKRSEKEMA-NH2	2373
JBT1697	8481	F	Ac-GYASFPPWFVQLHVHKRSEWEMA-NH2	223
JBT1698			Ac-GYASFSLAIQLHVSKRSEKEMA-NH2	2374
JBT1858		F	Ac-AYASFPPWFVQLHVHKRSEWEMA-NH2	2024
JBT1859			Ac-GAASFPPWFVQLHVHKRSEWEMA-NH2	2375
JBT1860		F	Ac-GYAAFPPWFVQLHVHKRSEWEMA-NH2	2025

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1861			Ac-GYASAPWVQLHVHKRSWEMA-NH2	2376
JBT1862			Ac-GYASFAWVQLHVHKRSWEMA-NH2	2377
JBT1863		G	Ac-GYASFPFVQLHVHKRSWEMA-NH2	2147
JBT1864		F	Ac-GYASFPWAVQLHVHKRSWEMA-NH2	2026
JBT1865			Ac-GYASFPWFAQLHVHKRSWEMA-NH2	2378
JBT1866		F	Ac-GYASFPWFVALHVHKRSWEMA-NH2	2027
JBT1867		G	Ac-GYASFPWFVQAHVHKRSWEMA-NH2	2148
JBT1868			Ac-GYASFPWFVQLAVHKRSWEMA-NH2	2379
JBT1869		G	Ac-GYASFPWFVQLHAHKRSWEMA-NH2	2149
JBT1870		G	Ac-GYASFPWFVQLHVAKRSWEMA-NH2	2150
JBT1871			Ac-GYASFPWFVQLHVHARSWEMA-NH2	2380
JBT1872			Ac-GYASFPWFVQLHVHKASWEMA-NH2	2381
JBT1874			Ac-GYASFPWFVQLHVHKRSAEMA-NH2	2382
JBT1875		G	Ac-GYASFPWFVQLHVHKRSWAMA-NH2	2151
JBT1876		G	Ac-GYASFPWFVQLHVHKRSWEAA-NH2	2152
JBT1877		F	Ac-CYASFPWFVQLHVHKRSWEMA-NH2	2028
JBT1878		F	Ac-GCASFPWFVQLHVHKRSWEMA-NH2	2029
JBT1879		F	Ac-GYCSFPWFVQLHVHKRSWEMA-NH2	2030
JBT1880		F	Ac-GYACFPWFVQLHVHKRSWEMA-NH2	2031
JBT1881		F	Ac-GYASCPWFVQLHVHKRSWEMA-NH2	2032
JBT1882		G	Ac-GYASFCWFVQLHVHKRSWEMA-NH2	2153
JBT1883		F	Ac-GYASFPFVQLHVHKRSWEMA-NH2	2033
JBT1884		F	Ac-GYASFPWCVQLHVHKRSWEMA-NH2	2034
JBT1885		F	Ac-GYASFPWFCVQLHVHKRSWEMA-NH2	2035
JBT1886		F	Ac-GYASFPWFVCLHVHKRSWEMA-NH2	2236
JBT1888		G	Ac-GYASFPWFVQLCVHKRSWEMA-NH2	2154
JBT1889		F	Ac-GYASFPWFVQLHCHKRSWEMA-NH2	2037
JBT1890		F	Ac-GYASFPWFVQLHVCCKRSWEMA-NH2	2038
JBT1891			Ac-GYASFPWFVQLHVHCRSWEMA-NH2	2383
JBT1892			Ac-GYASFPWFVQLHVHKCSWEMA-NH2	2384

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1893		F	Ac-GYASFPWFVQLHVHKRCWEMA-NH2	2039
JBT1894		F	Ac-GYASFPWFVQLHVHKRSCEMA-NH2	2040
JBT1895		F	Ac-GYASFPWFVQLHVHKRSCMA-NH2	2041
JBT1896		F	Ac-GYASFPWFVQLHVHKRSECA-NH2	2042
JBT1897		F	Ac-GYASFPWFVQLHVHKRSEMC-NH2	2043
JBT1898		F	Ac-DYASFPWFVQLHVHKRSEMA-NH2	2044
JBT1899		G	Ac-GDASFPWFVQLHVHKRSEMA-NH2	2155
JBT1900		G	Ac-GYDSFPWFVQLHVHKRSEMA-NH2	2156
JBT1901		G	Ac-GYADFPWFVQLHVHKRSEMA-NH2	2157
JBT1902		G	Ac-GYASDPWFVQLHVHKRSEMA-NH2	2158
JBT1903			Ac-GYASFDWFVQLHVHKRSEMA-NH2	2385
JBT1904			Ac-GYASFPDFVQLHVHKRSEMA-NH2	2386
JBT1905			Ac-GYASFPWDVQLHVHKRSEMA-NH2	2387
JBT1906			Ac-GYASFPWFVQLHVHKRSEMA-NH2	2388
JBT1907			Ac-GYASFPWFVQLHVHKRSEMA-NH2	2389
JBT1908			Ac-GYASFPWFVQDHHVKRSEMA-NH2	2390
JBT1909			Ac-GYASFPWFVQLDHHVKRSEMA-NH2	2391
JBT1910			Ac-GYASFPWFVQLHDHVKRSEMA-NH2	2392
JBT1911			Ac-GYASFPWFVQLHVDHVKRSEMA-NH2	2393
JBT1912			Ac-GYASFPWFVQLHVDHRSWEMA-NH2	2394
JBT1913			Ac-GYASFPWFVQLHVKDSWEMA-NH2	2395
JBT1914			Ac-GYASFPWFVQLHVKRDWEMA-NH2	2396
JBT1915			Ac-GYASFPWFVQLHVKRSEMA-NH2	2397
JBT1916		G	Ac-GYASFPWFVQLHVKRSDMA-NH2	2159
JBT1917			Ac-GYASFPWFVQLHVKRSEDA-NH2	2398
JBT1918			Ac-GYASFPWFVQLHVKRSEMD-NH2	2399
JBT1920			Ac-GEASFPWFVQLHVKRSEMA-NH2	2400
JBT1921		G	Ac-GYESFPWFVQLHVKRSEMA-NH2	2160
JBT1922		G	Ac-GYAEFPWFVQLHVKRSEMA-NH2	2161
JBT1923			Ac-GYASEFPWFVQLHVKRSEMA-NH2	2401

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1924			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2402
JBT1925			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2403
JBT1926			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2404
JBT1927			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2405
JBT1928			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2406
JBT1929			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2407
JBT1930			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2408
JBT1931			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2409
JBT1932			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2410
JBT1933			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2411
JBT1934			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2412
JBT1935			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2413
JBT1936			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2414
JBT1937			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2415
JBT1938			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2416
JBT1939		G	Ac-FYASFPWFVQLHVHKRSWEMA-NH2	2162
JBT1940		G	Ac-GFASFPWFVQLHVHKRSWEMA-NH2	2163
JBT1941		G	Ac-GYFSFPWFVQLHVHKRSWEMA-NH2	2164
JBT1942		G	Ac-GYAFSPWFVQLHVHKRSWEMA-NH2	2165
JBT1943			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2417
JBT1944		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2166
JBT1945		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2167
JBT1946		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2168
JBT1948			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2418
JBT1949		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2169
JBT1950		F	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2045
JBT1951			Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2419
JBT1952		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2170
JBT1953		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2171
JBT1954		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2172

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1955		G	Ac-GYASFPWFVQLHVHKRSWFMA-NH2	2173
JBT1956		G	Ac-GYASFPWFVQLHVHKRSWEFA-NH2	2174
JBT1959		F	Ac-GYGSFPWFVQLHVHKRSWEMA-NH2	2046
JBT1960		F	Ac-GYAGFPWFVQLHVHKRSWEMA-NH2	2047
JBT1961		G	Ac-GYASGPWFVQLHVHKRSWEMA-NH2	2175
JBT1962			Ac-GYASFGWFVQLHVHKRSWEMA-NH2	2420
JBT1963		G	Ac-GYASFPGFVQLHVHKRSWEMA-NH2	2176
JBT1964		G	Ac-GYASFPWGVQLHVHKRSWEMA-NH2	2177
JBT1965		G	Ac-GYASFPWFGQLHVHKRSWEMA-NH2	2178
JBT1966		G	Ac-GYASFPWFVGLHVHKRSWEMA-NH2	2179
JBT1967		G	Ac-GYASFPWFVQGHVHKRSWEMA-NH2	2180
JBT1968			Ac-GYASFPWFVQLGVHKRSWEMA-NH2	2421
JBT1969		G	Ac-GYASFPWFVQLHGHKRSWEMA-NH2	2181
JBT1970		G	Ac-GYASFPWFVQLHVHGKRSWEMA-NH2	2182
JBT1971			Ac-GYASFPWFVQLHVHGRSWEMA-NH2	2422
JBT1972			Ac-GYASFPWFVQLHVHKGWEMA-NH2	2423
JBT1973		F	Ac-GYASFPWFVQLHVHKRGWEMA-NH2	2048
JBT1974			Ac-GYASFPWFVQLHVHKRSGEMA-NH2	2424
JBT1975		G	Ac-GYASFPWFVQLHVHKRSWGMA-NH2	2183
JBT1976		G	Ac-GYASFPWFVQLHVHKRSWEGA-NH2	2184
JBT1979		G	Ac-GHASFPWFVQLHVHKRSWEMA-NH2	2185
JBT1980		F	Ac-GYHSFPWFVQLHVHKRSWEMA-NH2	2049
JBT1981		F	Ac-GYAHFPWFVQLHVHKRSWEMA-NH2	2050
JBT1982		F	Ac-GYASHPWFVQLHVHKRSWEMA-NH2	2051
JBT1984		G	Ac-GYASFPHFVQLHVHKRSWEMA-NH2	2186
JBT1985		F	Ac-GYASFPWHVQLHVHKRSWEMA-NH2	2052
JBT1986		G	Ac-GYASFPWFHQLHVHKRSWEMA-NH2	2187
JBT1987		G	Ac-GYASFPWFVHLHVHKRSWEMA-NH2	2188
JBT1989		G	Ac-GYASFPWFVQLHHHKRSWEMA-NH2	2189
JBT1990			Ac-GYASFPWFVQLHVHHRSWEMA-NH2	2425

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT1991			Ac-GYASFPWFVQLHVHKHSWEMA-NH2	2426
JBT1993			Ac-GYASFPWFVQLHVHKRSHEMA-NH2	2427
JBT1994		F	Ac-GYASFPWFVQLHVHKRSWHMA-NH2	2053
JBT1995		G	Ac-GYASFPWFVQLHVHKRSWEHA-NH2	2190
JBT1996		F	Ac-GYASFPWFVQLHVHKRSWEMH-NH2	2054
JBT1997		G	Ac-IYASFPWFVQLHVHKRSWEMA-NH2	2191
JBT1999		F	Ac-GYISFPWFVQLHVHKRSWEMA-NH2	2055
JBT2000		F	Ac-GYAIFFWFVQLHVHKRSWEMA-NH2	2056
JBT2001		G	Ac-GYASIPWFVQLHVHKRSWEMA-NH2	2192
JBT2002			Ac-GYASFIWFVQLHVHKRSWEMA-NH2	2428
JBT2003		G	Ac-GYASFPPIFVQLHVHKRSWEMA-NH2	2193
JBT2005		G	Ac-GYASFPFIQLHVHKRSWEMA-NH2	2194
JBT2006		G	Ac-GYASFPWFVILHVHKRSWEMA-NH2	2195
JBT2007		F	Ac-GYASFPWFVQIHVHKRSWEMA-NH2	2057
JBT2008		G	Ac-GYASFPWFVQLJIVHKRSWEMA-NH2	2196
JBT2010		F	Ac-GYASFPWFVQLHVIVIKRSWEMA-NH2	2058
JBT2011			Ac-GYASFPWFVQLHVHRSWEMA-NH2	2429
JBT2012			Ac-GYASFPWFVQLHVHKISWEMA-NH2	2430
JBT2013		F	Ac-GYASFPWFVQLHVHKRIWEMA-NH2	2059
JBT2014		F	Ac-GYASFPWFVQLHVHKRSIEMA-NH2	2060
JBT2017		F	Ac-GYASFPWFVQLHVHKRSWEMI-NH2	2061
JBT2018		F	Ac-KYASFPWFVQLHVHKRSWEMA-NH2	2062
JBT2019		F	Ac-GKASFPWFVQLHVHKRSWEMA-NH2	2063
JBT2020		F	Ac-GYKSEFPWFVQLHVHKRSWEMA-NH2	2064
JBT2021		F	Ac-GYAKFPWFVQLHVHKRSWEMA-NH2	2065
JBT2022		F	Ac-GYASKPWFVQLHVHKRSWEMA-NH2	2066
JBT2023		G	Ac-GYASFVKWFVQLHVHKRSWEMA-NH2	2197
JBT2024		G	Ac-GYASFVKFVQLHVHKRSWEMA-NH2	2198
JBT2025		F	Ac-GYASFPWKVQLHVHKRSWEMA-NH2	2067
JBT2027		F	Ac-GYASFPWFVKLHVHKRSWEMA-NH2	2068

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2028		F	Ac-GYASFPWFVQKHVHKRSWEMA-NH2	2069
JBT2029		G	Ac-GYASFPWFVQLKVHKRSWEMA-NH2	2199
JBT2030		F	Ac-GYASFPWFVQLHKHKRSWEMA-NH2	2070
JBT2032			Ac-GYASFPWFVQLHVHKKSHEMA-NH2	2431
JBT2033		F	Ac-GYASFPWFVQLHVHKRKSHEMA-NH2	2071
JBT2034		G	Ac-GYASFPWFVQLHVHKRSKEMA-NH2	2200
JBT2035		F	Ac-GYASFPWFVQLHVHKRSWKMA-NH2	2072
JBT2036		G	Ac-GYASFPWFVQLHVHKRSWEKA-NH2	2201
JBT2037		F	Ac-GYASFPWFVQLHVHKRSWEMK-NH2	2073
JBT2038		F	Ac-LYASFPWFVQLHVHKRSWEMA-NH2	2074
JBT2040		F	Ac-GYLSFPWFVQLHVHKRSWEMA-NH2	2075
JBT2041		F	Ac-GYALFPWFVQLHVHKRSWEMA-NH2	2076
JBT2042		G	Ac-GYASLPWFVQLHVHKRSWEMA-NH2	2202
JBT2043			Ac-GYASFLWFVQLHVHKRSWEMA-NH2	2432
JBT2044		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2203
JBT2045		G	Ac-GYASFPWLVQLHVHKRSWEMA-NH2	2204
JBT2046		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2205
JBT2047		F	Ac-GYASFPWFVLLHVHKRSWEMA-NH2	2077
JBT2048		G	Ac-GYASFPWFVQLLVHKRSWEMA-NH2	2206
JBT2049		G	Ac-GYASFPWFVQLHLHKRSWEMA-NH2	2207
JBT2050		G	Ac-GYASFPWFVQLHVLKRSWEMA-NH2	2208
JBT2051			Ac-GYASFPWFVQLHVHLRSWEMA-NH2	2433
JBT2052			Ac-GYASFPWFVQLHVHKL,SWEMA-NH2	2434
JBT2053		F	Ac-GYASFPWFVQLHVHKRLWEMA-NH2	2078
JBT2054		G	Ac-GYASFPWFVQLHVHKRSLEMA-NH2	2209
JBT2055		G	Ac-GYASFPWFVQLHVHKRSWMLA-NH2	2210
JBT2056		G	Ac-GYASFPWFVQLHVHKRSWELA-NH2	2211
JBT2057		F	Ac-GYASFPWFVQLHVHKRSWEML-NH2	2079
JBT2058		F	Ac-MYASFPWFVQLHVHKRSWEMA-NH2	2080
JBT2059		G	Ac-GMASFPWFVQLHVHKRSWEMA-NH2	2212

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2060		F	Ac-GYMSFPWFVQLHVKRSWEMA-NH2	2081
JBT2061		F	Ac-GYAMFPWFVQLHVKRSWEMA-NH2	2082
JBT2062		G	Ac-GYASMPWFVQLHVKRSWEMA-NH2	2213
JBT2063			Ac-GYASEMWFVQLHVKRSWEMA-NH2	2435
JBT2064			Ac-GYASFPWFVQLHVKRSWEMA-NH2	2436
JBT2065		G	Ac-GYASFPWMVQLHVKRSWEMA-NH2	2214
JBT2066		G	Ac-GYASFPWFMQLHVKRSWEMA-NH2	2215
JBT2067		G	Ac-GYASFPWFVMLHVKRSWEMA-NH2	2216
JBT2068		F	Ac-GYASFPWFVQMHHVKRSWEMA-NH2	2083
JBT2069			Ac-GYASFPWFVQLMVHVKRSWEMA-NH2	2437
JBT2070		G	Ac-GYASFPWFVQLHMHVKRSWEMA-NH2	2217
JBT2071		G	Ac-GYASFPWFVQLHVMKRSWEMA-NH2	2218
JBT2072			Ac-GYASFPWFVQLHVMRSWEMA-NH2	2438
JBT2073			Ac-GYASFPWFVQLHVKMSWEMA-NH2	2439
JBT2075		G	Ac-GYASFPWFVQLHVKRSMEMA-NH2	2219
JBT2076			Ac-GYASFPWFVQLHVKRSWMMMA-NH2	2440
JBT2077		F	Ac-GYASFPWFVQLHVKRSWEMM-NH2	2084
JBT2078		F	Ac-NYASFPWFVQLHVKRSWEMA-NH2	2085
JBT2079		G	Ac-GNASFPWFVQLHVKRSWEMA-NH2	2220
JBT2080		G	Ac-GYNSFPWFVQLHVKRSWEMA-NH2	2221
JBT2081		F	Ac-GYANFPWFVQLHVKRSWEMA-NH2	2086
JBT2082		G	Ac-GYASNPWFVQLHVKRSWEMA-NH2	2222
JBT2083			Ac-GYASENWFVQLHVKRSWEMA-NH2	2441
JBT2084		G	Ac-GYASFPNFVQLHVKRSWEMA-NH2	2223
JBT2085		G	Ac-GYASFPWNVQLHVKRSWEMA-NH2	2224
JBT2086			Ac-GYASFPWFNQLHVKRSWEMA-NH2	2442
JBT2087		G	Ac-GYASFPWFVNLHVKRSWEMA-NH2	2225
JBT2088		G	Ac-GYASFPWFVQNHVKRSWEMA-NH2	2226
JBT2089			Ac-GYASFPWFVQLNVHVKRSWEMA-NH2	2443
JBT2090			Ac-GYASFPWFVQLHNHVKRSWEMA-NH2	2444

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2091		G	Ac-GYASFPWFVQLHVNKRSWEMA-NH2	2227
JBT2092			Ac-GYASFPWFVQLHVNRSWEMA-NH2	2445
JBT2093			Ac-GYASFPWFVQLHVKNSWEMA-NH2	2446
JBT2094		F	Ac-GYASFPWFVQLHVKRNWEMA-NH2	2087
JBT2095			Ac-GYASFPWFVQLHVKRSNEMA-NH2	2447
JBT2096		G	Ac-GYASFPWFVQLHVKRSWNMA-NH2	2228
JBT2097		G	Ac-GYASFPWFVQLHVKRSWENA-NH2	2229
JBT2098		F	Ac-GYASFPWFVQLHVKRSWEMN-NH2	2088
JBT2099		F	Ac-PYASFPWFVQLHVKRSWEMA-NH2	2089
JBT2100		G	Ac-GPASFPWFVQLHVKRSWEMA-NH2	2230
JBT2101		G	Ac-GYPSFPWFVQLHVKRSWEMA-NH2	2231
JBT2103		G	Ac-GYASPPWFVQLHVKRSWEMA-NH2	2232
JBT2104			Ac-GYASFPFVQLHVKRSWEMA-NH2	2448
JBT2105		G	Ac-GYASFPWPVQLHVKRSWEMA-NH2	2233
JBT2106			Ac-GYASFPWFVQLHVKRSWEMA-NH2	2449
JBT2107		G	Ac-GYASFPWFVPLHVKRSWEMA-NH2	2234
JBT2108			Ac-GYASFPWFVQPHVKRSWEMA-NH2	2450
JBT2109			Ac-GYASFPWFVQLPVHKRSWEMA-NH2	2451
JBT2110			Ac-GYASFPWFVQLHPHKRSWEMA-NH2	2452
JBT2111			Ac-GYASFPWFVQLHVPKRSWEMA-NH2	2453
JBT2112			Ac-GYASFPWFVQLHVHPRSWEMA-NH2	2454
JBT2113			Ac-GYASFPWFVQLHVKPSWEMA-NH2	2455
JBT2114			Ac-GYASFPWFVQLHVKRPWEMA-NH2	2456
JBT2115			Ac-GYASFPWFVQLHVKRSPEMA-NH2	2457
JBT2116		G	Ac-GYASFPWFVQLHVKRSWPMMA-NH2	2235
JBT2118		G	Ac-GYASFPWFVQLHVKRSWEMP-NH2	2236
JBT2119		G	Ac-QYASFPWFVQLHVKRSWEMA-NH2	2237
JBT2120			Ac-GQASFPWFVQLHVKRSWEMA-NH2	2458
JBT2121		G	Ac-GYQSFPWFVQLHVKRSWEMA-NH2	2238
JBT2122		G	Ac-GYAQFPWFVQLHVKRSWEMA-NH2	2239

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2123		G	Ac-GYASQPWFVQLHVKRWSWEMA-NH2	2240
JBT2124			Ac-GYASFQWFVQLHVKRWSWEMA-NH2	2459
JBT2125			Ac-GYASFPPQFVQLHVKRWSWEMA-NH2	2460
JBT2126		G	Ac-GYASFPPWFVQLHVKRWSWEMA-NH2	2241
JBT2127			Ac-GYASFPPWFQQLHVKRWSWEMA-NH2	2461
JBT2128		G	Ac-GYASFPPWFVQQHVKRWSWEMA-NH2	2242
JBT2129			Ac-GYASFPPWFVQLQVHKRWSWEMA-NH2	2462
JBT2130			Ac-GYASFPPWFVQLHQHKRWSWEMA-NH2	2463
JBT2131		G	Ac-GYASFPPWFVQLHVQKRWSWEMA-NH2	2243
JBT2132			Ac-GYASFPPWFVQLHVHQRSWEMA-NH2	2464
JBT2133			Ac-GYASFPPWFVQLHVKQSWEMA-NH2	2465
JBT2134		F	Ac-GYASFPPWFVQLHVKRQWEMA-NH2	2090
JBT2135		G	Ac-GYASFPPWFVQLHVKRSQEMA-NH2	2244
JBT2136		G	Ac-GYASFPPWFVQLHVKRQSWQMA-NH2	2245
JBT2137		G	Ac-GYASFPPWFVQLHVKRQWEQA-NH2	2246
JBT2138		F	Ac-GYASFPPWFVQLHVKRQSWEMQ-NH2	2091
JBT2139		F	Ac-RYASFPPWFVQLHVKRWSWEMA-NH2	2092
JBT2140		F	Ac-GRASFPPWFVQLHVKRWSWEMA-NH2	2093
JBT2141		F	Ac-GYRSFPWFVQLHVKRWSWEMA-NH2	2094
JBT2142		F	Ac-GYARFPWFVQLHVKRWSWEMA-NH2	2095
JBT2143		F	Ac-GYASRPWFVQLHVKRWSWEMA-NH2	2096
JBT2144		G	Ac-GYASFRWFVQLHVKRWSWEMA-NH2	2247
JBT2145		F	Ac-GYASFPRFVQLHVKRWSWEMA-NH2	2097
JBT2146		F	Ac-GYASFPPWRVQLHVKRWSWEMA-NH2	2098
JBT2147		F	Ac-GYASFPPWFPRQLHVKRWSWEMA-NH2	2099
JBT2148		F	Ac-GYASFPPWFVRLHVKRWSWEMA-NH2	2100
JBT2149		F	Ac-GYASFPPWFVQRHVKRWSWEMA-NH2	2101
JBT2150		G	Ac-GYASFPPWFVQLRVHKRWSWEMA-NH2	2248
JBT2151		F	Ac-GYASFPPWFVQLHRHKRWSWEMA-NH2	2102
JBT2152		F	Ac-GYASFPPWFVQLHVRKRWSWEMA-NH2	2103

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2153		F	Ac-GYASFPWFVQLHVHRRSWEMA-NH2	2104
JBT2154		F	Ac-GYASFPWFVQLHVHKKRRWEMA-NH2	2105
JBT2155		F	Ac-GYASFPWFVQLHVHKKRSREMA-NH2	2106
JBT2156		F	Ac-GYASFPWFVQLHVHKKRWRMA-NH2	2107
JBT2157		G	Ac-GYASFPWFVQLHVHKKRSWERA-NH2	2249
JBT2158		F	Ac-GYASFPWFVQLHVHKKRSWEMR-NH2	2108
JBT2159		F	Ac-SYASFPWFVQLHVHKKRSWEMA-NH2	2109
JBT2160		G	Ac-GSASFPWFVQLHVHKKRSWEMA-NH2	2250
JBT2161		F	Ac-GYSSFPWFVQLHVHKKRSWEMA-NH2	2110
JBT2162		G	Ac-GYASSFPWFVQLHVHKKRSWEMA-NH2	2251
JBT2163			Ac-GYASFSPWFVQLHVHKKRSWEMA-NH2	2466
JBT2164		G	Ac-GYASFPSPFVQLHVHKKRSWEMA-NH2	2252
JBT2165		G	Ac-GYASFPWSVQLHVHKKRSWEMA-NH2	2253
JBT2166		G	Ac-GYASFPWFSQLHVHKKRSWEMA-NH2	2254
JBT2167		F	Ac-GYASFPWFVSLHVHKKRSWEMA-NH2	2111
JBT2168		G	Ac-GYASFPWFVQSHVHKKRSWEMA-NH2	2255
JBT2169			Ac-GYASFPWFVQLSVHKKRSWEMA-NH2	2467
JBT2170		G	Ac-GYASFPWFVQLHSHKKRSWEMA-NH2	2256
JBT2171		G	Ac-GYASFPWFVQLHVSKRSWEMA-NH2	2257
JBT2172			Ac-GYASFPWFVQLHVHSRSWEMA-NH2	2468
JBT2173			Ac-GYASFPWFVQLHVHKSSWEMA-NH2	2469
JBT2174			Ac-GYASFPWFVQLHVHKKRSSEMA-NH2	2470
JBT2175			Ac-GYASFPWFVQLHVHKKRSWSMA-NH2	2471
JBT2176			Ac-GYASFPWFVQLHVHKKRSWESA-NH2	2472
JBT2177			Ac-GYASFPWFVQLHVHKKRSWEMS-NH2	2473
JBT2178		F	Ac-TYASFPWFVQLHVHKKRSWEMA-NH2	2112
JBT2179		G	Ac-GTASFPWFVQLHVHKKRSWEMA-NH2	2258
JBT2180		F	Ac-GYTSFPWFVQLHVHKKRSWEMA-NH2	2113
JBT2181		F	Ac-GYATFPWFVQLHVHKKRSWEMA-NH2	2114
JBT2182		G	Ac-GYASTPWFVQLHVHKKRSWEMA-NH2	2259

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2183			Ac-GYASFTWVFVQLHVKRSWEMA-NH2	2474
JBT2184		G	Ac-GYASFTFVQLHVKRSWEMA-NH2	2260
JBT2185		G	Ac-GYASFPWTVQLHVKRSWEMA-NH2	2261
JBT2186		G	Ac-GYASFPWFTQLHVKRSWEMA-NH2	2262
JBT2187		G	Ac-GYASFPWFVTLHVKRSWEMA-NH2	2263
JBT2188		G	Ac-GYASFPWFVQTHVKRSWEMA-NH2	2264
JBT2189			Ac-GYASFPWFVQLTVHKRSWEMA-NH2	2475
JBT2190			Ac-GYASFPWFVQLHTHKRSWEMA-NH2	2476
JBT2191		G	Ac-GYASFPWFVQLHVTKRSWEMA-NH2	2265
JBT2192			Ac-GYASFPWFVQLHVHTRSWEMA-NH2	2477
JBT2193			Ac-GYASFPWFVQLHVKTSWEMA-NH2	2478
JBT2194		F	Ac-GYASFPWFVQLHVHKRTWEMA-NH2	2115
JBT2195			Ac-GYASFPWFVQLHVHKRSTEMA-NH2	2479
JBT2196			Ac-GYASFPWFVQLHVKRSWTMA-NH2	2480
JBT2197			Ac-GYASFPWFVQLHVKRSWETA-NH2	2481
JBT2198		G	Ac-GYASFPWFVQLHVKRSWEMT-NH2	2266
JBT2199			Ac-VYASFPWFVQLHVKRSWEMA-NH2	2482
JBT2200			Ac-GVASFPWFVQLHVKRSWEMA-NH2	2483
JBT2201			Ac-GYVSFPWFVQLHVKRSWEMA-NH2	2484
JBT2202		G	Ac-GYAVFPWFVQLHVKRSWEMA-NH2	2267
JBT2203		G	Ac-GYASVPWFVQLHVKRSWEMA-NH2	2268
JBT2204			Ac-GYASFVWFVQLHVKRSWEMA-NH2	2485
JBT2205			Ac-GYASFPVFVQLHVKRSWEMA-NH2	2486
JBT2206		F	Ac-GYASFPWVVQLHVKRSWEMA-NH2	2116
JBT2207		G	Ac-GYASFPWFVVLHVKRSWEMA-NH2	2269
JBT2208		F	Ac-GYASFPWFVQVHVKRSWEMA-NH2	2117
JBT2209			Ac-GYASFPWFVQLVVKRSWEMA-NH2	2487
JBT2210		G	Ac-GYASFPWFVQLHVVKRSWEMA-NH2	2270
JBT2211			Ac-GYASFPWFVQLHVHVRWEMA-NH2	2488
JBT2212			Ac-GYASFPWFVQLHVHKVSWEMA-NH2	2489

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2213		F	Ac-GYASFPWFVQLHVHKRVWEMA-NH2	2118
JBT2214		G	Ac-GYASFPWFVQLHVHKRSVEMA-NH2	2271
JBT2215		G	Ac-GYASFPWFVQLHVHKRSWVMA-NH2	2272
JBT2216		G	Ac-GYASFPWFVQLHVHKRSWEVA-NH2	2273
JBT2217		F	Ac-GYASFPWFVQLHVHKRSWEMV-NH2	2119
JBT2218		G	Ac-WYASFPWFVQLHVHKRSWEMA-NH2	2274
JBT2219		F	Ac-GWASFPWFVQLHVHKRSWEMA-NH2	2120
JBT2220		F	Ac-GYWSFPWFVQLHVHKRSWEMA-NH2	2121
JBT2221		G	Ac-GYAWFPWFVQLHVHKRSWEMA-NH2	2275
JBT2222		F	Ac-GYASWPWFVQLHVHKRSWEMA-NH2	2122
JBT2223			Ac-GYASFVWFVQLHVHKRSWEMA-NH2	2490
JBT2224		F	Ac-GYASFPWVQLHVHKRSWEMA-NH2	2123
JBT2225		G	Ac-GYASFPWFVQLHVHKRSWEMA-NH2	2276
JBT2226		G	Ac-GYASFPWFVWLHVHKRSWEMA-NH2	2277
JBT2227		F	Ac-GYASFPWFVQWVHKRSWEMA-NH2	2124
JBT2228			Ac-GYASFPWFVQLWVHKRSWEMA-NH2	2491
JBT2229		G	Ac-GYASFPWFVQLHWHKRSWEMA-NH2	2278
JBT2230		G	Ac-GYASFPWFVQLHVWKRSWEMA-NH2	2279
JBT2231			Ac-GYASFPWFVQLHVHWRSWEMA-NH2	2492
JBT2232			Ac-GYASFPWFVQLHVHKWSWEMA-NH2	2493
JBT2233		G	Ac-GYASFPWFVQLHVHKRWWEMA-NH2	2280
JBT2234		G	Ac-GYASFPWFVQLHVHKRSWWMA-NH2	2281
JBT2235		G	Ac-GYASFPWFVQLHVHKRSWEWA-NH2	2282
JBT2236		F	Ac-GYASFPWFVQLHVHKRSWEMW-NH2	2125
JBT2238		G	Ac-GYYSFPWFVQLHVHKRSWEMA-NH2	2283
JBT2239		G	Ac-GYAYFPWFVQLHVHKRSWEMA-NH2	2284
JBT2240		G	Ac-GYASYPWFVQLHVHKRSWEMA-NH2	2285
JBT2241			Ac-GYASFYWFVQLHVHKRSWEMA-NH2	2494
JBT2242		G	Ac-GYASFPYFVQLHVHKRSWEMA-NH2	2286
JBT2243		F	Ac-GYASFPWYVQLHVHKRSWEMA-NH2	2126

FIGURE 36

Object ID	IC50 [nM]	Affinity Class	Sequence	SEQ ID NO:
JBT2244		G	Ac-GYASFPWFYQLHVHKRSWEMA-NH2	2287
JBT2245		G	Ac-GYASFPWFVYLHVHKRSWEMA-NH2	2288
JBT2246		G	Ac-GYASFPWFVQYHVHKRSWEMA-NH2	2289
JBT2247			Ac-GYASFPWFVQLYVHKRSWEMA-NH2	2495
JBT2248		G	Ac-GYASFPWFVQLHYHKRSWEMA-NH2	2290
JBT2249		G	Ac-GYASFPWFVQLHVYKRSWEMA-NH2	2291
JBT2250			Ac-GYASFPWFVQLHVHYRSWEMA-NH2	2496
JBT2251			Ac-GYASFPWFVQLHVHKYSWEMA-NH2	2497
JBT2252		G	Ac-GYASFPWFVQLHVHKRYWEMA-NH2	2292
JBT2253		G	Ac-GYASFPWFVQLHVHKRSYEMA-NH2	2293
JBT2254		G	Ac-GYASFPWFVQLHVHKRSWYMA-NH2	2294
JBT2255		G	Ac-GYASFPWFVQLHVHKRSWEYA-NH2	2295
JBT2256		G	Ac-GYASFPWFVQLHVHKRSWEMY-NH2	2296

FIGURE 37

Object ID	EC50 [nM]	Sequence	SEQ ID NO:
JBT0126	55.6868	Biotinyl-Ttds-SGYASFPPLAVQLHVSKRSKEMALARLYYKTS-NH2	2498

FIGURE 38

Object ID	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0049	ND		Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKRTS-NH2	3025
JBT0050	2745	E	Ac-SGRGCTKVIVFTFRHKNKLGYERRYNCTS-NH2	3047
JBT0101	251	D	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3036
JBT0129	ND		Ac-SGRGICTKVIVFTFRHKNKLGYERRYNCTJS-NH2	3026
JBT0176*	39444	G	Ac-KKVGSVTRWSMYGPIFIKFTWLEQPVGWGDHKK-NH2	3056
JBT0177*	>50000		Ac-KKLTGDWTYFWSKVWGPVIERQMPVSTFHKK-NH2	3065
JBT0178	72	B	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3028
JBT0179	>50000		Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLKK-NH2	3066
JBT0180	>50000		Ac-KKSGVWQTHPRYFWTMWPDIKGEVKK-NH2	3067
JBT0181	>50000		Ac-KKSGVWQTHPRYFWTMWPDIKKK-NH2	3068
JBT0182	351	D	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3037
JBT0183	>50000		Ac-KKQTHPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3069
JBT0184	>50000		Ac-KKPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3070
JBT0185	45487	G	Ac-KKFWTMWPDIKGEVIVLFGTSKK-NH2	3057
JBT0186	>50000		Ac-KKSGVWQTHPRYFWTMWPDIKGKK-NH2	3071
JBT0187	>50000		Ac-KKWQTHPRYFWTMWPDIKGEVKK-NH2	3072
JBT0188	25532	G	Ac-KKHPRYFWTMWPDIKGEVIVLFGTSKK-NH2	3058
JBT0189	35115	G	Ac-KKYFWTMWPDIKGEVIVLFGTSKK-NH2	3059
JBT0190	100	C	Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKRTSKK-NH2	3031
JBT0191*	8935	F	Ac-MLGVLMRGISALTGDYTARFEFYLNKQTFN-NH2	3054
JBT0193	>50000		Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFKK-NH2	3073
JBT0194	>50000		Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQKK-NH2	3074
JBT0195	>50000		Ac-KKSGNTFVDERLLYFLTIGNMGMYKK-NH2	3075
JBT0196	3457	E	Ac-KKSGNTFVDERLLYFLTIGNMCK-NH2	3048
JBT0197	>50000		Ac-KKTFVDERLLYFLTIGNMGMYAAQLKRTSKK-NH2	3076
JBT0198	>50000		Ac-KKDERLLYFLTIGNMGMYAAQLKRTSKK-NH2	3077
JBT0199	>50000		Ac-KKLLYFLTIGNMGMYAAQLKRTSKK-NH2	3078
JBT0200	>50000		Ac-KKFLTIGNMGMYAAQLKRTSKK-NH2	3079
JBT0201	>50000		Ac-KKLLYFLTIGNMGMYAAQLKFRKK-NH2	3080
JBT0202	>50000		Ac-KKLYFLTIGNMGMYAAQLKFRTKK-NH2	3081
JBT0203	>50000		Ac-KKYFLTIGNMGMYAAQLKRTSKK-NH2	3082

FIGURE 38

Object ID	IC50 Mean (nM)	Affinity Class	Sequence	SEQ ID NO:
JBT0204	25693	G	Ac-KKSGNTFVDERLLYFLTIGNMGKK-NH2	3060
JBT0205	72	B	Ac-KKSGRGCTKVIVFTFRHNKLIGYERRYNCTSKK-NH2	3029
JBT0206*	3594	E	Ac-TNYTGSEKCFVTRRYLGVRINCFHKGS-NH2	3049
JBT0207*	4316	E	Ac-TRNVVRRYECFGSTGCIKYFIHSRTGLNK-NH2	3050
JBT0208	ND		Ac-KKSGRGCTKVIVFTFRHNKLIGYERRYNKK-NH2	3027
JBT0209	4756	E	Ac-KKSGRGCTKVIVFTFRHNKLIGYERKK-NH2	3051
JBT0210	20471	G	Ac-KKSGRGCTKVIVFTFRHNKLIGKK-NH2	3061
JBT0211	211	C	Ac-KKGCTKVIVFTFRHNKLIGYERRYNCTSKK-NH2	3032
JBT0212	117	C	Ac-KKKVIVFTFRHNKLIGYERRYNCTSKK-NH2	3033
JBT0213	>50000		Ac-KKVFTFRHNKLIGYERRYNCTSKK-NH2	3083
JBT0214	2277	E	Ac-KKGRGCTKVIVFTFRHNKLIGYKK-NH2	3052
JBT0215	6146	F	Ac-KKGCTKVIVFTFRHNKLIGYERKK-NH2	3055
JBT0216	2123	E	Ac-KKCTKVIVFTFRHNKLIGYERRKK-NH2	3053
JBT0217	47024	G	Ac-KKTKVIVFTFRHNKLIGYERRYKK-NH2	3062
JBT0218	32865	G	Ac-KKKVIVFTFRHNKLIGYERRYNKK-NH2	3063
JBT0219	78	B	Ac-KKVIVFTFRHNKLIGYERRYNCKK-NH2	3030
JBT0220	31914	G	Ac-KKIVFTFRHNKLIGYERRYNCTKK-NH2	3064
JBT0344	629	D	Ac-TFVDERLLYFLTIGNMGMYAAQLKF-NH2	3038
JBT0345	271	D	Ac-FVDERLLYFLTIGNMGMYAAQLKF-NH2	3039
JBT0346	214	C	Ac-VDERLLYFLTIGNMGMYAAQLKF-NH2	3034
JBT0347	434	D	Ac-TFVDERLLYFLTIGNMGMYAAQLK-NH2	3040
JBT0348	>5000		Ac-TFVDERLLYFLTIGNMGMYAAQ-NH2	3084
JBT0349	552	D	Ac-GCTKVIVFTFRHNKLIGYERRYNCTS-NH2	3041
JBT0350	527	D	Ac-CTKVIVFTFRHNKLIGYERRYNCTS-NH2	3042
JBT0351	948	D	Ac-TKVIVFTFRHNKLIGYERRYNCTS-NH2	3043
JBT0352	848	D	Ac-GCTKVIVFTFRHNKLIGYERRYNCT-NH2	3044
JBT0353	668	D	Ac-GCTKVIVFTFRHNKLIGYERRYNCT-NH2	3045
JBT0357	125	C	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGKK-NH2	3035
JBT0358	802	D	Ac-KKGVWQTHPRYFWTMWPDIKGEVIVLFGKK-NH2	3046

FIGURE 39

Object ID	EC50 [nM]	Object Name	SEQ ID NO:
JBT0052	2.8	Biotinyl-Ttds-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSSKK-NH2	3004
JBT0053	50.3	Biotinyl-Ttds-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-NH2	3006
JBT0054	2.1	Biotinyl-Ttds-SGRGCTKVIVTFRHNKLGYYRRYNCYS-NH2	3002
JBT0057	>5000	Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-Ttds-Lysin(biotin)-NH2	3018
JBT0058	2.4	Ac-SGRGCTKVIVTFRHNKLGYYRRYNCYS-Ttds-Lysin(biotin)-NH2	3003
JBT0103	4.8	Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTSS-Ttds-KK-Lysin(biotin)-NH2	3005
JBT0105	>10000	Biotinyl-Ttds-SGQFWHGLLLPKGIVLNWTLKPWWMIGAFTS-NH2	3015
JBT0106	>10000	Ac-SGQFWHGLLLPKGIVLNWTLKPWWMIGAFTS-Ttds-Lysin(biotin)-NH2	3016
JBT0113	458.7	Biotinyl-Ttds-LSLVGSFAVLCA-NH2	3007
JBT0117	>50000	Biotinyl-Ttds-SGRFTTRLWYFSDWDLRPWYMPFKQYVLSSTSS-NH2	3019
JBT0118	>50000	Biotinyl-Ttds-SGSYQWWARPYRMWFGLPYWNQRFVFPWNTS-NH2	3020
JBT0128	>5000	Ac-Ttds-SGRVSYWGVKWSQQMPMSWWPDTWYTFEDTS-NH2	3017
JBT0130	1.2	Biotinyl-Ttds-SGRGCTKVIVTFRHNKLGYYRRYNCYS-NH2	3001
JBT0135	>50000	Biotinyl-Ttds-LLYFLTIGNMGMYAAQLKFR-NH2	3021
JBT0136	16461.9	Biotinyl-Ttds-LYFLTIGNMGMYAAQLKFR-NH2	3014
JBT0137	4120.3	Biotinyl-Ttds-YFLTIGNMGMYAAQLKFRS-NH2	3013
JBT0138	2354.6	Biotinyl-Ttds-YFLTIGNMGMYAAQLKFR-NH2	3012
JBT0139	755.5	Biotinyl-Ttds-GRGCTKVIVTFRHNKLGYY-NH2	3008
JBT0140	924.0	Biotin-Ttds-GCTKVIVTFRHNKLGYYER-NH2	3010
JBT0141	800.3	Biotin-Ttds-CTKVIVTFRHNKLGYYER-NH2	3009
JBT0142	>50000	Biotinyl-Ttds-TKVIVTFRHNKLGYYERY-NH2	3022
JBT0143	4229.9	Biotinyl-Ttds-KVIVTFRHNKLGYYERY-NH2	3023
JBT0144	1327.0	Biotin-Ttds-VIVTFRHNKLGYYERYNC-NH2	3011
JBT0145	650.9	Biotin-Ttds-VIVTFRHNKLGYYER-NH2	3024